BIO KOREA
INTERNATIONAL CONVENTION

20TH BIOKOREA

2025 BIO KOREA

International Convention

May 7(Wed) ~ 9(Fri), 2025
COEX, SEOUL

Program Book

Johnson&Johnson

ST PHARM

SCIENCE
TECHNOLOGY
PROGRESS

OUR mRNA CDMO BUSINESS

The most recent step in the ST Pharm journey is the formation of our newest strategic business unit: the mRNA CDMO SBU. Offering a technology platform of proprietary 5' capping reagents and lipid nanoparticle (LNP) formulation, as well as R&D and cGMP in vitro transcription (IVT) capabilities, ST Pharm is ready to help you rapidly usher in the next generation of mRNA vaccines and therapeutics.

- One stop service : Offering in-house plasmid DNA production, IVT synthesis (including mRNA, circRNA and saRNA) to LNP formulation in both non-GMP and GMP grades



Science

- Deep know-how in IVT-based mRNA synthesis & codon optimization
- Analytical and biophysical characterization & analytical method development services

Technology

- SmartCap® proprietary novel 5'-capping analog
- Capping Library Screening Service using ORF-specific screening to identify most suitable cap analog
- STLNP® for xRNA delivery system with novel ionizable lipid to improve immune response and potency

>30 In-House Cap Analogs

Powder or Solution Form

Strong IP Position

Progress

- Applying our synthetic and enzymatic chemistry knowledge to a new paradigm
- Enabling the next generation of mRNA-based vaccines and therapeutics through an established manufacturing platform

BIO KOREA
KOREA 2025

Platform for sharing the cutting-edge technological trends and information among biohealth industry stakeholders

BIO KOREA CONFERENCE

BIO KOREA
KOREA 2025

2025 BIO KOREA International Convention

CONTENTS

01

BIO KOREA 2025

BIO KOREA 2025에 오신 여러분을 진심으로 환영합니다.

대한민국 대표 국제 바이오 컨벤션 BIO KOREA가 올해로 개최 20주년을 맞이하게 되었습니다.
2006년부터 그 동안 보내주신 많은 성원과 관심으로 국내외 기업, 기관 간 기술비즈니스 교류 및 글로벌 협력의 장으로 성장 할 수 있었습니다.

바이오헬스 산업은 미래 세대를 위한 향후 10년, 그리고 그 이상의 안전하고 건강한 미래의 성장을 견인할 핵심 동력입니다. 이번 BIO KOREA 2025에서는 "혁신과 협력으로 여는 미래"이라는 주제로 유망 원천 기술이 글로벌 오픈 이노베이션 및 대내외 협력을 통해 신약 개발로 이어지는 최근 산업 트렌드를 반영하고, 미래 고부가가치 기술을 중심으로 국내외 기업의 새로운 시도를 공유하고 산업의 전망과 가능성을 담아, 비즈니스 파트너링, 인베스트페어, 전시, 컨퍼런스 등 다양한 프로그램으로 진행됩니다.

전세계 각국의 연구자, 글로벌 유수기업, 국내외 투자자 등이 참여하여 바이오헬스 산업의 최신 기술 및 트렌드를 공유하고 폭넓은 교류를 통해 글로벌 파트너십을 이어가는 장이 될 것입니다.

BIO KOREA 2025를 통해 여러분들께 좋은 기회의 장이 될 수 있도록 많은 관심과 참여 부탁드리며, 이번 BIO KOREA 2025 개최를 위해 많은 도움을 주신 모든분들께 감사의 말씀을 드립니다.

차 순 도
한국보건산업진흥원장

BIO KOREA를 충청북도가 개최하는 이유를 아시나요?

2002년으로 거슬러 올라갑니다. 그해 9월 25일, 대한민국에서 최초로 'BIO'를 주제로 한 「2002 오송국제바이오엑스포」가 개최되었습니다. 당시만 해도 '생명과학'이란 용어가 주로 사용되었지만, 충청북도는 보건복지부와 함께 'BIO'라는 개념을 앞세워 행사를 성공적으로 이끌었고, 이를 통해 대한민국 바이오 산업의 새로운 지평을 열었습니다. 이러한 성과와 비전을 계승해 2006년 첫 회를 시작으로 충청북도와 한국보건산업진흥원이 공동으로 BIO KOREA를 매년 개최해 오고 있습니다.

2025년, BIO KOREA는 20주년을 맞이하였습니다.
그동안 대한민국 바이오 산업은 BIO KOREA와 함께 눈부신 발전을 이뤄왔습니다. 셀트리온은 대한민국 최초로 연매출 1조 원을 달성한 글로벌 블록버스터 의약품을 탄생시켰으며, 유한양행은 국산 항암제로서 최초로 미국 FDA의 허가를 받았습니다.

이제 세계가 '대한민국 BIO'를 바라보는 시선이 달라지고 있습니다.
국내 기업들은 글로벌 제약사에 기술을 이전하고 글로벌 임상 3상에 도전하는 등 세계시장을 무대로 활약하고 있습니다. 이러한 흐름 속에서 충청북도는 오송 바이오클러스터를 산·학·연·병·관이 집약된 'K-바이오 스퀘어'로 발전시켜, 국내 기업들의 글로벌 진출 기반을 더욱 강화하고자 합니다. 바이오와 AI(인공지능)를 융합한 KAIST 바이오메디컬 캠퍼스타운을 조성하고, 세계적인 R&D 임상연구센터를 유치해 노화, 희귀·난치성 질환 중심의 신약 개발과 혁신적인 치료기술을 선도할 계획입니다.

충청북도와 한국보건산업진흥원은 지난 20년간 BIO KOREA를 개최하며 수많은 도전과 변화를 겪으며 대한민국 바이오 산업의 발전을 견인해 왔습니다. 앞으로도 우리가 만들어갈 '대한민국 BIO'의 변화의 물결에 많은 관심과 참여를 부탁드립니다.

끝으로 국내 최대 바이오 행사인 BIO KOREA에 함께해 주신 여러분을 진심으로 환영하며, 여러분들의 건강과 행복을 기원합니다. 감사합니다.

김 영 환
충청북도지사

Dear Esteemed Members of the Biohealth Industry,

It is with great pleasure that we warmly welcome you to BIO KOREA 2025.

At a time when innovation in the biohealth industry is shaping the future of human health, BIO KOREA has been at the heart of this transformation, driving the growth of the global and Korean biohealth sectors over the past 20 years. Since its inception in 2006, BIO KOREA has established itself as a comprehensive platform encompassing the entire industry lifecycle—from research and development (R&D) to investment, technology commercialization, and global collaboration. Today, it stands as Korea's premier biohealth business forum and a central hub in the international network.

Under the theme "Innovation and Collaboration: Building the Future Together," BIO KOREA 2025 aims to explore bold visions for a healthier future for humanity beyond technological innovation. In an industry landscape rapidly evolving through convergence of technologies, advancements in digital healthcare, and AI-driven drug development, the need for more creative and strategic collaboration has never been greater.

BIO KOREA 2025 will feature keynote speeches that present the direction of innovation in biotechnology and strategies for global cooperation and success. The event will also provide biohealth companies with valuable insights and future-oriented strategies. Business Partnering and Exhibitions will provide opportunities for collaboration between domestic and international companies, as well as a close-up look at cutting-edge technologies and products from promising enterprises. The Invest Fair will showcase trends and strategies in bio investment from global investors, alongside presentations from leading Korean companies. The Conference will feature a wide range of sessions covering the latest technology trends and pressing issues in the biohealth industry

More than just a venue for information exchange, we hope that this event will serve as a meaningful milestone in building a sustainable bio industry ecosystem and a strong foundation for entering the global market. We firmly believe that the experience and insight of each and every one of you will enrich this event and give it even greater significance.

In closing, we extend our sincere gratitude to everyone who has worked so hard to prepare BIO KOREA 2025 and to all participants who have joined us. Your active participation and interest will be the driving force that propels the biohealth industry to the next level. We would like to ask for your continued support and encouragement as BIO KOREA grows to a global platform shaping the future of the bio industry.

Thank you.

Soondo Cha
President of Korea Health Industry Development Institute
Co-Chairman of BIO KOREA Organizing Committee

Are you aware why Chungcheongbuk-do Province hosts BIO KOREA?

It all goes back to 2002. On September 25 of that year, the first-ever "BIO"-themed event in South Korea, the 「2002 Osong International Bio Expo」 was held. At that time, the term, "life science" was more commonly used, but Chungcheongbuk-do Province, together with the Ministry of Health and Welfare, introduced the concept of "BIO" and successfully hosted the event, opening a new chapter in South Korea's bio industry. Building on this success and vision, Chungcheongbuk-do Province and the Korea Health Industry Development Institute (KHIDI) has been co-hosting BIO KOREA annually, starting with this inaugural event in 2006 and its legacy continues to this day.

In 2025, BIO KOREA celebrates its 20th anniversary.

Over the years, Korea's bio industry has made remarkable progress alongside BIO KOREA. Celltrion became the first South Korean company to develop a global blockbuster drug with annual sales exceeding KRW 1 trillion and Yuhan Corporation achieved a milestone by obtaining FDA approval for the first South Korean-made anticancer drug.

Now, the world is looking at "Korea BIO" differently.

Korean companies are transferring technologies to global pharmaceutical firms and taking on the challenge of global Phase 3 clinical trials, expanding their reach on the world stage. In line with these trends, Chungcheongbuk-do Province aims to further strengthen the global competitiveness of domestic companies by developing the Osong Bio Cluster into the "K-Bio Square", a hub integrating industry, academia, research, medicine and government. The province is also building a KAIST Bio Medical Campus Town that fuses biotechnology and Artificial Intelligence, and plans to attract a world-class R&D and clinical research center to lead new drug development and innovative therapies on aging, rare and intractable diseases.

Over the past 20 years, Chungcheongbuk-do Province and Korea Health Industry Development Institute (KHIDI) have faced numerous challenges and transformations while leading the growth of Korea's bio industry through BIO KOREA. We seek for your continued interest and participation in the waves of change we will create in the future of "Korea BIO".

Finally, I sincerely welcome everyone to BIO KOREA, the largest bio event in South Korea and wish all of you good health and happiness. Thank you.

Young Hwan Kim
Governor of Chungcheongbuk-do
Co-Chairman of BIO KOREA Organizing Committee

2025 BIO KOREA International Convention

20 Years of Bio Korea: A Milestone Journey in Biotechnology

Over the past 20 years of BIO KOREA International Convention,
417,049 participants
from **10,921** companies worldwide have joined
and created **15,196** business opportunities

2006
Visitors 15,117
Participating Companies 344
1:1 Meetings 250
START: Aspiring to Become One of the World's Top Seven Bio Nations

2007
Dynamic Korea: A Strong Leap Toward Becoming a Global Bio Power
Visitors 17,102
Participating Companies 380
1:1 Meetings 381

2008
Visitors 18,090
Participating Companies 336
Networking: Establishing a Marketplace for Innovative Bio Products and Technologies

2009
Potential: Exploring New Opportunities in Korea's Healthcare Industry
Visitors 17,073
Participating Companies 383

2010
Visitors 17,073
Participating Companies 414
1:1 Meetings 313
Grow-up: Establishing Itself as Korea's Premier International Bio Event

2011
Emerging Market: Becoming a Growth Engine for the Global Bio Industry
Visitors 16,849
Participating Companies 539
1:1 Meetings 466

2012
Visitors 17,877
Participating Companies 531
1:1 Meetings 479
Development: Pioneering a New Horizon for Korea and the Global Economy

2013
Convergence: Presenting Development Strategies Through Creative Convergence
Visitors 19,430
Participating Companies 548
1:1 Meetings 590

2014
Visitors 20,712
Participating Companies 546
1:1 Meetings 570
Open Innovation: A Platform for Technological Exchange Driving Open Innovation

2015
From Local Innovation to Global Collaborations
Visitors 20,907
Participating Companies 606
1:1 Meetings 1,129

2016
Visitors 23,942
Participating Companies 664
1:1 Meetings 1,130
Hub of Bio-industry: Strengthening Corporate Networks for the Advancement of the Bio-Health Industry

2017
The 4th Wave: Transforming the Industry Through Innovation in the Bio-Health Ecosystem
Visitors 24,308
Participating Companies 675
1:1 Meetings 1,392

2018
Visitors 24,032
Participating Companies 709
1:1 Meetings 1,452
Global: Envisioning the Future of the Global Healthcare Industry

2019
Springboard: Rising to the Challenge of Biotechnology Advancement
Visitors 26,181
Participating Companies 673
1:1 Meetings 1,728

2020
Visitors 40,051
Participating Companies 679
1:1 Meetings 757
2020 What Comes Next: Showcasing Future Bio-Health Technologies Integrated with IT

2021
New Normal: Overcoming Limitations Through Bio-Technological Innovation
Visitors 13,283
Participating Companies 781
1:1 Meetings 609

2022
Visitors 22,401
Participating Companies 624
1:1 Meetings 730
Technology: Showcasing Cutting-Edge Innovations Through New Platforms

2023
Transformation: Leading the Era of Digital Transformation
Visitors 29,405
Participating Companies 782
1:1 Meetings 1,320

2024
Visitors 33,216
Participating Companies 707
1:1 Meetings 1,900
Collaboration: Establishing Itself as a Center for Global Cooperation

2025
Future: BIO KOREA 2025 - Dreaming of Another Future Alongside 20 Years of Achievements



Since its inception in 2006, BIO KOREA has been committed to showcasing Korea's advancements in the bio-health industry on the global stage. By facilitating global technology exchanges and creating business collaboration opportunities, BIO KOREA has worked to elevate Korea's status in the international bio-health market.

Moving forward, we will continue to share cutting-edge trends and foster new business opportunities and international partnerships, striving for Korea to lead the global bio-health industry.

TITLE	BIO KOREA 2025 International Convention
PERIOD	May 7(Wed) ~ May 9(Fri), 2025
VENUE	COEX, Seoul
HOSTED BY	Korea Health Industry Development Institute (KHIDI), Chungcheongbuk-do
ORGANIZED BY	BIO KOREA Organizing Committee
PROGRAM	Business Partnering, Invest Fair, Exhibition, Conference, etc.

The 20th year for the convention leading the future of the Korean bio-health industry.

Welcome to the BIO KOREA 2025 International Convention at COEX. BIO KOREA, now in its 20th year, will be held from May 7th to May 9th and promises to be one of the most comprehensive biotechnology events ever. This is a superb platform for researchers, scholars and enterprises to share the latest information and cutting-edge trends related to the global biotech and pharmaceuticals industries. It is also an opportunity to discuss future directions for international collaboration. BIO KOREA debuted in 2006 and has become the most influential and well-known event of its kind in Asia. Here is a great opportunity for both domestic and foreign investors to meet fast-growing Korean bio-health companies and leading Korean research institutions. We greatly appreciate your interest in and contributions to BIO KOREA 2025 and are confident you will enjoy and benefit from the experience.

Meet the present and future of the global bio-industry at BIO KOREA 2025.

BUSINESS PARTNERING

Date & Time
May 7(Wed) 10:00~17:00
May 8(Thu) 10:00~17:00
May 9(Fri) 10:00~16:00

Venue
Hall C (Partnering Center), COEX

Participants
Domestic and Overseas Bio companies, Pharmaceutical Companies, Venture Capital, Governments across the country, Embassies, Investment institutions, and Research institutions.

Business Partnering Partners

AMGEN, Johnson&Johnson, sysmex, MSD, Boehringer Ingelheim, Lilly, novo nordisk, PRESTIGE BIOLOGICS, Roche, SK bioscience, Takeda

EXHIBITION

Date
May 7(Wed) ~ May 9(Fri) 2025

Venue
Hall C, COEX

Exhibition Categories
Biotechnology R&D Services, Pharma, Medical Device, Digital Health, Investor, Academic / Non-Profit , Professional Services and Consulting

INVEST FAIR

Date
May 7(Wed) ~ May 8(Thu) 2025

Venue
Rm.318(3F), COEX

Session Topic
1. New Horizons: Shifting Bio Investments to the Middle East and Asia
2. Breaking Barriers: Winning Strategies in Western Bio Markets

Conference

Date
May 7(Wed) ~ May 9(Fri) 2025

Venue
Conference Room 3~4F, COEX

Conference Topic

Innovative Biotechnology
New Drug Modality. Clinical Trial, Preclinical - Alternative Toxicology Solutions, Regenerative Medicine, Anti-aging and Rejuvenation

Bio-Convergence Technology
AI-based New Drug Development, Bio-Digital Convergence Technology, Space Biotechnology, Brain-Computer Interface

Business & Development
Global Bio Governance, Open Innovation - Pharmaceuticals

WELCOME RECEPTION

Date & Time
May 7(Wed) 2025, 18:00

Venue
The Platz(2F), COEX

Participating
Approximately 350 exhibitors, business partnering participate, and guest speakers

PARTNERING RECEPTION

Date & Time
May 8(Thu) 2025, 17:00

Venue
The Platz(2F), COEX

Participating
Approximately 200 business partnering participants

May 7 (Wed)

Program	Time	Title	Venue
Registration	08:00~17:00	All Pass, Conference Pass, Visitor	Hall E Lobby
Official Event	10:00~11:20	Opening Ceremony & Keynote Speech	Rm. 401
	18:00~21:00	Welcome Reception	The Platz
Business Partnering	10:00~17:00	1:1 Partnering	Partnering Center(Hall C)
Invest Fair	13:30~17:00	New Horizons: Shifting Bio Investments to the Middle East and Asia	Rm. 318
Exhibition	10:00~17:00	Bio-Health Technology & Product Promotion	Hall C
Conference	13:30~17:00	S1. AI-Driven Drug Development: A Journey Towards Viable Solutions	Rm. 401
	13:30~17:00	S2. The Great Connection of the 21st Century: Brain-Computer Interface (BCI)	Rm. 307
	13:30~17:00	S3. Advanced Regenerative Medicine: The Beginning of a New Medical Paradigm	Rm. 308
Open Session	13:00~17:30	OS1. Golden Triangle Open Innovation: Korea-UK-Japan Trilateral Collaboration in Life-Science -Digital -Health	Rm. 300
	13:00~17:30	OS2. Workshop on Strategic Collaboration between Korea and Saudi Arabia: Propelling the Growth of Global Biohubs	Rm. 327
	13:00~17:00	OS3. Healthy Aging: Advancing Science for Longevity	Rm. E1
	14:00~15:40	OS5. 2025 Spring Bio-health Policy and Research Forum	Rm. E4
	15:10~17:10	OS6. Advancing Biopharmaceutical Research, Manufacturing, and Workforce Development	Rm. E5
Company Presentation	13:30~17:00	Johnson & Johnson	Rm. 317

※ This program is subject to change depending on internal circumstances.

May 8 (Thu)

Program	Time	Title	Venue
Registration	08:00~17:00	All Pass, Conference Pass, Visitor	Hall E Lobby
Official Event	17:00~20:00	Partnering Reception	The Platz
Business Partnering	10:00~17:00	1:1 Partnering	Partnering Center(Hall C)
Invest Fair	10:00~17:00	Breaking Barriers: Winning Strategies in Western Bio Markets	Rm. 318
Exhibition	10:00~17:00	Bio-Health Technology & Product Promotion	Hall C
Conference	09:30~11:40	S4. The Key to Innovation: Global Open Innovation Strategy	Rm. 401
	13:00~17:00	S5. The Rise of New Modalities: A Game Changer in Drug Development	Rm. 401
	09:30~11:40	S6. Global Bio Governance 2025: Change and Future	Rm. 307
	13:30~16:00	S7. Strategies for Sustainable Global Biopharmaceutical Approval	Rm. 307
	09:30~11:45	S8. Strengthening the Competitiveness of Domestic Regenerative Medicine by Discovering Outstanding New Technologies for Cutting-edge Regenerative Medicine	Rm. 308
	13:30~17:00	S9. Life Sciences in Space: A New Horizon for Biohealth	Rm. 308
Open Session	13:30~14:20	OS9. Canada's Thriving Life Sciences: Innovation and Collaboration from British Columbia to Beyond	Rm. 300
	14:30~16:30	OS10. Global ATMP Forum	Rm. 300
	14:00~16:15	OS11. 2025 Joint Session on Regenerative Medicine Institution Designation and Regenerative Medical Treatment System	Rm. 327
	13:30~16:50	OS12. Current Status and Strategy of BioBigData.Korea	Rm. E1~E4
	13:40~17:00	OS13. Global Pharma Supply Chian from Industry Perspective	Rm. E5
	14:00~16:05	OS14. 2025 BioHealth Commercialization Promising Technology Briefing Session	Rm. E6
Company Presentation	10:00~12:10	AMGEN	Rm. 317
	13:30~14:30	ST PHARM	
	14:40~15:40	ACROBiosystems	
Luncheon Session	12:00~13:00	Global BIO Connection ①	Rm. 307
	12:00~13:00	Global BIO Connection ②	Rm. 308

※ This program is subject to change depending on internal circumstances.

May 9 (Fri)

Program	Time	Title	Venue
Registration	08:00~15:00	All Pass, Conference Pass, Visitor	Hall E Lobby
Business Partnering	10:00~16:00	1:1 Partnering	Partnering Center(Hall C)
Exhibition	10:00~16:00	Bio-Health Technology & Product Promotion	Hall C
Conference	09:30~12:00	S10. Innovative Aging Control Technologies: Immunity, Diagnostics, and Evaluation Platforms	Rm. 401
	13:30~15:30	S11. The Present and Future of Reverse-aging Technologies	Rm. 401
	09:30~12:00	S12. Evolving Global Trends and New Technologies in Clinical Trials	Rm. 307
	13:00~16:00	S13. Beyond Innovation: The Path to Successful Clinical Adoption and Market Expansion of Digital Therapy	Rm. 307
	09:30~15:35	S14. Alternative Toxicity Testing: Our Choice and Challenges for Leading the Future Bio Market	Rm. 308
Open Session	09:30~11:30	OS15. AI Research Cases Utilizing Healthcare Data from the National Institute of Health	Rm. 300
Company Presentation	10:00~11:00	MSD	Rm. 317
	11:10~12:10	SYSMEX	

※ This program is subject to change depending on internal circumstances.







CONFERENCE
307, 308, 401

EXHIBITION
Hall C

OPEN SESSION
300, 327, Hall E

BUSINESS PARTNERING
Partnering Center (Hall C)

COMPANY PRESENTATION
317

RECEPTION
THE PLATZ

INVEST FAIR
318

Exhibition


Rest Area
N6 N7 N8 N9 N10 N11 N12 N13 N14 N15 N16
Rest Area
N23 N24 N25 N26 N27 N28 N29 N30 N32
M17
A29 A28 A27 A30 A32
B29 B28 B27 B30 B31 B32
C29 C28 C27 C30 C32
D29 D27 D30 D31 D32
E29 E28 E27 E30 E31 E32
F29 F28 F27 F30 F31 F32
G29 G28 G27 G30 G31 G32
H29 H27 H30 H31 H32
I29 I28 I27 I30 I32
J29 J27 J30
K27
A22 A23 A19
B22 B23 B19
C22 C23 C19
D22 D21 D19 D23 D25
E21 E20 E19 E23 E25
F21 F19 F23 F25
G21 G19 G23 G25
H22 H21 H19 H23 H25
I21 I19 I23
J21 J19
K21 K19
L19
M16 M15 M13
Rest Area
M7 M6 M5 M4 M3 M2 M1
Korean Pavilion for Advanced Regenerative Medicine
A14 A11 B11
C14 C11 D11
E14 E11 F13 F11
G14 G13 G12 G11 G18 G17 G16 G15
H14 H13 H12 H11 H18 H17 H16 H15
I11
J13 J11
K14 K11
L11
A5 A4 A6 A7 A1 B1
C5 C4 C6 C7 C1 D1
National Pavilion
E4 E3 E5 E6 E2 E1 E7 E8
F2 F1 F3 F4 F6 F5 F7 F8
G4 G3 G5 G6 G2 G1 G7 G8
Rising Pavilion
H1
I4 I1
K5 K1
L1
Partnering Center
17 18 19 20 21 22 23 24 25
9 10 11 12 13 14 15 16
1 2 3 4 5 6 7 8
S1 S3 S4 S5 S6 S7 S8 S9 S10
34 33 32 31 30 29 28 27 26
42 41 40 39 38 37 36 35
50 49 48 47 46 45 44 43
51 52 53 54 S14 S13 S12 S11 S2
IN
OUT

Exhibitor List

Line A	
Company	Booth NO.
Bavarian Pavilion c/o Bayern International GmbH	A1
Aurigon GmbH	A1
Bayern International	A1
Cluster Biotechnology Bavaria c/o BioPark Regensburg GmbH	A1
FGK Clinical Research GmbH	A1
Granzer Regulatory Consulting & Services	A1
KoMo GmbH	A1
PAN-Biotech GmbH	A1
BIO ASIA—TAIWAN 2025	A4
BioJapan 2025	A5
Symeres drug discovery & development CRMO	A6
THAILAND (VNU Asia Pacific)	A7
Swedish Pavilion	A11
Anocca AB	A11
AstraZeneca Korea	A11
Business Sweden	A11
CCRM Nordic	A11
Cellcolabs	A11
NorthX Biologics	A11
QureTech Bio	A11
Salipro Biotech AB	A11
Biocom California	A14
Korea Innovative Pharmaceutical Company	A19
HANLIM PHARM. CO., LTD.	A19
Janssen Korea Ltd.	A19
Olix Pharmaceuticals, Inc.	A19
Axcelead Drug Discovery Partnerts, Inc.	A22
JCBIO.CO.,Ltd	A23
Microgentas	A27
SG MEDICAL, Inc.	A28
DUKSAN PURE CHEMICALS CO., LTD.	A29
TWIST BIOSCIENCE	A30
Bio Design Lab	A32

Line B	
Company	Booth NO.
Australian National Pavilion	B1
360Biolabs	B1
Acclime Corporate Services Australia Pty Ltd	B1
Amplia Therapeutics	B1
Aucentra Therapeutics	B1
Australian Trade and Investment Commission	B1
Avance Clinical	B1
Avion	B1
Bioforum – The Data Masters	B1
Biointelect Pty Ltd	B1
BIP FOCUS	B1
CMax Clinical Research	B1
Curezma Pharmaceutical	B1
Global Pharma Solutions	B1
GreenLight Clinical Pty Ltd	B1
Harvest Integrated Research Organization (HiRO)	B1
IDT Australia	B1
Invion Limited	B1
Linear Clinical Research	B1
MaH Clinical Trail Solutions	B1
Mobius Medical	B1
Molecule2Market	B1
Nucleus Network Pty Ltd	B1
Peter MacCallum Cancer Centre, Nexomics	B1
Prove Clinical Laboratories Pty Ltd	B1
Resonance Health	B1
Sacco System	B1
Scientia Clinical Research	B1
Southern Star Research Pty Ltd	B1
Taikun Pharmaceutical Technology Pty Ltd	B1
Tissue Repair Ltd	B1
Translational Research Institute (TRI)	B1
TrialKey	B1
Viral Vector Manufacturing Facility Pty Ltd (VVMF)	B1
Netherlands Bio Lounge	B11
2-BBB Medicines BV	B11
Cardialysis B.V.	B11
Embassy of the Kingdom of the Netherlands	B11
IMCD (KOREA)	B11
INTERFLON (KOREA)	B11
Liberi Group	B11
ORCA Therapeutics B.V.	B11
Osteo Pharma B.V.	B11
SeraNovo B.V.	B11
Starodub B.V.	B11
TNO	B11
Yonsei University K-NIBRT	B19
Baobab AiBIO	B19
Epi Biotech Co., Ltd	B19
Industrial Pharmaceutical Sciences	B19
Yonsei Qinitiative	B19
Yonsei University Institute of Advanced Bio-Industry Convergence (Department of Integrative Biotechnology)	B19
Curi Bio	B22
KNR	B23
BOTANIC HEALTHCARE	B27
Cencora PharmaLex	B28
CdmoGen Co., Ltd.	B29
HLB Pep Co., Ltd	B30
ST1	B31
SAPIENSBIO	B32

Line C	
Company	Booth NO.
Embassy of Canada to the Republic of Korea	C1
Acceleration Consortium	C1
Atuka Inc.	C1
CCRM	C1
CIDGOH (Centre for Infectious Disease Genomics and One Health), Simon Fraser University	C1
Juno Pharmaceuticals	C1
QurCan Therapeutics Inc.	C1
Spiderwort Biotechnologies Inc	C1
Variational AI	C1
VIDO (Vaccine and Infectious Disease Organization)	C1
AGILEX BIOLABS	C4
BioCina	C5
NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH	C6
ABL Bio	C11
Prestige Biologics	C14
Kyungpook National University Hospital	C19
Dongguk University	C22

CNUHH-APP	C23
CELLAMES Inc.	C27
Neumous Inc.	C28
InHandPlus	C29
HORIBA KOREA, Ltd.	C30
LAMEDITECH	C32

Line D

Company	Booth NO.
National Institute of Health	D1
DIPS 1000+ project	D11
AIGEN Sciences	D11
Arontier Co., Ltd.	D11
Astrogen, Inc	D11
Autotelic Bio Inc.	D11
Brexogen Inc.	D11
Exollence Co., Ltd	D11
Galux	D11
ILAb Co., Ltd.	D11
Korea Institute of Toxicology	D11
LABnPEOPLE	D11
MEDIAIPLUS, Inc.	D11
Medinno Inc.	D11
MolGenBio Co., Ltd.	D11
MVRIX Co.,Ltd.	D11
ProAbtech Co.,Ltd	D11
Sci-Key Biotech Inc	D11
YOUTH BIO GLOBAL Co., Ltd.	D11
AUMC - CBNU	D19
NOVOTECH ASIA KOREA	D21
BioSolution Co., Ltd.	D22
N-BIOTEK Inc	D23
APROGEN	D25
Miltenyi Biotec	D27
AIVIS Inc.	D29
DKSH Korea Ltd.	D30
C&G UNITY	D32

Line E

Company	Booth NO.
Rising Pavilion	E1
emocog	E1
Kogenebiotech	E2
D&C BIOTECHNOLOGY Inc.	E3
REMEDI Inc.	E4
VPIX Medical	E5
HaplnScience Inc.	E6
MedInTech Inc.	E7
NEURIVE Co., Ltd.	E8
WuXi AppTec Korea	E11
ProBio Korea	E14
Dt&C Bio GROUP	E19
ROKIT Genomics	E20
NPCHEMBIO	E21
APELOA PHARMACEUTICAL	E23
JEON TECH. CO., LTD	E25
Mindstech	E27
KS Medical Inc.	E28
BANSEOK PRECISION IND., CO., LTD.	E29
K LAB Co.,Ltd.	E30
SUNWOO ENG.CO.,LTD	E31
Labnote Scholar	E32

Line F

Company	Booth NO.
HITS Inc	F1
AZothBio	F2
Pharos iBio Co., Ltd.	F3
K-BioCELF Inc.	F4
Calici	F5
Standigm	F6
Inventage Lab Inc.	F7
DR.NOAH BIOTECH	F8
Charles River Laboratories	F11
Robots and Design	F13
Bertis	F19
JEIO TECH Co., Ltd.	F21
BK Instruments Inc.	F23
ZEISS	F25
KYMOS GROUP	F27
New England Biolabs Korea	F28
ORACLE	F29
KOMA BIOTECH	F30
TARGET HEALTH	F31
AGC Biologics	F32

Line G

Company	Booth NO.
AULBIO	G1
GI INNOVATION	G2
YiPSCELL	G3
STEMDEN	G4
RudaCure Co., Ltd	G5
Pharmicell Co., Ltd.	G6
CONNEXT Co., Ltd.	G7
HAll Corp.	G8
Korean Pavilion for Advanced Regenerative Medicine	G11
MEDIPOST	G11
CARM	G12
ExoCoBio Inc.	G13
Thermo Fisher Scientific Solutions	G14
CEFO., CO. Ltd.	G15
Karisbio Inc.	G16
Xcell Therapeutics	G17
CELLinCELLS	G18
CENYX Biotech	G19
Young Science, Inc.	G21
AJINOMOTO CELLiST KOREA CO., INC.	G23
PRECLINA Inc.	G25
HungaroTrial CRO	G27
BioMed Linkage	G28
NEXTROVE KOREA LLC	G29
SYNSMART	G30
CPC Scientific. Inc	G31
Top Cell Bio Health	G32

Line H

Company	Booth NO.
KBIOHealth, iPark Institute	H1
iPark Institute	H1
KBIOHealth	H1

RMAF	H11
LUCASBIO	H12
ENCell Co., Ltd.	H13
Dewcell, Inc.	H14
KOREA FUND FOR REGENERATIVE MEDICINE	H15
KEYFRONBIO/ARDENA	H16
KEYPRIME RESEARCH	H17
BIOTOXTECH	H18
Thermo Fisher Scientific	H19
BIOCYTOGEN	H21
CellPurics, Inc.	H22
DAIHAN FCS Co.,Ltd	H23
FUJIFILM Life Sciences Korea	H25
Evonik Korea	H27
BioDuro	H29
ICE Bioscience	H30
Asymchem Labs.	H31
INTOINWORLD CO., LTD.	H32

Line I

Company	Booth NO.
Celltrion	I1
Chungcheongbuk-do	I4
BloBigData.Korea	I11
WuXi Biologics	I19
GenScript Biotech Korea	I21
FUJIFILM Corporation	I23
Gene Universal	I27
SYMYOO	I28
Cyagen	I29
PCMO	I30
Synex Consulting Ltd.	I32

Line J

Company	Booth NO.
Amgen	J11
PURITECH	J13
ACROBiosystems	J19
CAREGEN CO., LTD.	J21
Health Insurance Review & Assessment Serviece	J27
EverEx	J27
SELTA SQUARE Inc.	J27
SCL Healthcare	J29
Porton Pharma Solutions Ltd.	J30

Line K

Company	Booth NO.
YUHAN Corporation	K1
Sysmex Corporation	K5
Johnson & Johnson	K11
Lonza	K14
ST PHARM	K19
Pharmaron Korea	K21
KCL	K27

Line L

Company	Booth NO.
K-Health MIRAE Initiative	L1
Gangwon Technopark	L11
Capio Biosciences Korea	L11
Cyron Therapeutics	L11
FMC Korea Co	L11
LNPsolution Inc.	L11
Nbios. Inc	L11
NOVAMEDILAB	L11
Peptoide, Inc.	L11
TS Cell Bio.Inc.	L11
Jeonbuk Technopark	L19
Biorheologics Co., Ltd.	L19
CBH Inc.	L19
Healthcare Claims Co., Ltd	L19
Medi N Research.Co.,LTD	L19
namuSum Co.,Ltd.	L19
ORGANELLE Co., Ltd	L19
ViEL-T Inc.	L19

Line M

Company	Booth NO.
BRAND INSTITUTE	M1
KOREA INSTITUTE OF INTELLECTUAL PROPERTY PROMOTION	M2
HELIOD	M3
DLG LAW CORP.	M4
DONGMOON ENT CO.,LTD.	M5
BETHESDASOFT	M6
KH Neochem	M7
Dongwoo-GCS	M13
CHA University Digital Healthcare	M15
DELVEINSIGHT BUSINESS RESEARCH	M16
Gyeonggi Business & Science Accelerator	M17
Blisstech	M17
DSLAB, Inc	M17
Four-O LAB	M17
Medihub Co., Ltd.	M17
Mediimg Inc.	M17
pixelRo	M17
SOCIOTECH Co., Ltd.	M17

Line N

Company	Booth NO.
ORTHOTECH.Co.Ltd	N6
DeepQure	N7
AXXAM SPA	N8
ERBC	N9
P&D Solution & revvity signals	N10
NOVALIX	N11
MABPLEX INTERNATIONAL CO.,LTD	N12
ChemCon GmbH	N13
GemPharmatech	N14
PSI CRO	N15
CHEMSPACE	N16
CYPROTEX|EVOTEC| JUST-EVOTEC BIOLOGICS	N23
CARBOGEN AMCIS	N24
EuBiologics Co., Ltd.	N25
OPIS Research CRO	N26
TruwayBio	N27
KBI BIOPHARMA	N28
BIOINTRON BIOLOGICAL	N29
Honam National Institute of Biological Resources	N30
JEONNAM BIO FOUNDATION	N32
Jeonnam Bio Foundation, Biopharmaceutical Research Center	N32
Jeonnam Bio Foundation, Nano Bio Research Center	N32
Jeonnam Bio Foundation, Natural Resources Research Center	N32

02

Business Partnering

Business Partnering Overview



BIO KOREA 2025 Business Partnering is a core program that offers opportunities to explore partnerships and collaborations with global bio companies, research institutes, and related organizations through 1:1 business meetings. The program actively supports discussions on a wide range of business opportunities and research collaboration proposals within the bio-health industry, including joint research, market entry strategies, and technology transfer.

Business Partnering will be held as face-to-face meetings from May 7 (Wed) to May 9 (Fri), 2025, at COEX, Seoul, providing an effective platform for domestic and international companies to network and achieve tangible business outcomes.

Date	May 7(Wed) ~ 9(Fri), 2025
Venue	Partnering Center, Hall C(3F), COEX
Hour of Operation	May 7(Wed) ~ May 8(Thu) 10:00~17:00, May 9(Fri) 10:00~16:00
Meeting Duration	30 minutes per meeting
Type of Categories	Pharma, Medical Device, Digital Health, Investor, Academic/Non-Profit, Professional Services and Consulting

Partnering Reception

This year, a special 'Partnering Reception' will be newly introduced for Business Partnering participants. The reception will take place at 17:00 on May 8 (Thu) at The Platz, 2nd floor of COEX, offering a valuable opportunity to further strengthen networking and exchanges among participants.

Experience new opportunities for collaboration and business in the global bio-health industry at BIO KOREA 2025 Business Partnering.

Date and Time	17:00~20:00, May 8(Thu), 2025
Venue	The Platz, 2F, COEX
Eligible Access	All Pass Delegates & Business Partnering Registrants
Program	Partnering Networking, Lucky Draw

Partnering Layout



Business Partners

- S2 AMGEN
- S11 sysmex
- S12 BainCapital LIFE SCIENCES
- S13 SOLASTA VENTURES
- S14 DEERFIELD
- S1 Johnson&Johnson
- S3 Boehringer Ingelheim
- S4 Lilly
- S5 MSD
- S6 novo nordisk
- S7 Roche
- S8 PRESTIGE BIOLOGICS
- S9 SK bioscience
- S10 Takeda

List of Partnering Companies

#	
Company	Country
1STBIO Therapeutics	Republic of Korea
2BBB Medicines BV	Netherlands
360biolabs	Australia
3billion	Republic of Korea
3H Bio	Republic of Korea

A	
Company	Country
AbbVie	USA
Abiogenesis Clinpharm Private Limited	India
ABION	Republic of Korea
AbTis	Republic of Korea
Abzena	United Kingdom
Acclime	Australia
ACROBiosystems	Republic of Korea
Adimab	USA
AevisBio, INC	Republic of Korea
Affilogic	France
AGC Biologics	USA
Agilex Biolabs Pty Ltd	Australia
AICLOUD	Republic of Korea
AIGEN Sciences	Republic of Korea
Aimed Bio Inc	Republic of Korea
AIVIS Inc.	Republic of Korea
Ajinomoto CELLiST Korea Co., Inc.	Republic of Korea
AJINOMOTO Co Inc	Japan
AJINOMOTO HEALTHY SUPPLY CO, INC	Japan
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION	Republic of Korea
Aleon Pharma International, Inc	USA
Alphasense	Singapore
Amarex Clinical Research	Republic of Korea
Amenis Bioscience	Republic of Korea
American Business Development	USA
Amgen Korea	Republic of Korea
Amplia Therapeutics	Australia
AnGes, Inc.	Japan
Anocca	Sweden
Antion Biosciences	Switzerland
Antiverse Ltd	United Kingdom
APELOA PHARMACEUTICAL	China
Aprogen	Republic of Korea
Aptamer Sciences, Inc.	Republic of Korea
Arog Pharmaceuticals, Inc	USA
Artixio Lifesciences Private Limited	India
Asahi Kasei Pharma Corporation	Japan
Aston sci. Inc.	Republic of Korea
AstraZeneca	Republic of Korea
Astrion	Republic of Korea
Asymchem Laboratories (Tianjin) Co., Ltd	China
Atuka	Canada
Aucentra Therapeutics	Australia
AULBIO	Republic of Korea
Aurigon GmbH	Germany
Aurigon Labs Ltd	Hungary
Australia State government of Victoria	Republic of Korea
Australian Trade and Investment Commission	Republic of Korea
Autetelic Bio	Republic of Korea
Automed	China
Avance Clinical	Republic of Korea
Avelos Therapeutics	Republic of Korea
Avion	Australia
Axcelead	Japan
Axcelead Drug Discovery Partners, Inc	Japan
AXXAM SPA	Italy
AZothBio	Republic of Korea

B	
Company	Country
Badalone Consulting	Canada
Bain Capital	USA
BANSEOK PRECISION IND., CO., LTD.	Republic of Korea
basgenbio	Republic of Korea
Batavia Biosciences	USA
Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd.	China
BENOBIO	Republic of Korea
Bertis	Republic of Korea
BiBo Pharma	China
Bio Design Lab Co Ltd	Republic of Korea
BIO KOREA	Republic of Korea
Biobankhealing	Republic of Korea
BioCina	Australia
Biocytogen Pharmaceuticals Beijing Co, Ltd	China
BioDlink Biopharm Co, Ltd	China
Bioforum The Data Masters	Australia
Biointelect	Australia
BioMed Linkage Tech Co, Limited	China
Bionsight Inc.	Republic of Korea
BioPark Regensburg GmbH	Germany
BioResearchAI	Republic of Korea
Biorheologics Co, Ltd	Republic of Korea
bioSeedin	USA
BioSpero	Republic of Korea
BiP Focus	Australia
BiP Focus	Republic of Korea
BiSiChem	Republic of Korea
BK Instruments Inc.	Republic of Korea
BL Melanis	Republic of Korea
BLnH	Republic of Korea
Boehringer Ingelheim	Japan
Boehringer Ingelheim Animal Health	Japan
Boostimmune	Republic of Korea
Bora Pharmaceutical CDMO	Republic of Korea
Boryung Corporation	Republic of Korea
Business Sweden	Republic of Korea
Bwave Inc.	Republic of Korea

C	
Company	Country
C Cube Lab, Inc	Republic of Korea
Calici	Republic of Korea
CAMBREX	USA
Carbogen Amcis	Switzerland
Cardialysis BV	Netherlands
CdmoGen Co., Ltd.	Republic of Korea
Cellames Inc	Republic of Korea
Cellcolabs	Sweden
CELLeBRAIN	Republic of Korea
CellenGene Inc	Republic of Korea
CELLinCELLS	Republic of Korea
Celltrion	Republic of Korea
Cellweaverse Co, Ltd	Republic of Korea
Centenaire Biosciences Inc	Republic of Korea
CentricsBio	Republic of Korea
Cenyxbiotech	Republic of Korea
Charles River Laboratories	Republic of Korea
Checkmate Therapeutics	Republic of Korea
ChemCon GmbH	Germany
ChemRar	Russian Federation
Chemspace LLC	Ukraine
CHO PHARMA INC	Taiwan

Chong Kun Dang Pharm.	Republic of Korea
Chonnam National University/ Medispan	Republic of Korea
Chungbuk Free Economic Zone Authority	Republic of Korea
Chungnam National Univ. IUC	Republic of Korea
CKD venture capital	Republic of Korea
Clarivate	Republic of Korea
Clinical Research Organization	Taiwan
CMAX Clinical Research	Australia
CNCure	Republic of Korea
Concept Life Sciences	United Kingdom
Connext	Republic of Korea
CPC Scientific,Inc	USA
CrossPoint Therapeutics	Republic of Korea
CRScube	Republic of Korea
CRU Global	Singapore
CSI Medical Research Pte Ltd	Singapore
Curacle	Republic of Korea
CUREZMA PHARMACEUTICAL SOLUTIONS	Australia
Curie Bio	USA
Curigin	Republic of Korea
Curocell	Republic of Korea
Curome Biosciences Inc	Republic of Korea
Cyagen	Republic of Korea
Cyprotex Discovery - Macclesfield, Cheshire	United Kingdom

D

Company	Country
Daiichi Sankyo	Japan
Dark Horse Consulting	Singapore
DeepQure Inc.	Republic of Korea
deepsonbio	Republic of Korea
DelveInsight Business Research LLP	India
Digmbio	Republic of Korea
Divamics Inc	China
DLG Law Corporation	Republic of Korea
DnC Biotechnology	Republic of Korea
DONGBANG FUTURE TECH & LIFE CO., LTD.	Republic of Korea
DongWha Pharm	Republic of Korea
Dongwoo-GCS	Republic of Korea
DR NOAH BIOTECH Inc	Republic of Korea
DRK Pharma solutions	Switzerland
DtnC Bio GROUP	Republic of Korea
DxVx	Republic of Korea

E

Company	Country
Edgene, Inc	Republic of Korea
EFIL BioScience Inc	Republic of Korea
Eli Lilly	Japan
Embassy of Canada to the Republic of Korea	Republic of Korea
Embassy of the Kingdom of the Netherlands	Netherlands
Emerald Clinical Trials	Japan
Emocog	Republic of Korea
Empire State Development South Korea Office	Republic of Korea
Enamine Ltd	Ukraine
ENCELL Co. Ltd.	Republic of Korea
Enmore Healthcare	China
EONE laboratories	Republic of Korea
EverEx	Republic of Korea
Evotec	France
Evotec SE	Germany
Experimental Drug Development Center (EDDC)	Singapore

F

Company	Country
FGK Clinical Research GmbH	Germany
FieldCure	Republic of Korea
FUJIFILM Diosynth Biotechnologies Japan	Japan
Fujifilm Pharmaceuticals USA, Inc	USA
FUJIFILM Toyama Chemical Co.,Ltd.	Japan

G

Company	Country
G2GBIO	Republic of Korea
Galux	Republic of Korea
GC Biopharma	Republic of Korea
GC Cell	Republic of Korea
GCCL	Republic of Korea
GemPharmatech	USA
Genetox Inc	Republic of Korea
Genexine	Republic of Korea
Genixcure Inc	Republic of Korea
Gensenta	Türkiye
Genuine Biotech	China
GEROPHARM	Russian Federation
GI INNOVATION	Republic of Korea
Gifted Molecular Science	Republic of Korea
Global Brain	United Kingdom
Global Pharma Solutions	Australia
Good T Cells, Inc	Republic of Korea
Government of Ontario, Canada	Republic of Korea
Government of Western Australia	Republic of Korea
Gradiant Bioconvergence	Republic of Korea
Granzer Pharmaceutical Services GmbH	Germany
Granzer Regulatory Consulting Services GmbH	Germany
Great Bay Bio Limited	Hong Kong
Greenlight Clinical Pty Ltd	Australia
Guardant Health	USA

H

Company	Country
HAll Corp	Republic of Korea
Hanmi Fine Chemical	Republic of Korea
HapInScience Inc.	Republic of Korea
Harvest Integrated Research Organization (HiRO)	Republic of Korea
Health Advances	Hong Kong
Healthcare Claims Co, Ltd	Republic of Korea
Hetero Lab Korea	Republic of Korea
HITS Inc	Republic of Korea
HK innoN	Republic of Korea
HLB PEP	Republic of Korea
HORIBA KOREA, Ltd.	Republic of Korea
Humanase	Republic of Korea
HungaroTrial CRO	Hungary

I

Company	Country
ICE Bioscience	China
Ice Miller LLP	USA
Ideals	China
IDT Australia Ltd	Australia
IEUMBIO	Republic of Korea
Iktos	France
iLAb Co, Ltd	Republic of Korea
Ildong Pharmaceutical Co Ltd	Republic of Korea
IMBiologics	Republic of Korea
IMCD KOREA	Republic of Korea
ImmunAbs	Republic of Korea
Industry-Academic Cooperation Foundation of Kyungpook National University	Republic of Korea
Ingenium Therapeutics Inc	Republic of Korea
InnoPharmaScreen	Republic of Korea
Insilico Medicine	China

INTERFLON KOREA	Republic of Korea
Intertek	United Kingdom
IntoCell, Inc	Republic of Korea
IntoInworld Co., Ltd.	Republic of Korea
Inventage lab	Republic of Korea
Invion	Australia
InVitria	USA
iPark Institute Co, Ltd	Japan
IPON	Republic of Korea
IQHQ	USA

J

Company	Country
JD Bioscience	Republic of Korea
JEIL PHARMACEUTICAL	Republic of Korea
Jeonnam Bio Foundation	Republic of Korea
Johnson & Johnson	Republic of Korea
Johnson and Johnson Innovation	Japan
JRF International Limited	India
Juno Pharmaceuticals/Cpoint Capital	Canada

K

Company	Country
Kairos Bioconsulting LLC	Republic of Korea
KAKEN Pharmaceutical co, Ltd	Japan
KANAPH Therapeutics Inc	Republic of Korea
Karisbio Inc.	Republic of Korea
KBI Biopharma	Republic of Korea
K-BioCELF Inc.	Republic of Korea
KFRM	Republic of Korea
KH Neochem	Japan
KHIDI USA	USA
KINESCIENCES	Republic of Korea
King's College London	United Kingdom
KOLON LIFE SCIENCE, INC.	Republic of Korea
KOMA BIOTECH	Republic of Korea
Korea Brain Research Institute	Republic of Korea
KOREA DRUG DEVELOPMENT FUND	Republic of Korea
Korea Fund for Regenerative Medicine	Republic of Korea
Korea Institute of Science and Technology	Republic of Korea
Korea Otsuka Pharmaceutical	Republic of Korea
KOREA UNIVERSITY MEDICINE	Republic of Korea
KYMOS GROUP	Republic of Korea
K—MEDI hub	Republic of Korea

L

Company	Country
Laboratorios Silanes	Mexico
LAMEDITECH	Republic of Korea
Laurus Bio Pvt Ltd	India
LG Chem	Republic of Korea
Liberi Group	Netherlands

M

Company	Country
MaH Clinical Trial Solutions	Australia
MATICA Biolabs	Republic of Korea
MD Anderson Cancer Center	USA
MEDIAIPLUS	Republic of Korea
MediMabBio	Republic of Korea
Medinno Inc	Republic of Korea
MEDIPOST	Republic of Korea
Mewburn Ellis LLP	United Kingdom
microdigital	Republic of Korea
MINT Venture Partners	Republic of Korea
Mitoimmune Therapeutics	Republic of Korea
MMV Medicines for Malaria Venture	Switzerland
Mobius Medical	Australia
Molecule2Market	Australia
MSD	Australia
Mthera Pharma	Republic of Korea
MTPConnect	Australia
Mustbio	Republic of Korea
Myriad Partners	Republic of Korea

N

Company	Country
namuSum Co,Ltd	Republic of Korea
National Cancer Center	Republic of Korea
National Institute of Health	Republic of Korea
National Institute of Health and Care Research	United Kingdom
N-BIOTEK	Republic of Korea
Neortesbio Inc	Republic of Korea
Neumous Inc.	Republic of Korea
NEURIVE Co, Ltd	Republic of Korea
NEUROPHET	Republic of Korea
New England Biolabs Korea	Republic of Korea
NEX-I	Republic of Korea
NEXTROVE KOREA LLC	Republic of Korea
Nihon Servier	Japan
Nippon Shinyaku	Japan
Nobo Medicine	Republic of Korea
Nona Biosciences US, Inc	Japan
NorthX Biologics	Sweden
Novacell Technology Inc	Republic of Korea
Novalix	France
NovMetaPharma	Republic of Korea
Novo Nordisk	China
Novotech Asia Korea	Republic of Korea
NPChemBio	Republic of Korea
Nucleus Network Pty Ltd	Australia
NuriScience Inc.	Republic of Korea
NUTSHELL THERAPEUTICS	USA

O

Company	Country
OBI Pharma, Inc	Taiwan
OliX Pharmaceuticals	Republic of Korea
OmniAb	Singapore
OncoLab Co, Ltd	Republic of Korea
Oncomaster	Republic of Korea
OneSource Specialty Pharma	India
ONO Pharma	Japan
OPIS srl	Poland
Orbimed	China
ORCA Therapeutics BV	Netherlands
Orum Therapeutics	USA
OsteoPharma BV	Netherlands
Otsuka Pharmaceutical Factory, Inc	Japan
Oxford Vacmedix	United Kingdom

P

Company	Country
PADO IP Law Firm	Republic of Korea
PAEAN BIOTECHNOLOGY INC	Republic of Korea
PAN-Biotech GmbH	Germany
PathoQuest	France
PCMO	Republic of Korea
Peptron Inc	Republic of Korea
Perceptive	Republic of Korea
Peter MacCallum Cancer Centre	Australia
Pfizer	USA
PharmaLex	Australia
pharmalink	United Arab Emirates
Pharmaron Korea	Republic of Korea
PHARMASPHERE	USA
Pharmgen science	Republic of Korea
Pharmicell Co Ltd	Republic of Korea
Pharos iBio	Republic of Korea
Pin Therapeutics	Republic of Korea
Piramal Pharma Solutions	Japan

Porton Pharma Solutions Ltd.	China
Portrai Inc	Republic of Korea
PPD by Thermo Fisher Scientific	Netherlands
Prazer Therapeutics	Republic of Korea
Preclina Inc.	Republic of Korea
Prestige Biologics	Republic of Korea
ProAbTech Co., Ltd.	Republic of Korea
ProBio Korea	Republic of Korea
Progeneer	Republic of Korea
ProImmune Limited	Singapore
Protierbiotech	Republic of Korea
Prove Clinical Laboratories Pty Ltd	Australia
PSI CRO Korea	Republic of Korea

Q

Company	Country
Quantoom Biosciences	Singapore
Quantum House Australia	Australia
QurCan Therapeutics	Canada
QureTech Bio	Sweden

R

Company	Country
RAPHAS	Republic of Korea
Ravis Technology	Thailand
Recerise Therapeutics	Republic of Korea
REMEDI INC	Republic of Korea
Revvity Japan Co, Ltd	Japan
RM Global Partners	USA
Roche	Republic of Korea
ROKIT Genomics	Republic of Korea
RudaCure	Republic of Korea

S

Company	Country
S&K Therapeutics	Republic of Korea
Sacco System Australia Pty Ltd	Australia
Salipro Biotech AB	Sweden
Samsung Medical Center	Republic of Korea
Sanofi	China
SANWA KAGAKU KENKYUSHO CO, LTD	Japan
SapiensBio	Republic of Korea
Scendea AUS PTY Limited	Australia
Schrodinger	USA
SCICLONE PHARMACEUTICALS (CHINA) CO., LTD.	China
Scientia Clinical Research	Australia
SDNK Holdings	Republic of Korea
Selvita	Poland
Senelix co ltd	Republic of Korea
Senju Pharmaceutical Co, Ltd	Japan
SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL	Republic of Korea
SeraNovo	Netherlands
SERVIER	China
SG Medical, Inc.	Republic of Korea
Shanghai YAFO Capital	China
Shaperon Inc	Republic of Korea
SHIFTBIO	Republic of Korea
Shin Poong Pharm Co, Ltd	Republic of Korea
Siegfried AG	Switzerland
SK bioscience	Republic of Korea
SML Biopharm	Republic of Korea
Southern Star Research	Australia
Spiderwort Biotechnologies Inc	Canada
SpringerNature	Republic of Korea
ST PHARM	Republic of Korea
ST1 Co., Ltd.	Republic of Korea
Standigm	Republic of Korea
Starodub BV	Netherlands
StemDen	Republic of Korea
SuperNOVA Clinical Research, Inc	USA
Suzhou Truway Biotechnology Inc.	China
Symeres	Netherlands
SYMYOO	Republic of Korea
Syngene International Ltd	India
SYNSMART RASAYAN RESEARCH PVT LTD	India
Syntekabio	Republic of Korea
SyVento BioTech	Poland

T

Company	Country
Tadpole Bio Pty Ltd	Australia
TaiGen Biotechnology Co, Ltd	Taiwan
Taikun Pharmaceutical Technology Pty Ltd	Australia
Takeda Pharmaceutical	Japan
Tenshi Kaizen Private Limited	India
Texcell Asia	Taiwan
The Rosalind Franklin Institute	United Kingdom
Thermo Fisher Scientific	China
TNO	Netherlands
Toregem BioPharma	Japan
Trade and Invest BC – Korea Office	Republic of Korea
Trade and Investment Queensland	Republic of Korea
Translational Research Institute	Australia
TransPerfect	China
TransPerfect International LLC	USA
TrialKey	Australia
Turn Bio	USA
TWINPIG BIOLAB, INC	Republic of Korea
Twinpig Biolab, INC	Republic of Korea
Twist Bioscience	Singapore

V

Company	Country
Vaccine and Infectious Disease Organization (VIDO)	Canada
Variational AI Inc	Canada
VAXCELL-BIO CO., LTD.	Republic of Korea
VelocityHealth LLC	Taiwan
Venable LLP	USA
Venture Valuation/Biotechgate	Switzerland
ViELT	Republic of Korea
Viral Vector Manufacturing Facility	Australia
Vivozon Pharmaceutical Co, Ltd	Republic of Korea
VNU Asia Pacific	Thailand
VPIX Medical	Republic of Korea
VSPharmTech	Republic of Korea

W

Company	Country
Wacker Biotech	Germany
WEnnovation	Republic of Korea
WittGen Inc	Republic of Korea
WuXi Biologics	China

X-Z

Company	Country
Xsphera Biosciences	USA
Yonsei University Health System	Republic of Korea
Yuhan Corporation	Republic of Korea
ZEISS	Republic of Korea
Zentiva Group, as	Czech Republic
Zhejiang Jiuzhou Pharmaceutical Co,Ltd	Republic of Korea
ZOETIS	India
Zoetis	USA

03

Invest Fair

BIO KOREA
KOREA 2025

Invest Fair Overview

An opportunity to provide the latest investment trends and strategies in the bio-health industry, and to support technology presentations by innovative domestic and foreign companies and network exchanges between investors and companies.

DATE & VENUE	May 7(Wed) - May 8(Thu), 2025 | Room 318 (3F), COEX
SESSION	· Global Trends in Bio Investment · Strategies for Expanding into Asia and Attracting Investment · Introduction to Saudi Arabia's Biotechnology Vision 2030 · Innovative Korean Bio Startups Pitching (1) · Korea Innovation QuickFire Challenge: Outcomes and Case Highlights · NewCo Creations & Cross Border Deals · Strategies for Entering the European Market and Attracting Investment · Innovative Korean Bio Startups Pitching (2)
OFFICIAL LANGUAGES	English, Korean

May 7(Wed), 13:30~17:00, Rm.318

Day1. New Horizons: Shifting Bio Investments to the Middle East and Asia		
13:30-14:10	**Session1.** Global Trends in Bio Investment	**Hyojin Park** Senior Consultant Clarivate
14:20-15:00	**Session2.** Strategies for Expanding into Asia and Attracting Investment	**Billy Cho** Senior Managing Director, PE and Head of JVC CBC Group
15:10-15:50	**Session3.** Introduction to Saudi Arabia's Biotechnology Vision 2030	**Hesham M. Almasaud(TBD)** Deputy Director, Korea Desk Ministry of Investment of Saudi Arabia (MISA)
16:00~17:00	**Session4.** Innovative Korean Bio Startups Pitching	**Innovative company IR**

May 8(Thu), 10:00~17:00, Rm.318

Day2. Breaking Barriers: Winning Strategies in Western Bio Markets		
10:00~12:00	**Session5.** Korea Innovation QuickFire Challenge: Outcomes and Case Highlights	**Sharon Chan** VP J&J Innovation – JLABS Asia Pacific
12:00~13:20	Break Time	
13:20 - 14:20	**Session6**. NewCo Creations & Cross Border Deals	**Derek Yoon** President & CEO Solasta Ventures, Inc. **Evan Greif** Principal Bain Capital **Jason Fuller** Partner Deerfield
14:30-15:50	**Session7**. Strategies for Entering the European Market and Attracting Investment	**Department for Business and Trade (DBT)** **Mr. Bob Damms** Senior Life Science Investment Advisor UK - Department for Business & Trade **Ms. Alexandra Esteras** King's College London Industry Research Partnerships **Ms. Laura Holland** The Rosalind Franklin Institute Director of Strategic Marketing **Mr. Casey Kee-Choel Chang** Neuracle Science CFO **Minsik Spencer Kong** SD&K Holdings Managing Director
16:00~17:00	**Session8**. Innovative Korean Bio Startups Pitching	**Innovative company IR**

04

Conference

BIO KOREA
KOREA 2025

BIO KOREA
KOREA 2025

The BIO KOREA 2025 Conference is an international forum where global bio-health companies and experts gather to explore the latest technological trends and innovations. This year's program features 11 major themes:

AI-Based Drug Development, New Drug Modalities, Regenerative Medicine, Brain-Computer Interface (BCI), Space Biotechnology, Anti-Aging and Rejuvenation, Clinical Trials, Bio-Digital Convergence, Alternative Toxicology, Global Bio Governance, and Global Open Innovation—all explored through the lens of 2025's evolving technological and policy landscape.

Core topics such as AI-Based Drug Development, Regenerative Medicine, New Drug Modalities, and Bio-Digital Convergence will be reexamined under a new paradigm shaped by generative AI, robotics, regulatory shifts, and digital transformation—shedding light on how these areas are transforming from research innovation into scalable, real-world solutions.

Meanwhile, emerging topics such as BCI, Anti-Aging, Space Biotechnology, and Alternative Toxicology highlight the industry's potential for high-value, next-generation breakthroughs across healthcare, longevity, and space bioscience.

With active participation from leading multinational pharmaceutical companies and top Korean biotech firms, the conference will present real-world collaboration cases, strategic insights, market expansion opportunities, and investment outlooks.

BIO KOREA 2025 serves as a practical and strategic business platform for innovation and global cooperation in the bio-health sector.

BIO KOREA 2025 will take place from May 7 to 9 at COEX in Seoul.

DATE	May 7(Wed) ~ 9(Fri), 2025
VENUE	Conference Room 3F, 4F, COEX
EXPECTED NO. OF PARTICIPANT	Approximately, 4,500 experts from Bio industry, Research Institutes, Academia, and interested individuals from all over the world.
CATEGORIES ELIGIBLE TO ATTEND	* Conference Sessions: All Pass, Conference Pass * Open Sessions/Company Presentations: Visitor and the above
OFFICIAL LANGUAGES	English, Korean

Conference Session

Innovative Biotechnology | Bio-Convergence Technology | Business & Development

May 7 (Wed)

Time	Rm.401	Rm.307	Rm.308
AM	Keynote Speech 10:30~11:20		
PM	**AI-based New Drug Development** S1. 13:30~17:00 AI-Driven Drug Development: A Journey Towards Viable Solutions	**Brain-Computer Interface** S2. 13:30~17:00 The Great Connection of the 21st Century: Brain-Computer Interface (BCI)	**Regenerative Medicine** S3. 13:30~17:00 Advanced Regenerative Medicine: The Beginning of a New Medical Paradigm

May 8 (Thu)

Time	Rm.401	Rm.307	Rm.308
AM	**Open Innovation – Pharmaceuticals** S4. 09:30~11:40 The Key to Innovation: Global Open Innovation Strategy	**Global Bio Governance** S6. 09:30~11:40 Global Bio Governance 2025: Change and Future	**Regenerative Medicine** S8. 09:30~11:45 Strengthening the Competitiveness of Domestic Regenerative Medicine by Discovering Outstanding New Technologies for Cutting-edge Regenerative Medicine
		[Luncheon] Global BIO Connection	
PM	**New Drug Modality** S5. 13:00~17:00 The Rise of New Modalities: A Game Changer in Drug Development	**Global Bio Governance** S7. 13:30~16:00 Strategies for Sustainable Global Biopharmaceutical Approval	**Space Biotechnology** S9. 13:30~17:00 Life Sciences in Space: A New Horizon for Biohealth

May 9 (Fri)

Time	Rm.401	Rm.307	Rm.308
AM	**Anti-aging and Rejuvenation** S10. 09:30~12:00 Innovative Aging Control Technologies: Immunity, Diagnostics, and Evaluation Platforms	**Clinical Trial** S12. 09:30~12:00 Evolving Global Trends and New Technologies in Clinical Trials	**Preclinical – Alternative Toxicology Solutions** S14. 09:30~15:35 Alternative Toxicity Testing: Our Choice and Challenges for Leading the Future Bio Market
PM	**Anti-aging and Rejuvenation** S11. 13:30~15:30 The Present and Future of Reverse-aging Technologies	**Bio-Digital Convergence Technology** S13. 13:00~16:00 Beyond Innovation: The Path to Successful Clinical Adoption and Market Expansion of Digital Therapy	

※ This program is subject to change depending on internal circumstances.

Open Session

	Rm.300	Rm.327	Rm.E1	Rm.E2~E3	Rm.E4	Rm.E5	Rm.E6
Day 1 May 7 (Wed)	**OS1.** Golden Triangle Open Innovation: Korea-UK-Japan Trilateral Collaboration in Life-Science-Digital-Health 13:00~17:30	**OS2.** Workshop on Strategic Collaboration between Korea and Saudi Arabia: Propelling the Growth of Global Biohubs 13:00~17:30	**OS3.** Healthy Aging: Advancing Science for Longevity 13:00~17:00	**OS4.** K-BIC Venture Café 12:00~13:00	**OS5.** 2025 Spring Bio-health Policy and Research Forum 14:00~15:40	**OS6.** Advancing Biopharmaceutical Research, Manufacturing, and Workforce Development 15:10~17:10	
Day 2 May 8 (Thu)	**OS9.** Canada's Thriving Life Sciences: Innovation and Collaboration from British Columbia to Beyond 13:30~14:20 **OS10.** Global ATMP Forum 14:30~16:30	**OS11.** 2025 Joint Session on Regenerative Medicine Institution Designation and Regenerative Medical Treatment System 14:00~16:15	**OS12.** Current Status and Strategy of BioBigData.Korea 13:30~16:50			**OS13.** Global Pharma Supply Chian from Industry Perspective 13:40~17:00	**OS14.** 2025 BioHealth Commercialization Promising Technology Briefing Session 14:00~16:05
Day 3 May 9 (Fri)	**OS15.** AI Research Cases Utilizing Healthcare Data from the National Institute of Health 09:30~11:30						

Company Presentation

Time	May 7 (Wed) Rm.317	May 8 (Thu) Rm.317	May 9 (Fri) Rm.317
10:00~11:00		AMGEN	MSD
11:00~11:10			Break
11:10~12:10			Sysmex
12:10~13:30	Lunch Break		
13:30~14:30	Johnson & Johnson * Registration begins at 13:30 * Session begins at 14:00	ST PHARM	
14:30~14:40		Break	
14:40~15:40		ACROBiosystems	
15:40~15:50			
15:50~16:50			

※ This program is subject to change depending on internal circumstances.

Keynote Speaker



Can AI and robotics create a drug and extend life?

Alex Zhavoronkov

Insilico Medicine
Founder and CEO

May 7 (Wed) 10:30~11:20 / Rm. 401

#AI #Drug discovery & development
#Generative biology

Speech Abstract

The process of discovering and developing a drug usually takes decades, costs over two billion dollars, and fails more than ninety percent of the time. Every step from disease modeling, target discovery, target-to-hit, hit-to-lead, lead optimization, preclinical candidate nomination, and preclinical studies, as well as Phase I, Phase II, and Phase III studies in humans, have defined average costs and probabilities of failure. All of these steps can be supported and augmented with AI.
Generative AI and robotics can substantially improve the success rate, reduce the cost, and accelerate pharmaceutical R&D. Our end-to-end platform, Pharma.AI, integrates biology, chemistry, medicine, robotics, and materials science, and has already produced over 20 preclinical candidates, and a completed Phase 2a study. To accelerate experimental validation, we established a fully-automated robotics lab, LifeStar1, and developed a multi-agent research platform, DORA, capable of generating research outputs including reports and manuscripts. In this talk, I will cover the applications of AI and next-generation laboratory robotics in therapeutic target discovery, small molecule generation, and aging research. I will review several case studies and the current state of the industry, while discussing its limitations and development opportunities. I will also highlight successful collaborations with global pharmaceutical companies, research institutions, and government agencies that demonstrate the real-world impact and scalability of our technologies.

* The Keynote Speech is open to all participants with VISITOR or above.

Professional Experience

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data. He also pioneered the applications of transformers and other deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated more than 20 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule.

Prior to founding Insilico, he worked in senior roles at ATI Technologies (GPU company acquired by AMD). Since 2012, he has published over 200 peer-reviewed research papers with over 30 papers in the field of generative adversarial networks, generative reinforcement learning, and multi-modal transformers, and 3 books, including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Macmillan, 2013). He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, and Frontiers in Genetics, and founded and co-chairs the Annual Aging Research and Drug Discovery (11th Annual in 2024), the world’s largest event on aging research in the biotechnology industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

SESSION 01

AI-Driven Drug Development: A Journey Towards Viable Solutions

Sharing Practical Achievements and New Possibilities in the Drug Development Ecosystem through AI and Converging Technologies

May 7 (Wed), 13:30~17:00 / Rm. 401

More detail ▲

The application of AI technology in drug development is significantly reducing the immense time and costs involved, enhancing efficiency and driving continued global investment. By 2030, the global AI-driven drug discovery market is expected to grow at an annual rate of 30%, reaching approximately 10 trillion KRW. Global big tech such as Google, Amazon, and Nvidia are actively developing AI platforms for drug discovery, providing them to pharmaceutical companies or engaging in collaborative research efforts. With the 2024 Nobel Prize in Chemistry awarded to scientists who developed AI-powered 3D protein structure prediction technology, the AI-driven drug discovery sector is anticipated to experience explosive growth, ushering in a new era of paradigm shifts in research methodologies. This session will delve into how AI is transforming the drug development process, explore real-world applications and future potential, and address key legal issues related to patents and data governance. Together, we will engage in an in-depth discussion to identify practical and implementable solutions in this rapidly evolving landscape.

Session Chair	**Jae-Mun Choi , CEO, Calici**
13:30 ~ 14:00	**Global Trends in AI-Driven Drug Discovery and the Path Forward for Pharmaceutical and Biotech Companies** Junhee Pyo, Vice Head of Research Institute, Convergence AI Institute for Drug Discovery, Korea Pharmaceutical and Bio-Pharma Manufacturers Association
14:00 ~ 14:30	**Accelerating Discovery with Self-Driving Labs** Brandon Sutherland, Director, Research Operations, University of Toronto, Acceleration Consortium
14:30 ~ 15:00	**Accelerate Generative AI applications in Drug Discovery and Life Sciences** Tianjing Zhang, Developer Relations Manager, APAC Lead, Healthcare Start-ups, NVIDIA
15:00 ~ 15:10	Break
15:10 ~ 15:40	**Legal Issues in AI based New Drug Development** Eui Seok Kim, Member of the Korean Bar, KIM & CHANG
15:40 ~ 16:10	**AI-driven Drug Discovery in the LLM Era** Jaewoo Kang, CEO, AIGEN Sciences
16:10 ~ 16:40	**AI Drug Discovery Platform and Its Application: CHEMIVERSE** KyYoub Nam, CTO, R&D Center, Pharos iBio
16:40 ~ 17:00	**Panel Discussion**

SESSION 02

The Great Connection of the 21st Century: Brain-Computer Interface (BCI)

Global Innovation Trends and Future Technological Prospects of Brain–Computer Interface (BCI)

May 7 (Wed), 13:30~17:00 / Rm. 307

More detail ▲

The global competition in the brain-computer interface (BCI) market is heating up, driven by Elon Musk's Neuralink. Neuralink has attracted investments totaling $600 million to date, while its competitor, Synchron, has secured significant funding from venture capital firms led by Bill Gates and Jeff Bezos. In November of last year, Precision Neuroscience, a spin-off from Neuralink, announced its success in raising 130 billion KRW. These companies have already obtained FDA approval for clinical trials and are progressing toward the commercialization of BCI technology for human use. Efforts to commercialize BCI technology have also begun in South Korea, with startups being established one by one. This session aims to introduce global innovation trends in BCI technology, as well as the current state of BCI industrialization in Korea and future technological prospects.

Session Chair	**ChangHwan Im, Professor, Department of Biomedical Engineering, Hanyang University**
13:30 ~ 14:00	**Introduction to Brain-Computer Interfaces and the Current State of Technology and Industry in Korea** ChangHwan Im, Professor, Department of Biomedical Engineering, Hanyang University
14:00 ~ 14:30	**Wireless Microsystems for Communication with a Brain** Il-Joo Cho, Professor, School of Medicine, Korea University
14:30 ~ 15:00	**Industry-driven BCI Development in South Korea : Healthcare and Beyond** Kiwon Lee, CEO, Ybrain
15:00 ~ 15:10	Break
15:10 ~ 15:40	**Personalized Mental Health Evaluation and Intervention Using BCI Technology: Introducing Bwave's MindCare Platform and EBSI-Matched Digital Therapeutics** Seung Hwan Lee, CEO, Bwave Inc.
15:40 ~ 16:10	**Industrialization of Brain-Computer Interfaces in China** Bo Hong, Professor, Biomedical Engineering, Tsinghua University
16:10 ~ 16:40	**BCI Regulation: Trends and Implications** Jeong Yeon Park, Associate Professor, Hankyong National University
16:40 ~ 17:00	**Panel Discussion**

SESSION 03

Advanced Regenerative Medicine: The Beginning of a New Medical Paradigm

May 7 (Wed), 13:30~17:00 / Rm. 308

More detail ▲

With regards to the full-scale implementation of the Advanced Regenerative-Bio Act Amenment(effective as of February 2025), this session will provide the main contents of the Amendment, guidelines and indicators after the Act's enforcement, and examine the macro and micro impacts on the bio industry. We will introduce major issues, including implications for stakeholders such as government, researchers, companies, and patients, and analyze the impact of legal and institutional changes on the field of regenerative medicine; thereby expecting to provide a networking platform for stakeholders in the medical community, researchers, and industry to discuss new opportunities and challenges, and ultimately contribute to strengthening the sustainability and global competitiveness of the regenerative medicine.

Session Chair	**So Ra Park, President, Regenerative Medicine Acceleration Foundation**
13:30 ~ 14:00	**Current Status and Future Direction of Policies Supporting Advanced Regenerative Medicine** SunGill Jung, Director, Regenerative Medicine Policy Division, Korean Ministry of Health and Welfare
14:00 ~ 14:30	**The Act on the Safety of Regenerative Medicine in Japan** Morikuni Tobita, Associate Professor(DDS, PhD), Medical Technology Innovation Center, Juntendo University
14:30 ~ 15:00	**Current Status of South Korea's Advanced Regenerative Medicine Industry and Strategies for Development through Collaboration** KyoungHwan Roh, Member, Policy Committee, CARM
15:00 ~ 15:10	Break
15:10 ~ 15:40	**Current Environment and Trends in Regenerative Medicine Products in Japan -How FIRM is Tackling with the Hurdles Toward Industrialization-** Yoshitsugu Shitaka, Chairperson, FIRM/Astellas Pharma Inc.
15:40 ~ 16:10	**A Swedish Perspective on the European ATMP Ecosystem** Jim Lund, Chief Business Development Officer, CCRM(Centre for Commercialization of Regenerative Medicine) Nordic
16:10 ~ 16:40	**Global Collaboration in Cell and Gene Therapy: The CCRM Model is Needed Now More than Ever** Michael H May, President & CEO, Cell&Gene Therapies, CCRM (Centre for Commercialization of Regenerative Medicine)
16:40 ~ 17:00	**Panel Discussion**

SESSION 04

The Key to Innovation: Global Open Innovation Strategy

May 8 (Thu), 09:30~11:40 / Rm. 401

More detail ▲

In the rapidly evolving pharmaceutical and biotechnology industries, open innovation has become a key strategy for driving innovation, accelerating drug development, and maximizing resource efficiency. Beyond simple research and development (R&D) collaborations, open innovation serves as an essential factor for sustainable growth and industry leadership. To remain competitive in this rapidly changing environment, not only global pharmaceutical companies but also small and mid-sized biotech firms must actively leverage various forms of open innovation, including licensing, joint R&D, partnerships with startups, digital healthcare, and AI-driven technologies. To effectively utilize open innovation, companies must establish strategic direction, build collaborative models, conduct technology evaluation and licensing strategies, and understand contractual and regulatory considerations. Thorough preparation is essential for fostering successful global partnerships. This session will explore the latest trends in open innovation within the global pharmaceutical and biotech industries. By examining successful case studies, we will delve into practical strategies for collaboration, licensing, and joint R&D, providing actionable insights for industry professionals.

Session Chair	**Minji Kim, President, Cross Border Partners, LLC**
09:30 ~ 09:50	**Beyond Borders: Unlocking Global Open Innovation in Biopharma** Minji Kim, President, Cross Border Partners, LLC
09:50 ~ 10:00	**E2I - External & Exploratory Innovation** Ja Young Kim, Innovation Lead, BioInnovation Hub, Novo Nordisk US R&D
10:00 ~ 10:10	**AstraZeneca BioVentureHub: A New Paradigm in Open Innovation for Big Pharma and SMEs** Magnus Björsne, CEO, AstraZeneca BioVentureHub
10:10 ~ 10:20	**Collaborate to Innovate - Partnering with Bayer Pharmaceuticals** Friedemann Janus, SVP, Head of Business Development & Licensing, Co.Lab, Regional and Divestitures, Bayer
10:20 ~ 10:30	**Open Innovation to Accelerate New Medicines for Patients** Oliver Kast, Global Head Oncology Business Development and Licensing, Business Development and Licensing, Boehringer Ingelheim International GmbH
10:30 ~ 10:40	**Better Molecules, Faster: Unlocking Innovation Through Collaboration with Schrödinger** Hamish Wright, Senior Vice President, Translational Science and Therapeutics Business Development, Schrödinger
10:40 ~ 11:00	**Streamlining Biotech Licensing and Partnerships** Sean Kim, Partner, Ice Miller LLP
11:00 ~ 11:40	**Panel Discussion**

SESSION 05

The Rise of New Modalities: A Game Changer in Drug Development

May 8 (Thu), 13:00~17:00 / Rm. 401

More detail ▲

The rise of new modalities is creating a major turning point across the pharmaceutical and biotech industries, going beyond the traditional framework of drug development.Innovative treatment approaches such as CAR-T, mRNA, gene and cell therapies, and antibody-drug conjugates (ADCs) are rapidly advancing, moving past the conventional focus on small molecules and biologics.This session brings together leaders from global pharmaceutical companies, law firms, investment firms, and promising domestic biotech ventures to explore the core concepts and latest trends in new modalities. The discussion will delve into how these approaches are expanding the paradigm of drug development, and examine the challenges and opportunities faced during the research, development (R&D), and commercialization stages.

Session Chair	**Byoung-Chul Lee, CEO, KANAPH Therapeutics Inc**	
13:00 ~ 13:30	**Opportunities and Prospects for New Modalities** Young-Min Park, CEO, Korea Drug Development Fund	
13:30 ~ 13:50	**Advancing Cell and Gene Therapy** Friedemann Janus, SVP, Head of Regional Business Development & Licensing, Co.Lab, Regional and Divestitures, Bayer	
13:50 ~ 14:10	**Collaborate to Innovate** Koji Yashiro, Director, Business Development and Licensing, MSD	
14:10 ~ 14:30	**From Molecules to Platform: The Vertical Revolution in Pharma** Junghee Lim, Managing Director, Bioteam, InterVest	
14:30 ~ 14:50	Alex Chung, Partner, Sheppard Mullin	
14:50 ~ 15:10	**IntoCell ADC Platform Technology: OHPAS, PMT, and Nexatecan** YOSUP REW, CTO/EVP, R&D, IntoCell, Inc.	
15:10 ~ 15:30	Break	
Panel Discussion		
15:30 ~ 17:00	Panel 1	Koji Yashiro, Director, Business Development and Licensing, MSD
	Panel 2	Junghee Lim, Managing Director, Bioteam, InterVest
	Panel 3	Alex Chung, Partner, Sheppard Mullin
	Panel 4	YOSUP REW, CTO/EVP, R&D, IntoCell, Inc.

SESSION 06

Global Bio Governance 2025: Change and Future

With a Focus on Policy, Regulation, Economy, and Approval

May 8 (Thu), 09:30~11:40 / Rm. 307

More detail ▲

Since the inauguration of President Trump in 2025, the America First policy has been reinforced, bringing rapid changes to the global bio-governance landscape. The revision of the U.S. Biosecure Act and discussions surrounding the repeal of the Inflation Reduction Act (IRA) are directly impacting the regulatory environment and investment strategies of global biotech companies. These shifts are expected to further intensify technological competition, particularly among the U.S., Europe, and China.
In response, countries worldwide are adjusting their strategies across key areas of the biotech industry, including policy, regulation, economic frameworks, and drug approvals. South Korean pharmaceutical and biotech companies must develop optimal strategies to navigate these changes and successfully enter the global market.
This session will provide a comprehensive analysis of how the Trump 2.0 administration is shaping bio-health industry policies, regulatory frameworks, and drug pricing policies. It will also examine global biotech investment trends and strategies for securing biopharmaceutical approvals. The discussion aims to offer strategic insights for Korean biotech firms to achieve sustainable competitiveness in this rapidly evolving global environment. Additionally, it will explore opportunities for South Korea's innovative biotech sector to expand its presence on the global stage.

Session Chair	**Kyenghee Kwon, Professor, Dongguk University**
09:30 ~ 09:35	**Address** Andrew Gately, Minister Counselor for Commercial Affairs, US Embassy Seoul
09:35 ~ 09:55	**Trump 2.0: Navigating the Future of U.S. Biotech & Healthcare Policy and Global Implications** Ernesto Chanona, CEO, American Business Development
09:55 ~ 10:15	**Trends of US Law and Regulations** Jorge A. Goldstein, Director, Sterne, Kessler, Goldstein, and Fox PLLC
10:15 ~ 10:35	**Trends of US Law and Regulations** Carla Ji-Eun Kim, Director, Sterne, Kessler, Goldstein, and Fox PLLC
10:35 ~ 10:50	Break
10:50 ~ 11:10	Samuel Ngai, Former Head of Danaher Ventures, Danaher Corporation
11:10 ~ 11:30	**Challenges and Opportunities for Korean Pharmaceutical Companies** Sang Mok Chung, President, Global Clinical R&D, Biostar
11:30 ~ 11:40	**Q&A**

SESSION 07

Strategies for Sustainable Global Biopharmaceutical Approval

Expanding into Global Markets Through Collaboration and Innovation

May 8 (Thu), 13:30~16:00 / Rm. 307

More detail ▲

The global biopharmaceutical industry faces the dual challenge of ensuring regulatory compliance while maintaining sustainable management (ESG) in an increasingly complex regulatory landscape. Compliance with current Good Manufacturing Practice (cGMP) is no longer just a legal requirement; it has become a critical component of ESG management, encompassing environmental sustainability, social responsibility, and transparent corporate governance.

To remain globally competitive, biotech companies must adopt eco-friendly production processes, prioritize quality and safety, strengthen ethical management, and ensure regulatory compliance. Meeting the standards of major regulatory agencies such as the FDA, EMA, and MFDS—while integrating ESG principles—will be key to ensuring long-term sustainability.

This session will explore how cGMP certification aligns with ESG management and the strategies that biotech firms can implement to achieve sustainable growth in global markets. It will also feature case studies of successful cGMP approvals and best practices in global ESG management. Through these insights, biotech companies can learn how to build global trust by linking regulatory compliance with ESG initiatives and develop practical strategies for sustainable growth.

Session Chair	Kyenghee Kwon, Professor, Dongguk University	
13:30 ~ 14:10	**USFDA's Regulatory Perspective: 21st Century CGMP Points to Consider Narrowing the Gap** Charles Ahn, president, Aegis Beacon Consulting Inc	
14:10 ~ 14:30	**ESG Business Landscape and Strategies in Global Pharmaceutical and Biotech Companies** Inhwa Choi, Executive Director, Healthcare Access Innovation Team, KRPIA	
14:30 ~ 14:50	**Adapting cGMP from a Governance Perspective** MIN WOO NA, Vice President, Business Development-AP, PHARMASPHERE	
14:50 ~ 15:00	Break	
Panel Discussion		
15:00 ~ 16:00	Panel 1	Jun Park, Executive Consultant, Bureau of Health Industry Promotion, Korea Health Industry Development Institute
	Panel 2	Georgina Kim, Business Development Manager, Ice Miller LLP
	Panel 3	Sang Mok Chung, President, Global Clinical R&D, Biostar
	Panel 4	Charles Ahn, president, Aegis Beacon Consulting Inc
	Panel 5	Jaewoo Lee, Vice President, Head of Department of Development, GC Biopharma

SESSION 08

Strengthening the Competitiveness of Domestic Regenerative Medicine by Discovering Outstanding New Technologies for Cutting-edge Regenerative Medicine

Technology Showcase for Outstanding Korean Regenerative Medicine Technologies

May 8 (Thu), 09:30~11:45 / Rm. 308

More detail ▲

This session will introduce the innovative technologies and achievements of promising companies and researcher-centered projects active in the Korean regenerative medicine field, and provide a venue for cooperation by forming a network with investors, the medical community, and researchers. This will revitalize the regenerative medicine ecosystem and strengthen global competitiveness. Through the technology showcase, we will inform the public and industry of the technology and potential of Korean regenerative medicine, promote commercialization by attracting investment and establishing cooperative partnerships, and seek to develop the regenerative medicine industry ecosystem and build a stepping stone for global expansion. In addition, to address the persistent imbalance between blood supply and demand for transfusion caused by demographic shifts such as declining birth rates, population aging, and the impact of infectious diseases like COVID-19, advanced healthcare nations are actively pursuing research on the generation of transfusion-grade red blood cells (RBCs) and platelets from stem cells. In Korea, a pioneering R&D initiative was launched in 2023 under the Multi-Ministerial Research Support Program. This initiative is focused on advancing the clinical translation and mass production of stem cell-derived cultured RBCs and platelets. The program aims to disseminate the core proprietary technologies developed over the past three years and share its technological advancements with the global scientific community.

Session Chair	Byoungjun Bae, President, Secretariat, HYUNDAI BIOSCIENCE CO., LTD.
09:30 ~ 10:00	**Designer Pluripotent Stem Cell-derived Red Blood Cells** Stella Chou, Professor, Pediatrics, Transfusion Medicine, University of Pennsylvania School of Medicine
10:00 ~ 10:15	**Development of a Commercial Manufacturing Technology for Clinical- grade iPSC-derived Artificial Red Blood Cell Production and IND Application** Ji Hyeon Ju, CEO, Management, YiPSCELL
10:15 ~ 10:30	**Antigen-Specific Memory T-Cell Therapy: Clinical Outcomes and Future Strategies for Viral Infections and Virus-Associated Cancers** KEONIL IM, Director, LucasBio Co.,Ltd.
10:30 ~ 10:45	**RX001: AAV2-Mediated RUNX3 Gene Therapy for KRAS-Mutant Lung Cancer – A Novel Approach Beyond Rare Diseases** Yousoub Lee, CTO, R&D Center, GeneCraft Inc.
10:45 ~ 11:00	**Stem Cells-derived Mitochondrial Transplantation Therapy and Modified Mitochondria Platform (MitoCeutical)** KYUBOEM HAN, CEO, PAEAN BIOTECHNOLOGY INC
11:00 ~ 11:15	**Stem Cell Exosome Therapy for Intractable Brain Diseases** Oh Young Bang, CEO, S&E bio Co., Ltd.
11:15 ~ 11:30	**Development of Gut-Homing Regulatory T Cell Therapy for Clinical Applications in Inflammatory Bowel Disease** Chun Pyo Hong, CEO, GI CELL
11:30 ~ 11:45	**Allogeneic Anti-CD5 CAR-T Development for the Treatment of T-cell Lymphoma** Hyung Cheol Kim, Head of R&D Center, R&D Center, Curocell

SESSION 09

Life Sciences in Space: A New Horizon for Biohealth

Innovation and Challenges in the Low Earth Orbit Environment

May 8 (Thu), 13:30~17:00 / Rm. 308

More detail ▲

In the low Earth orbit (LEO) economy, key sectors are expected to include space tourism and related healthcare services, space-based research and development focusing on biotechnology and advanced materials, and space-based manufacturing technologies. Compared to advancements in launch vehicles, satellites, and payloads, South Korea's progress in human spaceflight and LEO utilization research—particularly leveraging microgravity environments—has been relatively delayed. Now, with advancements in technological capabilities within the bio-health industry, these strengths should be leveraged as a resource for South Korea to secure a competitive position in the emerging LEO economy. Through this session, we aim to explore and examine the current state of LEO-utilized bio-healthcare and discuss future directions to position South Korea as a key player in this evolving field.

Session Chair	**Kyu-Sung Kim, Director, Inha Research Institute for Aerospace Medicine, Inha University Hospital**
13:30 ~ 13:50	**Understanding and Challenges of Space Biomedicine** Kyu-Sung Kim, Director, Inha Research Institute for Aerospace Medicine, Inha University Hospital
13:50 ~ 14:50	Koichi Wakata, Astronaut, Astronaut Office, Axiom Space
14:50 ~ 15:00	Break
15:00 ~ 15:20	**Current Status of the Space Industry and Introduction to Space Technology for the Bio Industry** HyeonJun Kim, Principal Researcher, Small Launch Vehicle Research Division, Korea Aerospace Research Institute(KARI)
15:20 ~ 15:40	**Ground-based Research Platform for Space Biology and Medicine** Gyutae Kim, Research Professor, Inha University
15:40 ~ 16:00	**Humans in Space: Multiplanetary Human Life Enabler** Jack Lim, Executive Director, Boryung/BRAX
16:00 ~ 16:20	**Academic Research Collaboration and Commercial Activities in Low Earth Orbit** Hargsoon Yoon, CEO, Head Quarter, Space LiinTech
16:20 ~ 16:30	Break
	Pitching
16:30 ~ 16:40	**Space Radiation and Personal Radiation Dose Management** Jung-in Kim, CEO, PAPRICALAB Co., Ltd.
16:40 ~ 16:50	**Smart Toilet to Check the Health Status of Astronauts** Won Suk Lee, Management director, Management Planning, Biobankhealing
16:50 ~ 17:00	**The Microsatellite Platform For Biological Experiment** Nikolay Vedenkin, CTO, KAIROSPACE Co., Ltd.

SESSION 10

Innovative Aging Control Technologies: Immunity, Diagnostics, and Evaluation Platforms

May 9 (Fri), 09:30~12:00 / Rm. 401

More detail ▲

Aging research has shifted its focus from merely extending lifespan to promoting healthy longevity. This session explores key technologies for aging modulation, covering immune-based aging control, precision diagnostics, and next-generation evaluation platforms. Discussions will include immune system modulation for aging intervention, AI-driven diagnostics and biomarker analysis, and novel platform technologies for evaluating aging therapeutics. This session aims to highlight the latest advancements and practical applications in aging research, paving the way for innovative strategies to bring aging control technologies closer to real-world implementation.

Session Chair	**Kyung A Cho, Professor/CEO, Chonnam National University/ Medispan**
09:30 ~ 10:10	**Beneficial Immune Cell Senescence as a Broad Defense and Healthspan-Extending Strategy** Dmitry Bulavin, Director, IRCAN INSERM
10:10 ~ 10:35	**Immune-targeted Rejuvenation as a Novel Therapeutic Strategy for Controlling Aging** Kyung A Cho, Professor/CEO, Chonnam National University/ Medispan
10:35 ~ 11:00	**Retinal AI: The Most Effective Digital Biomarker for Measuring Aging** Kevin Choi, CEO, Mediwhale
11:00 ~ 11:30	**Turquoise Killifish: A GAME CHANGER for Evaluating Anti-Aging Substances for Promoting Healthy Aging** Yumi Kim, CEO, IEUMBIO
11:30 ~ 12:00	**Transient Epigenetic Reprogramming: Rejuvenation of the Skin and Beyond** Edward Hsia, Vice President, Turn Bio

SESSION 11

The Present and Future of Reverse-aging Technologies

May 9 (Fri), 13:30~15:30 / Rm. 401

More detail ▲

For over half a century, scientists have pursued technologies to alter the fate of living cells: from somatic cell nuclear transfer (SCNT) and cell fusion to cellular reprogramming. Today, these advancements have led to groundbreaking reverse-aging technologies that challenge the natural aging process, as well as cancer-reversal technologies that seek to restore cancer cells to their normal state.
Unlike traditional anti-aging approaches, reverse-aging technology aims to rejuvenate aged cells, restoring them to a youthful and healthy state. This innovation holds the potential to address a wide range of age-related diseases, offering new solutions for the aging population.
This session will explore the latest developments in reverse-aging technologies, examine their impact on human health, and discuss future directions in the field.

Session Chair — **Kwang-Hyun Cho, Professor, Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST)**

13:30 ~ 13:50	**Reversion of Cancer and Aging** Kwang-Hyun Cho, Professor, Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST)
13:50 ~ 14:10	**Finding of Reverse Cellular Senescence Protein, HAPLN1** HAKBAE CHOI, CEO, HapInScience Inc.
14:10 ~ 14:30	**Reprogramming Senescent Microglia: A Dual Approach to Brain Aging Reversal and Developing Neurodegenerative Diseases Theraputics** Min-Soo Kwon, CEO/Professor, R&D center, Brainimmunex Inc./Department of Pharmacology, School of Medicine, Brainimmunex Inc./CHA university
14:30 ~ 14:50	**Small Molecule-Mediated Rejuvenation and Therapeutic Activation of Fibroblasts for the Treatment of Spinal Cord Injury** Kyeong Kyu Kim, Professor/CEO, School of Medicine, Sungkyunkwan University/Cellapeutics Bio
14:50 ~ 15:10	**Future Prospects for the Anti-Aging Market and Korea's Strategy as a Future Growth Engine** BG Rhee, Chairman CEO, Chairman's Office, GI Innovation
15:10 ~ 15:30	**Panel Discussion**

SESSION 12

Evolving Global Trends and New Technologies in Clinical Trials

Emerging Trends and Innovations in Global Clinical Trials: Navigating an Evolving Landscape for Successful Drug Development

May 9 (Fri), 09:30~12:00 / Rm. 307

More detail ▲

The global clinical trial landscape is rapidly evolving, driven by regulatory changes from major agencies the growth of emerging markets (Asia, the Middle East, and South America), and cost-saving strategies. To help companies effectively navigate these shifts, this session will provide the latest insights into global clinical trial trends and strategic approaches. Additionally, it will explore how advanced technologies, such as AI-driven trial design, decentralized clinical trials (DCT), real-world data (RWD) and real-world evidence (RWE) utilization, and digital patient recruitment and retention strategies, are transforming clinical trials to enhance efficiency and success rates. The session will also discuss collaboration models with global CROs, pharmaceutical companies, and biotech firms. By doing so, it aims to showcase Korea's clinical trial capabilities and innovative technologies to international stakeholders while offering domestic companies practical strategies to strengthen their global competitiveness.

Session Chair — **Hanlim Moon, CEO, Medirama**

09:30 ~ 09:55	**2025: What to look out for - Trends in AI and Disruptive Technology in Clinical Development** Ben Phillips, Consultant, Consulting, Syneos Health
09:55 ~ 10:20	**Insights into MFDS Conditional Approval: Speeding up the Availability of New Drugs** Jeong-Hee Yoo, CEO, MEDITIP
10:20 ~ 10:45	**FDA Expedited Programs: Navigating the Path to Faster Drug Development** Shawn Lee, Senior Manager, Regulatory Affairs and Strategy, Harvest Integrated Research Organization (HiRO)
10:45 ~ 11:10	**Evolving Global Trends and New Technologies in Clinical Trials - Investors' Perspectives** May Lo, Director, ABC Impact
11:10 ~ 11:30	**Panel Discussion**
	Pitching
11:30 ~ 11:40	**Data Interface Solutions for Efficient Clinical Trials** Donghyun Park, Director, Research Center, PLANIT SQUARE
11:40 ~ 11:50	**Digital Healthcare Era: How Connected Medical Devices are Transforming Clinical Trials** Sanghak Lee, CEO, TriBell Lab
11:50 ~ 12:00	**From Clinic to Smartphone: A Randomized Controlled Trial of a Novel Digital Therapeutic for Patellofemoral Pain, Integrating Exercise and Cognitive-Behavioral Therapy** Chan Yoon, Chief Executive Officer, EverEx

SESSION 13

Beyond Innovation: The Path to Successful Clinical Adoption and Market Expansion of Digital Therapy

Key Requirements and Strategies for Clinical Utility and Market Success of Digital Therapy

May 9 (Fri), 13:00~16:00 / Rm. 307

More detail ▲

Despite its potential to transform healthcare, digital therapies have yet to achieve widespread clinical adoption and market success. This session explores the key factors that move digital therapy beyond innovation into practical implementation. Discussions will cover strategies to ensure clinical efficacy and usability, challenges in integrating digital therapy into healthcare systems, ways to enhance acceptance among patients and providers, and sustainable business models for market viability. By bringing together experts from various fields, this session aims to provide actionable insights and strategic directions for the future of digital therapeutics in both clinical and commercial settings.

Session Chair	**Jae Heon Kang, President/Professor, Korean Society for Digital Therapy/ Kangbuk Samsung Hospital**
13:00 ~ 13:25	**Digital Therapeutics in Practice: System-Level Integration and Patient Uptake** Jaeyong Shin, Professor, Department of Preventive Medicine, Yonsei University
13:25 ~ 13:50	**From Clinical Evidence to Practical Therapeutic Tools: Realizing the Innovation of Digital Therapies** Chul-Hyun Cho, Professor, Psychiatry, Korea University College of Medicine
13:50 ~ 14:20	**The Digital Therapeutics-Revolution in Germany: DiGA - A Template for Success?** Jonas Albert, Partner, fBeta GmbH
14:20 ~ 14:40	**Market Expansion and Sustainable Business Models for Digital Therapies: Key Success Factors** Sean G. Kang, CEO, WELT corp.
14:40 ~ 15:00	Jae-jun Song, Professor, Korea University Guro Hospital
15:00 ~ 15:30	**Panel Discussion**
	Pitching
15:30 ~ 15:40	**Digital Diagnostics and Therapeutics in Psychiatry : Minds.NAVI, CHEEU.Forest, VARABOM-D** Jeongho SEOK, CEO, MindsAI
15:40 ~ 15:50	**AimNext Company Introduction** IL YONG MUN, CPO, Aimnext
15:50 ~ 16:00	**AI Agent-Based Digital Therapeutics for Mental Health Management** Choongki Min, Senior Manager, Waycen

SESSION 14

Alternative Toxicity Testing: Our Choice and Challenges for Leading the Future Bio Market

Our task for commercializing a new paradigm for bio–research and development systems such as new drugs and alternative animal testing methods

May 9 (Fri), 09:30~15:35 / Rm. 308

More detail ▲

This session will focus on the development and successful commercialization of alternative toxicity assessment solutions for global biohealth market entry, sharing innovative cases of global market expansion. With increasing ethical and legal restrictions on animal testing, rising drug development costs, and limitations in predictive accuracy due to physiological differences between animals and humans, the demand for alternative toxicity assessment technologies is growing. As a result, in vitro organoid-based platforms that mimic human organs and AI-driven predictive toxicity models are emerging as next-generation assessment technologies. This session will explore the commercialization process and success factors of AI-based toxicity prediction models and advanced toxicity assessment platforms across various fields, including drug development, medical device evaluation, and regenerative medicine, while also examining the potential for global business expansion. Furthermore, practical strategies and approaches for researchers and companies to effectively penetrate the global market will be presented, enhancing the competitiveness of AI and in vitro model-based next-generation toxicity assessment technologies.

Session Chair	**Seokjoo Yoon, Principal Research Scientist, Prediction Model Research Center, Korea Institute of Toxicology**
09:30 ~ 10:05	**Advanced Human Cell Models and Technologies for Pre-clinical Safety and Efficacy Testing** Nicholas Geisse, CEO, Curi Bio
10:05 ~ 10:40	**Development of Endotoxin Testing Reagents through Large-Scale Cultivation of Horseshoe Crab Blood Cells** GUNSIK CHO, CEO, Cellweaverse Co, Ltd
10:40 ~ 11:15	**Latest Trends and Future of Organoid Technology** Bo Eun Lee, Senior Manager, ORGANOIDSCIENCES Ltd.
11:15 ~ 11:50	**Application of Impedance and MEA (Microelectrode Array) Measurement Systems for Cell Toxicity Assessment and Alternative Methods to Animal Testing** SANGJUN CHO, CEO, Cellames Inc
11:50 ~ 13:30	Break
13:30 ~ 14:05	**Organs-on-chips for Drug Toxicity Tests** Sungho Ko, CEO, Humanase, Ltd.
14:05 ~ 14:40	**Development of an Alternative Immunotoxicity Testing Platform Based on Humanized Mouse Models** YOUNG MO KANG, Chief Executive Officer (CEO), Board of Directors, PRECLINA INC
14:40 ~ 15:15	**Advancing Animal-Free Testing with AI: Overcoming CYP Diversity and Cross-Species Differences** JaeMun Choi, CEO, Management, Calici Co., Ltd
15:15 ~ 15:35	**Panel Discussion**

OPEN-SESSION

01

Golden Triangle Open Innovation: Korea-UK-Japan Trilateral Collaboration in Life-Science -Digital -Health

May 7 (Wed) 13:00~17:25, Rm.300

Session 1. Opening & Keynote Talk

Session Chair	**Kei Cho, Professor of Neuroscience, Basic and Clinical Neuroscience, King's College London**
13:00 ~ 13:05	**Opening Session** Kei Cho, Professor of Neuroscience, Basic and Clinical Neuroscience, King's College London
13:05 ~ 13:10	**Congratulatory Address**
13:10 ~ 13:30	**Keynote Lecture: Innovation of Optogenetics-Controlling and Visualizing Cellular Behavior in Living Cells and Animals** Won Do Heo, Professor, Dept. of Biological Sciences, KAIST

Session 2. Open Innovation for Life Science & Digital Applications for Better Quality of Life

Session Chair	**Alexandra Esteras, Programme Manager, Industry Research Partnerships, King's Innovation Catalyst, King's College London** **Hiroki Takai, Director, Investment Group, Global Brain**
13:40 ~ 13:55	**Leveraging iPSC Technology and AI for ALS Research** Haruhisa Inoue, PI, Center for iPS Cell Research and Application (CiRA), Kyoto university
13:55 ~ 14:10	**Data mining & AI based Phathophysiological Prediction and Therapeutic Discovery in Alzheimer's disease** Kei Cho, Professor of Neuroscience, Basic and Clinical Neuroscience, King's College London
14:10 ~ 14:25	**Patient-Centered Care in the Era of Generative AI** Hyung-Jin Yoon, Professor, Seoul National University College of Medicine
14:25 ~ 14:40	Break
14:40 ~ 14:55	**Digital Brains: How to build and how to use** Kenji Doya, Professor, Neural Computation Unit, Okinawa Institute of Science and Technology Graduate University
14:55 ~ 15:10	**Using epigenetics to understand how different brain cells malfunction in Alzheimer's disease** Sarah Marzi, Associate Professor, King's College London
15:10 ~ 15:25	**Bridging the Gap: Leveraging Open Innovation for AI Research and Clinical Practice** So Hyun Kang, Professor, Seoul National University Bundang Hospital
15:25 ~ 15:40	**King's Unique Environment for Medical Robotics Innovation** Christos Bergeles, Head of Research Department, School of Biomedical Engineering & Imaging Sciences, King's College London
15:40 ~ 15:55	**A New Model of Dementia Care: AI and Technology Assisted Dementia Care.** Ramin Nilforooshan, Professor in Psychiatry, Director of R and D, University of Surrey, SABP, Imperial College

Session 3. Open Innovation Ecosystem in UK-Korea-Japan

Session Chair	**So Hyun Kang, Professor, Seoul National University Bundang Hospital**
15:55 ~ 16:10	**Korean Health R&D: Government Policies and Global Collaboration** Junghwan Park, Senior Deputy Director, Division of Health Industry Policy, Ministry of Health and Welfare
16:10 ~ 16:25	**UK Ecosystem and Opportunity in UK** Bob Damms, Senior Life Science Investment Advisor, Department for Business & Trade Venture Capital Unit
16:25 ~ 16:40	**Innovation, Collaboration, and Open Science in the Oxfordshire/Harwell Ecosystem** Laura Holland, Director of Strategic Marketing, The Rosalind Franklin Institute
16:40 ~ 16:55	**The National Institute for Health and Care Research (NIHR): Our Offer to the Life Sciences and Digital Health Industry: Enabling Global Collaboration and Innovation.** Richard Brooks, Senior Business Development Manager, National Institute of Health and Care Research
16:55 ~ 17:10	**Strategic Venture Investing in Global Biotech: Lessons from Global Brain's CVC Experience** Hiroki Takai, Director, Investment Group, Global Brain
17:10 ~ 17:20	**Q&A**
17:20 ~ 17:25	**Closing**

OPEN-SESSION

02 Workshop on Strategic Collaboration between Korea and Saudi Arabia: Propelling the Growth of Global Biohubs

May 7 (Wed) 13:00~17:30, Rm.327

13:00 ~ 13:10	**Opening Remarks**
13:10 ~ 13:35	**Introduction to Saudi Arabia's Biotechnology Vision 2030**
13:35 ~ 14:00	**Current Status of the Saudi Pharmaceutical and Bio Industry**
14:00 ~ 14:25	**Global Competitiveness of Korean Biotech** Daniel Zang, Lawyer, Kiyeon Law
14:25 ~ 14:50	**Saudi Government's Global Bio Investment Strategy**
14:50 ~ 15:15	**Unlocking Biotech Synergies: Korea-Saudi Collaboration for Vision 2030** Yun Kyoung KANG, Founder/CBDO, Corp Dev, Y2K Global Innovation LAB
15:15 ~ 15:30	Break
15:30 ~ 16:30	**Presentations of Promising Companies/Technologies**
16:30 ~ 17:30	**Partnering & Networking**

OPEN-SESSION

03 Healthy Aging: Advancing Science for Longevity

May 7 (Wed) 13:00~17:00, Rm.E1

With the rise of aging populations, healthy aging has become a key research focus. This session covers the future of aging research in Korea, recent advancements in biotechnology, frailty prevention, digital therapeutics and biomarkers, the role of nutrition, and new approaches for aging in super-aged societies. We will also discuss strategies for building a national research infrastructure to support a healthy 100-year life. This session offers a platform for experts from academia, industry, and policy sectors to collaborate on innovative solutions for healthy aging.

Session Chair	**Hyun-Young Park, Director, Korea National Institute of Health(KNIH)**
13:00 ~ 13:05	**Opening Address** Hyun-Young Park, Director, Korea National Institute of Health(KNIH)
13:05 ~ 13:35	**The Future Direction of Aging Research** Yunhwan Lee, Professor, Preventive Medicine and Public Health, Ajou University School of Medicine
13:35 ~ 14:05	**Latest Trends in Advanced Biotechnological Aging Research** Kyung Jin Min, Professor, Biological Science, Inha University
14:05 ~ 14:35	**Research on Frailty Prevention for Healthy Aging** Chang won WON, Director, Elderly Frailty Research Center, Kyung Hee University Medical Center
14:35 ~ 14:45	**MOU Signing Ceremony**
14:45 ~ 14:55	Break
Session Chair	**YONG KYUN ROH, President, The Korean Association of Gerontology and Geriatrics** **Won Ho Kim, Director General, Department of Chronic Disease Convergence Research, Korea Disease Control and Prevention Agency, National Institute of Health**
14:55 ~ 15:15	**Longer and Healthier: How Social Environments Shape the Pace of Aging** Haena Lee, Associate Professor, Department of Sociology, Sungkyunkwan University
15:15 ~ 15:35	**The Era of Healthy Aging: Nutritional Strategies for a Healthier Life** HeeSook Lim, Associate Professor, Department of Gerontology, Kyung Hee University
15:35 ~ 15:55	**Digital Therapeutics and Digital Biomarkers for Well-Aging** Sean G. Kang, CEO, WELT corp.
15:55 ~ 16:15	**The Future of Aging in Place: Innovations and Research in a Super-Aged Society** Belong Cho, Professor, Dept.of Family Medicine, Seoul National University Hospital
16:15 ~ 16:35	**Strategies for Building a National Research Infrastructure for Healthy Aging in Korea** Joongyeon Lim, Director, Division of Population Health Research, Korea National Institute of Health
16:35 ~ 17:00	**Q&A, Closing**

OPEN-SESSION

04 K-BIC Venture Cafe

May 7 (Wed) 12:00~13:00, Rm.E2~E3

(Seminar) Sharing insights on overseas business expansion, investment strategies through case studies of startups accelerated by the Cambridge Innovation Center(CIC) in the U.S.
(Networking) Providing a platform for industry experts, investors, and startups to network and explore opportunities for research collaboration, joint development, and investment partnerships.

12:00 ~ 12:20	**Connecting innovators to make things happen : supporting startups locally and globally** Alex Cheung, Director, Venture Cafe Cambridge
12:20 ~ 13:00	**Networking**

OPEN-SESSION

05 2025 Spring Bio-health Policy and Research Forum

Field & Future Research Outcomes for Bio-health Innovation and Security

May 7 (Wed) 14:00~15:40, Rm.E4

The bio-health sector demands spontaneous adaptation to changes driven by innovative technologies such as AI, the securing of pharmaceutical supply chains, and the fulfillment of national health security roles in responding to infectious diseases. For this reason, case studies of e-ICUs adopting cutting-edge technologies in medical institutions, as well as those on domestic and international pharmaceutical self-sufficiency, will be reviewed and policy directions will be proposed to prepare for the future. Through an analysis of recent cases of public hospital constructions and the management performance of medical institutions, the operations and management status of major healthcare providers will be reviewed, with the goal of presenting recommendations that align with on-site demands.

14:00 ~ 14:05	**Opening speech** Heonwoo Hong, Planning Director, Korea Health Industry Development Institute
14:05 ~ 14:10	**Welcome Address** HaengShin Lee, Director, Department of Biohealth Policy and Research, Korea Health Industry Development Institute
14:10 ~ 14:30	**Direction for activating e-ICU network** JI SUN LEE, Principal Researcher, Center for Biohealth policy and Research, KHIDI (Korea Health Industry Development Institute)
14:30 ~ 14:50	**Case study on the Supply of Pharmaceuticals and Its Policy Implications** Hyeyun Jung, Principal Researcher, Center for Biohealth Policy and Research, Korea Health Industry Development Institute
14:50 ~ 15:10	**Analysis of the Trends and Implications in Public Hospital Construction** Daewook Kang, Chief Researcher, CHIP, KHIDI
15:10 ~ 15:30	**Management Analysis Utilizing Financial Statements of Medical Institutions from 2016 to 2022** JiEun Kim, senior researcher, CHIP, KHIDI
15:30 ~ 15:40	**QnA / Wrap up**

OPEN-SESSION

06 Advancing Biopharmaceutical Research, Manufacturing, and Workforce Development

May 7 (Wed) 15:10~17:00, Rm.E5

Review the latest corporate research achievements and industry trends in bioprocess development, and explore strategies for training and developing professionals to meet workforce demands.

Session Chair	**JAEHUN SHIN, Vice Chairperson of External Affairs, K-NIBRT, Yonsei University K NIBRT Education Centre**	
15:10 ~ 15:20	**Keynote Speech** Seong-Bo Kim, Associate Professor, Global Leaders College, Yonsei University	
15:20 ~ 15:40	**Road map for product development and quality strategies of biologics** Seong Hoon Jeong, Professor, College of Pharmacy, Yonsei University	
15:40 ~ 16:00	**Experiences in FIC Drug Development at a Bioventure: Insights into Research, Manufacturing, and Workforce Development** Nam Hoon Kwon, CTO, ZYMEDI	
16:00 ~ 16:20	**Current Status and Strategies for Biopharmaceutical Practical Workforce Training** Jaeseon Jang, Professor, Dept. of Biopharmaceutical Analysis, Korea Specialized Polytechnics	
16:20 ~ 16:40	**Development of Lipid Nanoparticle Formulation for Delivery of mRNA Therapeutics and Vaccines** Hyukjin Lee, Professor, School of transdisciplinary innovations, Seoul National University	
16:40 ~ 16:45	Break	
Panel Discussion		
16:45 ~ 17:00	Panel 1	Seong Hoon Jeong, Professor, College of Pharmacy, Yonsei University
	Panel 2	Nam Hoon Kwon, CTO, ZYMEDI
	Panel 3	**Recommendations for Fostering Biopharmaceutical Manufacturing Workforce** Jaeseon Jang, Professor, Dept. of Biopharmaceutical Analysis, Korea Specialized Polytechnics
	Panel 4	Hyukjin Lee, Professor, School of transdisciplinary innovations, Seoul National University

OPEN-SESSION

09 Canada's Thriving Life Sciences: Innovation and Collaboration from British Columbia to Beyond

May 8 (Thu) 13:30~14:20, Rm.300

This session will introduce Canada's dynamic life sciences ecosystem, with a special focus on British Columbia. Experts from leading organizations will present key innovations, industry strengths, and global collaboration opportunities. Discussions will highlight BC's life sciences landscape, advancements in medical diagnostics, AI-driven drug discovery, and pandemic research initiatives.

13:30 ~ 13:40	**Opening & Overview of Canada's Thriving Life Sciences Industry** Jimin Kim, Trade Commissioner, Trade Commissioner Service, Embassy of Canada
13:40 ~ 13:50	**Overview of British Columbia Life Sciences Ecosystem** Gil Hwan Lew, Commercial Officer, Trade and Invest BC – Korea Office
13:50 ~ 14:00	**Modern-day medical diagnostics using microbial genomics and the global innovation ecosystem to improve data interoperability** Soyean Kim, Product Lead, Centre for Infectious Disease Genomics and One Health (CIDGOH), Simon Fraser University
14:00 ~ 14:10	**Enki™ platform overview & drug discovery case studies** Handol Kim, CEO, Variational AI Inc
14:10 ~ 14:20	**Canada's Centre for Pandemic Research** Paul Hodgson, Director, Operations, Vaccine and Infectious Disease Organization (VIDO)

OPEN-SESSION

10 Global ATMP Forum

What's now and How is the future

May 8 (Thu) 14:30~16:35, Rm.300

Recent advances in regenerative medicine and advanced therapy medicinal products (ATMPs) are transforming the conventional treatment methods for both incurable and dangerous diseases. Korea's recent amendment to the Regenerative Medicine and Advanced Biopharmaceuticals Act signals a strong commitment to fostering clinical innovation and global competitiveness. As Korean biotech companies look outward for clinical trials, manufacturing support, and strategic partnerships, the demand on international collaboration to support the transition/ application of cell and gene therapies in the real life is growing.
The objectives of the Global ATMP Round table would include;

- Address the current challenges and innovations in ATMP sector: Deeping the understanding on current challenges that ATMP businesses face including challenges in new technology, progress/process development, and funding& market entry, and how international collaboration can provide solutions
- Showcase global innovation and infrastructure: Providing insights based on case studies and experiences of international companies/ organizations that are relevant to Korea's ATMP roadmap
- Facilitate open discussion in international level: Providing a platform for direct dialogue between international and Korean companies to form partnerships and explore investment opportunities translate this in Korean

14:30 ~ 14:40	**Opening** Lars Hammarström, Science & Innovation Counsellor, Office of Science & Innovation, Embassy of Sweden in Korea
14:40 ~ 14:50	**Congratulatory Remarks** Heon Woo Hong, Planning Director, Korea Health Industry Development Institute (KHIDI)
14:50 ~ 15:00	**Keynote Speech** So Ra Park, President, Regenerative Medicine Acceleration Foundation
15:00 ~ 15:10	**Company presentations; Future of ATMP: Next generation solutions and what are the expectations of global synergies** Mark Farmery, Chief Development Officer, Anocca
15:10 ~ 15:20	Teodor Norhagen, Business Manager, Business Development, Cellcolabs
15:20 ~ 15:30	**Brain-Targeted Delivery of RNA Therapeutics with TERP Nanotechnology** John Reid, Chief Business Officer, QurCan Therapeutics Inc
15:30 ~ 15:40	Magnus Gustafsson, Chief Commercial Officer, Commercial, NorthX Biologics
15:40 ~ 15:50	Sukmo Kang Ph.D., Executive Director, BTT Group
15:50 ~ 15:55	Hyun Sook Park, CEO, Research Institute, Cefobio

Panel Discussion

What are the current challenges and how to overcome the challenges?

Session Chair	**Duckjoo Lee, Vice Chairman/Standing Senior Advisor, Council for Advanced Regenerative Medicine/ GC Holdings**	
15:55 ~ 16:25	Panel 1	Anita van der Meer, Head of Business Development Partnerships, Viral Vector Manufacturing Facility
	Panel 2	Jim Lund, Chief Business Development Officer, Center for Commercialization of Regenerative Medicine Nordic
	Panel 3	Michael H May, President & CEO, Cell&Gene Therapies, CCRM (Centre for Commercialization of Regenerative Medicine)
	Panel 4	So Ra Park, President, Regenerative Medicine Acceleration Foundation
	Panel 5	Eun Young Yang, Sr VP, R&D, CHA BIO GROUP
16:25 ~ 16:30	**Closing Remarks**	

OPEN-SESSION

11 2025 Joint Session on Regenerative Medicine Institution Designation and Regenerative Medical Treatment System

May 8 (Thu) 14:00~16:15, Rm.327

After the enforcement of the Amendment to The Advanced Regenerative Bio Act as of February 21, 2025, we plan to provide medical institutions and researchers with the guideline on related systems and procedures in order to expand the designation of advanced regenerative institutions and clinical research support. We will study the current status of advanced regenerative medicine policy, instructions for applying for 2025 Call for Applications for the Designation of Advanced Regenerative Institutions and filling out submission documents, preparations for regenerative medical treatment, clinical research plan review and research funding procedures, and public IRB support projects. Through this, we aim to help stakeholders to better understand the systems and procedures related to advanced regenerative medicine and provide information necessary for future research and treatment.

Session Chair	**Hyung Jun Kim, Team Leader, RM Institution Designation Team, Regenerative Medicine Acceleration Foundation**
14:00 ~ 14:05	**Introduction on the Event and List of Attendees** Hyung Jun Kim, Team Leader, RM Institution Designation Team, Regenerative Medicine Acceleration Foundation
14:05 ~ 14:15	**Trends and Future Outlook of Advanced Regenerative Medicine Policies** Division of Regenerative Medicine Policy, Korean Ministry of Health and Welfare
14:15 ~ 14:40	**2025 Call for Applications for the Designation of Advanced Regenerative Medical Institutions** Hyung Jun Kim, Team Leader, RM Institution Designation Team, Regenerative Medicine Acceleration Foundation
14:40 ~ 14:50	**Essential Training Program in Regenerative Medicine** Jaegwon Yu, Lead Researcher, Human Resources Development Team, RMAF
14:50 ~ 15:00	**Guideline on Advanced Regenerative Medical Treatment Procedure** SeoHyun Kim, Researcher, Therapeutics System Support Team, Regenerative Medicine Acceleration Foundation
15:00 ~ 15:10	Break
15:10 ~ 15:20	**Information on Public IRB Specializing in Regenerative Medicine** YOONJUNG HO, Team Leader, KOREA NATIONAL INSTITUTE FOR BIOETHICS POLICY
15:20 ~ 15:40	**Session on Advanced Regenerative Medicine Implementation Plan and Review Process** Suwon Kim, Deputy Director, Ministry of Health and Welfare
15:40 ~ 15:50	**Information on Advanced Regenerative Medicine Clinical Research Funding Support Project** Kyounglim Lee, Senior Researcher, RM Support Devision Industry support team, Regenerative Medicine Acceleration Foundation
15:50 ~ 16:10	**Q & A**
16:10 ~ 16:15	**Closing Remarks**

OPEN-SESSION

12

Current Status and Strategy of BioBigData.Korea
Domestic and International Examples of Bio Big Data Utilization

May 8 (Thu) 13:30~16:50, Rm.E1~E4

An overview of the current status of the BioBigData.Korea, the largest participant-consent-based large-scale project in Korea, will be presented, along with strategies for building a bio big data repository with data from 1 million participants. Through this initiative, we aim to promote the development of data-driven science and the bio-health industry, while enhancing Korea's national competitiveness in healthcare as a research and development infrastructure. The session will also explore the future of domestic healthcare.

Session Chair	**RONG-MIN BAEK, Principal Investigator, BioBigData.Korea, Korea Health Industry Development Institute** **Si Young Song, Professor Emeritus/CEO, Yonsei University College of Medicine, Internal Medicine(Gastroenterology)/Cowell Biodigm, Inc.**
13:30 ~ 13:45	**Introduction to the BioBigData.Korea** RONG-MIN BAEK, Principal Investigator, BioBigData.Korea, Korea Health Industry Development Institute
13:45 ~ 14:30	**Global Case Studies on the Utilization of Bio Big Data and Implications** JOONSEOK LEE, Associate Partner, Healthcare Strategy Unit, VAIIM
14:30 ~ 15:00	**The Singapore National Precision Medicine Program – Driving Research, Innovation and Enterprise on a Global Scale** Weiling Zheng, Senior Business Development Lead, Precision Health Research, Singapore (PRECISE)
15:00 ~ 15:30	**Experiences from National Bio Big Data Project: Diagnoses from WGS** Jong Won Kim, Professor, Department of Laboratory Medicine and Genetics, Samsung Medical Center
15:30 ~ 15:40	Break
Panel Discussion	
	Strategies for Successfully Recruiting 1 Million Bio Big Data Participants
15:40 ~ 16:50	Panel 1: JOONSEOK LEE, Associate Partner, Healthcare Strategy Unit, VAIIM Panel 2: Weiling Zheng, Senior Business Development Lead, Precision Health Research, Singapore (PRECISE) Panel 3: Jong Won Kim, Professor, Department of Laboratory Medicine and Genetics, Samsung Medical Center Panel 4: Hee Hwang, CEO, Kakao Healthcare Corp. Panel 5: Sangheon Lee, Professor/CEO, Korea University Anam Hospital/Huniverse Panel 6: Hwa Jong Kim, Head, K-MELLODDY Project, KPBMA

OPEN-SESSION

13

Global Pharma Supply Chain from Industry Perspective

May 8 (Thu) 13:40~17:00, Rm.E5

Pharmaceutical supply chain has become a critical issue of national security worldwide. Various factors, such as raw materials, drug price reductions and a sudden surge in drug demand are contributing to the drug shortage. In addition, the structural shift in the pharmaceutical industry, which separates development from production is positioning CDMOs as key players in the supply chain. This session will explore the efforts of global companies in stabilizing pharmaceutical supply amidst these changes and seek implications for domestic companies and the government.

Session Chair	**JIN HYUN JEONG, Professor/Director, SNU Biopharm Training Center, Seoul National University**
13:40 ~ 13:50	**Opening Remarks** Korea Health Industry Development Institute
13:50 ~ 14:10	**[Keynote Speech] Global Pharma Supply Chain Overview** JIN HYUN JEONG, Professor/Director, SNU Biopharm Training Center, Seoul National University
14:10 ~ 14:30	**GSK-CDMO Strategic Partnership Driving Operational Excellence and Success** James Taylor, Global Supply Director, GSK
14:30 ~ 14:50	**Amgen's Strategic Partnership with Our CDMO Network** Gerard Dempsey, Executive Director, Asia Pacific Supply Chain, Amgen
14:50 ~ 15:10	**Navigating Development Challenges with CDMO Partners** Masashi Mizoguchi, Innovation Technology Lead, Development Sciences & Management, Boehringer Ingelheim
15:10 ~ 15:30	**LOTTE BIOLOGICS CDMO Supply Chain Stabilization Strategy** HYUNGDUK YOO, Chief Operating Officer, Board of Director, Business Operations, LOTTE BIOLOGICS
15:30 ~ 15:50	**How CDMO Helps Korean Pharmaceutical Companies Expand into the Global Market** Corrine Hu, Global SME for Biologics and Sterile Fill Finish, Pharma Services, Thermo Fisher Scientific
15:50 ~ 16:10	Coffee Break & Free Networking
16:10 ~ 16:30	**Strategic Approaches to U.S Trade Challenges and Supply Chain Resilience** Min-Woo Jung, Partner, Samil PricewaterhouseCoopers
16:30 ~ 17:00	**Q&A / Panel Discussion**

OPEN-SESSION

14 2025 BioHealth Commercialization Promising Technology Briefing Session

May 8 (Thu) 14:00~16:05, Rm.E6

The Korea Health Industry development institute supports health care TLO to foster and revitalize an organization dedicated to technology transfer in the health care sector. In this regard, we introduce promising technologies in the health care sector with five consortiums (10 institutions) currently supported. Through the introduction of excellent technologies in the health care field, we hope that technology will be transferred and commercialized smoothly to the private sector and become a place for technology exchange between health care TLO officials such as hospitals and universities

14:00 ~ 14:05	**Opening**
14:05 ~ 14:17	**A Composition for Prevention, Improvement or Treatment of Metabolic Diseases** HyengJin Jang, Professor, Department of Korean Medicine, College of Korean Medicine, Kyung Hee University
14:17 ~ 14:29	**Composition for Diagnosing or Treating Kidney Diseases** SangYoub HAN, Professor, Internal medicine department, INJE University, ILSAN PAIK Hospital
14:29 ~ 14:41	**Development of Precision Cancer Diagnosis and Personalized Treatment Technology Based on TMEM165-CLOCK Fusion Gene** Sungwook Seo, Professor, Department of orthopedic surgery, Samsung Medical Center
14:41 ~ 14:53	**Anticancer Drug Screening and Personalized Precision Therapy Using Lung Cancer Organoids** Chaeuk Chung, Professor, College of Medicine, Chungnam National University
14:53 ~ 15:05	**The Treatment of Heart Failure Using the Inhibitor of Histone Deacetylase 8** Haejin Kee, Research Professor, Biomedical Research Institute, Chonnam National University Hospoital
15:05 ~ 15:17	**Novel CNS-penetrating Ghrelin Receptor Agonists(Therapeutic agents for Brain & Skeletal Muscle Disorders)** Jae Sung Bae, Professor, Physiology, Kyungpook National University
15:17 ~ 15:29	**Anti-Inflammatory Peptide for Preventing or Treating Atopic Dermatitis** Seonghyang Sohn, Professor, Microbiology, Ajou University Medical Center
15:29 ~ 15:41	**Diagnostic Kit for Predicting Acute Exacerbation of Bronchiectasis** Bumhee Yang, Professor, Medicine, College of Medicine, Chungbuk National University
15:41 ~ 15:53	**Composition for Preventing or Treating ATOPIC DERMATITIS** ChangOok Park, Professor, Department of Dermatology, College of Medicine, Yonsei University Health System
15:53 ~ 16:05	**AI-Based Breast Surgery Technology (S-BEST)- AI Technology for Detecting Landmarks Evaluating Breast Aesthetics** GyuHyeong Park, Professor, Plastic surgery, SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL

OPEN-SESSION

15 AI Research Cases Utilizing Healthcare Data from the National Institute of Health

May 9 (Fri) 09:30~11:30, Rm.300

This session will present AI research cases utilizing various healthcare datasets curated and generated by the National Institute of Health. Initially focused on clinical, epidemiological, genomic, and omics data, the institute has expanded its scope to include multimodal data, such as medical imaging and life-log data, leveraging the latest digital technologies. Active research is being conducted to develop and apply AI technologies based on these datasets. This session will introduce the latest trends and real-world applications of AI research using multimodal healthcare data. Additionally, it will explore AI research conducted through projects supported by the National Institute of Health, discuss the future direction of healthcare AI research, and provide an opportunity to foster collaboration among researchers.

Session Chair	**Jae Pil Jeon, Director General, Precision Medicine, National Institute of Health, Korea Disease Control and Prevention Agency**
09:30 ~ 10:00	**AI technologies for drug response prediction and biomarker discovery** Sun KIM, Professor/CEO, Computer Science and Engineering/ R&D division, Seoul National University/ AIGENDRIG Co. Ltd
10:00 ~ 10:20	**Predicting severity using a multi-omics data from a COVID-19 cohort** Inuk Jung, Associate Professor, School of Computer Science and Engineering, Kyungpook National University
10:20 ~ 10:40	**Lifelog Data Analysis Using Everyday Digital Devices and AI Applications** Jaeseok Yun, Associate professor, Dept. Internet of Things, Soonchunhyang University
10:40 ~ 11:00	**Developing a Mental Disorder Prediction Model Using Smart Wearables and Social Data** Sungkyu Park, Assistant Professor, Master of Data Science, KDI School of Public Policy and Management
11:00 ~ 11:20	**Preprocessing, Analysis, and AI Integration for Medical Imaging Data** Woo Hyun Shim, Associate Professor, Radiology, Asan Medical Center
11:20 ~ 11:30	**AI research using Korean Brain Image Data** SANG CHEOL KIM, Director, Division of Healthcare and Artificial Intelligence, National Institute of Health

Company Presentation

1 Growing Innovations Through Collaboration and Personalized Support

May 7 (Wed) 14:00~16:50, Rm.317

Join us for an engaging event, "Growing Innovation Through Collaboration and Personalized Support!" We're excited to welcome leading scientific heads from oncology, immunology, Discovery, Product Development & Supply (DPDS), neuroscience, and our new business development leaders. They will share their expertise, insights, and passion for the Korean market. During this event, you'll hear from our esteemed speakers about the latest advancements in their specialties and how collaboration can drive innovation in healthcare. It's a fantastic opportunity to connect, network, and explore how we can work together to create personalized solutions for patients in Korea. We can't wait to see you there and share our vision for a collaborative future in the life sciences! Let's inspire each other and grow together!

14:00 ~ 14:05	**Opening**
14:05 ~ 14:15	**Johnson&Johnson leader remarks** Dan Wang, Regional Head of J&J Innovation, Asia Pacific Johnson & Johnson
14:15 ~ 14:20	**Group Photo**
14:20 ~ 14:35	**Introduction of J&J Oncology team and what we're looking for** Stefan Hart, Senior Director, Scientific Innovation, Oncology, Johnson & Johnson
14:35 ~ 14:50	**Introduction of J&J Innovation Team Open (INTO) and what we're looking for** Kai Stoeber, Senior Director, EMEA External Innovation Lead, J&J Interventional Oncology, Johnson & Johnson
14:50 ~ 15:05	**Introduction of J&J Immunology and what we're looking for** Terence Rooney, Vice President, Rheumatology, Immunology Disease Area Leader, Johnson & Johnson
15:05 ~ 15:25	**Q&A**
15:25 ~ 15:40	**Introduction of J&J Discovery, Product Development & Supply (DPDS) and what we're looking for** Jay Lin, Senior Director, External Innovation, Discovery, Product Development & Supply, Johnson & Johnson
15:40 ~ 15:55	**Introduction of J&J New Business Development (New BD) and what we're looking for** Laurence Mallick, Director, New Business Development, Asia Pacific, Johnson & Johnson
15:55 ~ 16:10	**Introduction of J&J Nuero Science (NS) and what we're looking for** Terence Rooney, Vice President, Rheumatology, Immunology Disease Area Leader, Johnson & Johnson
16:10 ~ 16:30	**Q&A**
16:30 ~ 16:40	**QuickFire Challenge Announcement**
16:40 ~ 16:50	**Closing remarks** Sharon Chan, Vice President, J&J Innovation – JLABS Asia Pacific, Johnson & Johnson

Johnson&Johnson

Introduction

Johnson & Johnson JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors.
JLABS is a no-strings-attached model, which means innovators are free to develop their science and technology while holding on to their intellectual property. Our goal is to catalyze and accelerate the delivery of lifesaving, life-enhancing solutions to patients around the world.

Introduction of Products and Technologies

JLABS Korea activate the global JLABS network to enhance the competitiveness of Korean biotech and medtech startups, catalyzing the country's innovation ecosystem to serve the critical mission of enhancing and saving lives.
Our global network provides early-stage innovators with:
· Access to expertise & resources
· Funding & investor connections
· Programming and talent development
· Visibility
· Global Network

Company Name	Johnson & Johnson
Address	3F, Yonsei University Bongnae Building, 36 Chilpae-ro, Jung-gu, Seoul, Korea 04512
Tel.	+82 10 4972 2777
Website	https://jnjinnovation.com/locations/jlabs/jlabs-korea
E-mail	Hjoo8@its.jnj.com

Company Presentation

2 KHIDI-Amgen Science Academy – Bioday

May 8 (Thu) 10:00~12:00, Rm.317

The 'KHIDI-AMGEN Science Academy BioDay' is a distinguished open innovation program jointly organized by Amgen Korea and the Korea Health Industry Development Institute (KHIDI). Its primary goal is to promote knowledge exchange about Amgen's cutting-edge R&D technologies and strategies with local pharmaceutical and biotech companies, while also fostering networking opportunities. Since its inception in 2021, the program has annually invited Amgen's global R&D team to present various research domains and technologies of interest. Additionally, it offers insights into Amgen's business development and innovative strategies alongside the global Business Development team. This year's event, marking the fifth occasion, will feature Paul Burton, Senior Vice President (Chief Medical Officer) at Amgen, as the keynote speaker. He will discuss "AI and Amgen Future"

10:00 ~ 10:05	**Opening Remarks** Sooa Kim, Country Medical Director, Medical, Amgen Korea
10:05 ~ 10:45	**Keynote Session:AI & Amgen's future, TBD** Paul Burton, Senior Vice President and Chief Medical Officer, OCMO (Office of Chief Medical Officer), AMGEN
10:45 ~ 11:00	**Transforming Therapeutic Protein Discovery with Protein Design and Generative Biology** Ai Ching Lim, Associate Vice President, R&D, AMGEN
11:00 ~ 11:15	**Amgen Oncology: Engineering Breakthroughs in Cancer Research** Andy Rankin, Executive Director, R&D, AMGEN
11:15 ~ 11:30	**Advancing Science and Building Value Through Partnerships** Helen Kim, Executive Director, BD, Amgen
11:30 ~ 11:50	**Q&A and Discussion**
11:50 ~ 12:00	**Closing Remarks** Sooa Kim, Country Medical Director, Medical, Amgen Korea

AMGEN

Introduction

Amgen harnesses the best of biology and technology to fight the world's toughest diseases, and make people's lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today.
Amgen opened an affiliate in Korea in November, 2015, to market its innovative bio medicines for Korean patients under the mission of "To Serve Patients" in therapeutic areas of bone disease, cardiovascular, and oncology. Amgen Korea is committed to playing an active role in biotechnology and thereby helping to advance the growth of the local pharmaceutical industry.

Company Name	Amgen (Headquarters)
Address	One Amgen Center Drive Thousand Oaks, CA 91320-1799, USA
Website	https://www.amgen.com
BD proposal	https://www.amgenbd.com/s/opportunity-submission-form

Company Name	Amgen Korea
Address	20th Floor, Ferrum Tower, 19 Eulji-ro 5 gil, Jung-gu, Seoul, Korea (04539)
Tel.	+82-2-3434-4800
Fax	+82-2-6322-2754
Website	https://www.amgen.co.kr/
E-mail	Glee14@amgen.com

Company Presentation

3 ST Pharm's Journey to become a Solution Provider for RNA-based Therapeutics

May 8 (Thu) 13:30~14:30, Rm.317

ST Pharm is expanding its role as a comprehensive solution provider in the RNA therapeutics space, covering ASO, siRNA, guide RNA, mRNA, and circRNA, along with their formulations. This session will introduce ST Pharm's strategic growth, proprietary technologies, and manufacturing platforms that support partners in developing next-generation RNA-based drugs. Additionally, we will highlight the efficient and scalable process development of SmartCap®, a novel capping reagent essential for mRNA therapeutics, enabling improved capping efficiency and product quality.

13:30 ~ 14:00	**ST Pharm's Journey to become a Solution Provider for RNA-based Therapeutics [From ASO, siRNA, guide RNA, mRNA, circRNA and their formulations]** Kris S. Choi, Senior Vice President, Business Development, Operation and Marketing & Sales, ST PHARM
14:00 ~ 14:30	**Efficient and Scalable Process Development of the Novel mRNA Capping Reagent, SmartCap®** Jun Choi, Senior Vice President, R&D Center, ST PHARM

ST PHARM

Introduction

ST PHARM Co., Ltd. is a global custom API CDMO based in South Korea, specializing in small molecules, oligonucleotides, mRNA-LNPs, and xRNAs including circRNA and gRNA. The company operates two cGMP-certified facilities in Sihwa and Banwol and has a strong regulatory track record with agencies such as the US FDA, EMA, and PMDA.

With decades of expertise in nucleoside/tide chemistry, ST PHARM has supported antiviral drug development for HIV, HBV, and HCV. Since entering the oligonucleotide CDMO market in the early 2000s, it has become one of the top three global providers, supplying APIs for multiple commercialized oligonucleotide therapeutics.

ST PHARM has developed proprietary technologies such as SmartCap®, a 5′-capping analogue, and STLNP®, a novel lipid nanoparticle formulation, both of which were validated in a Phase I clinical trial for a SARS-CoV-2 mRNA vaccine. Leveraging its integrated expertise in nucleic acid and lipid-based drug development, ST PHARM provides manufacturing solutions to global pharmaceutical and biotech partners developing and commercializing RNA therapeutics.

Company Name	ST PHARM Co., Ltd.
Address	7F, I Park Tower Bldg., Yeongdongdae-ro 520, Gangnam-gu, Seoul, S.Korea (06170)
Tel.	+82-2-527-6367
Fax	+82-2-2035-8605
Website	https://www.stpharm.co.kr/en
E-mail	info@stpharm.co.kr

Company Presentation

4 Addressing Challenges in Antibody-Drug Conjugate Development

May 8 (Thu) 14:40~15:40, Rm.317

Antibody-drug conjugates (ADCs) represent a groundbreaking approach to cancer treatment. They involve combining monoclonal antibodies with chemotherapy drugs, enabling the precise targeting of cancer cells while minimizing damage to healthy tissues. Despite their considerable potential, the development of ADCs poses challenges such as conjugation efficiency, drug release at the target site, and side effect management. This report will explore the recent advancements in ADC technology, delve into the components that influence ADC functionality, and propose strategies to address the pivotal challenges encountered during the development phase, including optimizing the antibody, improving payload conjugation and evaluating payload delivery.

14:40 ~ 15:40

Addressing Challenges in Antibody-Drug Conjugate Development
ZHICHENG DONG, Product manager, Product Development Team, ACROBiosystems

BIOSYSTEMS Acro

Introduction

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in over 10 different cities within the United States, Switzerland, England and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.
ACROBiosystems' brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.
Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Company Name	ACROBiosystems
Address	1 Innovation Way, Newark, DE 19711, USA
Tel.	+1 800-810-0816
Fax	+1 888-377-6111
Website	https://kr.acrobiosystems.com/
E-mail	order.kr@acrobiosystems.com

Company Presentation

5 MSD Business Development & Licensing

May 9 (Fri) 10:00~11:00, Rm.317

MSD has established a strong legacy of transforming innovative research into life-saving medical breakthroughs, positively impacting millions of patients worldwide. From pioneering the first measles and mumps vaccines to developing advanced treatments for cancer and diabetes, we are a leader in the pharmaceutical industry, with operations in over 140 countries and a revenue of $64.2 billion in 2024. Building strategic partnerships is essential to our success. In 2024, over half of our human health revenue stemmed from acquisitions, alliances, and patents, supported by our business development & Licensing teams. We are committed to exploring innovative biomedical research across various therapeutic areas and modalities. In this seminar, I will discuss our interests and licensing opportunities, aiming to foster collaborations with Korean academic institutions and companies to drive future healthcare innovations.

Session Chair	**Chiyoung Ryu, Assoc. Director, Policy and Government Relations, MSD Korea**	
10:00 ~ 10:15	**MSD Business Development & Licensing -Invent with Us** Koji Yashiro, Director, Business Development and Licensing, MSD	
10:15 ~ 10:30	**Driving Healthcare Innovation: Collaboration with K-biopharma** Albert Kim, Managing Director, MSD Korea	
Panel Discussion		
Fostering Korea Biopharma Industry: Pathways to Global Collaboration		
10:30 ~ 11:00	Panel 1	Koji Yashiro, Director, Business Development and Licensing, MSD
	Panel 2	Albert Kim, Managing Director, MSD Korea
	Panel 3	Amy Lee, Executive Director, GCTO, MSD Korea

MSD

Introduction

A Legacy of Innovation

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD's development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines to patients. We operate in more than 140 countries and had revenue of $64.2 billion in 2024.

Partnering With MSD

We recognize that building partnerships is one of our most important jobs. In 2024 more than half of our human health revenue was attributable to acquisitions, alliance partnerships and patents and our team executed 75 significant business development transactions. We have BD professionals based in key innovation epicenters including Boston, San Francisco, London, Shanghai, Tokyo and our headquarters in Rahway, NJ.

We're pursuing the most innovative areas in biomedical research emerging today without regard to therapeutic area or modality and working on collaborations from discovery to clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

Company Name	MSD
Address	126 East Lincoln Avenue P.O. Box 2000 Rahway, NJ 07065 USA
Tel.	+1-908-740-4000
Website	http://msdlicensing.com
E-mail	mrlbdlm@merck.com

Company Presentation

6 Cell therapy and Quality control in manufacturing

May 9 (Fri) 11:10~12:10, Rm.317

Sysmex is a company that develops in vitro diagnostics, but has recently been active in the development of cell therapies. We also utilize our testing technology and know-how to provide quality control testing for cell manufacturing to pharmaceutical companies, bioventures, research institutes and medical institutions. In a presentation, Dr. Kim of Catholic Blood Hospital will introduce the latest cell therapy research. We will also introduce cell therapy and quality control in manufacturing.

11:10 ~ 11:40	HEEJE KIM, Director/Professor, Catholic Hematology Hospital, Seoul St Marys Hospital, College of Medicine, The Catholic University of Korea
11:40 ~ 12:10	Tomohiro Hayakawa, Vice President, Next Genereation Medical Business Development, Sysmex Corporation

sysmex

Introduction

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives.

Company Name	Sysmex Corporation
Address	4-4-4 Takatsukadai, Nishi-ku, Kobe 651-2271, Japan
Tel.	+81-78-991-1911
Fax	+81-78-992-3284
Website	https://www.sysmex.co.jp/en/
E-mail	info_rcm@sysmex.co.jp

05

Exhibition

BIO KOREA
KOREA 2025

BIO KOREA
KOREA 2025

Exhibition Overview

BIO KOREA 2025 Exhibition is anticipated to welcome over 300 companies and draw in approximately 20,000 visitors from around the globe. This prestigious event presents an unparalleled opportunity to exhibit state-of-the-art technologies and products within the pharmaceutical and bio-health industries, as well as to forge and augment market presence. With the active involvement of a multitude of companies and institutions from the bio-health sector, BIO KOREA 2025 serves as the ideal platform for fostering fruitful business engagements.

DATE	May 7(Wed) ~ May 9(Fri), 2025
VENUE	Hall C (3F), COEX
EXHIBITION CATEGORIES	Academic/University, Analytical Services, Business Development, CDMO/CMO, Cell Therapy Products, CRO, Digital Health System, Drug Delivery, Gene Therapy Drugs, Health Analytics, Hospital, Industry Association, Medical Instruments, Medical Supplies, Non-Profit Organization / Institute / Government, Protein Drug, Reagents for In vitro Diagnostics (IVD Reagents), Sales & Marketing, Synthetic drugs, Therapeutic Antibody, Vaccine
EXHIBITION HOURS	May 7(Wed) 10:00 ~ 17:00 May 8(Thu) 10:00 ~ 17:00 May 9(Fri) 10:00 ~ 16:00

2-BBB Medicines BV

Country
Netherlands

Booth No.
B11

CEO Name
Pieter Gaillard

Pavilion
Netherlands Bio Lounge

Main Sector
Professional Services and Consulting

Website
www.2-BBB.com

Company Description

2-BBB develops brain-targeted drug delivery systems combined with neuro-active molecules to create innovative treatments for brain and eye diseases. Its affiliate, Mireca Medicines GmbH in Germany, is a growing preclinical-stage startup pioneering cGMP analogue development to address disorders linked to dysregulated cGMP signaling. Targeting protein kinase G (PKG) and potassium channels Kv1.3 and Kv1.6, Mireca focuses on CNS and retinal diseases such as Retinitis Pigmentosa. Using proprietary delivery systems and a broad patent portfolio, Mireca is expanding its research into neuroprotective, neuroinflammatory, and systemic indications through strategic regional and global partnerships.

To Buy or Sell Technology/Product

1. Brain-targeted Drug Delivery Platform
2-BBB and its affiliate Mireca Medicines develop innovative therapies for brain and eye diseases using a proprietary CNS-targeted drug delivery system. The platform utilizes specific ligands on a liposomal base and supports clinical programs as well as partner-led proof-of-concept studies.
2. cGMP Analogues
cGMP analogues designed to treat CNS and retinal diseases like Retinitis Pigmentosa by targeting dysregulated cGMP signaling, PKG, and potassium channels Kv1.3/1.6. This technology is protected by a broad and active patent portfolio.
3. PEArlboost (PEA-based Nutraceutical)
PEArlboost is a patented nutraceutical mouth spray and shampoo using Palmitoylethanolamide (PEA) to support brain, eye, and skin health, while promoting pain relief and inflammation recovery.

360biolabs

Country
Australia

Booth No.
B1

Delegate Name
William Hunter

Pavilion
Australian National Pavilion

Main Sector
Professional Services and Consulting

Website
www.360biolabs.com

Company Description

360biolabs is Australia's most comprehensive specialty laboratory services company, providing bioanalytical clinical trial support for development of new therapeutics, vaccines and diagnostics in a quality-assured environment.

To Buy or Sell Technology/Product

We support pharmacokinetic (PK) analysis (small molecule, peptide and biologics), a diverse range of pharmacodynamic (PD) endpoints (including but not limited to flow cytometry, cytokine profiling, virus neutralisation, ELISPOT, qPCR, virological endpoints etc) and central lab services. 360biolabs provides a single laboratory for all of your global clinical trial requirements (Phase 1-4).
Combined with onsite technical support and training, companies will be able to scaleup and continue ongoing cGMP manufacturing for Phase 1, Phase 2 and Phase 3 clinical trials that meets both international and Australian requirements.

Companies will be able to manage their own manufacturing processes, giving them control over production and scheduling and the flexibility to use capacity across their pipeline, while preserving their intellectual property.

ABL Bio

Country
Republic of Korea

CEO Name
Sang Hoon Lee

Main Sector
Pharma

Website
http://ablbio.com

Booth No.
C11

Pavilion

Company Description
ABL Bio is a research-led biotechnology company, a pioneer in bispecific antibodies for immuno-oncology and neurodegenerative diseases. Delivering new approaches to address the highest unmet needs, we are committed to improving the lives of people all over the world.

To Buy or Sell Technology/Product
ABL Bio is a biotechnology company developing novel anticancer drugs and treatments for neurodegenerative diseases, centered around its IGF1R-based BBB shuttle platform, "Grabody-B," and its 4-1BB-based bispecific antibody platform, "Grabody-T."

Acceleration Consortium

Country
Canada

Contact Name
Brandon R. Suthernad, Director of Research Operations

Main Sector
Academic/Non-Profit

Website
https://acceleration.utoronto.ca/

Booth No.
C1

Pavilion
Embassy of Canada to the Republic of Korea

Company Description
Based at the University of Toronto, we are a global network of government, academia, and industry working to accelerate the discovery of materials using AI and robotics.

To Buy or Sell Technology/Product
Accelerated discovery of materials (such as small molecule drugs, semiconductors, polymers, and more) using AI and automation.

Acclime Corporate Services Australia Pty Ltd

Country
Australia

Booth No.
B1

Delegate Name
Luis Silva

Pavilion
Australian National Pavilion

Main Sector
Professional Services and Consulting

Website
https://australia.acclime.com/

Company Description

Acclime specializes in supporting **life sciences companies** looking to enter the **Australian** or **Asian** markets. Whether your goal is **R&D, clinical trials, asset investment, or establishing a local sales and marketing presence**, we provide **comprehensive market entry advisory, company incorporation, and operational support** to ensure a smooth expansion.

To Buy or Sell Technology/Product

Whether your goal is **R&D, clinical trials, asset investment, or establishing a local sales and marketing presence**, we provide **comprehensive market entry advisory, company incorporation, and operational support** to ensure a smooth expansion.
For **life sciences companies** in early or pre-clinical phases, Acclime advises on the benefits of conducting **R&D in Australia**, including access to the **government's R&D tax incentive**, which offers **up to 43.5 cents per dollar spent** on eligible activities.
For later-stage development or commercialization, we provide strategic support by:

- Helping businesses **scale in new markets** with tailored expansion strategies.
- Conducting **market studies**, including **product-market fit assessments** and **opportunity identification**.
- Facilitating **one-on-one meetings** with potential partners.
- Securing **distribution partners** to support market expansion and product distribution.

With **expertise across 15 Asian markets and Australia**, Acclime ensures businesses **navigate regulatory complexities, optimize operations, and achieve sustainable growth**. We'd be delighted to discuss **how we can support your expansion efforts**—let us know a convenient time to connect.

ACROBiosystems

Country
China

Booth No.
J19

CEO Name
YIDING CHEN

Pavilion

Main Sector
Pharma

Website
http://kr.acrobiosystems.com

Company Description

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in over 10 different cities within the United States, Switzerland, England and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes.

To Buy or Sell Technology/Product

ACROBiosystems' brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

AGC Biologics

Country
United States of America

Booth No.
F32

CEO Name
Alberto Santagostino

Pavilion

Main Sector
Professional Services and Consulting

Website
http://agcbio.com

Company Description
AGC Biologics is a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) delivering the highest standard of service as we work side-by-side with clients and partners.

To Buy or Sell Technology/Product
We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.

AGILEX BIOLABS

Country
Australia

Booth No.
C4

CEO Name
Stephen McIntyre

Pavilion

Main Sector
Professional Services and Consulting

Website
https://www.agilexbiolabs.com/

Company Description
Agilex Biolabs, Australia's largest most technologically advanced regulated bioanalytical and toxicology laboratory, provides reliable and defendable bioanalytical, biomarker, and toxicology data, enabling their clients globally to improve human health. They have been recognised for their scale and proven track record for large and small molecule bioanalysis including quality method development, method validation and sample analysis services.

To Buy or Sell Technology/Product
Agilex Biolabs' FDA inspected, world-class immunoassay and immunobiology laboratories feature state-of-the-art equipment, including Gyrolab xPlore, MSD Quickplex 120, Luminex Magpix, BD FACSymphony A3 flow cytometer and the droplet digital quantitative real-time analysis for RNA, siRNA, and miRNA clinical trials, which
includes vaccines and gene therapy trials. Agilex Biolabs has ISO/IEC17025 accreditation and OECD GLP recognition with NATA to ensure the highest quality standards are met for seamless end-to-end testing for preclinical to clinical analysis.

AIGEN Sciences

Country
Republic of Korea

CEO Name
Dr. Jaewoo Kang

Main Sector
Professional Services and Consulting

Website
https://www.aigensciences.com/

Booth No.
D11

Pavilion
DIPS 1000+ project

Company Description

AIGEN Sciences is an AI-powered drug discovery company in Seoul, South Korea. We specialize in creating next-generation therapies for oncology and genetically defined diseases. Our proprietary Agent LLM platform combines large language models, multi-omics, and medicinal chemistry to drastically reduce drug discovery timelines. Founded by experts from Korea University, AIGEN integrates cutting-edge systems biology and deep learning to deliver meaningful results faster.

To Buy or Sell Technology/Product

AIGEN's Agent LLM platform is a fully autonomous AI system for drug discovery. It performs literature mining, target ID, molecule generation, docking, ADMET prediction, and synthesis planning in a seamless loop. This system powers our internal pipeline, including AIG01 (SOS1 inhibitor for KRAS-mutant cancer) and AIG07 (USP1 inhibitor for HRD-positive tumors). The platform enables efficient discovery of lead compounds in oncology and rare diseases. We invite partners for co-development, target validation, or drug repurposing projects.

AIVIS Inc.

Country
Republic of Korea

CEO Name
DAEHONG LEE

Main Sector
Digital Health

Website
http://www.aivis.kr

Booth No.
D29

Pavilion

Company Description

Founded in 2021, AIVIS is dedicated to revolutionizing the accuracy of cancer diagnosis and treatment through AI-based digital pathology solutions. The company develops and supplies digital medical devices that precisely analyze digital pathology images with AI, enabling the detection of even ultra-low HER2 expression. AIVIS has demonstrated its technological excellence and product quality by securing both domestic and international certifications, including MFDS approval, ISO13485, and GMP certification.

To Buy or Sell Technology/Product

Digital Medical Device Products: Using a proprietary algorithm, the solution precisely detects and counts cell nuclei, cell membranes, and other features in histopathology images to support pathological diagnosis and treatment decisions.

[PathoAiD®-Qanti IHC]
- Quantitative analysis of four biomarkers: ER, PR, HER2, and Ki-67
- Precise analysis of HER2 Low/Ultra-Low expression
- Analysis of digital pathology scanned images

[PathoAiD®-Qanti Ki-67 micro]
- Quantitative analysis of the Ki-67 biomarker
- Microscopic image analysis
- Deployable without a digital pathology scanner

AJINOMOTO CELLiST KOREA CO., INC.

Country	Booth No.
Republic of Korea	G23
CEO Name	
SUGIYAMA MASAKAZU	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.ajinomotocellistkorea.com/	

Company Description

Ajinomoto Celllist Korea provides services such as the development and manufacturing of animal cell culture media, as well as contract production of media. Building on Ajinomoto's 30 years of expertise in serum-free media research, we have developed the CELLiST series, which contributes to the growth of the biopharmaceutical market with cutting-edge technology. Our commitment to high-quality, high-value-added pharmaceutical development drives our continuous growth in the industry.

To Buy or Sell Technology/Product

1. Product
We provide chemically-defined cell culture media that are effective for the growth and protein expression of CHO and HEK293 cell lines, as well as supplements that enhance titer improvement.

2. Service
We offer end-to-end services for customized product development, including custom media development, switch programs, media CMO, trace metal analysis, and more tailored solutions for customer-specific needs.

Amgen

Country	Booth No.
Republic of Korea	J11
CEO Name	
Suhee Shin	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.amgen.co.kr/	

Company Description

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.

To Buy or Sell Technology/Product

Amgen Korea, established in 2015, markets innovative bio-medicines for bone disease, cardiovascular, and oncology patients. It actively contributes to the growth of the Korean pharmaceutical industry through biotechnology.
- Osteoporosis : Prolia(Denosumab) for injection Pre-filled Syringe, Evenity(Romosozumab) for injection Pre-filled Syringe
- Lipid Lowering agent : Repatha(Evolocumab) for injection Pre-filled Pen
- Antineoplastic agent : Blincyto(Blinatumomab) for injection, Kyprolis(Carfilzomib) for injection, Lumakras(Sotorasib) tablet
- Cancer related bone disease : Xgeva(Denosumab) for injection Pre-filled Syringe

Amplia Therapeutics

Country	Booth No.
Australia	B1
Delegate Name	
Chris Burns	**Pavilion**
Main Sector	Australian National Pavilion
Pharma	
Website	
www.ampliatx.com	

Company Description

Amplia Therapeutics Limited (ASX:ATX) is an Australian drug development company with two small-molecule FAK inhibitors in our pipeline, narmafotinib (AMP945) and AMP886.

Our lead asset narmafotinib is currently in a Phase 2a trial in advanced pancreatic cancer, in Australia and Korea. The preliminary data is positive with the drug showing promising early signs of efficacy and good tolerability.

Amplia is interested in exploring regional out-licensing or co-development opportunities for our FAK inhibitors.

To Buy or Sell Technology/Product

Amplia is developing FAK inhibitors for use in oncology and fibrotic diseases.

Narmafotinib (AMP945) is the best-in-class FAK inhibitor and shows the highest selectivity amongst those in active clinical development. Higher selectivity is underlined by a favourable safety and tolerability profile in its recently completed phase 1 program.

Narmafotinib is currently being tested in a phase 2 trial in Pancreatic Cancer (in combination with standard of care) with sites in Australia and Korea.

Narmafotinib has been awarded Orphan Drug Designation by the US FDA for use in treating pancreatic cancer and IPF.

Anocca AB

Country	Booth No.
Sweden	A11
CEO Name	
Reagan Jarvis	**Pavilion**
Main Sector	Swedish Pavilion
Pharma	
Website	
www.anocca.com	

Company Description

Anocca is a rapidly growing, privately held biotechnology company focusing on the development of TCR-T cell therapies in oncology using its unique deep tech platform built for precision mapping of T-cell targets, and generation, characterization and optimization of targeted TCR assets. Based on standardized and automated analyses of engineered human cells, enabled by a set of unique biotechnologies and powered by a proprietary software ecosystem, our discovery engine fuels scalable development of TCR-T cell therapies to address the immense and unaddressed target space in solid tumors. The Anocca platform is validated and can be applied in the development of novel therapeutics in the autoimmune and infectious disease spaces.
Operating from state-of the-art R&D and GMP manufacturing facilities near Stockholm, and using non-viral gene engineering, the company is advancing its precision TCR-T cell therapies into clinical development.
Anocca's pipeline comprises more that 40 TCR-T oncology products that target driver mutation, dysregulated gene and onco-viral antigens in solid tumor cancers.
Following CTA approval in March 2025, Anocca is initiating a Phase I/2 multi-center European clinical trial with an in-house discovered, developed and manufactured KRAS:G12V A*11 TCR-T product in advanced pancreatic cancer.

To Buy or Sell Technology/Product

- Anocca is developing the broadest TCR-T oncology pipeline in the world
- Over 40 products are in development that are specific for a range of solid tumor targets, including driver mutation, dysregulated gene, and onco-viral targets.
- One product, targeting mutant KRAS, is in clinical development and 11 products are at the IND enabling stage. More information is here:

- https://www.anocca.com/pipeline/tcrt-oncology
- The Anocca platform has validated capabilities to map HLAI and HLAII peptide targets in diverse disease targets in addition to TCR discovery, novel characterization workflows and directed evolution for optimizing TCR function.
- Outside of oncology, Anocca's platform can be applied in the infectious and autoimmune disease spaces and is configured for approaches such as therapeutic and prophylactic vaccine design, TCR-Treg and tolerizing therapeutics.

APELOA PHARMACEUTICAL

APELOA 普洛

Country	Booth No.
China	E23
CEO Name	**Pavilion**
Brian Zhu, George Cai	
Main Sector	
Professional Services and Consulting	
Website	
http://www.apeloa.com	

Company Description

Apeloa CDMO is the contract manufacturing focused business of Apeloa, with strategically developed its business towards becoming one of the world's premier contract service organizations. Supported by a global network of manufacturing, development, and analytical facilities, Apeloa CDMO provides world-class discovery, development, and manufacturing services for Active Pharmaceutical Ingredients (APIs), Intermediates, and Registered Starting Materials (RSMs). The company's commitment to leading-edge science, best-in-class customer service, and regulatory compliance drives its success in the CDMO industry.

To Buy or Sell Technology/Product

1)8 manufacturing sites with cGMP, ISO9001, ISO14001, OSHAS18001 and IPMS certifications, 4 sites passed US FDA, 3 sites passed PMDA, 2 sites passed EDQM
2)Total chemical synthesis capacity: 11,000 m^3 (Stainless Steel/Glass/Hastelloy/Titanium alloy/Teflon)
3)Total bio-production capacity: 6,570 m^3 (Stainless Steel)
4) 3 new multi-functional API workshops for parallel productions at varied scales (658 m^3 in total)
5)High Potency API Facility for clinical & commercial scale (75 m^3 in total)

APROGEN

Country	Booth No.
Republic of Korea	D25
CEO Name	
Jaeseob Kim, Misuk Kim	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.aprogen.com	

Company Description

Aprogen is a fully integrated biopharmaceutical company in South Korea, focusing on the development of antibody biosimilars and novel antibody therapeutics. With its proprietary antibody engineering platform and GMP-compliant manufacturing facilities, the company develops biopharmaceuticals and provides CDMO services targeting global markets. Aprogen is expanding its global presence based on clinical and regulatory experience in the United States and Europe.

To Buy or Sell Technology/Product

Aprogen specializes in the development of high-value antibody biosimilars and next-generation biologics, leveraging advanced upstream technologies including perfusion-based cell culture systems. Our perfusion-based bioprocess enables efficient high-density cell cultivation, optimized for the production of complex monoclonal antibodies, offering excellent scalability and cost-efficiency.

Arontier Co., Ltd.

Country	Booth No.
Republic of Korea	D11
CEO Name	
Junsu Ko	**Pavilion**
Main Sector	DIPS 1000+ project
Digital Health	
Website	
https://www.arontier.co/	

Company Description

Arontier is a cutting-edge digital healthcare company spearheading innovation in global biohealthcare through its proprietary AI-driven drug discovery platform. By leveraging advanced artificial intelligence and deep learning, Arontier streamlines the entire drug development cycle—from data integration and analysis to hit candidate identification—making the process faster and more cost-effective than traditional experimental methods. With a commitment to precision medicine and robust data-driven decision-making, the company is dedicated to transforming how new drugs are discovered. Arontier actively collaborates with leading research institutions, pharmaceutical companies, and biotech innovators worldwide to create breakthrough solutions that ultimately enhance patient outcomes and improve global healthcare.

To Buy or Sell Technology/Product

Arontier's AD3 platform is an innovative AI-powered drug discovery system that leverages protein structure design for novel therapeutic development. It employs state-of-the-art deep learning algorithms to predict target protein–drug binding configurations and facilitates de novo design of new compounds. The platform offers a suite of services—including "Docking of Millions" for high-throughput screening with over 40 million compounds, and modules like "Monomer", "Complex" and "S-Pred" for detailed structural and stability analysis via molecular dynamics simulations. By integrating genomic, proteomic, and clinical data, AD3 delivers comprehensive insights into drug design, drastically reducing development time and costs compared to conventional laboratory-based approaches.

AstraZeneca Korea

Country
Republic of Korea

CEO Name
Se Whan Chon

Main Sector
Pharma

Website
https://www.astrazeneca.com/

Booth No.
A11

Pavilion
Swedish Pavilion

Company Description

Founded in May 1992, AstraZeneca Korea is a science-led biopharmaceutical business delivering life changing medicines to patients through innovative science and excellence in development and commercialization. It focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Rare disease, Cardiovascular, Renal & Metabolism, Respiratory and immunology.

To Buy or Sell Technology/Product

Oncology
• TAGRISSO (Small cell lung cancer, Non-small cell lung cancer)
• Imfinzi (Non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma)
• Lynparza (Ovarian cancer, Breast cancer)
• Faslodex (Breast cancer)
• Calquence (Chronic lymphocytic leukemia)
• Enhertu (Breast cancer)
• IRESSA (Non-small cell lung cancer)

Rare Disease
-Soliris (PNH, aHUS)
-Koselugo (Neurofibromatosis type 1)

Cardiovascular, Renal & Metabolism
• Sidapvia (Ty p e 2 diabetes)
• B r i l i n t a (A c u t e coronary syndrome)
• Atacand (high blood pressure)
• Fo r x i g a (Ty p e 2 diabetes, Chronic heart failure)

Respiratory and immunology.
• Symbicort (Asthma, COPD)
• Fasenra (Asthma)
• Daxas (COPD)
• Synagis (RSV)

Astrogen, Inc

Country	Booth No.
Republic of Korea	D11
CEO Name	
Su-Kyeong Hwang, MD, PhD	**Pavilion**
Main Sector	DIPS 1000+ project
Pharma	
Website	
www.astrogen.co.kr	

Company Description

Astrogen, Inc., founded in 2017 by pediatric neurologist Dr. Su-Kyeong Hwang, is a PE-backed specialty biopharmaceutical company focused on the research and development of innovative therapies for diseases with significant unmet needs in the central nervous system (CNS) field.

To Buy or Sell Technology/Product

Astrogen's lead program, AST-001, is a potential first-in-disease pharmacological therapy for core symptoms of autism spectrum disorder (ASD) in the pediatric population. AST-001 has been designated an orphan drug by Korea's MFDS and has completed Phase 3 in South Korea.

Astrogen's pipeline includes AST-035, a proprietary molecular glue degrader targeting glioblastoma multiforme (GBM) and hepatocellular carcinoma (HCC) indication, demonstrating strong blood-brain barrier penetration, oral bioavailability, potent preclinical efficacy, and favorable safety. Non-GLP toxicology and pre-formulation studies are ongoing.

Additionally, Astrogen is advancing preclinical programs for Rett Syndrome (AST-004) and ADHD (AST-031), reinforcing its focus on neurological and neurodevelopmental diseases.

Asymchem Labs.

Country	Booth No.
China	H31
CEO Name	
Hao Hong	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.asymchem.com.	

Company Description

Asymchem (Stock Code: 002821.SZ/6821.HK) is a global CDMO leader with 25 years of experience, providing one-stop solutions across the pharmaceutical value chain. Specializing in small molecules, chemical macromolecules, biologics, synthetic biology, and more, Asymchem operates R&D and manufacturing facilities in China, the U.S., and the U.K., supported by a team of 9,000 professionals. Trusted by global pharma and biotech leaders, Asymchem delivers cGMP-compliant, cost-effective services to accelerate drug development and address diverse client needs.

To Buy or Sell Technology/Product

Asymchem has established mature capabilities in chemical macromolecular, biologics, drug product services, clinical research services, synthetic biology, and technology transfer. Asymchem's commitment to excellence is reflected in its robust global presence, spanning R&D and manufacturing facilities in China, the United States, and United Kingdom.

Atuka Inc.

Country
Canada

CEO Name
Dr. Jonathan Brotchie

Main Sector
Pharma

Website
https://atuka.com/

Booth No.
C1

Pavilion
Embassy of Canada to the Republic of Korea

Company Description

Preclinical CRO: Historically focused on Parkinson's disease, we have now expanded our services to include cognition assessments, biodistribution studies (e.g., AAVs for gene therapy), and non-GLP safety evaluations.

To Buy or Sell Technology/Product

Specialists: We are experts in non-human primate models of neurodegenerative diseases, providing our partners with the most relevant and translatable data for their therapeutic development programs.

Key advantages: Atuka empowers our partners to make critical, informed decisions at the crucial juncture between preclinical and clinical phases of drug development. We leverage our unparalleled expertise in neuroscience and Parkinson's disease, along with a leading array of rodent and non-human primate models and gene therapy experience, to craft the most tailored programs for any potential therapeutic.

Study design: Unlike organizations that offer standardized approaches, we design each preclinical study based on the unique mode of action and potential indication of our partner's therapeutic. This ensures the highest degree of translatability to Phase II clinical proof-of-concept, whether for overall efficacy or target engagement.
Quality: Atuka delivers the highest-quality studies and data, interpreted by world-leading neuroscientists, to provide results that are consistently predictive and translatable.

Aucentra Therapeutics

Country
Australia

Delegate Name
Shudong Wang

Main Sector
Pharma

Website
www.aucentra.com

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Founded by Professor Shudong Wang in November 2017, Aucentra Therapeutics develops groundbreaking therapies that address critical unmet needs in the treatment of some of the most challenging cancers.
Aucentra's mission is to revolutionise cancer care by creating highly targeted and effective treatments with fewer side effects. In collaboration with the University of South Australia, Aucentra Therapeutics has developed a pipeline of seven robust proprietary anti-cancer compounds. These candidates are aimed at treating a broad range of cancers, including leukaemia, glioblastoma, and cancers of the breast, colon, lung, pancreas, and ovary.
Aucentra's expertise spans across drug discovery, manufacturing, and clinical trials, allowing them to streamline development and accelerate the transition from research to patient care. Aucentra Therapeutics is committed to advancing oncology treatments that demonstrate first-in-class or best-in-class efficacy, with significantly reduced toxicity compared to traditional therapies. This positions Aucentra Therapeutics at the forefront of oncology drug development, offering hope for innovative and transformative cancer treatments.

To Buy or Sell Technology/Product

Aucentra is advancing a pipeline of seven kinase inhibitors, either targeting CDKs, FLT3-ITD or TAM (Tyro3, AXL and Mer), with four key assets highlighted:

i. **Auceliciclib**, a second-generation CDK4/6 inhibitor, demonstrates exceptional potency and superior blood-brain barrier (BBB) penetration. Validated in Phase I/IIa trial, auceliciclib shows promising efficacy in advanced solid tumours and recurrent glioblastoma, coupled with a favourable safety profile, positioning it to address unmet needs in CNS malignancies and overcome limitations of existing therapies.

ii. **AU2-94**, a highly selective CDK4 inhibitor in late-stage preclinical development, combines potent antitumor activity with immunomodulatory effects, synergising with anti-PD1 therapies. Its superior BBB penetration targets brain tumours and metastases, with first-in-human trials in due course.
iii. **AU2-85**, a potent CDK8 inhibitor, demonstrates robust preclinical efficacy in AML, targeting both tumour cells and immune evasion through enhanced NK cell activity, positioning it as a novel hematologic oncology strategy.
iv. **AU7-55**, an oral TAM inhibitor, exhibits strong anti-cancer activity across various cell lines and induces tumour regression in animal models. Furthermore, it promotes cancer immunity by increasing CD3+/CD8+ T cells, highlighting its potential as an immunotherapy.

All these assets represent significant opportunities for strategic partnerships by out licensing/co-development, aiming to speedily advance to patients.

AULBIO

Country
Republic of Korea

CEO Name
Kim, Aram

Main Sector
Pharma

Website
http://aulbio.com/

Booth No.
G1

Pavilion
Rising Pavilion

Company Description

AULBIO is a bio-venture developing medicines based on innovative drug delivery technology. Using the Extenna microsphere platform technology, we are developing long-acting injectables for the treatment of obesity, diabetes, dementia, schizophrenia and prostate cancer that are administered once a month or once a quarter. In particular, we have been researching long-acting technologies for peptide drugs for many years. Our peptide pipeline includes monthly injectables of semaglutide, tirzepatide, exenatide and leuprolide.

To Buy or Sell Technology/Product

[Platform technology]
AULBIO's Extenna microsphere platform technology is advanced microfluidic technology. This technology is designed to enable uniform microsphere and high drug loading, and is a technology that maximizes production(KR2024/0172632).

[Pipeline]
· Semaglutide monthly injectables
· Tirzepatide monthly injectables
· Exenatide monthly injectables
· Leuprolide monthly and quarterly injectables
· Donepezil monthly injectables
· Varenicline monthly injectables

AUMC - CBNU

Country
Republic of Korea

CEO Name
Byungmin Ahn

Main Sector
Academic/Non-Profit

Website
https://iacf.ajou.ac.kr/iacf/index.do

Booth No.
D19

Pavilion

Company Description

Ajou University(Medical School)-Chungbuk National University Consortium, equipped with excellent technology commercialization capabilities, is focusing on the dissemination of healthcare research outcomes. Through the Biohealth Clinical Site-Linked Technology Commercialization Support Program by the Korea Health Industry Development Institute, the consortium aims to promote early commercialization and technological advancement of healthcare technologies by utilizing mutual infrastructure in the Gyeonggi-Chungcheong regions. It identifies promising commercialization technologies and the needs of local enterprises to achieve this goal.

To Buy or Sell Technology/Product

Ajou University Medical Center excels in advanced medical technology, biosignal analysis, precision medicine solutions, and innovative treatment research. Chungbuk National University Industry-Academic Cooperation Foundation demonstrates outstanding capabilities in the research and commercialization of cutting-edge biotechnology, including gene editing, biosensors, and cell therapy.

Aurigon GmbH

Country
Germany

CEO Name
Dr. István Gacsályi

Main Sector
Professional Services and Consulting

Website
https://aurigon.com

Booth No.
A1

Pavilion
Bavarian Pavilion c/o Bayern International GmbH

Company Description

Aurigon is an independent GLP-certified CRO dedicated to non-clinical services and since 2000 we are a trusted partner in drug-development. Since 2025 Aurigon further holds a full ISO 14385 accredidation.
We're big enough to provide a full service, but small enough to fully adapt to your needs.
• Our qualified staff consists of 70+ professionals, with 35+ years of experience.
• Our proven track record of 6500+ studies gives us a solid base to serve your needs.
• Your direct contact to the Study Director gives you full control of your study.
• We believe in long-term partnerships.
• Our flexible approach makes us a problem-solver in your projects; keeping your budget, timeline and goals.

To Buy or Sell Technology/Product

Aurigon offers a full range of in vivo and in vitro non-clinical services from development candidate to marketed products including:
• In vivo PK/PD
• In vitro ADME (in all animal species and human matrix)
• Bioanalytics on LC/MS/MS and ELISA platforms (method development, validation, sample measurement)
• Acute to chronic toxicology and safety pharmacology
• Genotoxicity and tailored immuntoxicology services
• In vitro and in vivo biocompatibility testing according to ISO-10993
• Customized biological activity assays for batch release (GMP)
Available species: mice, rats, guinea pigs, hamsters, rabbits, Beagle dogs and Göttingen mini pigs.
Available routes: oral, s.c., i.m., i.v. bolus and infusion, intranasal, sublingual, and more.
For more detailed information you may visit our website (www.aurigon.eu).

Autotelic Bio Inc.

Country
Republic of Korea

CEO Name
Tae Hun Kim

Main Sector
Pharma

Website
www.autotelic.co.kr

Booth No.
D11

Pavilion
DIPS 1000+ project

Company Description

Autotelic Bio is pioneering the development of next-generation RNA-based therapeutics to address serious unmet medical needs across oncology, neurodegenerative, inflammatory skin, and rare diseases.
ASODE™ (AntiSense Oligonucleotide DEvelopment) is an integrated, AI-driven platform that supports the full spectrum of ASO drug development—from sequence design through in vitro and in vivo validation—accelerating discovery timelines, reducing R&D costs, and improving success rates.
atDOA™ (Advanced Targeting Delivery of ASO) enables precise, tissue-specific delivery of ASO, enhancing efficacy, safety, and tolerability, with a particular focus on targeted delivery to the brain, skin, and tumors.

To Buy or Sell Technology/Product

ATB-101 is an IMD/FDC that combines dapagliflozin, a treatment for diabetes, and olmesartanl, a treatment for hypertension, into a single formulation with enhanced blood pressure-lowering efficacy. This IMD offers a novel treatment for patients with both diabetes and hypertension, with plans to expand to chronic kidney disease.
ATB-720 is a first-in-class ASO pipeline targeting Chitinase-3-like protein1 by inhibiting CHI3L1 mRNA. It is the first AI-driven program on the ASODE™ platform, which identified multiple active ASO candidates within three months, validating the platform's enhanced capability.

Avance Clinical

Country
Australia

Delegate Name
YoungJi (Jessica) Han

Main Sector
Professional Services and Consulting

Website
www.avancecro.com

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, will attend BIO Korea 2025 to meet with biotechs and share clinical trial capabilities across the region including Australia, New Zealand, South Korea, Taiwan, North America and beyond.
The conference is scheduled from May 7 to 9 2025, at COEX in Seoul. This year marks the 20th edition of BIO KOREA, which is recognized as Korea's largest international life sciences convention, organized by the Korea Health Industry Development Institute (KHIDI).
Avance Clinical's Director, Asian Operations, Jessica Han; Associate Director, Operations Taiwan, Kelly Yang; SE Asia, Scientific and Regulatory Affairs Senior Specialist, Hee NamGung; Associate Director, Business Development, James Lumicisi; and Director of Strategic Partnerships, Robert Jones, will be attending and available for partnering meetings at BIO KOREA 2025.
Jessica Han, based in Seoul, brings over 18 years of experience in healthcare and clinical research. As Director of Asian Operations, her leadership is instrumental in driving Avance Clinical's regional strategy and operational excellence across Asia.
Kelly Yang, with over 15 years in the pharmaceutical and clinical research industries, leads Avance Clinical's operations in Taiwan. Her strong background in clinical operations and project management reinforces our capabilities and local execution in the region.

Recently, Avance Clinical formalized strategic partnerships with leading Korean institutions, including CHA University Bundang Medical Center, Korea University Medicine, and Dong-A University Hospital. These Memorandums of Understanding (MOUs) strengthen Avance Clinical's capacity to offer flexible and high-quality clinical trial services across the Asia-Pacific region.
Jessica Han said, "Avance Clinical's participation in BIO KOREA 2025 underscores our commitment to advancing clinical research in South Korea and across the broader Asia region.

We look forward to meaningful engagement with industry leaders and uncovering new opportunities to drive innovation and growth in the bio-health sector.”

Avance Clinical offers a seamless solution for biotechs looking for a CRO partner with deep experience in regulatory strategy and site relationships across Asia, North America, Australia and New Zealand. Clients benefit from rapid start-up and patient recruitment, with global quality data accepted by all major regulatory authorities including the FDA and EMA. The Asia-Pacific region is increasingly attractive due to the patient recruitment advantages, high-quality data, and advanced medical infrastructure in countries such as South Korea.

The team will be at Booth B1 during the event.

To Buy or Sell Technology/Product

Avance Clinical is a leading Contract Research Organization (CRO) offering biotech companies faster, more flexible, and higher-quality clinical trial services. As the largest premium full-service CRO headquartered in Australia, Avance Clinical delivers globally accepted data across Australia, New Zealand, Asia, North America, and Europe for international biotechs. With 30 years of experience and expertise spanning over 250 indications, the company provides comprehensive clinical research services from early to late-phase trials.

• Discover Avance Clinical’s Australian Advantage and Asia Advantage

• Get into clinic faster with Avance Clinical’s ClinicReady service

• Learn about Avance Clinical’s GlobalReady model for biotechs

• Speak with our clinical trial experts about your upcoming study

• Book a meeting or request a proposal

Avion

Avion Full-Service CRO & Imaging Specialists

Country
Australia

Booth No.
B1

Delegate Name
Jerome Barley

Pavilion
Australian National Pavilion

Main Sector
Professional Services and Consulting

Website
www.avionmedical.com.au

Company Description

Avion Full-Service CRO & Research Imaging Specialists

Avion is a leading full-service CRO & research imaging specialist partner for clinical trials and medical research delivering end-to-end clinical trial solutions. With expertise in Oncology, Nuclear Medicine & Theranostics, Research Imaging, Dermatology, Nutrition and more, we partner with pharmaceutical, biotech, and medical device companies to ensure successful completion of trials in all stages of development.

Headquartered in Melbourne, Avion fully understand the highly favourable research environment that Australia provides and also work globally with far reaching capabilities and experience. Our team’s commitment to quality and innovation ensures seamless execution of complex clinical studies, providing tailored solutions to meet the unique needs of each trial, optimising outcomes and accelerating the development of life-changing treatments.

We specialise in early phase clinical trials and understand how critical and complex early-stage clinical development is. By leveraging decades of research experience and an unparalleled working relationship with industry and clinicians, we provide a solution that is driven by the latest knowledge to deliver on company needs. We also possess niche expertise in the clinical development of radiopharmaceuticals to ensure successful completion of theranostic projects.

To Buy or Sell Technology/Product

Avion is a leading full-service CRO & research imaging specialist partner for clinical trials and medical research delivering end-to-end clinical trial solutions:

- Study Startup
- Trial Design & Protocol Development
- Ethics & Regulatory
- Vendor Selection & Management
- Site Feasibility, Selection & Monitoring
- Project Management
- Recruitment & Retention
- Medical Monitoring
- Pharmacovigilence & Safety
- Data Management
- Biostatistics
- Logistics & Supply Chain Management

Axcelead Drug Discovery Partnerts, Inc.

Country	Booth No.
Japan	A22
CEO Name	**Pavilion**
Kengo Okada	
Main Sector	
Pharma	
Website	
http://axcelead-us.com	

Company Description

Axcelead Drug Discovery Partners (ADDP) is a Japan-based CRO offering end-to-end drug discovery solutions from target identification to IND-enabling studies. Founded as a spin-out from Takeda and now a JV with Teijin, Axcelead leverages deep scientific expertise, legacy data from 1,000+ projects, and a 1.5 million compound library. With over 370 researchers, including 100 PhDs, and fully integrated operations at its Shonan and Hino sites, the company delivers pharma-grade capabilities and flexible project-based models. Axcelead empowers global clients to accelerate discovery, reduce time to clinic, and co-create high-value drug candidates across diverse therapeutic areas and modalities.

To Buy or Sell Technology/Product

Axcelead provides an integrated discovery platform combining in-house wet lab excellence with AI-driven technologies. Services span hit finding, lead optimization, and IND-enabling studies across modalities like small molecules, peptides, oligonucleotides, and targeted protein degraders. Key technologies include high-throughput screening, cell-free assays, AI-based molecule generation, safety evaluation, and pharmacology profiling. Clients can fast-track discovery by leveraging ready-to-go compounds and curated project data from 1,000+ legacy programs. The platform supports therapeutic areas such as oncology, CNS, metabolic, and autoimmune diseases-delivering customized, scalable, and efficient solutions that boost success rates and shorten timelines.

AXXAM SPA

Country	Booth No.
Italy	N8
CEO Name	
Ciriaco Maraschiello	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.axxam.com	

Company Description

Axxam is a leading Contract Research Organization (CRO) providing integrated early discovery services across the life sciences industries. It is headquartered in Milan, Italy, with medicinal chemistry laboratories in Naples, Italy and a subsidiary in Cambridge (Boston), USA. Within the drug discovery disciplines, Axxam supports pharmaceutical and biotech companies, start-ups, patient foundations, and academic groups in their journey from target validation to lead optimization across all therapeutic areas and target classes. Our approach extends to the identification of new bioactive compounds for the food & beverage, flavors & fragrances, pet food, cosmetics, and perfume industries through our AXXSense platform.

To Buy or Sell Technology/Product

Cell-free (functional and binding) and cell-based (functional and phenotypic) assay development for hit identification campaigns and compound profiling activities.
Fully automated High-Throughput Screening stations (fluorescence, luminescence, TR-FRET, electrophysiology, phenotypic screenings, TaqMan and ASMS). Screening can be performed using Axxam proprietary compound collections (up to 450K small molecules) or external libraries.
Integrated hit characterization through physicochemical parameter analysis, ADME studies, and MedChem assessments, enabling more efficient lead selection, including hit expansion, computational chemistry, SAR studies, IP evaluation, and database support.
Expertise with challenging targets, iPS derived cells, RNA - Mitochondria - Lysosomes platform, aggregates/condensates assays, protein degradation, organellar electrophysiology and optogenetics.

AZothBio

Country	Booth No.
Republic of Korea	F2
CEO Name	
Jae-Min Shin	**Pavilion**
Main Sector	
Pharma	**Rising Pavilion**
Website	
https://www.azothbio.com/	

Company Description

AZothBio is a biotech company specializing in AI-driven drug discovery. Leveraging over 12 proprietary AI platforms, we offer AI-driven drug discovery services and specialize in small molecule drugs and advanced peptide-based delivery system development. With its innovative approach, AZothBio is transforming traditional drug development, accelerating the process of bringing new therapies to market while maintaining cost-effectiveness. Founded with a vision to integrate AI technology with bioscience expertise, AZothBio is dedicated to enhancing human life by tackling seemingly insurmountable challenges through the use of AI to decode and interpret vast bioscience datasets

To Buy or Sell Technology/Product

AZothBio's proprietary AI modules enhance key pharmaceutical R&D processes by streamlining compound generation, screening, and optimization, as well as supporting peptide design and drug metabolism prediction. These AI-driven tools accelerate the discovery of new therapeutics by improving the quality, safety, and efficacy of drug candidates. By reducing repetitive experimental steps and accelerating validation, our approach significantly increases development speed and cost efficiency. Our lead candidate, AZB-101, is an AI-designed small molecule developed for autoimmune disease treatment. It selectively targets the TYK2-JH2 kinase domain, minimizing JAK-related adverse effects. AZB 101 has demonstrated efficacy in both in vitro and in vivo proof-of-concept (PoC) studies, with early toxicity tests confirming a favorable safety profile. In addition, AZothBio provides intracellular organelle-targeting delivery systems that enhance precision in drug and gene delivery.

Using peptide-based carriers such as AZent N, AZent R, and AZent M, we can target specific cellular organelles—the nucleus, endoplasmic reticulum, and mitochondria—enabling more accurate and efficient delivery of therapeutic agents. This technology has the potential to improve the treatment of various diseases with greater precision and fewer side effects. AZothBio is setting new standards in drug development through the integration of advanced biotechnologies and AI, driving groundbreaking advancements in therapeutic solutions

BANSEOK PRECISION IND., CO., LTD.

Country	Booth No.
Republic of Korea	E29
CEO Name	
Seng Hak Lee	**Pavilion**
Main Sector	
Medical Device	
Website	
http://www.banseok.co.kr/	

Company Description

Banseok Precision, no. 1 dispenser manufacturer in Korea, can make any customized dispensing solution equipment with about 30 years of history and knowledge in various industrial, bio fields. From bio fluid filling for medical manufacturing, conformal coating in various bio materials, bonding components in surgical instruments, etc., Banseok Precision has all the experience of handling based on customer needs. It's only us who can handle this problem in Bio fields with more than 7 years of inspection and development, with desire for the technology in various fluid dispensing fields.

To Buy or Sell Technology/Product

Banseok has the world's only Coated needle technology which can handle the low-viscosity fluid material preventing the material climbs on the pipe due to surface tension. When the fluid climbs on the pipe, it causes the contamination of the product, and the fluid itself. Also the dispensed amount will never be accurate since the clustered fluid on the pipe will cause the dispensed variation to a huge rate. It's only us who can handle this problem in Bio fields with more than 7 years of inspection and development, with desire for the technology in various fluid dispensing fields.

Bayern International GmbH

Country	Booth No.
Germany	A1
CEO Name	
Martina Maschauer	**Pavilion**
Main Sector	Bavarian Pavilion c/o Bayern International GmbH
Academic/Non-Profit	
Website	
www.bayern-international.de	

Company Description

Welcome to BAVARIA /Meet Bavaria - The joint Bavarian company stand

Bavaria is situated in the south of Germany, right at the heart of Europe. Germany’s most successful state not only boasts an unparalleled natural beauty, but is also one of the world's leading high-tech locations: side by side, traditional family-run companies and global corporations create an outstanding economic landscape, with products and services that are in demand all over the world.
At our joint company stand, you can meet Bavarian companies and discover more about the latest developments, technologies and services. We help you establish new contacts with Bavarian companies and provide you with extensive information about Bavaria as a business location.

Bertis

Country	Booth No.
Republic of Korea	F19
CEO Name	
Seungman Han, Dongyoung Noh	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://bertis.com	

Company Description

Bertis is a pioneer of proteomics-based disease detection and therapy companion diagnostics. Bertis' capabilities range from cancer, non-cancer diseases biomarker discovery, low-cost diagnostics manufacturing and analysis services. Since its incorporation in 2014, the company has been focused on developing and improving technologies for early diagnosis solutions with the most advanced quantitative proteomics research, precision medicine based on discovering companion diagnostic markers, and target discovery for oncology drug development and personalized treatment. Flagship solutions include MASTOCHECK, the world’s first commercialized proteomics-based blood test for early breast cancer detection, and PASS, a service for integrative analysis of multi-omics data.

To Buy or Sell Technology/Product

Bertis was the first in the world to commercialize Mastocheck, a proteomics-based blood test for the early detection of breast cancer, and is currently conducting clinical studies on biomarkers for various types of cancer.

In addition, Bertis offers customized proteomics analysis services, leveraging its know-how in mass spectrometry-based biomarker development and commercialization for cancer and other major diseases, as well as its state-of-the-art mass spectrometry equipment.

BETHESDASOFT

Country	Booth No.
Republic of Korea	M6
CEO Name	
Moon Wi Whan	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.bethesdasoft.co.kr	

Company Description

Since its establishment in 2014, the company has been providing total clinical trial services, from clinical trial consulting to solution development and operation for the past 10 years. Its representative solution, myTrial, accelerates the clinical trial process for users and patients at various institutions, making it easy and convenient to proceed.

To Buy or Sell Technology/Product

myTrial complies with CDISC standards, ODM, and provides easy and intuitive functionality based on our experience in conducting various clinical trials. We use cloud servers to ensure server management, and our responsive web implementation makes it available on a variety of devices.

BIO Asia-Taiwan 2025

Country	Booth No.
Taiwan	A4
CEO Name	
Lee Cheng Liu, John See Lee	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
https://bioasiataiwan.com	

Company Description

BIO Asia-Taiwan is Asia's largest gathering of the biotechnology industry. This prestigious event is co-organized by the Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO)

Each year the event attracts global stakeholders to Taiwan to foster cross-border collaboration, showcase innovation, and advance the region's biotechnology ecosystem. It aims to serve as a reliable platform for international exchange and to develop long-term industry partnerships.

To Buy or Sell Technology/Product

BIO Asia-Taiwan brings together industry leaders, innovators, researchers, and investors from around the world-fostering global dialogue and partnerships across the life sciences and biotechnology sectors.

With its unique combination of events, including an international exhibition, BIO Partnering, and a full week of onsite programming, BIO Asia-Taiwan provides a trusted platform for connection, collaboration, and discovery.

Bio Design Lab

Country
Republic of Korea

Booth No.
A32

CEO Name
HyunJin Choi, Kwang-il Lim

Pavilion

Main Sector
Pharma

Website
http://www.biodesignlab.net

Company Description
Bio Design Lab (BDL) applies key concepts in systems and synthetic biology to develop safe and efficient viral vector platforms. BDL's viral vector platforms improve upon the current generation of retroviral and lentiviral vectors that have long established histories and well understood mechanisms of action. BDL's viral vector platforms are designed to be safer and more efficient at gene delivery than existing vectors. They serve as foundational technologies for therapies that require sustained gene expression.

To Buy or Sell Technology/Product
We developed RetroNext® and LentiNext® vector platforms to significantly improve safety and enhance transduction efficiency. RetroNext® and LentiNext® vector platforms were engineered to insert away from transcription start sites and genes, thereby minimizing the risks of clonal cell expansion and other detrimental events. Additionally, our vectors are more efficient at gene delivery than conventional vectors, which reduces the risk of immune responses and lowers production costs.

BioBigData.Korea

Country
Republic of Korea

Booth No.
I11

CEO Name
RONG-MIN BAEK

Pavilion

Main Sector
Academic/Non-Profit

Website
http://www.biobigdata.kr

Company Description
Established within Korea Health Industry Development Institute(KHIDI) in 2024, it is dedicated to the establishment of a bio-data bank on approximately 1 million persons in conjunction with four ministries/agencies: the Ministry of Health and Welfare(MOHW), Ministry of Science and ICT(MSIT), Ministry of Trade, Industry and Energy(MOITE), Korea Disease Control and Prevention Agency(KDCA). By building Korean integrated bio big-data, it aims to lay foundation for the nation to join the ranks of global bio-health powerhouses.

To Buy or Sell Technology/Product
It recruits participants with individual consent, obtains samples (blood, tissue, etc.) and collects data such as clinical information, public data, genomic data, and multi-omics data (transcriptome, proteome, metabolome), etc. The collected data are the building blocks of openly available/sharable data banks and bio banks as R&D infrastructure.

BioCina

Country	Booth No.
Australia	C5
CEO Name	
Mark Womack	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.biocina.com	

Company Description

BioCina delivers end-to-end solutions for biologics and small molecules. Our Adelaide facility offers a full suite of biologics services, including microbial, pDNA, mcDNA, mRNA, and LNP manufacturing, with world-class cell line development, process development, and GMP production. The Perth facility specializes in sterile fill-finish services, such as Blow-Fill-Seal (BFS), cytotoxic and non-cytotoxic vial filling, pre-filled syringes, and cartridges. With compliance to US FDA, EMA, Health Canada, and TGA standards, BioCina ensures reliable, high-quality manufacturing. Drug developers partnering with us benefit from tax incentives of up to 48.5%, alongside industry-leading on-time and full delivery, supporting seamless scaling and production.

To Buy or Sell Technology/Product

End-to-end capabilities: Cell line development, process development, microbial-based drug substance production, and sterile fill-finish for biologics and small molecules
Drug Substance:
- Modalities: Microbial, plasmid DNA (pDNA), minicircle DNA (mcDNA), messenger RNA (mRNA), and lipid nanoparticle (LNP)
- Capabilities: Advanced fermentation, chromatography skids, TFF systems, GMP mRNA production, and stability testing to support clinical and commercial production
Drug Product
- Formats: Blow-Fill-Seal (BFS) technology with seven Rommelag lines, cytotoxic/non-cytotoxic vial filling, pre-filled syringes and cartridges
- Capabilities: Includes high-capacity production with expertise in handling oxygen- and metal-sensitive formulations, supporting diverse drug delivery formats

Biocom California

Country	Booth No.
United States of America	A14
CEO Name	
Scott Tim	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
http://www.biocom.org	

Company Description

Biocom California is the leader and advocate for California's life science sector. We work on behalf of our members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs.

Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition.

To Buy or Sell Technology/Product

In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.

As the largest life science trade association in the world, we connect our members with the resources they need to seed, scale and succeed. For more information on Biocom California, please visit our website at www.biocom.org

BIOCYTOGEN

Country
China

Booth No.
H21

CEO Name
Yuelei Shen

Pavilion

Main Sector
Professional Services and Consulting

Website
http://en.biocytogen.com.cn/

Company Description

Biocytogen (02315.HK) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide.

To Buy or Sell Technology/Product

Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration.

BioDuro

Country
United States of America

Booth No.
H29

CEO Name
Armin Spura

Pavilion

Main Sector
Professional Services and Consulting

Website
http://bioduro.com

Company Description

BioDuro is a US company founded in 1996, and headquartered in Irvine, California. We leverage our broad capabilities and unique technology platforms to empower biotech and pharmaceutical partners worldwide. Our integrated approaches accelerate and de-risk new drug discovery and development, creating higher value outcomes for our clients. Committed to the highest standards of compliance and business operations, we maintain a science-driven, customer-oriented, innovative and people-focused culture.

As a pure-play CRDMO, BioDuro operates under one global standard, providing integrated, fast, and flexible services to meet the unique needs of our clients and accelerate development timelines.

To Buy or Sell Technology/Product

With more than 2,000+ scientists, we have 7 R&D and manufacturing campuses across the US and China. We offer fully integrated CRDMO services from discovery to commercial manufacturing across medicinal chemistry, biology, DMPK, drug substance and drug product, including multiple modalities small molecules, peptides, oligonucleotides and antibody drug conjugates.

Bioforum – The Data Masters

Country
Australia

Delegate Name
Otto Damsma

Main Sector
Professional Services and Consulting

Website
https://bioforumgroup.com/

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Bioforum is an international Biometrics focused CRO assisting Korean companies to undertake international clinical studies and collect, clean, integrate, and statistically analyse and report all data for submission to the US and European regulators, FDA and EMA, in compliance with regulatory data conventions (CDISC).

We assist Sponsors engaging and reaching agreement with the FDA for data integration and study pooling strategies to prepare the mandatory Integrated Summaries of Safety and Efficacy (ISS/ISE).

For international studies we create IBs, Protocols, EDC Databases, Tables/Listings/ Figures, Statistical Analyses, and Clinical Study Reports in close collaboration with the Sponsor's representatives. We often act as the central data centre for pivotal phase 2-3 international studies to gain efficiencies in time and money.

We offer real-time project status access and clinical data dashboards and analytics for Project Managers, Medical Monitors, Data Managers, Statisticians, and other stakeholders.

To Buy or Sell Technology/Product

Our processes in Biometrics are enabled by BioGRID (data visualization and data analytics), Smartsheet (real-time, online project status), JetConvert (automated conversion of raw data to SDTM datasets), Validify (automated system validation), EDC systems (Medidata, Veeva, Viedoc, etc.), and SAS and other statistical software solutions for Biostatistics.

Biointelect Pty Ltd

Country
Australia

CEO Name
Jacqui Wade

Main Sector
Professional Services and Consulting

Website
www.biointelect.com

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Biointelect is a world-leading strategic planning, research, and commercialisation advisory firm with clients in Australia and internationally. Our team of experts has deep knowledge of the life science ecosystem, local and global reach, and experience from research and clinical trials though to commercialisation, market access and health system policy shaping.

We partner every step of the way, ensuring the success of our clients' innovation. We have completed over 500 projects for 170 clients across various therapeutic areas, modalities and geographies. We offer a quality network, strategic advice, and technical expertise throughout the full innovation journey, streamlining project work in every phase of the development cycle. We deliver experience-driven insights, and high-quality, integrated, and tailored solutions, increasing confidence in the success of our client's goals.

Our full-service Contract Research Organisation (CRO) capabilities deliver clinical excellence and a bespoke approach catering to complex challenges, whilst leveraging the broader Biointelect capabilities in Commercialisation when required. Our Director Services support team can help international clients setup in Australia ensuring compliance and governance in accordance with local requirements. Our Early phase research and preclinical team can help with product development and commercialisation planning offering expertise starting with the end in mind.

Our Expert Regulatory team can support with product registration, regulatory and compliance strategy across key jurisdictions. Our Market Access, and economic modelling team can support with policy, market shaping and reimbursement ensuring that access to patients who need lifesaving medicines.

We work with Universities and Medical Research Institutions, Biotech and medtech companies, pharmaceutical companies, not-for-profit organisations, Industry associations and government.

BIOINTRON BIOLOGICAL

Country

United States of America

Booth No.

N29

CEO Name

Changchun Zha

Pavilion

Main Sector

Professional Services and Consulting

Website

http://www.biointron.com

Company Description

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.

Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 2,000 biotech and pharma companies worldwide. Contact us: +1(732)790-8340, or info@biointron.com. Visit our website: www.biointron.com

To Buy or Sell Technology/Product

VHH Antibody Discovery/Single B Cell Screening/Hybridoma Sequencing/High-throughput Fully Human Antibody Discovery Platform/Affinity Maturation/Antibody Humanization/HTP Recombinant Antibody Production/Bispecific Antibody Production/Large Scale Antibody Production/Afucosylated Antibody Expression/RushMab - Small Scale Expression Packages/Recombinant Protein Expression in Mammalian Cells & E.coli/CHO-K1 Stable Cell Line Generation/Commercial License for CHOK1BN

BioJapan 2025

Country	Booth No.
Japan	A5
CEO Name	
Minoru Yoshida, Takayuki Fujiwara	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://jcd-expo.jp/en/	

Company Description

We host BioJapan, the largest partnering event in Asia for the global biotech industry. BioJapan 2025 will take place from Oct. 8-10, 2025 in Yokohama, Japan. We anticipate over 20,000 one-to-one and company-to-company partnering meetings this year (Last year 22,045 meetings held in period). We are looking to partner international organizations with Japanese and Asian organizations, particularly those working in the pharmaceutical, regenerative medicine arenas and digital health.

To Buy or Sell Technology/Product

Largest biotech- , regenerative medicine-, healthtech- related exhibition / partnering event in Japan: Oct. 8-10, 2025.
Please refer to the attached file for additional information.
https://jcd-expo.jp/PDF/BJ2025_data_en_master.pdf

BioMed Linkage

Country	Booth No.
China	G28
CEO Name	
Baoli Wei	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
https://www.biomedlinkage.com/	

Company Description

BioMed Linkage offers comprehensive, one-stop solutions for CRO and CDMO services in China. We collaborate with top-tier CDMOs, pharmacology CROs, and GLP-certified CROs to provide end-to-end support in drug manufacturing, pharmacology, DMPK, and toxicology studies-designed to support both IND and NDA submissions.

We bring particular strengths in two key areas:
1. DMPK and toxicology studies specifically designed for IND and NDA regulatory submissions.
2. Extensive NHP capabilities in China, including disease models, as well as DMPK and toxicology studies in NHPs.

With an experienced, China-based project management team, we ensure high-quality execution and strict adherence to timelines.

To Buy or Sell Technology/Product

Pharmacology:
Our model capabilities include: NHP Disease Models | Oncology and lmmuno-Oncology |Autoimmune Inflammation | Metabolic/Liver Disease | Cardiovascular Disease | Bone Metabolism/Orthopedics | Respiratory Disease | Infectious Disease | Ocular Disease | CNS | Pain

DMPK and Toxicology:
Our strength lies in providing comprehensive DMPK and toxicology support, especially for IND/NDA-enabling studies. We excel in assessing a broad range of molecular entities, including: Small Molecules | Monoclonal, Bispecific, and Trispecific Antibodies | ADC | AAV | Oligo | mRNA | Cell Therapies.

Biorheologics Co., Ltd

(주)바이오리올로직스 Biorheologics Co., Ltd.

Country	Booth No.
Republic of Korea	L19
CEO Name	
Dong Hwan Lee	**Pavilion**
Main Sector	Jeonbuk Technopark
Digital Health	
Website	

Company Description

Korea's leading blood viscosity tech company enabling precise diagnostics in clinical settings.

To Buy or Sell Technology/Product

RHEOVIS 200 is the first medical device in Korea designed to quantitatively measure blood viscosity for blood flow analysis. It overcomes the limitations of conventional, ambiguous indicators of blood flow health by enabling objective, data-driven diagnostics. With automatic calibration, an intuitive user interface, and a compact design, it enhances usability and accessibility. The measurement results are digitized for easy EMR integration and data management. Applicable across various clinical settings, it supports chronic disease prevention and personalized health management through precise blood flow analysis.

BioSolution Co., Ltd.

BioSolution

Country	Booth No.
Republic of Korea	D22
CEO Name	
Young Soo Park, Taejin Yang	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.keraskin.co.kr/	

Company Description

Biosolution is a global leader in cell application technology and researches and develops cell therapy products and human tissue models.
The human tissue model developed with the technology and tissue engineering technology to isolate and culture cells from various human tissues is used as an alternative animal test method to evaluate the safety and effectiveness of cosmetics or medicines.

To Buy or Sell Technology/Product

Developed a safety/efficacy evaluation test method based on human tissue models.
Skin models and cornea models are listed in the OECD toxicity assessment guidelines.
The skin irritation test method for medical devices using human skin models (ISO 10993-23:2021) has been approved as an international standard test method by the International Organization for Standardization.
Regarding skin irritation and eye irritation tests, it has also obtained GLP certification from the Ministry of Food and Drug Safety.

BIOTOXTECH

Country
Republic of Korea

CEO Name
JongKoo Kang

Main Sector
Professional Services and Consulting

Website
http://biotoxtech.com

Booth No.
H18

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description
Biotoxtech is the first nonclinical toxicology CRO established in Korea, providing preclinical testing services to evaluate the safety of pharmaceuticals, medical devices, agrochemicals, food, cosmetics, and chemical substances. Made up of a team of highly qualified professionals and possessing state-of-the-art facilities, Biotoxtech also holds the largest number of GLP certifications in Korea, making the company a valued partner in meeting the regulatory standards of authorities worldwide, including in the United States, Japan, and Europe.

To Buy or Sell Technology/Product
Biotoxtech offers a wide range of GLP-compliant studies, including general toxicity, carcinogenicity, reproductive and developmental toxicity, genotoxicity, immunotoxicity, local toxicity, antigenicity, local tolerance, safety pharmacology, juvenile animal studies, and alternative test methods. Leveraging expertise in specialized administration routes, such as intravitreal and intrathecal dosing, as well as electronic data integrity systems and SEND conversion support, we provide reliable, preclinical solutions meeting international standards and tailored to our clients' needs.

BIP FOCUS

Country
Australia

Delegate Name
Jiwon Go

Main Sector
Professional Services and Consulting

Website
http://www.bipfocus.com

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description
BIP FOCUS is a leading consulting firm specializing in healthcare and technology, dedicated to helping clients expand their reach with innovative products and solutions. Our mission is to deliver customized services that create lasting value while supporting licensing and trading activities in regulated markets for pharmaceuticals, biotechnology, and medical devices. Additionally, we assist clients in accessing Australian government support for research and development (R&D) and provide guidance on establishing a corporate presence in Australia.

To Buy or Sell Technology/Product
Our core service offerings include:

- Business Development Consulting
- Global Partnership Building
- Licensing and Deal-Making
- Commercial Strategy Development
- Advisory Services for R&D and establishing a business in Australia

BK Instruments Inc.

Country
Republic of Korea

CEO Name
Geeduk Jeon, Seunghyun Shin

Main Sector
Medical Device

Website
http://www.bkinstruments.co.kr

Booth No.
F23

Pavilion

Company Description

BK Instruments Inc. established in 1999, is a trusted leader in analytical and spectroscopy solutions. At Bio Korea 2025, we would like to introduce Arxspan ELN and LOGS SDMS - cutting edge digital platforms that streamline data management, enhance collaboration, and ensure compliance in research environments. Our mission is to empower scientists with more efficient work flows through seamless integration of software and hardware. Backed by decades of expertise and customer-first service, BK Instruments Inc. is your partner in building the future of data-driven, digital laboratories.

To Buy or Sell Technology/Product

SciY's Arxspan ELN is a cloud-based electronic lab notebook that enables secure data capture, sharing, and real-time collaboration while ensuring regulatory compliance. It supports diverse data types and integrates with workflows like inventory and registration. LOGS is a scientific data management system (SDMS) that centralizes real-time data from instruments, automates collection, and minimizes error. It integrates with LIMS and analytical tools, offering fast search, cloud/on-premises deployment, and flexible scalability. Together, Arxspan ELN and LOGS drive digital transformation by enhancing efficiency, data integrity, and reproducibility in research and regulated environments.

Blisstech

Country
Republic of Korea

CEO Name
KIM Kyungbum

Main Sector
Medical Device

Website
www.blisstech.kr

Booth No.
M17

Pavilion
Gyeonggi Business & Science Accelerator

Company Description

Bristec's business and technology status focuses on developing medical devices for preventing bedsores using AI and sensor fusion technology. Key element technologies include smart mattress technology that optimizes body pressure distribution, AI-based body pressure and temperature and humidity monitoring systems, and electrorheological fluid (ERF) application pressure control technology. Currently, it has nine domestic and international patents registered, BEDSOREM brand patents secured, medical device class 1 certification, US FDA approval, and CES Innovation Award, and plans to accelerate its entry into the global market based on these achievements.

To Buy or Sell Technology/Product

Bristec has developed an AI-based smart bedsore prevention system that has shown an effect of reducing bedsore incidence by more than 60% compared to existing systems. This system features pressure distribution optimization, real-time monitoring, and automatic pressure control functions, and has improved response speed and accuracy compared to existing air mattresses.

BOTANIC HEALTHCARE

Country	Booth No.
India	B27
CEO Name	**Pavilion**
Gaurav Soni, Madhu Krishnamani	
Main Sector	
Pharma	
Website	
http://www.botanichealthcare.net/	

Company Description

Botanic Healthcare commands a leading position in the global nutraceutical and organic ingredient industry, distinguished by its mastery in the identification, development, and production of natural compounds through state-of-the-art and sustainable extraction technologies. With a robust R&D infrastructure and cutting-edge manufacturing facilities that adhere to the most stringent international quality and safety standards, we specialize in creating clinically validated botanical extracts and proprietary branded ingredients. Our expansive portfolio, catering to health and nutrition, personal care, and related industries, embodies excellence with its organic extracts, essential oils, and plant-based vitamins and minerals, setting new benchmarks in innovation and efficacy.

To Buy or Sell Technology/Product

Lipsobio®, powered by Dietary Fiber Stabilized (DFS) Technology, enhances nutrient absorption, stability, and efficacy. Using non-GMO sunflower lecithin and optimized formulations, our liposomal range includes Liposomal Vitamin C, Iron, Magnesium, Ashwagandha, Curcumin, and CoQ10, targeting immune support, energy, stress relief, and heart health. Scientifically validated through Cryo-EM, TEM, and clinical studies, Lipsobio® ensures superior bioavailability and sustained release. With state-of-the-art manufacturing and third-party validation, Botanic Healthcare is redefining liposomal science for functional foods, supplements, and personal care-delivering next-gen health solutions with proven efficacy.

BRAND INSTITUTE

Country	Booth No.
Republic of Korea	M1
CEO Name	**Pavilion**
Kurt Yoon, John Song	
Main Sector	
Pharma	
Website	
http://brandinstitute.com	

Company Description

Brand Institute is a U.S.-based healthcare naming agency, focusing its core expertise on the development of WHO International Nonproprietary Names (INN) as well as brand names that meet the stringent approval standards of global regulatory authorities such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and HC (Health Canada)

To Buy or Sell Technology/Product

Brand Institute specializes in creating product names, trademarks, and brand identities for the pharmaceutical, biotechnology, and healthcare sectors, leveraging its strengths in naming strategies and regulatory approval processes to support successful market entry.

Brexogen Inc.

Country	Booth No.
Republic of Korea	D11
CEO Name	
Sue Kim	**Pavilion**
Main Sector	DIPS 1000+ project
Pharma	
Website	
http://brexogen.com/	

Company Description

Brexogen is a clinical-stage biotech company developing therapeutic exosomes as a cell-free regenerative medicine. We have developed a cutting-edge platform technology called the BG-platform, which focuses on therapeutic exosomes targeting autoimmune diseases, metabolic diseases requiring regeneration, and neurodegenerative diseases. Our platform primarily utilizes iPSC-derived mesenchymal stem cells (MSCs) known as BxC, along with a priming procedure that enhances the therapeutic function of the exosomes they produce. Through this approach, we create exosomes enriched with specific therapeutic cargo tailored to various indications.

To Buy or Sell Technology/Product

Brexogen has developed a specialized exosome production platform technology (BG platform) to overcome the limitations of stem cell therapies. Instead of using stem cells directly as therapeutic agents, we use the function-enhanced exosome as an active drug to treat and alleviate various diseases. Exosomes produced using this technology can be utilized in the development of various exosome therapeutics targeting a wide range of indications. Currently, we have candidates for atopic dermatitis (AD), myocardial infarction (MI), and metabolic dysfunction-associated steatohepatitis (MASH). Clinical study with patients of AD program has been conducted in the US since 4Q, 2022. and it is planned to file IND of MI program in 4Q, 2025.

Business Sweden

Country	Booth No.
Republic of Korea	A11
CEO Name	
Johan Yong-suk Chun	**Pavilion**
Main Sector	Swedish Pavilion
Academic/Non-Profit	
Website	
https://www.business-sweden.com/	

Company Description

Business Sweden is dedicated to promoting Sweden as an attractive destination for international investment and supporting Swedish businesses to expand in the global market. It provides comprehensive support to foreign companies looking to establish or expand their operations in Sweden. By offering strategic insights, market intelligence, and access to a robust network of industry contacts, Business Sweden facilitates seamless entry into the Swedish market. The organisation assists with everything from identifying investment opportunities to navigating regulatory landscapes, ensuring that businesses can leverage Sweden's innovative environment, skilled workforce, and favourable business climate.

To Buy or Sell Technology/Product

Business Sweden is participating in Bio Korea 2025 together with leading Swedish companies in ATMP and innovative technology, including Anocca, Cellcolabs, NorthX Biologics, CCRM Nordic, Salipro, Quretech, and AstraZeneca Korea. We provide information on Sweden's life science industry, investment opportunities, and potential cross-border partnerships.

C&G UNITY

Country	Booth No.
Republic of Korea	D32
CEO Name	
Kevin Choi	**Pavilion**
Main Sector	
Medical Device	
Website	
http://cngunity.com	

Company Description

C&G Unity is a company that provides equipment in Korea by cooperating with excellent overseas manufacturers of laboratory and production equipment. We supply solutions for pharmaceutical and bio companies by importing proven equipment. We also build trust with our customers based on friendly and reliable technical services such as direct installation, immediate after-sales service, and detailed training.

Translated with DeepL.com (free version)

To Buy or Sell Technology/Product

We handle a wide range of process equipment needed in the pharmaceutical bio industry, including manufacturing equipment such as autoclaves, jet mills, continuous centrifuges, and large capacity dryers used for cell disruption in vaccine and liposome manufacturing, syrup and ointment manufacturing, and laboratory equipment such as moisture activity meters, concentrators, and titrators.

Calici

Country	Booth No.
Republic of Korea	F5
CEO Name	
Choi, Jae Mun	**Pavilion**
Main Sector	
Pharma	Rising Pavilion
Website	
https://calici.co/	

Company Description

Calici Inc. has developed Pharmaco-Net (http://pharmaco-net.org), an open AI platform for collaborative drug discovery, led by experts with over 20 years of experience in protein structure analysis. Designed as a global platform, Pharmaco-Net provides AI-powered solutions for efficient small molecule, peptide, and protein discovery based on structural biology. Currently, Pharmaco-Net serves diverse clients worldwide, including universities, national research institutes, and small to mid-sized pharmaceutical companies in South Korea, the United States, and Japan. Its applications extend beyond pharmaceuticals to natural product research, livestock, agriculture, and the cosmetics industry, offering a broad range of AI-driven solutions tailored to various scientific and commercial needs.

To Buy or Sell Technology/Product

1. Pharmaco-Net: AI-Driven Collaborative Drug Discovery Platform Pharmaco-Net (www.pharmaco-net.org) is an AI-powered collaborative drug discovery platform designed to facilitate seamless cooperation among researchers, pharmaceutical companies, and academic institutions. Operating as a SaaS model, it has grown from 21 users at launch in June 2023 to 496 users in 2024, reaching TRL 7 with over 25 real-world drug discovery projects completed.

2. Overcoming AI Hallucination through Expert Collaboration To address errors from AI models like AlphaFold3 and RF Diffusion, Pharmaco-Net integrates a Multi Human-in-the-Loop system, leveraging protein structure experts to validate and refine AI-generated predictions. This ensures a more reliable and accurate drug development process.

3. Node-per-Model (NpM) – Cost-Effective AI Approach Pharmaco-Net introduces the pharmaceutical industry's first Drag & Connect system, simplifying complex drug discovery tasks.

Its modular AI model reduces training costs by 1 million times while enhancing efficiency and accuracy, offering a scalable, cost-effective solution (patented technology).

4. AI & Big Data Integration – 14,000x Efficiency Boost By incorporating reinforcement learning-based exploration agents, Pharmaco-Net accelerates the screening of billions of compounds, reducing a 1,000-year computational challenge to just 25 days. Already deployed on dedicated servers at leading institutions, Pharmaco-Net is advancing its global expansion strategy to establish itself as the standard for AI-driven drug discovery.

Capio Biosciences Korea

Country
Republic of Korea

Booth No.
L11

CEO Name
William Hunter

Pavilion
Gangwon Technopark

Main Sector
Medical Device

Website
www.capiobiosciences.com

Company Description

◉Company
- Deliver A Highly Accurate Multi-Omic Liquid Biopsy Technology Platform To Develop High-Calue Oncology Diagnostics Across The Entire Cancer Journey
- Tools company focused on the development of new platform for oncology biomarkers cofounded in 2015

◉Scientific Advisory Board
- World-Leading Scientific Advisory Board with Recognized Global Leaders in Their Respective Fields
- Clinical Need : New oncology biomarkers needed for early detection, personalization of cancer treatment and monitoring therapy

To Buy or Sell Technology/Product

◉ Novel liquid biopsy platform, CapioCyte™
-The capture of Circulating Tumor Cells (CTCs) and tumor-derived exosomes (EVs) from whole blood

◉ Our Differentiation Vs. Existing Technologies
- Our Platform Incorporates Three Independently Effective Isolation Strategies That Overcome Previous Barriers

CARBOGEN AMICS

Country	Booth No.
Switzerland	N24
CEO Name	
Stephan Fritschi	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.carbogen-amcis.com	

Company Description

CARBOGEN AMCIS provides drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) - as well as drug products for preclinical studies, clinical trials and commercial use. Besides being a service provider we also offer high quality Cholesterol and Vitamin D analog products produced at our facility in The Netherlands. These products are used in a variety of markets around the globe.

To Buy or Sell Technology/Product

Drug Substance: API development and manufacturing.
Sterile Drug Product: Development and manufacturing of your injectable Drug Product.
Specialities: from GMP cosmetics to high quality Cholesterol and Vitamin D analog products.

Cardialysis B.V.

Country	Booth No.
Netherlands	B11
CEO Name	
Ernest Spitzer	**Pavilion**
Main Sector	
Professional Services and Consulting	Netherlands Bio Lounge
Website	
www.cardialysis.nl	

Company Description

Cardialysis, a leading Dutch cardiovascular research organization with over 40 years of experience and 400+ clinical trials, is eager to collaborate with Korean companies. Based in Rotterdam and founded at Erasmus Medical Center, it offers expertise in trial design, data management, and advanced cardiovascular imaging (QCA, OCT, IVUS). With access to 1,400+ European sites and data from 200,000+ patients, Cardialysis delivers global-standard, regulation-compliant results. Through its partnership with ECRI, it conducts international investigator-initiated trials and seeks Korean partners to co-develop innovative cardiovascular solutions.

To Buy or Sell Technology/Product

1. Cardiovascular CRO and Imaging Core Lab
Cardialysis is a Dutch CRO and core lab with 40+ years of experience and 400+ trials. It offers full-service support for cardiovascular studies, including trial design, recruitment, and data management.

2. Intracoronary Imaging and SYNTAX Score
Specializing in IVUS, OCT, and QCA, Cardialysis provides precise coronary imaging. It co-developed the SYNTAX score, widely used in coronary artery disease research and treatment planning.

3. Structural Heart Imaging (Echo, CT, MRI)
Cardialysis offers advanced imaging for heart failure and structural heart disease, supporting global approvals with precise data. It welcomes Korean partners at BioKorea 2025.

CAREGEN CO., LTD.

CAREGEN CO., LTD.

Country	Booth No.
Republic of Korea	J21
CEO Name	
Yongji Chung	**Pavilion**
Main Sector	
Medical Device	
Website	
http://caregen.co.kr	

Company Description

Caregen, a global leader in peptide research and development,is a global biotechnology company that has commercialized the unlimited expandability of its patented peptides as many innovative products since its establishment in 2001. Over 600 different functional peptides developed by Caregen for the past 19 years have opened new paradigm in the field of biotechnology by expanding its applications to cosmeceutical, Class III medical devices, food supplement, and pharmaceuticals.

To Buy or Sell Technology/Product

The protein we are researching and producing and the more than 600 different types of peptides developed to date have functions as substances acting on cells of various tissues of the human body, and are highly stabilized through many years of R & D and process technology development. We have built mass production technology in high purity and have the world class peptide manufacturing capability.

CARM

CARM 첨단재생의료산업협회 COUNCIL FOR ADVANCED REGENERATIVE MEDICINE

Country	Booth No.
Republic of Korea	G12
CEO Name	
Duck-joo Lee, Ducksang Kim	**Pavilion**
Main Sector	
Academic/Non-Profit	Korean Pavilion for Advanced Regenerative Medicine
Website	
http://carm.or.kr	

Company Description

CARM is a corporation-centered organization founded on May 9 of 2016 aiming to revitalize domestic advanced regenerative industry and lead in the global regenerative medicine market.

To Buy or Sell Technology/Product

- A Non-profit corporation affiliated with the MoHW
- 117 member organizations in total
- Regulation Improvement
- Open Innovation
- Global Networking

CBH Inc.

Country
Republic of Korea

CEO Name
Yoon Jongkyu

Main Sector
Medical Device

Website
http://c-bh.co.kr

Booth No.
L19

Pavilion
Jeonbuk Technopark

Company Description

It is a company that contributes to the world and people through health.
- CBH Inc. was established in 2016 to develop products that improve the quality of life of the people by looking at patients suffering from various diseases and improving disease prevention and treatment methods.
- We are constantly conducting research and development through the operation of a corporate research institute composed of professional engineers in each field, have been certified as a research institute company in recognition of its technology, and operate a more systematic organizational culture.
- We are doing our best to become a company that contributes to the laughter and mental and physical health of people around the world by delivering products that convey attractive and high-quality impressions based on the mission of "contributing to the world with health."

To Buy or Sell Technology/Product

Our portable waist towing device applies customized decompression towing technology to provide a lumbar spine treatment solution optimized for the patient's condition. It has superior technology compared to other companies' products through precise towing control and user-friendly design, and is manufactured in the form of a foldable bag for excellent mobility and convenience, enabling effective back pain management in various environments such as home, business trips, and medical sites.

CCRM

Country
Canada

CEO Name
Dr. Michael May

Main Sector
Academic/Non-Profit

Website
www.ccrm.ca

Booth No.
C1

Pavilion
Embassy of Canada to the Republic of Korea

Company Description

CCRM, a Canadian public-private partnership established with seed funding by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.

A network of academic researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding and infrastructure. CCRM sources and evaluates IP from around the globe, conducts development projects with partners, and establishes new companies built around strategic bundles of IP.

To Buy or Sell Technology/Product

CCRM has a 40,000 ft2 space dedicated to advanced cell manufacturing that includes a fully resourced process development facility and a GMP facility.

In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-scale CDMO for manufacturing gene-modified cells and viral vectors. CCRM is hosted by the University of Toronto and launched in 2011.

CCRM Nordic

Country	Booth No.
Sweden	A11
CEO Name	
Fredrik Wessberg	**Pavilion**
Main Sector	Swedish Pavilion
Pharma	
Website	
www.ccrmnordic.se	

Company Description

CCRM Nordic, a national not-for-profit organization that supports academic, small, and large industrial advanced therapy medicinal products (ATMP) developers to translate research and early-stage clinical programs into treatments for patients. With a strategic focus on eliminating ATMP development bottlenecks in Sweden, the Nordics, and Europe, CCRM Nordic offers the specialized expertise and facilities needed to support both company and process development. Further, the organization is developing a GMP facility to support the journey from concept to clinic, ensuring ATMP projects can achieve their full potential and eventually benefit patients.

To Buy or Sell Technology/Product

CCRM Nordic offers process development, analytics, and other contract services to cell and gene therapy and related technology developers.

CdmoGen Co., Ltd.

Country	Booth No.
Republic of Korea	B29
CEO Name	
KEERANG PARK	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.cdmogen.com/	

Company Description

CdmoGen is a gene therapy new drug development company specializing in therapeutics for ocular diseases.
It is also a one-stop, full-service CTDMO offering a comprehensive suite of customizable contract testing, development, and manufacturing services for virus vector- and mRNA technology-based biopharmaceuticals.

To Buy or Sell Technology/Product

CdmoGen provides various types of customized CDMO services, including GMP manufacturing, QC testing, and banking services for virus vector-based in-vivo and ex-vivo gene therapy products, and mRNA-based therapeutics, and other vaccines.
CdmoGen also provides CRO services for Advanced Therapy Medicinal Products (ATMPs). Included are GMP manufacturing In-Process Control (IPC) testing, as well as lot release test of DS and DP.

CEFO., CO. Ltd.

Country
Republic of Korea

CEO Name
Hyun Sook Park

Main Sector
Pharma

Website
http://cefobio.com/

Booth No.
G15

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description

CEFO was founded in September 2011 with the goal of researching, developing, and commercializing stem cell therapies. As a venture company, we have faced numerous challenges and trials, but thanks to the unwavering dedication of our employees in securing large-scale stem cell cultivation and differentiation technologies, we are now on the verge of achieving significant milestones.

To Buy or Sell Technology/Product

Currently, CEFO is focused on developing stem cell therapies for bone defects, with our first new drug targeting osteonecrosis of the femoral head (ONFH). In July 2021, we received Phase 1 clinical trial approval from the Ministry of Food and Drug Safety, produced clinical trial drugs in our own GMP facility, and conducted trials at Kyungpook National University Hospital. Based on the safety and exploratory efficacy data obtained in Phase 1, we secured approval for Phase 2 clinical trials in September 2024, marking a significant step forward.

CELLAMES Inc.

Country
Republic of Korea

CEO Name
Sang Jun Cho

Main Sector
Medical Device

Website
http://www.cellames.com

Booth No.
C27

Pavilion

Company Description

Cellames Inc. develops label-free, real-time impedance systems for monitoring cell growth, differentiation, cytotoxicity, and drug effects. We analyze drug toxicity reactions by measuring LFP of cardiac and neuron cells. Additionally, we develop disk electrode array plates with transparent electrodes for microscopy.

To Buy or Sell Technology/Product

1. The cell analysis systems are devices that monitor and analyze the cell activities in non-destructive and real-time by measuring the electrical signal of cells such as impedance and local field potential
2. By measuring impedance, can analyze cell activities such as cell differentiation and death and by measuring local field potential, can analyze activities of cardiomyocyte and neuron cells.

Cellcolabs

Country
Sweden

CEO Name
Mattias Bernow

Main Sector
Pharma

Website
cellcolabs.com

Booth No.
A11

Pavilion
Swedish Pavilion

Company Description

Cellcolabs is a Swedish biotech company specializing in industrial GMP production of high-quality mesenchymal stem cells. The company was founded on two decades of research conducted by Professor Katarina Le Blanc at Karolinska Institute in Sweden. Cellcolabs' mission is to leverage this expertise to provide high-quality stem cells on a larger scale, accelerate research and facilitate future market approvals. Today, Cellcolabs provides mesenchymal stem cells to patients and clinical trials in several continents.

To Buy or Sell Technology/Product

We offer GMP-grade and research-grade allogeneic mesenchymal stem cells (MSCs) for clinical and preclinical applications. We also produce custom-made MSC products from various sources.

Our manufacturing is EU-GMP approved by the Swedish Medical Products Agency. Our MSCs are xeno free and derived from bone marrow or adipose tissue.

CELLinCELLS

Country
Republic of Korea

CEO Name
Cho Jaejin

Main Sector
Pharma

Website
http://www.cellincells.com/

Booth No.
G18

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description

CELLinCELLS is a clinical-stage biotech company that develops advanced regenerative medicine therapies. Its proprietary "3D Tissue Reforming Technology Platform" for regenerative organoid therapy targets medical unmet needs in conditions such as skin, cartilage, and other regenerative therapies.

To Buy or Sell Technology/Product

3D Tissue Reforming Technology Platform: leveraging stem cell self-organization and human embryology principles to create organoids for regenerative therapies. This platform resolves key challenges in organoid manufacturing and commercialization, positioning us at the forefront of the organoid field.

CellPurics, Inc.

Country
Republic of Korea

CEO Name
Shin Ji-Woong

Main Sector
Professional Services and Consulting

Website
http://cellpurics.com

Booth No.
H22

Pavilion

Company Description
CellPurics is a specialized biopharmaceutical company in the field of companion animal medicine, developing stem cell therapies and immune cell therapies based on specialized stem cell and immune cell cultivation technologies. Additionally, leveraging its outstanding research team, facilities, and molecular biological analysis techniques, CellPurics provides a variety of preclinical efficacy evaluation services using various animal models. Particularly, it specializes in conducting efficacy assessments of immune oncology agents using humanized mice.

To Buy or Sell Technology/Product
CellPurics' Technologies and Services
1. Pet Mesenchymal Stem Cell Therapy:
- Harnesses stem cells isolated from the gonadal tissue of dogs and cats using large-scale culture and cryopreservation techniques
2. Mesenchymal Stem Cell Anti-inflammatory Activity Measurement Kit:
- Quantitatively measures the anti-inflammatory effects of stem cells using Multiplex Real-time PCR technology
3. Anti-Cancer Immunotherapy Efficacy Evaluation Services:
- Evaluates the efficacy of immunotherapeutic agents using diverse humanized mouse models
4. Molecular Biological Analysis Services:
- Conducts various molecular biological analyses including gene or protein expression analysis, cell signaling pathway analysis, and more

Celltrion

Country
Republic of Korea

CEO Name
Soyeon Yim

Main Sector
Pharma

Website
http://www.celltrion.com

Booth No.
I1

Pavilion

Company Description
Celltrion is a leading global biopharmaceutical company dedicated to improving the health and well-being of patients. We have presented a new paradigm to the global biologics market with the launch of the world's first monoclonal antibody biosimilar. Celltrion will continue to pursue its goal in promoting the health and well- being of patients.

To Buy or Sell Technology/Product
With the launch of the world's first mAb biosimilar, Remsima, we have successfully developed and commercialized various biosimilar products. Based on our experience and expertise in biosimilar development, we are also expanding our new drug pipeline.

Cencora PharmaLex

Country	Booth No.
Australia	B28
CEO Name	
Christopher Gauglitz	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.pharmalex.com/	

Company Description

PharmaLex is now part of Cencora, a leading global pharmaceutical solutions organization centered on improving lives around the world.

PharmaLex adds to Cencora's expanding suite of pharma solutions and serves the pharma, biotech, and medtech industries. We guide clients from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-elevated solutions to support clients through the entire product lifecycle.

To Buy or Sell Technology/Product

Development Consulting
Regulatory Affairs
Pharmacovigilance
Market Access
Medical Device and IVD Services
Quality Management & Compliance

Cenyx Biotech Inc.

Country	Booth No.
Republic of Korea	G19
CEO Name	
Seung-Hoon Lee	**Pavilion**
Main Sector	
Pharma	
Website	
https://cenyxbiotech.com/kr/index.php	

Company Description

Cenyx Biotech Inc. is a biotech company that uses the latest knowledge of nanocatalytic medicine, an exciting and emerging field of biomedicine, to develop diagnostic and therapeutic nanocompounds: nanozymes and nanoparticles.

To Buy or Sell Technology/Product

CX213 is a nanozyme drug candidate for the treatment of subarachnoid hemorrhage. Nanozymes are nanomaterials that exhibit enzyme-like activities in human body. CX213, as a nanozyme drug, inhibits the early inflammatory response after subarachnoid hemorrhage. CX213 which is currently in the preclinical stage of development, has demonstrated excellent biocompatibility, efficacy, and safety.

CHA University Digital Healthcare

Country
Republic of Korea

CEO Name
Won Tae Cha

Main Sector
Academic/Non-Profit

Website
http://aihealthcare.cha.ac.kr/

Booth No.
M15

Pavilion

Company Description

The Department of Digital Healthcare at CHA University is a major designed to cultivate professionals who will lead the digital transformation of future biohealth by fostering a comprehensive understanding of healthcare, industry, and social welfare, as well as the ability to utilize digital technologies

To Buy or Sell Technology/Product

- A specialized curriculum integrating the fields of biohealth and welfare with digital transformation and social change
- Fostering convergence professionals with expertise in healthcare policy, industry, and social welfare services.
- Cultivating versatile professionals equipped to work in hospitals, pharmaceutical and medical device companies, and social welfare organizations.
- Nurturing future leaders in digital health and medical welfare.
- Offering domestic and international internship programs to develop global talent in health and medical welfare.

Charles River Laboratories

Country
Republic of Korea

CEO Name
James C. Foster

Main Sector
Pharma

Website
https://www.criver.com/products-services/biologics-testing-solutions

Booth No.
F11

Pavilion

Company Description

For more than 75 years, Charles River has delivered solutions to accelerate the development of drugs, chemicals, and medical devices for the people and patients who need them. Our products and services support clients from basic research, discovery, and safety assessment, to manufacturing and commercialization. With this expansive end-to-end portfolio, global capacity, and proven scientific and regulatory advisors, our integrated approach enables maximum speed and confidence on the drive to market.
With over 40,000 tests run annually at our global biologics testing facilities and 200+ products supported. These include monoclonal antibodies/recombinant proteins, viral vectors, vaccines, and cell therapies.

To Buy or Sell Technology/Product

We can accelerate your new drugs development by providing Biologics Testing Solutions (Viral Clearance Studies, Cell Line/Protein Characterization, Cell Banking, Contamination & Impurity Testing), Cell Sourcing for Research and GMP Human Cells (Human Peripheral Blood Products, Human Stem Cells), Discovery (Integrated Drug Discovery, Antibody Discovery Services, Pharmacology Studies), Preclinical CRO Services for Safety Assessment (IND-Enabling Studies, Toxicology Services), Laboratory Sciences (Bioanalytical Services, Molecular Biology Services), Cell and Gene Therapy CDMO Solutions (Viral Vector Packaging Services, Viral Vector Manufacturing, Plasmid and Viral Vector Products), Microbial Testing for Quality Control (Endosafe® Endotoxin Testing, Accugenix® Microbial Identification & Strain Typing).

ChemCon GmbH

Country	Booth No.
Germany	N13
CEO Name	
Raphael Vogler	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://chemcon.com	

Company Description

ChemCon is a CDMO for APIs and fine chemicals specialized in transferring R&D projects into fully cGMP-compliant manufacturing processes. The FDA-inspected production facilities in Germany are optimized for g to multi kg quantities, as typically encountered in preclinical research and all clinical phases of API approval. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds including trace elements, polymers, and highly potent or controlled substances - all in full cGMP quality up to injection grade.

To Buy or Sell Technology/Product

Custom Development & Manufacturing
Synthesis and process development
GMP production
Analytical Services
APIs and fine chemicals
GMP polymers

CHEMSPACE

Country	Booth No.
Ukraine	N16
CEO Name	
Olga Tarkhanova	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://chem-space.com	

Company Description

Chemspace is a global provider of drug discovery services. Our platform integrates advanced Computational Chemistry, Bioinformatics, and Machine Learning-driven services to accelerate hit discovery and optimization. By exploring ultra-large chemical spaces like Freedom Space (142 billion molecules) and Enamine REAL Space (5 trillion molecules), we identify high-quality hit molecules for further biological validation. Additionally, our platform enables online searches across more than 13 billion small molecules and over 880,000 biologics, including antibodies, peptides, and proteins.

To Buy or Sell Technology/Product

Discovery CRO: We provide end-to-end services covering every facet of the Drug Discovery process up to pre-clinical studies.

The Largest Online Catalog: Our website offers powerful database functionality with advanced search options, providing quick access to over 13 billion molecules.

Purchasing SaaS: Chemspace's Purchasing Software as a Service (SaaS) is a complex solution designed to simplify the procurement process in a cost- and resource-effective way. To meet all your needs we offer a few integration options: Custom Platform, Punchout Site, and Chemspace API.

Chungcheongbuk-do

Country	Booth No.
Republic of Korea	I4
CEO Name	
Younghwan Kim	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
http://www.biotion.or.kr/	

Company Description

Chungcheongbuk-do Province is the center of the Korean bio industry with the Osong bio cluster, which was created by the government.
Osong has an optimal environment for industry, academy, research, hospital, and government to cooperate, such as the Ministry of Food and Drug Safety and Korea Disease Control and Prevention Agency.
In the future, we would like to become a global bio cluster by integrating KAIST Bio Campus, research institutes, and companies in the newly created Osong 3rd Industrial Complex.

To Buy or Sell Technology/Product

Not applicable

CIDGOH (Centre for Infectious Disease Genomics and One Health)

Country	Booth No.
Canada	C1
Contact Name	
Ms. Soyean Kim, Product Lead	**Pavilion**
Main Sector	
Academic/Non-Profit	**Embassy of Canada to the Republic of Korea**
Website	
https://cidgoh.ca/	

Company Description

CIDGOH, at Simon Fraser University, combines knowledge engineering techniques (e.g. ontology modeling, data curation, semantic web), bioinformatics tools (e.g. genomic sequence analysis, phylogenetic, comparative genomics, text mining, workflow and platform development) and molecular laboratory experiments (microbial genomics, metagenomics, eDNA, and virome) to understand the impact of infectious diseases on human and animal health.

Developing technologies to foster data harmonization and sharing, and building trusted networks of health care practitioners, researchers, and policy makers are therefore key focuses of the Centre.

To Buy or Sell Technology/Product

We are interested in working with partners to generate data, to analyze data, and to share (and re-use) data for the broader benefit of the scientific community.

Our facility includes a state-of-the-art molecular laboratory for microbial sample processing and omics data generation and access to high-performance computing clusters and cloud computing (courtesy of Compute Canada) to provide a “one-stop-shop” for research and collaboration

Cluster Biotechnology Bavaria c/o BioPark Regensburg GmbH

Country
Germany

CEO Name
Dr. Thomas Diefenthal

Main Sector
Professional Services and Consulting

Website
www.biopark-regensburg.de

Booth No.
A1

Pavilion
Bavarian Pavilion c/o Bayern International GmbH

Company Description

The Bavarian Biotechnology Cluster in Germany with a focus on medical biotechnology offers a unique and internationally outstanding ecosystem - with over 500 companies from the biopharma sector, two universities of excellence, a large number of renowned research institutions and a strong financial investor landscape. The cluster is home to a highly innovative biotech scene with hotspots in Munich, Regensburg, Würzburg, Straubing and Nuremberg/Erlangen.
BioPark Regensburg GmbH is an enterprise of the City of Regensburg and part of the Cluster. We operate at three laboratory buildings with an area of a total of 18,000 m2 on the grounds of the University and have currently 37 leaseholders with 683 employees. In the Regensburg Bioregion are 66 companies and 5,671 employees active.

To Buy or Sell Technology/Product

Current trends such as personalized medicine and diagnostics, the use of artificial intelligence (AI) and advancing digitalization play a central role. These developments enable more precise diagnoses, individualized therapies and more efficient drug development.
Especially for founders, the cluster offers comprehensive advice, tailored coaching and an outstanding network of experts and investors. Please find more details under https://www.bio-m.org/en/our-cluster/company-database.html

CMax Clinical Research

Country
Australia

Delegate Name
Dr. Shu Lam

Main Sector
Clinical trials site

Website
www.cmax.com.au

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

CMAX Clinical Research has been a leader in delivering early phase clinical trials for over 30 years, making it one of the most respected clinical trial businesses in Australia.

Their modern custom-built facility is equipped with 78 inpatient beds and located opposite Royal Adelaide Hospital and Adelaide's Bio-Med City, providing ready access to state-of-the-art facilities, equipment and world-class medical and pharmacology specialists.

As Australia's longest-operating early phase unit, CMAX conducts successful world-leading research for local and international clients, specialising in a range of early-phase trials and first-time-in-human studies (FTIH).

To Buy or Sell Technology/Product

- Complex adaptive FTIH protocols, including single ascending dose, multiple ascending doses (SAD/MAD)
- Food-effect studies, Drug-drug interaction (DDI) studies
- Bioequivalence/bioavailability/PK studies (505b2 programs)
- Vaccine studies at all phases
- Biosimilar protocols
- Early phase patient studies (currently no oncology), including proof-of-concept studies
- Experienced in most drug types; small and large molecule, GMO and gene therapies and most routes of administration
- Work in most therapeutic areas, able to support EEG monitoring, CSF sampling and 12-lead holter monitoring

CNUHH-APP

화순전남대학교병원 첨단정밀의료산업화지원센터 Accelerator Platform of Precision Medicine

Country
Republic of Korea

CEO Name
Jeong-Jun Min, Myeong-Geun Shin

Main Sector
Professional Services and Consulting

Website
http://cnuhhapp.cafe24.com/main.php

Booth No.
C23

Pavilion

Company Description

Chonnam National University Hwasun Hospital's Accelator Platform of Precision Medicine Industrialization Support Center, supported by the Ministry of Trade, established a foundation for industrializing precision medicine products using cancer big data, GLP infrastructure, and advanced equipment to accelerate diagnostic devices, new drug development, and nutraceutical commercialization

To Buy or Sell Technology/Product

Chonnam National University Hwasun Hospital's Accelator Platform of Precision Medicine Industrialization Support Center provides diverse corporate support services for the industrialization of high-value products like diagnostic devices, drug materials, and nutraceuticals. These include R&D using hospital resources, shared use of research equipment, non-clinical trials, clinical consulting, and technology commercialization.

CONNEXT Co., Ltd.

connexT Innovation for Regeneration

Country
Republic of Korea

CEO Name
Lee, Sangho

Main Sector
Pharma

Website
www.connext.co.kr

Booth No.
G7

Pavilion
Rising Pavilion

Company Description

Founded in 2017, Connext is a clinical-stage biotechnology company spun-off from a government-funded research institute in South Korea. Connext's pipeline includes a recombinant TLR5 agonist for radiation induced diseases (first-in-class), and recombinant collagenase for musculoskeletal diseases (best in-class). Connext is expanding indications to cover a wide range of therapeutic areas and is seeking opportunities to collaborate with partners globally.

To Buy or Sell Technology/Product

CNT201 (recombinant Collagenase Clostridium Histolyticum)
CNT201 is an injectable recombinant collagenase in development for fibrotic conditions, particularly Dupuytren's contracture. It works by breaking down collagen cords that cause contractures, improving finger mobility. CNT201 offers a potential biobetter (better biosimilar) alternative to an existing injectable, with its better quality already established, though superior efficacy will be validated through upcoming clinical trials. The combined prevalence in the US and major European markets (EU5) is around 16 million patients. CNT201 targets a major unmet need, especially in European markets where only surgical options are available. Connext is aiming for early EU market access around 2027, utilizing early access program in some European countries. Phase 1 study for Dupuytren's contracture patients is currently underway in Australia, and expected to complete in H1 2025.

CNT101 (xempritolimod, recombinant TLR5 agonist)
Innate immune activation by TLR5 agonists has been previously demonstrated to control inflammation and promote the regeneration of damaged tissues. Connext is developing a recombinant TLR5 agonist as a preventative therapeutic to limit the extent of downstream sequelae of radiation, such as acute radiation syndrome and acute graft vs. host disease (aGvHD).

Connext has successfully completed a Phase 1 study involving healthy volunteers, and the IND application for Phase 1 in aGvHD has been granted approval by the Korea Ministry of Food and Drug Safety (MFDS). In addition to the cancer supportive care, CNT101's application is potentially expanded into the immuno-oncology field as evidenced by an animal study, where CNT101 in combination with anti-PD-1 treatment enhances anti-tumor response

CPC Scientific. Inc

CPC scientific
Peptide Partners. Concept to Commercial.

Country	Booth No.
China	G31
CEO Name	**Pavilion**
Shawn Lee	
Main Sector	
Pharma	
Website	
http://cpcscientific.com/	

Company Description

Founded in 2001, we are one of the most comprehensive peptide-focused CRDMO globally offering complete life-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production.

To Buy or Sell Technology/Product

We focus on (i) contract research organization ("CRO") services, including peptide new chemical entity ("NCE") discovery synthesis; (ii) contract development and manufacturing organization ("CDMO") services, including peptide chemistry, manufacturing, and controls ("CMC") development; and (iii) contract manufacturing organization ("CMO") services, including peptide NCE and generic drug commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets in the United States, China, Japan, Europe, South Korea, and Australia. We also provide customers with peptide drug development, production, and CMC filing support services that meet regulatory requirements in major markets worldwide.

Curezma Pharmaceutical

Country
Australia

CEO Name
Jai Uniyal

Main Sector
Pharma

Website
https://curezma.com/

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Curezma is a Sydney based health start-up that provides breakthrough steroid-free solution for atopic dermatitis, commonly known as eczema.

Eczema (atopic dermatitis) is an incurable immune dysregulation skin disease and one of the most prevalent chronic inflammatory skin conditions globally.
It affects up to 2.8 million Australians and approximately 223 million people worldwide.

Curezma is Australia's first patented , steroid-free & clinically proven eczema care range.

Curezma successfully went through one of the largest clinical trials for any Australian over-the - counter (OTC) eczema care brand to ensure safety & efficacy of our products

We currently have a topical patented treatment range for mild-moderate eczema, and we are working on an advanced product range that will include an ingestible product that will enable us to address moderate to severe eczema.

Our mission is to provide an affordable and effective steroid-free solution for eczema, by addressing its root causes and symptoms.

Our vision is to create a world where eczema warriors can live their lives fully, free from the discomfort and limitations of eczema.

We work with Universities and Medical Research Institutions, Biotech and medtech companies, pharmaceutical companies, not-for-profit organisations, Industry associations and government.

To Buy or Sell Technology/Product

We currently have a topical eczema treatment range to address mild-moderate eczema.
Our unique formulation range utilizes naturally derived medical grade actives & ingredients to reduce trans-epidermal water loss (TEWL), retain moisture for extended periods, alleviate redness and inflammation immediately, all without steroids, parabens, sulphates, or preservatives.
Our current eczema treatment regime includes the following products:

- Hydrating Hypoallergenic Cleanser: A gentle formulation that contains prebiotic inulin to promote a healthy skin microbiome.
- Barrier Repair Serum: It uses our patented Skin Barrier Repair technology to restore & repair skin barrier function in less than five (5) days as proven in clinical trials.
- Intensive Ointment: It reduces occurrence of symptoms of eczema. It prevents trans-epidermal water loss (TEWL) and helps the skin to retain moisture for up to 100 hours.
- Anti-Flare Oil: It instantly relieves eczematic flare-ups by leveraging our patented technology and medical-grade biologically targeted actives. It offers an effective instant solution from skin redness, inflammation & itch.
-
- Our products are listed with Therapeutic Goods Administration (TGA) , clinically proven, hypoallergenic, dermatologically and paediatrician approved for eczema-prone skin.

Curi Bio

Country	Booth No.
United States of America	B22
CEO Name	
Heejoon Choi, Nicholas Geisse	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.curibio.com	

Company Description

"Human Data for Next Generation Medicines"
Curi Bio unlocks novel workflows and critical human data to inform R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio merges functional and analytical assessments for drug safety, efficacy, and potency.

To Buy or Sell Technology/Product

With a focus on human disease models of contractile and excitable tissues, Curi Bio has developed a workflow that spans the preclinical drug development process.

Cyagen

Country	Booth No.
China	I29
CEO Name	
Lanqing Han	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.cyagen.kr	

Company Description

Cyagen Biosciences is a leading Contract Research Organization (CRO) with nearly 20 years of experience, dedicated to accelerating drug discovery and development through the integration of data, algorithms, and advanced modeling techniques. Leveraging our expertise in genetically modified rodent models, we offer comprehensive preclinical services to meet the diverse needs of researchers worldwide.

To Buy or Sell Technology/Product

Combining cutting-edge AI technologies with extensive experience, Cyagen provides full-service solutions for target research, virus design and packaging, model construction, and efficacy evaluation. Our mission is to empower researchers across the globe by delivering innovative and intelligent solutions that drive breakthroughs in both fundamental research and drug development.

CYPROTEX | EVOTEC | JUST-EVOTEC BIOLOGICS

Country
United Kingdom

Booth No.
N23

CEO Name
Christian Wojczewski

Pavilion

Main Sector
Professional Services and Consulting

Website
http://www.cyprotex.com

Company Description

Cyprotex serves a number of different industries including the pharmaceutical and biotech, personal care and cosmetics, household products, and the chemical and agrochemical industries. We offer a comprehensive range of different services in the following areas:
ADME PK
Toxicology
Physicochemical Profiling
Modeling & Simulation

To Buy or Sell Technology/Product

Cyprotex offers a comprehensive and flexible range of in vitro and in vivo DMPK/ADME studies designed to cover from hit-to-lead and lead optimization phase through candidate selection and to the clinic . We also offer in vitro metabolite profiling, structural elucidation and DDI (drug-drug interaction) studies for IND and NDA submissions during preclinical development and clinical stage projects.

Cyron Therapeutics

Country
Republic of Korea

Booth No.
L11

CEO Name
Yoon Sangsoon

Pavilion
Gangwon Technopark

Main Sector
Pharma

Website
-

Company Description

Cyron Therapeutics, founded in June 2020 and headquartered in Daegu, South Korea, is a biotech company specializing in the discovery and development of therapeutic antibodies. With a strong focus on antibody-based modalities—including bispecific/trispecific antibodies, ADCs (antibody-drug conjugates), and T cell engagers—the company aims to deliver next-generation cancer immunotherapies. The R&D center is located in Seoul, and the team consists of 8 members, including seasoned experts in immunology, antibody engineering, and preclinical development.

To Buy or Sell Technology/Product

Cyron's core technologies include:
• T cell engager platform (Signal 2 TCE): A next-generation multispecific antibody platform that introduces co-stimulatory signals to enhance T cell potency and overcome tumor immune evasion. Lead asset (DLL3-targeting trispecific TCE) demonstrates superior in vitro and in vivo efficacy over competitors.
• DualBurster ADC platform: Combines immune checkpoint inhibition with ADC cytotoxic payloads using bispecific formats. Cyron is developing bispecific ADCs targeting CD155 and 2nd Tumor target, with humanized anti-CD155 antibody (hu5D1) showing high internalization, potent cytotoxicity, and promising tumor-specific selectivity in xenograft models.
• Antibody discovery services: Cyron offers a comprehensive antibody generation platform utilizing in vivo immunization with human antibody gene Tg mice and rapid selection using Beacon-based single B cell sequencing. The company actively partners for joint discovery and out-licensing of therapeutic antibodies.

The company's pipeline includes:
• DLL3 T cell engager (preclinical, targeting small cell lung cancer)
• CD155 ADC (preclinical, strong in vitro/in vivo data)
• Cancer-specific TROP2 ADC (in development with novel epitope selectivity)
With proprietary technology, differentiated targets, and validated preclinical data, Cyron is positioning itself as a next-generation antibody therapeutics leader.

D&C BIOTECHNOLOGY Inc.

Country	Booth No.
Republic of Korea	E3
CEO Name	**Pavilion**
SeongSu Park	Rising Pavilion
Main Sector	
Digital Health	
Website	
www.dncbiotechnology.com	

Company Description

D&C Biotechnology Co., Ltd., established in September 2021, develops next-generation in vitro diagnostic medical devices to address global healthcare challenges through innovation. The company has introduced the Cup Type KIT and Flexible Type urine analyzer, which improve the safety, accuracy, and efficiency of urine testing while overcoming the limitations of traditional methods. These advanced solutions aim to provide a more convenient and reliable diagnostic environment for both healthcare professionals and patients. By continuously researching and developing innovative diagnostic technologies, D&C Biotechnology enhances medical professionals' safety and efficiency while enabling early and precise disease detection. The company is committed to transforming urine testing practices worldwide and contributing to the advancement of global public health.

To Buy or Sell Technology/Product

[PRODUCT]
Simple Testing Process, High Accuracy
D&C Biotechnology offers innovative urine diagnostic solutions, including URINE CHECK-UP (a dedicated urine test cup kit), URINE CHECK-IT (a biochemical urine analyzer for medical institutions), and URINE CHECK-ER (a personal urine analyzer).

- The URINE CHECK-IT and URINE CHECK-ER devices are equipped with Flexible Optical Biosensor Technology, addressing key issues in conventional urine tests such as contamination, infection risks, complex procedures, and low accuracy. These devices enable a one-step testing process, significantly improving efficiency and reliability.

- With a Cup KIT-based system, users simply insert the collected sample into the device's insertion slot, and the test proceeds automatically.

[Key Differentiators]
- CUP Type Design eliminates direct contact with the sample, preventing contamination and secondary infection.
- Simplified Testing Process, reducing preparation steps from 8 to 1 for enhanced convenience.
- Advanced Optical Sensing Algorithm corrects reflectance, refractive index, and transmittance for improved precision.
- Flexible Optical Biosensor ensures optimal testing time based on the test parameters, enhancing accuracy.
- Automated Turbidity Analysis, replacing subjective visual inspection for greater objectivity and reliability.
- Expanded Interpretation Range, increasing evaluation criteria from 8-9 levels for more precise and quantitative results.

DAIHAN FCS Co.,Ltd

Country
Republic of Korea

Booth No.
H23

CEO Name
KANG CHIN CHUNG

Pavilion

Main Sector
Pharma

Website

Company Description
DAIHAN FCS Co., Ltd. handles the product line required for Cell & Gene Therapy research and commercial, and provides process support and development assistance with various knowledge and experience.
The product line handled includes products from CYTIVA and Aseptic Technologies S.A

To Buy or Sell Technology/Product
ASEPTIC TECHNOLOGIES S.A
1. Small Scale Fillings station
2. Refrigerated homogenization system
3. Single-use Closed-Vial

CYTIVA
1. Biorector
2. Cell Isolation & Centrifue
3. VIA-Freezer
4. VIA-THAW
5. Filter
6. Aseptic connector

DeepQure Inc.

Country
Republic of Korea

CEO Name
Keewan Kim

Main Sector
Medical Device

Website
http://www.deepqure.com

Booth No.
N7

Pavilion

Company Description

DeepQure is an innovative MedTech company developing 'HyperQure', the world's first laparoscopic renal denervation (RDN) device. By overcoming the limitations of conventional intravascular catheter-based RDN, DeepQure introduces a minimally invasive extravascular RDN technology, pioneering innvation in resistant hypertension treatment. The company is currently conducting clinical trials in Korea and the U.S. with a vision to expand globally.

To Buy or Sell Technology/Product

HyperQure is the world's first laparoscopic renal denervation (RDN) device, featuring extravascular RDN technology that overcomes the limitations of conventional intravascular methods.
By targeting sympathetic nerves externally around the renal artery with precise 360-degree ablation, HyperQure ensures enhanced nerve disruption and safety.
Beyond treating resistant hypertension, it also holds promise for reducing atrial fibrillation (Afib) recurrence, establishing a new standard in RDN therapy.

DELVEINSIGHT BUSINESS RESEARCH

Country
India

CEO Name
Dr. Vishal Agrwal

Main Sector
Professional Services and Consulting

Website
http://www.delveinsight.com

Booth No.
M16

Pavilion

Company Description

DelveInsight is a business consulting firm with deep expertise in the healthcare industry, with a core focus on the pharma and biotech sectors. The company consistently helps clients make informed decisions, driving better business performance and remarkable growth.

Since its inception, DelveInsight has been a pioneer in delivering cutting-edge services, enabling clients to anticipate market trends and stay ahead in a rapidly evolving industry.

To Buy or Sell Technology/Product

DelveInsight offers a range of specialized services tailored for the pharma and biotech industries. Here are three of its main services:

Market Intelligence & Competitive Insights - DelveInsight provides in-depth market research, competitive analysis, and strategic insights to help companies navigate the evolving healthcare landscape and make data-driven decisions.

Business Consulting & Growth Strategy - The firm offers expert consulting services, including portfolio management, asset valuation, and growth strategy development, empowering clients to optimize their market position and expand their business.

Pipeline & Drug Development Analysis - DelveInsight delivers comprehensive reports on drug pipelines, clinical trials etc

Dewcell, Inc.

Country	Booth No.
Republic of Korea	H14
CEO Name	
MinWoo Lee	**Pavilion**
Main Sector	Korean Pavilion for Advanced Regenerative Medicine
Pharma	
Website	
http://www.dewcell.com/	

Company Description

DewCell, Inc. possesses stem cell differentiation-based technology for the production of artificial platelets and is dedicated to R&D to ensure the stable supply of safe and consistent-quality products. DewCell, Inc will continue to pursue innovative technological development to realize a future where anyone can receive platelets instantly when needed.

To Buy or Sell Technology/Product

DewCell, Inc. has developed a proprietary platform technology that enables the differentiation and maturation of stem cells into platelet-producing cells within bioreactors. The resulting artificial platelets exhibit hemostatic functions and growth factor profiles comparable to, or exceeding, those of human blood-derived platelets. Leveraging these advanced properties, we are actively expanding into therapeutic applications such as arthritis treatment and the development of next-generation biomaterials.

DKSH Korea Ltd.

Country	Booth No.
Republic of Korea	D30
CEO Name	
Gye Rim Kim	**Pavilion**
Main Sector	
Medical Device	
Website	
http://www.dksh.kr/scs	

Company Description

The DKSH Machinery Business Unit's SCS (Scientific Solution) team is a comprehensive solutions provider in the pharmaceutical, biotechnology, laboratory, and scientific equipment fields, offering support for machinery, general equipment, consumables, applications, and services.

We help laboratories and production sites across various industries overcome complex challenges, improve results, and enhance productivity.

To Buy or Sell Technology/Product

* PythoN Tissue Dissociator:
An automated device for isolating single cells from tissue samples.

* Synthgene:
Provides raw materials for the R&D and production of mRNA therapeutics and vaccines (such as cap analogs, modified UTP, enzymes, etc.).

* Thermo Fisher Scientific Special Promotion
Take advantage of exclusive discounts from Thermo Fisher Scientific.

DLG LAW CORP.

Country
Republic of Korea

CEO Name
Won H. Cho, Hee Chul An

Main Sector
Professional Services and Consulting

Website
http://dlglaw.co.kr/

Booth No.
M4

Pavilion

Company Description
DLG Law Corporation provides specialized legal services for the Fourth Industrial Revolution, with a focus on startups, tech ventures, and M&A. We have strong expertise in ICT, AI, blockchain, Web3.0, content, media, healthcare, and fintech. Headquartered in Seoul, we operate offices and local desks in nine major countries worldwide

To Buy or Sell Technology/Product
Leveraging our expertise and extensive practical experience in legal services and the bio-industry, we offer tailored legal solutions for the bio and healthcare sectors. Our services include licensing agreements, domestic and international contracts, IP, M&A, regulatory compliance, and corporate legal affairs. The Healthcare Practice Group, composed of industry experts, supports global bio-market entry and regulatory strategies.

Dongguk University

Country
Republic of Korea

CEO Name
Sung Min Kim

Main Sector
Academic/Non-Profit

Website

Booth No.
C22

Pavilion

Company Description
Department of Medical Device and Healthcare and Department of Regulatory Science for Biohealth Medical Devices

To Buy or Sell Technology/Product
A hub for innovative and interdisciplinary education tailored to the full-cycle needs of the medical device industry-Dongguk University's Department of Medical Device Industry and Department of Regulatory Science for Biohealth Medical Devices.

DONGMOON ENT CO.,LTD.

동문이엔티(주)

Country	Booth No.
Republic of Korea	M5
CEO Name	
YO ILL SONG	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.dongmoonent.co.kr/	

Company Description

Dongmoonent is performing system integration, automation/plant, laboratory, and maintenance projects in various fields such as abnormal biology, pharmaceuticals, food, and environment.

To Buy or Sell Technology/Product

We install/operate and maintain various laboratory automation system equipment such as automatic hexane extractor, PCR, 2nd generation ATP measuring device, and ecotoxicity analyzer.

Dongwoo-GCS

DONGWOO GCS
Global Control Solution

Country	Booth No.
Republic of Korea	M13
CEO Name	
Min Woo Choi	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://gcsd.co.kr	

Company Description

Pharmaceutical / Biotech Solution provider for
Compliance
Security
System Asset management

To Buy or Sell Technology/Product

Octoplant is a solution that provide asset management of critical devices in pharmaceutical and biotech processes. The services includes version control/backup/disaster recovery of PLC programs and management Windows system as well as database.

DR.NOAH BIOTECH

DR.NOAH BIOTECH

Country
Republic of Korea

Booth No.
F8

CEO Name
Lee, Ji Hyun

Pavilion
Rising Pavilion

Main Sector
Pharma

Website
www.drnoahbiotech.com

Company Description

[AI-based New Drug Combination development company]
DR.NOAH BIOTECH is AI based pharmaceutical company that development of innovative new drug combination usig DR.NOAH's Unique AI platform, ARK. Our technology involves creating new drug combination with novel indications by using existing commercially available. Our area of interest is rare diseases related to neuronal and muscular disorders, but is not limited to them. To advance drug development quickly and effectively, we are developing and utilizing ARK. We have proven the accuracy of ARK with successful development of our pipeline. We are collaborating with pharmaceutical companies (Daewon Pharmaceutical, SK Chemicals, and Amore pacific) for co-development, based on ARK platform.

To Buy or Sell Technology/Product

<Pipeline>
1) NDC-002:
- The treatment for stroke recovery with Neuroprotection effect and Neurogenesis promoting effect.
- Finished clinical trial phase 1 in the Korea.

2) NDC-011
- The ALS treatment with motor neuron protection effect and motor neuron generation promoting effect
- Granted ODD from the US FDA
- Approved IND for clinical trial phase 1 in US FDA and it will be started in early of 2025.

3) NDC-026
- The DMD treatment with muscle atrophy inhibition effect and myocyte differentiation promoting effect.
- Granted RPDD and ODD from US FDA.

<ARK: AI Solution for New Drug Development>
ARK consists of four AI analysis programs

1) CombiNet: System that predicts the efficacy of single drugs or new drug combinations.
2) VLab: System that predicts binding affinity using drug structures and protein structures.
3) NeuroRG: Rapid drug efficacy screening system connected with HTS equipments.
4) SF-Rx: System that predicts interaction that ma occure when combining or co-administering durgs.

DSLAB, Inc

Country
Republic of Korea

CEO Name
Jo Deok Su

Main Sector
Medical Device

Website
www.lumi-pet.com

Booth No.
M17

Pavilion
Gyeonggi Business & Science Accelerator

Company Description
PBM Bio-OLED and Cooling-based home healthcare wearable device, Munelight, for cesarean section keloid wound treatment and pruritus relief. LumiPet Bio-OLED dish that can boost immunity while eating.

To Buy or Sell Technology/Product
The goal is to develop prototypes and applications of cooling photonic devices that can treat wounds (suturing), relieve pain, reduce inflammation, and relieve itching by utilizing photobiomodulation (PBM) or low-level light therapy technology and the cooling technology of thermoelectric devices. PBM phototherapy technology mainly uses red and near-infrared light to improve cell survival without side effects, induce new protein synthesis, and reduce inflammation and have been confirmed to have therapeutic effects in various diseases such as surgical sedation, joint disease, traumatic injury, lung disease, and brain disease depending on the intensity of the light.

Dt&C Bio GROUP

Country
Republic of Korea

CEO Name
Chaegyoo Park

Main Sector
Professional Services and Consulting

Website
http://www.dtncro.com

Booth No.
E19

Pavilion

Company Description
We are Dt&Bio Group, comprising Dt&CRO, HuScience, and SafeSoft. We offer services from non-clinical to clinical stages for pharmaceuticals, medical devices, cosmetics, and health foods. HuScience provides GCLP-certified analysis, and SafeSoft develops eClinical solutions, with CDMS (Epro) and C-LAB data meeting CDISC standards.

To Buy or Sell Technology/Product
One-stop testing from nonclinical to clinical with advanced PK/PD center and SEND data expertise.

DUKSAN PURE CHEMICALS CO., LTD.

REAGENTS DUKSAN

Country	Booth No.
Republic of Korea	A29
CEO Name	
Ko Young-Chae	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.duksan.kr	

Company Description

Founded in 1970, Duksan Pure Chemicals Co., Ltd. is a leading fine chemical company specializing in high-quality reagents and raw materials for the pharmaceutical and biotechnology industries. With continuous R&D and quality innovation, we provide optimized solutions across various industries worldwide.

To Buy or Sell Technology/Product

Duksan Pure Chemicals Co., Ltd. provides high-quality products optimized for the biotechnology industry. Our key offerings include 70% Iso-Propyl Alcohol and 70% Ethyl Alcohol in sterile and non-sterile spray forms, ensuring maximum safety and quality. The trigger mechanism is equipped with a 2-micron filter to prevent contamination, and sterile products are double-packaged for strict microbial control.

Embassy of the Kingdom of the Netherlands

NL Netherlands

Country	Booth No.
Netherlands	B11
CEO Name	
Peter van der Vliet	**Pavilion**
Main Sector	
Academic/Non-Profit	Netherlands Bio Lounge
Website	
http://www.netherlandsandyou.nl/web/south-korea/about-us	

Company Description

The Netherlands is a global leader in Life Sciences & Health (LSH), known for its innovation, research, and public-private partnerships. With over 3,100 companies and institutions in biotechnology, pharmaceuticals, medical tech, and digital health, it is a hub for R&D and clinical trials. The Embassy of the Kingdom of the Netherlands in South Korea strengthens trade relations and fosters collaboration between both countries. Through partnerships in key industries like life sciences, the Embassy supports knowledge exchange, policy dialogue, and innovation, aiming to drive advancements in healthcare at BIO KOREA 2025.

To Buy or Sell Technology/Product

The Embassy of the Kingdom of the Netherlands supports Dutch and Korean companies in the life sciences and health sectors by facilitating matchmaking, providing market insights, and organizing networking events. We host trade missions, investment forums, and policy dialogues to enhance bilateral cooperation. At BIO KOREA 2025, we'll host the NL Lounge with 10 Dutch companies, offering opportunities for collaboration. If you are interested in partnerships with participating Dutch companies, we encourage you to use the Partnering Center or contact the embassy. We aim to foster innovation and success in global healthcare through strategic connections.

emocog

emocog

Country	Booth No.
Republic of Korea	E1
CEO Name	
Noh Yoohun	**Pavilion**
Main Sector	Rising Pavilion
Digital Health	
Website	
emocog.com	

Company Description

Emocog builds an ecosystem that supports the entire patient journey, from dementia screening to diagnosis and treatment. To overcome the physical limitations of providing daily care for every patient, we offer an innovative solution leveraging digital technology. Emocog is a digital therapeutics-based platform company that implements a home-based healthcare integration system, enabling the prevention, early diagnosis, and management of chronic diseases at home.

To Buy or Sell Technology/Product

< Cogscreen >
Cogscreen is an assessment tool designed to evaluate cognitive function, detect dementia risk, and identify individuals who require further screening. This advanced tool includes depression and Subjective Cognitive Decline (SCD) questionnaires and meticulously analyzes memory and executive function. Users can access the test anytime, anywhere with ease, and complete a 5-minute self-assessment using a user-friendly interface optimized for elderly individuals.

< Cogthera >
Cogthera is a software as a medical device for improving memory. By periodically monitoring the cognitive function of patients and providing customized cognitive training, it strengthens the brain's neural network and enhances cognitive reserve. Cogthera simplifies interaction through a minimalistic design and advanced voice commands, making it accessible for all, including the elderly.

< Easy Breath >
EasyBreath is a software-based medical device designed for patients requiring pulmonary rehabilitation due to chronic obstructive pulmonary disease (COPD), asthma, lung cancer, or bronchiectasis. By analyzing exercise data collected through pulmonary rehabilitation assessments, EasyBreath delivers personalized exercise prescriptions and enables real-time monitoring to support effective rehabilitation therapy.

< Easy Cough >
EasyCough is an electrically powered medical device designed to assist patients with impaired cough function. By utilizing positive and negative pressure, it effectively clears airway secretions, reducing respiratory complications. Ideal for patients with respiratory diseases, tracheostomy, or post-surgical recovery, EasyCough enhances mucus clearance and supports at-home respiratory care.

ENCELL Co. Ltd.

Country
Republic of Korea

CEO Name
Jong-Wook Chang

Main Sector
Pharma

Website
http://www.encellinc.com/en/

Booth No.
H13

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description

Cell and Gene Therapy (CGT) CDMO and new drug development specialized company.

To Buy or Sell Technology/Product

ENCell Co., Ltd. was founded in 2018 by Professor Jong-Wook Chang of Samsung Medical Center. The company specializes in CDMO (Contract Development and Manufacturing Organization) services for advanced biopharmaceuticals, including cell and gene therapies. ENCell is also actively conducting clinical trials to commercialize EN001, a next-generation mesenchymal stem cell therapy aimed at treating rare and intractable diseases such as Charcot-Marie-Tooth disease type 1A, Duchenne muscular dystrophy, and sarcopenia.

ERBC

Country
France

CEO Name
Christophe PRIOU

Main Sector
Professional Services and Consulting

Website
https://www.erbc-group.com/

Booth No.
N9

Pavilion

Company Description

ERBC is a leading preclinical CRO dedicated to bridging the gap between research and clinical success. We provide innovative models and services that better predict the efficacy and safety of new compounds.
Our comprehensive portfolio of services, preclinical models, and expert consultancy empowers biopharmaceutical, chemical, agro-chemical, veterinarian drug and cosmetics industry professionals to de-risk innovation and accelerate R&D productivity.
Operating from state-of-the-art facilities in Europe, our highly qualified teams deliver a customer-centric approach, prioritizing the refinement of study design and execution. At ERBC, we are committed to advancing alternatives to animal testing, ensuring ethical and cutting-edge solutions for our clients.

To Buy or Sell Technology/Product

ERBC is a European preclinical CRO offering integrated services in regulatory toxicology, pharmacology, DMPK, bioanalysis, and clinical pathology. Our innovative translational models and NAMs support the development of drugs, chemicals, cosmetics, medical devices, and agrochemicals. With in vivo and in vitro platforms, scientific expertise, and GLP-compliant facilities, ERBC helps clients accelerate and de-risk their product development.

EuBiologics Co., Ltd.

Country
Republic of Korea

CEO Name
Youngkyu Song

Main Sector
Pharma

Website
http://www.eubiologics.com

Booth No.
N25

Pavilion

Company Description

Established in March 2010, our company is a bio venture company listed on the KOSDAQ market in January 2017. It is headquartered in Gangnam-gu, Seoul, and has the first and second factories and a corporate research center in Chuncheon.

To Buy or Sell Technology/Product

The oral cholera vaccine 'Euvichol-Plus' received WHO PQ approval in 2017 and has been supplied through UNICEF. We develop various vaccines using conjugate protein and adjuvant platforms and provide customized CRMO services and pharmaceuticals based on GMP facilities and expertise.

EverEx

Country
Republic of Korea

CEO Name
Chan Yoon

Main Sector
Digital Health

Website
http://everex.health

Booth No.
J27

Pavilion
Health Insurance Review & Assessment Service

Company Description

EverEx is a digital therapeutics company advancing musculoskeletal care through **vision AI-driven, prescription digital therapeutics**. Our solution delivers **personalized, exercise-based therapy** combined with **cognitive behavioral interventions**, targeting conditions such as low back pain, knee pain, shoulder rotator cuff injuries and ankylosing spondylitis.

To Buy or Sell Technology/Product

MORA Cure is EverEx's clinically validated **digital therapeutic (DTx)** for musculoskeletal pain, powered by **vision AI** and personalized rehabilitation. Our pipeline targets **knee pain, low back pain, and shoulder pain**, delivering adaptive exercise and cognitive behavioral therapy through mobile devices. In a **multicenter randomized controlled trial (RCT)** I nvolving **216 patients**, MORA Cure demonstrated proven **effectiveness and safety**, leading to significantly higher adherence, reduced pain, improved functional mobility, and increased muscle strength. By enabling remote, objective functional assessment and delivering individualized care at scale, EverEx is redefining musculoskeletal care with a mission:"Bringing Personalized Rehabilitation to Everyone."

Evonik Korea

Country	Booth No.
Republic of Korea	H27
CEO Name	
Jake Cho, Rachel Roh	**Pavilion**
Main Sector	
Pharma	
Website	
http://evonik.com	

Company Description

Evonik partners with the world's pharmaceutical, medical device and nutraceutical companies to advance human health. Our core competencies allow us to specialize where you need us most, ensuring access to the right people, products and capabilities. Our global network includes 10 manufacturing sites, 14 application and formulation laboratories and more than 20 sales offices.

To Buy or Sell Technology/Product

Parenteral Drug Delivery
Evonik supports global pharmaceutical companies by providing the development and production of complex injectable products requiring formulation technologies, such as lipid nanoparticles(LNP).
- RESOMER, LACTEL: Biodegradable polymers for sustainable pharmaceuticals

Cell Culture Application
Evonik's cell culture technologies address a wide range of biopharmaceutical research and development needs.
- cQrex: Specially developed dipeptides designed to enhance the performance of cell cultures

ExoCoBio Inc.

Country	Booth No.
Republic of Korea	G13
CEO Name	
Byong Seung Cho	**Pavilion**
Main Sector	
Pharma	Korean Pavilion for Advanced Regenerative Medicine
Website	
http://www.exocobio.com/	

Company Description

As a global leader in the field of exosomes, a next-generation innovative material, it is a biotech venture that researches and develops technologies in the fields of regeneration, anti-inflammation, and anti-cancer using exosomes derived from stem cells and non-stem cells. It is growing rapidly every year and achieved sales of KRW 95.4 billion in 2024. It plans to grow into a commercialization platform based on exosome regeneration aesthetics and regenerative medicine.

To Buy or Sell Technology/Product

ExoSCRT™ possesses high-efficiency/high-purity exosome production technology, and is leading the exosome-based medical aesthetic field for improving damaged skin with ASCE+™ 3 types (skin, hair, and intermediate) regenerative aesthetic products. In addition, it is developing new drugs for serious diseases such as atopic dermatitis and inflammatory bowel disease (IBD), ARDS and among them, therapy for atopic dermatitis is scheduled to receive IND for phase 1 clinical trial targeting US FDA.

Exollence Co., Ltd

Country	Booth No.
Republic of Korea	D11
CEO Name	
Kihwan Kwon	**Pavilion**
Main Sector	DIPS 1000+ project
Professional Services and Consulting	
Website	
https://www.exollence.com/	

Company Description

Excellence Co., Ltd. is a biopharmaceutical company harnessing extracellular vesicles to develop first-in-class therapeutics.

To Buy or Sell Technology/Product

Next-Generation Drug Delivery System - SWEET™ (Shock Wave Extracellular vesicles Engineering Technology) Platform Technology

FGK Clinical Research GmbH

Country	Booth No.
Germany	A1
CEO Name	
Martin Krauss (Founder and Owner)	**Pavilion**
Main Sector	Bavarian Pavilion c/o Bayern International GmbH
Professional Services and Consulting	
Website	
fgk-cro.com	

Company Description

FGK is an owner-driven clinical CRO, providing full service to biotechnology, medical device and pharmaceutical companies. With our 240 highly qualified medical, scientific and regulatory experts office-based in Europe and the US, we are the right size to manage international multi-center studies with hundreds of patients or single country studies with few patients, while still being small enough to guarantee a personal service to the sponsor.
With more than 22 years on the market, we have all knowledge necessary to guide you through the clinical trial process. Our experience spans all clinical phases and major indications, including rare diseases and personalized medicine approaches.

To Buy or Sell Technology/Product

Conduct of clinical trials including: clinical trial management and clinical monitoring, regulatory submissions, biostatistics, data management, eSolutions, medical writing, medical safety, quality assurance, pharmacovigilance, consulting services
All study phases, local or global approach including Europe and US (FGK CRO)

Representative Service: Provision of legal requirements of sponsor companies that do not have a subsidiary within the EU, Switzerland and the United Kingdom, for the purpose of performing clinical research projects in this region (FGK RS)
Services offered for clinical development in Europe: Legal Representative, SME Status Application, Orphan Drug Designation, Marketing Authorisation

Pharmacovigilance Service for Post-marketing phase (FGK PV)

FMC Korea Co

Country
Republic of Korea

CEO Name
Dong-Jin Jang

Main Sector
Professional Services and Consulting

Website
http://koreafmc.co.kr

Booth No.
L11

Pavilion
Gangwon Technopark

Company Description

- Korea FMC Co., Ltd. is a company specializing in pharmaceutical formulation research.
- Since its establishment in October 2023, it has been conducting joint research projects with various pharmaceutical companies.

To Buy or Sell Technology/Product

The company is developing its own R&D pipeline, with a particular focus on the development of GLP-1 generic products.

Four-O LAB

Country
Republic of Korea

CEO Name
KIM KYUNG SOO

Main Sector
Medical Device

Website
www.fourolab.com

Booth No.
M17

Pavilion
Gyeonggi Business & Science Accelerator

Company Description

After washing the soft endoscope scopes such as the upper and lower gastrointestinal endoscopes with purified water (or tap water), the device operates an electrolysis device to directly generate sodium hypochlorite (NaOCL), which has a sterilizing effect, and supply it to the disinfection tank. This device performs a high level of disinfection (contains 650 to 675 ppm or more of active free chlorine produced by electrolysis at the point of use) according to the Ministry of Health and Welfare notice.

To Buy or Sell Technology/Product

- Forlab's 'OCTA-SELL' is a disinfectant that is washed once and is not returned to the disinfectant storage tank, but is directly discharged into the sewer, so clean disinfectant can be used and there is no risk of cross-infection.
- Since a new disinfectant is used each time, the effective concentration is maintained to the highest level, so the risk of cross-infection is blocked at the source and additional medical expenses caused by cross-infection can be prevented.
- Our product uses purified salt to produce disinfectant, so it is environmentally friendly and does not use any chemicals.
- Existing disinfectants are disposed of as medical waste after reuse, so waste disposal costs are incurred, but our disinfectant uses purified salt, so it can be disposed of as sewage immediately after use, so there are no medical waste disposal costs.

FUJIFILM Corporation

FUJIFILM

Country	Booth No.
Japan	I23
CEO Name	**Pavilion**
Teiichi Goto	
Main Sector	
Professional Services and Consulting	
Website	
http://www.fujifilmpharma.com/	

Company Description

Fujifilm provides contract services supporting our partners in the development and manufacturing of innovative new therapies. At BIO KOREA 2025, the following two divisions will be present at the exhibition;

FUJIFILM Toyama Chemical, a specialized CDMO with unique technology platform and a state-of-the-art facility to support the commercialization of drugs based on lipid nanoparticles (LNPs) and liposomes. New mAb production facilities are under construction at the company's site in Japan.

FUJIFILM Diosynth Biotechnologies Japan, an industry-leading CDMO with global locations, offering a range of services for biologics, including antibodies, recombinant proteins, cell and gene therapies.

To Buy or Sell Technology/Product

Contract Services for;
-LNP-based pharmaceuticals
-Liposome based pharmaceuticals
-Cell Therapies
-Gene Therapies
-Monoclonal antibodies including ADCs
-Recombinant proteins
-Vaccines

Services are tailored to clients, typically including;
-Process and analytical development from early phase
-CMC support
-Manufacturing scale-up study
-cGMP clinical manufacturing
-Commercial manufacturing
-Fill & Finish services

More information available on the Partnering Center. Search "FUJIFILM Toyama Chemical" or "FUJIFILM Diosynth Biotechnologies Japan" and feel free to send meeting requests!

FUJIFILM Life Sciences Korea

Country
Republic of Korea

CEO Name
Jun Muto

Main Sector
Professional Services and Consulting

Website
http://www.irvinesci.com

Booth No.
H25

Pavilion

Company Description

FUJIFILM Life Sciences Korea is a life science company that provides cell culture media and services to support the development of the biopharmaceutical industry.

To Buy or Sell Technology/Product

We supply high-quality cell culture media for the development and production of Bioproduction and Cell & Gene therapy. We offer the entire range of FUJIFILM Irvine Scientific products, Vaccine Production Media from FUJIFILM Wako Pure Chemical.

Galux

Country
Republic of Korea

CEO Name
Chaok Seok

Main Sector
Pharma

Website
https://www.galux.co.kr/

Booth No.
D11

Pavilion
DIPS 1000+ project

Company Description

Galux is an AI-driven protein design company developing de novo therapeutic proteins to tackle some of the most challenging targets in drug discovery. Our proprietary platform, GaluxDesign, combines deep learning with physics-based modeling to design molecules with high precision, including epitope-specific antibodies. We are one of only few companies globally to have successfully designed epitope-specific antibodies from scratch against multiple therapeutically relevant targets, demonstrating the power and potential of our platform. Galux is advancing both internal pipeline projects and driving innovations through collaborations with biopharma partners to deliver next-generation biologics.

To Buy or Sell Technology/Product

GaluxDesign is built upon a deep understanding of the physical principles underlying protein folding and molecular interactions. This foundation enables a modality-agnostic approach, enabling the design of diverse therapeutic proteins across a wide range of targets. It's core capabilities lie in de novo protein design and simultaneous optimization of multiple molecular properties.

1. **De novo design** of epitope-specific antibodies and related modalities, such as VHH and general protein scaffolds, like mini-proteins tailored to specific therapeutic targets.

2. **Simultaneous optimization of multiple molecular properties** through precise amino acid substitutions, insertions, and deletions, GaluxDeisgn accelerates development timeline.

Gangwon Technopark

재단법인 강원테크노파크 GANGWON TECHNOPARK

Country
Republic of Korea

CEO Name
Jang-Hyun Hur

Main Sector
Academic/Non-Profit

Website
http://www.gwtp.or.kr/gwtp/index.php

Booth No.
L11

Pavilion
Gangwon Technopark

Company Description

Gangwon Technopark is a regional innovation hub that establishes industrial development strategies and policies suited to its characteristics by developing a cooperative network with other regional innovation organizations in Gangwon State.
The Hongcheon National Antibody Cluster, which is being promoted as part of the Gangwon State's bio-industry development strategy, provides comprehensive support for R&D facility and equipment utilization, commercialization, workforce development and dedicated space for businesses

To Buy or Sell Technology/Product

New Biopharmaceuticle Development Support

1. (Research facilities and equipment support) Strategic investment in and promotion of shared use of research facilities and equipment for new biopharmaceutical development.
2. (R&D Support) Support for global technology transfer, investment attraction, investor relations (IR), startup space and more.
3. (Commercialization Support) Support for global technology transfer, investment, IR(I, startup space, etc.
4. (Technical Professional Training support) Support for training of professionals related to equipment operation and biopharmaceutical development.

GemPharmatech

GemPharmatech

Country
United States of America

CEO Name
Jing Zhao

Main Sector
Professional Services and Consulting

Website
http://www.gempharmatech.com

Booth No.
N14

Pavilion

Company Description

GemPharmatech is a global contract research organization that provides genetically engineered mouse models and preclinical research services to the scientific community.

To Buy or Sell Technology/Product

We have an extensive library of over 25,000 models including KO/cKO mice, humanized mice, immunodeficient mice, and germ-free mice, and continually expand our library to assist our customers in achieving their research goals. To further support our customers, we also offer custom model generation, breeding, and compound efficacy testing in our offices across China and the United States.

Gene Universal

Country	Booth No.
United States of America	I27
CEO Name	
Kevin Zheng	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
https://www.geneuniversal.com/	

Company Description

Gene Universal is a leading technology and service provider in life science research. Based in Delaware, USA, we serve over 10,000 customers across 100+ countries with cost-effective, high-quality solutions. Our streamlined operations ensure top-tier service, while strategic collaborations drive biotech innovation. We are dedicated to enhancing research efficiency, reducing biologics production costs, and advancing human health and sustainability. With a customer-centric approach, we provide tailored solutions that accelerate scientific progress. Partner with Gene Universal to shape the future of life science research and unlock new frontiers in discovery.

To Buy or Sell Technology/Product

Gene Universal provides advanced solutions for life science research and biopharmaceutical development, specializing in gene synthesis, DNA synthesis, recombinant protein and antibody production, and virus packaging services.

Gene & DNA Synthesis: High-fidelity synthesis tailored for seamless expression and functional studies.
Recombinant Protein & Antibody Services: Optimized expression systems for high-yield, high-purity proteins and antibodies.
Virus Packaging Services: Reliable lentivirus and AAV packaging for gene therapy and functional studies.
With cutting-edge technologies and a customer-centric approach, Gene Universal equips scientists with the tools to accelerate groundbreaking discoveries.

GenScript Biotech Korea

Country	Booth No.
Republic of Korea	I21
CEO Name	
Lingling Pan	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.genscript.com/	

Company Description

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in healthcare and consumer goods by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than 200,000 customers across 100 countries. Learn more here: https://www.genscript.com

To Buy or Sell Technology/Product

Genscript provides a comprehensive range of services required for research and development processes, including the synthesis of genes, peptides, antibodies, oligos, and proteins, as well as necessary reagents and tools. Additionally, it offers services spanning the entire spectrum of biopharmaceuticals, from process development to production, meeting the diverse needs of its clients. With its excellent technical capabilities and expertise, Genscript is able to offer the latest technology and the highest quality services to its customers.

GI INNOVATION

Country	Booth No.
Republic of Korea	G2
CEO Name	
Myoung Ho Jang, Jun Ho Hong	**Pavilion**
Main Sector	Rising Pavilion
Pharma	
Website	
www.gi-innovation.com	

Company Description

GI Innovation, a KOSDAQ-listed biotech, pioneers fusion protein drugs for cancer and allergies. Since 2017, it secured $230 million through funding rounds, IPO, and licensing deals for preclinical and clinical assets. Leveraging global partnerships for rapid development, the leading programs under clinical trials include immuno-oncology assets GI-101A, subcutaneous form GI-102, anti-allergy asset GI-301, and metabolic immune-oncology asset GI-108 alongside other innovative programs under preclinical stage. The company specializes in the licensing-out (L/O) of novel drug candidates at the preclinical or early clinical stages.

To Buy or Sell Technology/Product

Through its proprietary GI-SMART™ platform, a high-throughput screening system designed for the discovery and production of next-generation bispecific fusion proteins, the company enables one-stop early identification of bispecific fusion proteins with exceptional productivity and structural stability.

The company’s pipeline, developed using this platform, consists exclusively of bispecific fusion proteins, including the immune-oncology therapeutics GI-101A and GI-102, as well as the metabolic immune-oncology agent GI-108. GI-101A and GI-102 are composed of the extracellular domain of CD80 and an IL-2 variant, making them the world's first first-in-class drugs capable of simultaneously exerting dual immunoactive effects: CTLA-4 inhibition and IL-2 receptor stimulation for T-cell activation. GI-108 is a novel drug combining an anti-CD73 antibody and an IL-2 variant, uniquely targeting both CD73 and IL-2 receptors.

The company is also developing GI-301, an anti-allergic treatment that acts as an IgE trap, effectively capturing IgE to suppress allergic reactions. It offers lower immunogenicity and greater safety than conventional anti-IgE antibodies and may also help prevent chronic idiopathic urticaria (CIU) by targeting mast cell-activating autoantibodies.

Alongside its pipeline development, the company is enhancing its clinical development capabilities to address unmet medical needs. It has established a strong business strategy by forming a global KOL advisory board, refining its clinical approach for emerging therapies (e.g., ADCs and cell therapies), and fostering open innovation through partnerships with domestic pharma and biotech firms.

Global Pharma Solutions

Country
Australia

Delegate Name
Margaret Jenkins

Main Sector
Professional Services and Consulting

Website
https://globalpharmasolutions.com/

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Global Pharma Solutions (GPS) is staffed by a team of highly skilled professionals who each have more than 25 years experience in developing and registering small molecules, biologics, cell therapies and devices.
For the last 22 years, we have helped small to medium biotech companies as well as major multi nationals such as CSL, GSK, Hospira, Pfizer etc. to develop new medicines, devices and cell therapies and maintain existing ones. We also help you by generating global development and Regulatory strategies and lead you to meetings and engagements with major regulators such as the US FDA, Australian TGA and European EMA. In this way, you gain early advice which can lead to expedited pathways to approval, saving you time and money.
Our target audience is small to medium biotech companies at early clinical or preclinical stages, who are seeking a global Regulatory strategy as well as support with technical and clinical development.
In addition, Australia offers a unique and attractive expedited process for early clinical trials that is unmatched anywhere. There is no IND required and you may claim up to 43.5% of every dollar invested. Since GPS has operations in both Australia and the US, we are uniquely positioned to support your early clinical trials, followed by supporting your progress in the US including opening an IND, writing your regulatory dossier (NDA or BLA) to ultimate FDA approval and market launch.

To Buy or Sell Technology/Product

Global Pharma Solutions (GPS) is staffed by a team of highly skilled professionals who each have more than 25 years experience in developing and registering small molecules, biologics, cell therapies and devices.
For the last 22 years, we have helped small to medium biotech companies as well as major multi

nationals such as CSL, GSK, Hospira, Pfizer etc. to develop new medicines, devices and cell therapies and maintain existing ones. We also help you by generating global development and Regulatory strategies and lead you to meetings and engagements with major regulators such as the US FDA, Australian TGA and European EMA. In this way, you gain early advice which can lead to expedited pathways to approval, saving you time and money.
Our target audience is small to medium biotech companies at early clinical or preclinical stages, who are seeking a global Regulatory strategy as well as support with technical and clinical development.
In addition, Australia offers a unique and attractive expedited process for early clinical trials that is unmatched anywhere. There is no IND required and you may claim up to 43.5% of every dollar invested. Since GPS has operations in both Australia and the US, we are uniquely positioned to support your early clinical trials, followed by supporting your progress in the US including opening an IND, writing your regulatory dossier (NDA or BLA) to ultimate FDA approval and market launch.

Granzer Regulatory Consulting & Services

Country
Germany

CEO Name
Dr. Ulrich Granzer

Main Sector
Pharma

Website
www.granzer.biz

Booth No.
A1

Pavilion
Bavarian Pavilion c/o Bayern International GmbH

Company Description

Granzer Regulatory Consulting & Services offers support in all phases of drug and device development. From defining the right development strategy to submitting your marketing authorisation application, all the way through to approval and beyond.
We have been involved in many “firsts”, such as the first peptide-based vaccine developments, first m-RNA developments, CARTs, CRISPR/CAS and the first Covid vaccine marketing authorisation.

To Buy or Sell Technology/Product

We offer:

- Global Regulatory Strategy
- Regulatory Procedures
- PRIME and Accelerated Approval Pathways
- Drug Development
- Orphan Development
- Paediatric Development
- Medical Devices and Combination Products
- Borderline Products
- Due Diligence
- Project Management
- Medical and Scientific Writing
- Regulatory Operations
- GMP Compliance & Storage

GreenLight Clinical Pty Ltd

Country
Australia

CEO Name
Dr Robert Lin

Main Sector
Professional Services and Consulting

Website
https://www.greenlightclinical.com

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

GreenLight Clinical (GLC) is a physician-led full-service clinical CRO established in 2016 in Sydney, Australia. Combining medical expertise, deep industry knowledge, and a close relationship with clinical research sites. GLC provides customized clinical research solutions to expedite pharmaceutical and biotech product development at high standards of quality and ethics in clinical research.
Our head office is based in Australia however, we have teams in the USA and Asia.

At GreenLight Clinical we offer customized solutions to fit the specific needs of our clients, particularly small and mid-sized biotech companies. Our agile and flexible approach allows us to adapt to different study requirements and timelines, ensuring a smooth and successful trial process.

To Buy or Sell Technology/Product

Our clinical networks and regulatory expertise are strongly focused on the USA and Asia-Pacific region, with our ongoing collaborations and operations extending worldwide. We provide a full-service CRO solutions to sponsors and investigators, ranging from study startup, regulatory affairs, ethics/IRB submission, to clinical operations, study monitoring, data management and ongoing safety and pharmacovigilance services.

Specialist knowledge and experience in ophthalmology, oncology, cell therapies, rare and infectious diseases and medical devices.

Our strengths
First-in-Human / First-In-Class
New drugs & devices
Phase I / Phase Ib-IIa /Phase III
Translation from healthy volunteers to in-patient populations
Smooth transition from Australia to US based studies
Strong expertise and experiences in medical devices registration

Gyeonggi Business & Science Accelerator

Country	Booth No.
Republic of Korea	M17
CEO Name	
KIM HYUN KON	**Pavilion**
Main Sector	Gyeonggi Business & Science Accelerator
Academic/Non-Profit	
Website	
https://gbsa.or.kr/	

Company Description

Since its launch as an integrated corporation in January 2017, the Gyeonggido Business & Science Accelerator(GBSA) has been solidifying its position as a comprehensive support institution for SMEs, both in name and reality, throughout the entire business cycle - including start-up, commercialization, investment, and export - as well as for science and technology R&D, cluster creation, and the fostering of bio- and regionally specialized industries.

To Buy or Sell Technology/Product

In addition th the challenges posed by the global economic downturn, SMEs have to adapt to an environment of structural change, which includes the acceleration of the Fourth Industrial Revolution, global efforts to achieve carbon neutrality, and the reorganization of global value chains. GBSA will upgrade to "GBSA 2.0" under a new organization, new mission, and new vision to help Gyeonggi Province's SMEs respond to this rapidly changing business environment.

HAII Corp.

Country	Booth No.
Republic of Korea	G8
CEO Name	
Jinwoo Kim	**Pavilion**
Main Sector	Rising Pavilion
Digital Health	
Website	
www.haiiglobal.com	

Company Description

HAII Corp. is a pioneering digital health company specializing in AI-driven digital biomarkers and digital therapeutics (DTx). Our technology leverages smartphones to deliver accurate, non-invasive health assessments for cognitive function, mental health, and speech disorders.
Our flagship solutions include:
• Alzguard – AI-powered early detection and monitoring for Alzheimer's disease
• Repeech – A digital speech therapy solution for stroke rehabilitation
• Mind Check (Anzielax-D) – Mental health monitoring using HRV and voice analysis
• Anzielax-T – A real-time stress and cognitive load assessment tool for individual and workplace mental wellness
HAII collaborates with global institutions, including Mass General Brigham (MGH), Yonsei University, and pharmaceutical leaders, to advance digital health solutions.

To Buy or Sell Technology/Product

HAII's digital biomarker technology integrates AI, smartphone sensors, and real-world data to transform early disease detection, treatment monitoring, and patient engagement.
Key Products & Technologies:
• Alzguard: AI-driven cognitive assessment tool for detecting Alzheimer's and dementia via smartphone- based eye-tracking, keystroke dynamics, and speech analysis.
• Repeech: A digital speech therapy solution for stroke survivors with speech impairments, validated by clinical research.
• Mind Check (Anzielax-D): A mental health assessment tool using HRV and voice biomarkers to evaluate stress, depression, and anxiety levels.
• Anzielax-T: A cognitive load and stress assessment tool designed for individual mental wellness and workplace wellness programs.

HaplnScience Inc.

Country	Booth No.
Republic of Korea	E6
CEO Name	
Choi, Hakbae	**Pavilion**
Main Sector	Rising Pavilion
Pharma	
Website	
www.haplnscience.com	

Company Description

We, HaplnScience inc. is a bioventure established in November, 2018 with the aim to develop innovative therapies for age-related, intractable diseases and has been doing research to resolve the unmet needs in the target diseases. The leaders of the company are co-founders, Daekyong Kim, Chief Scientific Officer and Hakbae Choi, Chief Executive Officer. Daekyong Kim found a reverse cellular senscence protein and has been doing research for the mechanism of action and functions of the protein. He is an emeritus professor of ChungAng Universtity. Hakbae Choi has specialties in prduct development planning, project management, business development, and management of bioventure and pharmaceutical compnay. He was CEO of Hankuk Kolmar and C&C Researsh Labs, a joint venture between Chugai and JW pharma.

To Buy or Sell Technology/Product

- Our anti-aging research started with parabiosis studies between young and old mice. Three weeks after the parabiosis operation, we could find that old mice skin paired with young mice were rejuvenated with the increase of dermal thickness. Through the aptamer based proteome analysis, we could discover that HAPLN1 plays the most critical role in rejuvenation of aged skin. HAPLN1(Hyaluronan and Proteoglycan Link Protein1) is an endogeneous glycoprotein widely present in the extracellular matrix (ECM) and binds proteoglycan to hyaluronan chain, strengthens the integrity of ECM. We are the first research group to discover HAPLN1's function as a rejuvenation factor and published an articla at Matrix Biology. The title is "HAPLN1- A novel signaling molecule for rejuvenating aged skin". Hapln1 plays a key role in forming strong aggregates, which can fabricate water rich pericellular matrix, and thereby transduce rejuvenation related signals via CD44 and TGFβR. We found HAPLN1 modulate CD44 signaling and TGFβ signaling and disclosed multiple functions of rhHAPLN1 including reversal of cellular senescence, reduction of oxidative stress, increase of efferocytosis, regeneration, inhibition of inflammation,and

formation of water rich pericellular matrix. These multi functions are related to pathogenesis of age-related, chronic intractable diseases and required for the treatment of the diseases. We develop disease modifying drugs for COPD, Osteoarthritis, Dry eye disease, and Skin aging. We have finished the non clinical studies of HS-401(COPD), HS-101(Osteoarthritis) and are preparing the non clinical studies of HS-601(Dry eye disease), HS-201(Skin aging).

Harvest Integrated Research Organization (HiRO)

HiRO

Country	Booth No.
Australia	B1
CEO Name	
Gerard Kim	**Pavilion**
Main Sector	Australian National Pavilion
Professional Services and Consulting	
Website	
www.harvestiro.com	

Company Description

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative CRO, offering comprehensive cross-border solutions.

For over 20 years, our ANZ team has been at the forefront of leveraging Australia's advantages for clinical trials. With deep knowledge in diverse therapeutic areas and experience in the international pharmaceutical, medical device, and biotech sectors, our team excels at overcoming complex challenges. We have successfully supported patient needs and delivered outstanding results for global pharma and biotechs across hundreds of studies.

HiRO's dedication is to become a market-leading, integrated global CRO, partnering closely with biotech and pharmaceutical companies to bring innovative products from the laboratory to the market, providing more effective solutions for patients worldwide.

To Buy or Sell Technology/Product

With integrated capabilities and extensive expertise, HiRO provides a full suite of clinical research services, including pre-clinical planning, trial design, regulatory affairs, pharmacovigilance, statistics, data management, project management, and clinical monitoring.

Health Insurance Review & Assessment Service

Country
Republic of Korea

CEO Name
Jung-Gu Kang

Main Sector
Digital Health

Website
http://www.hira.or.kr

Booth No.
J27

Pavilion
Health Insurance Review & Assessment Service

Company Description
HIRA ensures appropriate use of healthcare funds and evaluates the quality of medical services to support health policy decisions, including medical fee and drug pricing.

To Buy or Sell Technology/Product
Introduction to HIRA's startup support programs, including the Healthcare Big Data Utilization Competition, and presentation of products and services from two award-winning teams of the competitions.

Healthcare Claims Co., Ltd

Country
Republic of Korea

CEO Name
HA KI-CHAN

Main Sector
Professional Services and Consulting

Website
http://www.hfoodcro.com

Booth No.
L19

Pavilion
Jeonbuk Technopark

Company Description
We provide services from all document preparation to clinical trials that must be conducted to obtain individual recognition of functional food.

To Buy or Sell Technology/Product
We provide tailored consulting services for obtaining individual recognition of Functional Ingredients for Health, covering everything from standardization, safety, preclinical evaluation, to clinical trials.

- Provide information on understanding and related regulations for the development of health functional foods
- Consulting on overall content for obtaining individual recognition of Functional Ingredients for Health
- Transfer of know-how to increase the utilization of research results on Functional Ingredients for Health and increase the possibility of success for developed items

HELIOD

Country	Booth No.
Republic of Korea	M3
CEO Name	
kyung sook yoon	**Pavilion**
Main Sector	
Pharma	
Website	
http://heliodkorea.com	

Company Description

Let's share our experience of a beautiful, mysterious, and enjoyable life.
We're HELIOD.

To Buy or Sell Technology/Product

7 types of basic cosmetics
(Cleaning oil, cleansing balm, cream, ampoule, toner, sun cream, BB cream)
1 type of health functional food
(Giantgram (psyllium husk))
We are dealing with .

HITS Inc.

Country	Booth No.
Republic of Korea	F1
CEO Name	
Wooyoun, Kim	**Pavilion**
Main Sector	
Digital Health	Rising Pavilion
Website	
https://hits.ai/	

Company Description

HITS Inc. is revolutionizing traditional drug discovery with AI, empowering global pharmaceutical companies to accelerate innovation and bring new treatments to market faster.
At the core of our technology is a patent-backed, physics-based deep learning model powering HyperLab— the first all-in-one AI platform for early-stage drug discovery. Designed for accuracy and ease of use, HyperLab streamlines every step of HIT discovery, reducing time, costs, and complexity.
Composed of experts in artificial intelligence, computer-aided drug design (CADD), and drug development, HITS has earned the trust of leading pharmaceutical companies worldwide—setting a new standard for AI driven drug discovery.

To Buy or Sell Technology/Product

HyperLab: The Most Intuitive, All-in-One AI Drug Discovery Platform
HITS' flagship platform HyperLab is the first truly all-in-one AI-powered web solution designed to accelerate the identification and optimization of new drug candidates.
Unlike traditional computational tools that require coding expertise or multiple disconnected solutions, HyperLab provides a seamless, intuitive environment that integrates molecular docking, virtual screening, ADME/T prediction, and drug design—all in one platform.

Advanced AI for Real-World Drug Discovery
Powered by peer-reviewed, patent-backed AI models, HyperLab blends deep learning with physics-informed methodologies, ensuring high accuracy and real-world applicability. Since 2018, our core technology has resulted in over 1000 citations and been verified through 30+ successful collaborations with leading global pharmaceutical companies, universities, and esteemed research institutes.
With its user-friendly web-based interface, HyperLab enables researchers—regardless of CADD expertise— to harness AI-driven insights, making drug discovery more efficient, accurate, and accessible than ever before.

HLB Pep Co., Ltd

Country	Booth No.
Republic of Korea	B30
CEO Name	**Pavilion**
JAEIL KIM	
Main Sector	
Pharma	
Website	
http://hlbpep.com	

Company Description

ANYGEN supplies various types of high-quality peptides promptly by applying our optimal synthesis technology and extensive experiences in the peptide synthesis.
We manufacture high-quality custom-made peptides by applying our thorough product managing system (ISO 9001, 14001, 45001, GMP Certificated) in the synthesis and purification of peptides, and we supply the peptides demanded by customers by applying custom-made synthesis and purifications according to the level of difficulty in the synthesis and types of modification.

To Buy or Sell Technology/Product

1. Development of peptide biomaterials
1) Pharmaceutical peptide materials (GMP)
(1) Active Pharmaceutical Ingredients (API)
(2) Contract manufacturing organization (CMO)
2) Industrial peptide materials (Non-GMP)
(1) Peptide biomaterials for research on new drug development
(2) Biomaterials of peptides for cosmetics
2. Amino acid peptides bio-new drug development: AGM-130, AGM-380, AGM-290, AGM-212, AGM-217, AGM-260

Honam National Institute of Biological Resources

국립호남권생물자원관

Country	Booth No.
Republic of Korea	N30
CEO Name	
Jin-Yeong Park	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
http://hnibr.re.kr	

Company Description

The Bank of Bioresources form Island and Coast (BOBIC), Honam National Institute of Biological Resources (HNIBR) is a public research institute under the Ministry of Environment. The BOBIC provides the services performed by preservation, and distribution of biological resources for consumers from industry, academia, and research institutes. The Bank of Bioresources form Island and Coast operates three banks: a natural product, a genetic resource, and a culture (bacteria, fungi, and microalgae).

To Buy or Sell Technology/Product

The Advanced Research Group for Island Wildlife Bioresources was launched on May 19, 2023. As part of the national strategy to build big data for biological research resources, this initiative is promoted by multiple government departments to foster the bio-resources infrastructure and accelerate growth in the bio field. In order to increase the utilization of island and coastal wildlife materials, we plan to secure high-quality biological resource materials (functional natural products, fermented microorganisms, and peptides) and omics big data, establish a quality preservation management system, and distribute them to industry, academia, and research researchers through BOBIC.

HORIBA KOREA, Ltd.

HORIBA

Country	Booth No.
Republic of Korea	C30
CEO Name	
Hideyuki Koishi, Shoji Yamamoto	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.horiba.com/kor/	

Company Description

The HORIBA Group of worldwide companies provides an extensive array of instruments and systems for applications ranging from automotive R&D, process and environmental monitoring, in-vitro medical diagnostics, semiconductor manufacturing and metrology, to a broad range of scientific R&D and QC measurements. Proven quality and trustworthy performance have established widespread confidence in the HORIBA Brand.

To Buy or Sell Technology/Product

Particle size can be determined by measuring the random changes in the intensity of light scattered from a suspension or solution. This technique is commonly known as dynamic light scattering (DLS), but is also called photon correlation spectroscopy (PCS) and quasi-elastic light scattering (QELS).

The unique combination of CBC+CRP on whole blood micro sampling, performed on hematology analyzer provides a meaningful determination of inflammation marking and hence capable to screen microbial infection.

HungaroTrial CRO

HungaroTrial Contract Research Organization

Country
Hungary

CEO Name
Lajos Sarosi

Main Sector
Professional Services and Consulting

Website
https://hungarotrial.com/

Booth No.
G27

Pavilion

Company Description

HungaroTrial is a CRO with extensive expertise in managing Phase I- III clinical trials in Central and Eastern Europe (CEE).
The CEE region offers significant advantages; outstanding patient enrolment, modern infrastructure, with cost-saving benefits.
In 2023, we opened an operational office in Atlanta, Georgia.
With expertise in opening trial sites across Central & Eastern Europe and the USA, we help our clients benefit from tailored strategies that optimize clinical trials, boost patient recruitment, and improve overall efficiency.
We are committed to accelerating the study start-up and delivering results within tight timelines while maintaining the highest quality standards.

To Buy or Sell Technology/Product

HungaroTrial offers the following services for Phase I-IV clinical trials:
- Project Management
- Study Planning and Feasibility
- Site Selection and Support
- Study start-up
- Regulatory and EC Affairs Management
- Hospital and Investigator Grant Negotiation
- Project Training
- Site Monitoring and Site Management
- Processing SAEs
- IMP management

For medical device manufacturers we offer full-service clinical trials with regulatory consultancy for MDR compliance and CE marking.

ICE Bioscience

Country	Booth No.
China	H30
CEO Name	
Yingji Li	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://en.ice-biosci.com	

Company Description

ICE Bioscience Inc., established in 2010 in Beijing, focuses on an integrated biological services platform for innovative drug discovery, encompassing target identification and validation, lead compound screening, optimization, and pre-clinical candidate stages. It pioneers an innovative CRO+ model in biological and pharmacological research technologies across oncology, immunology, cardiovascular, central nervous system, and metabolism diseases. ICE Bioscience is attuned to the needs of new drug development enterprises for quality, speed, efficiency, and cost, offering professional technical expertise and efficient communication to enhance the drug development process.

To Buy or Sell Technology/Product

- Target-based drug screening platform: Established over 130 ion channel, more than 160 GPCR, over 1200 kinase and enzymatic targets, and over 40 nuclear receptor screening cell lines and validation methods.
- In vitro and in vivo pharmacology screening and evaluation platform: Includes oncology immunology, cardiovascular, and central nervous system pharmacodynamic evaluation based on cell, tissue, or animal models.
- DMPK and safety assessment platform: Includes ADME and PK studies, drug off-target effect screening (hERG, safety panel, kinase panel, etc.)

We support various drug screenings and biological services for small molecules, antibodies, ADCs, PROTACs, and small nucleic acids.

IDT Australia

Country	Booth No.
Australia	B1
Delegate Name	
Paul McDonald	**Pavilion**
Main Sector	Australian National Pavilion
Professional Services and Consulting	
Website	
https://en.idtaus.com.au/	

Company Description

IDT is a 50-year-old contract and development manufacturing organisation with expertise in translating medicine from bench to patient supporting the Australian clinical trial ecosystem. IDTs three pillars include API development and manufacture including high potent, solid oral dose formulation, tablet, capsule and liquid manufacturing and sterile fill and finish including complex formulations such as lyophilisation, lipid nanoparticle and antibody drug conjugate.

ILAb Co., Ltd.

Country	Booth No.
Republic of Korea	D11
CEO Name	
Taegwon Oh	**Pavilion**
Main Sector	DIPS 1000+ project
Pharma	
Website	
www.ilab.co.kr	

Company Description

ILAb is a biotech company with a specialty in immuno-therapy with small molecules. Since its foundation in April 2017, ILAb has concentrated on the discovery and development of first-in-class small molecules for well-validated immune targets. Our aim is to provide competitive alternatives to expensive and painful injectable biologic products on the market for treating chronic inflammatory diseases and cancers. We use CISCOVERY, our own Cytokine Inhibitor Discovery platform, to generate small molecule hits. The hits modulate interactions between a cytokine and its cognate receptor. CISCOVERY has enabled us to successfully discover potential pipelines including TNF, IL-1beta, IL-6, IL-2, IL-4 and IL-17 inhibitors.

To Buy or Sell Technology/Product

The first asset is an orally active, small-molecule TNF inhibitor that is currently in development for the first indication of rheumatoid arthritis. It binds to TNF and selectively inhibits the interaction of TNF and TNF receptor 1. The Ph 1 single and multiple ascending dose study in healthy subjects was completed successfully in the US, demonstrating a favorable safety and PK profile. The Phase 1b study which involves RA patients on stable oral doses of methotrexate, is currently ongoing in the US and EU. Another asset is a small-molecule oral PD-L1 inhibitor which is ready for IND-enabling study. Our compound demonstrated at least a comparable anti-tumor effect to the commercially available biologic PD-L1 inhibitor and small molecule PD-L1 inhibitor in a tumor bearing mouse model.

IMCD (KOREA)

Country	Booth No.
Republic of Korea	B11
CEO Name	
Valerie Diele-Braun.	**Pavilion**
Main Sector	Netherlands Bio Lounge
Pharma	
Website	
www.imcdgroup.com	

Company Description

IMCD is a global leader in the distribution and formulation of specialty chemicals and ingredients, serving over 60,000 customers with a €5.16 billion turnover. With 4,300+ professionals, IMCD operates across 50+ countries, offering sustainable, innovative solutions backed by strong ESG values. IMCD Korea, a top local distributor, focuses primarily on pharmaceuticals (90% of sales) and also serves sectors like advanced materials, personal care, and food. With €66 million turnover, 710 customers, and 83 staff, it operates 8 warehouses and 1 lab. IMCD combines global expertise with local insight to deliver high-quality, conscious solutions to diverse industries.

To Buy or Sell Technology/Product

Specialty Chemical Ingredients & Solutions
IMCD Korea supplies specialty chemical ingredients across five sectors: Pharmaceuticals, Beauty & Personal Care, Coatings & Construction, Food & Nutrition, and Advanced Materials. Pharmaceuticals account for 91% of total revenue, covering APIs, excipients, nutraceuticals, biopharmaceuticals, and regulated synthesis. With over 700 customers—400 in pharma—IMCD Korea provides reliable ingredient supply with full technical support and timely delivery. As Korea's leading specialty chemical distributor, IMCD combines global expertise with local service to support innovation and operational efficiency across industries.

InHandPlus

Country	Booth No.
Republic of Korea	C29
CEO Name	
Hwiwon Lee	**Pavilion**
Main Sector	
Digital Health	
Website	
https://www.inhandplus.com/	

Company Description

InHandPlus was established in 2019. InHandPlus is developing an On-Device AI smartwatch and AI-based digital healthcare platform for personalized medication management. InHandPlus Medication Management Platform provides real-world data and evidence of medication adherence. InHand-Care platform improves more than 30% of medication adherence, and InHand-Watch analyzes medication behaviors with more than 99% accuracy. InHandPlus was selected for both global Merck and Bayer startup accelerating programs. InHandPlus actively collaborate with many global Pharmaceutical companies, CROs, hospitals, insurance companies, and telemedicine companies for successful clinical trials and better patient healthcare. InHandPlus won the CES Innovation Award in both 2022 & 2023.

To Buy or Sell Technology/Product

InHand-Watch is a smartwatch that comes with health management features such as medication administration and diet management. The On-Device AI technology enables users to easily track their medication and dietary habits through the watch. Moreover, it can be connected to ChatGPT, which provides personalized health information. The InHand-Care App allows users and caregivers to monitor health records, while administrators can access this information through the InHand-Care Web. The smartwatch's monitoring system automatically collects medication adherence data without requiring any additional user input. It can monitor medication, inhalers, glucometers, auto-injectors, and more. It can monitor medication, inhalers, glucometers, auto-injectors, and more.

INTERFLON (KOREA)

Country	Booth No.
Republic of Korea	B11
CEO Name	
Frédéric Mus	**Pavilion**
Main Sector	
Chemicals	Netherlands Bio Lounge
Website	
https://interflon.com/kr	

Company Description

Interflon Korea specializes in high-performance lubricants and maintenance products designed to enhance equipment efficiency, reliability, and lifespan. Its MicPol® technology significantly reduces friction, wear, and maintenance costs. Serving industries such as manufacturing, automotive, and food processing, Interflon delivers innovative solutions that improve operational performance. By reducing energy consumption and increasing efficiency, Interflon Korea supports industrial sustainability and lower environmental impact, making it a trusted partner for companies seeking both performance and eco-conscious maintenance solutions.

To Buy or Sell Technology/Product

MicPol Technology

It is an advanced lubrication innovation that enhances equipment performance and longevity. MicPol uses micronized particles that form a micro-layer on metal surfaces, significantly reducing friction and wear. Interflon specializes in high-performance lubricants and industrial chemicals for diverse industries such as automotive, manufacturing, food processing, and logistics. Its products perform under extreme conditions—high pressure, heat, and contamination—while lowering maintenance costs and extending equipment life. Interflon also offers eco-friendly solutions for cleaning, corrosion protection, and waterproofing. Operating globally, Interflon supports industrial efficiency, safety, and sustainability through its innovative product range and technical expertise.

INTOINWORLD CO., LTD.

Country	Booth No.
Republic of Korea	H32
CEO Name	
John Choi, David Lee	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://intoinworld.com	

Company Description

"Intoinworld Co., Ltd." is a professional Contract Research Organization(CRO) that offers end-to-end services for clinical trials, including consulting, liaison with the Ministry of Food and Drug Safety (MFDS) and hospitals, as well as clinical trial protocol developement, monitoring, data management, statistical analysis, and the preperation of interim and final reports, all of which can be fully outsourced. "IntoinWorld Co., Ltd." will do its utmost to ensure the success of our customers projects.

To Buy or Sell Technology/Product

"IntoinWorld Co., Ltd." is a Contract Research Organization (CRO) that provides comprehensive clinical trial services from A to Z, covering oncology treatments as well as pharmaceuticals and medical devices.
- Patent Status: Holds one patent for an AI-based clinical trial protocol design method, device, and system.
- Technical Expertise: Possesses knowledge in developing ICF and (e)CRF, Clinical Monitoring, and DM/STAT Management.

Inventage Lab Inc.

Country	Booth No.
Republic of Korea	F7
CEO Name	
Juhee Kim	**Pavilion**
Main Sector	
Pharma	**Rising Pavilion**
Website	
https://www.inventagelab.com/ko/	

Company Description

Inventage Lab (KOSDAQ:389470) is a clinical-stage biopharmaceutical company specializing in Drug Delivery Systems (DDS). The company has two core platforms:
IVL-DrugFluidic® – A microsphere-based long-acting injectable (LAI) platform IVL-GeneFluidic® – A lipid nanoparticle (LNP) platform utilizing a microfluidic manufacturing system
In addition to developing proprietary technologies, we provide services and offer our HANDYGENE™ Series—a line of LNP manufacturing equipment available in Lab, GMP, and Commercial scales.
#Microfluidics #DDS #Platform technology #LAI #IVL-DrugFluidic® #Clinical stage #Joint development #Licensing #Drug re-positioning #LNP #IVL-GeneFluidic® #HANDYGENE

To Buy or Sell Technology/Product

<IVL-DrugFluidic®>
- This platform enables the production of high-quality long-acting injectable formulations by eliminating initial burst and ensuring the mass production of uniform microspheres[Fig1]. It has been successfully applied to veterinary medicine and clinical trials for androgenic alopecia, dementia, and addiction treatments. The platform also supports drug re-discovery and partnerships for novel drug formulations with global pharmaceutical companies.

<IVL-GeneFluidic®>
- Harnessing our HANDYGENE™ system, this platform focuses on developing lipid nanoparticles (LNPs) for vaccines and gene therapies. Inventage Lab also offers services, including LNP formulation and non-clinical and clinical sample production, while diversifying its business through selling and subscribing to its LNP manufacturing equipment. [Fig2]

<HANDYGENETM Series>
Please contact us for Demo and quotation
- HANDYGENETM Lab : Launched in 2025
- HANDYGENETM GMP : Launched in 2024

Invion Limited

INVION

Country
Australia

Booth No.
B1

Delegate Name
Prof Thian Chew

Pavilion
Australian National Pavilion

Main Sector
Pharma

Website
www.inviongroup.com

Company Description

Invion (ASX: IVX) is a clinical-stage company developing the next-generation Photodynamic Therapy (PDT), called Photosoft, for the treatment of a range of cancers and infectious diseases.

Invion released positive results from a Phase II prostate cancer trial with a 40% response rate and a strong safety profile. It is undertaking a Phase I/II trial on skin cancer with more trials to treat other cancers scheduled over the next 12-24 months.

Additionally, Invion signed agreements with Hanlim Pharma and Dr. inB. They will fund and undertake studies using Photosoft to treat brain malignancy GBM, oesophageal cancer and Human Papilloma Virus (HPV).

Pre-clinical results undertaken by Invion's research partners, the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research, showed that the technology completely regressed a range of cancers, such as triple negative breast and ovarian cancers, and stimulated the body's immune system to continue fighting the cancer.

Invion has developed a portfolio of patent protected compounds. Its lead drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.

To Buy or Sell Technology/Product

PDTs have been around for decades, and some have even been approved by the US FDA. It involves the use of a photosensitive drug and a light source to activate the drug, but severe side effects and other limitations have hampered their widespread use.

Invion's **Photosoft** has the potential to overcome many of these shortcomings. Results from a Phase 2 prostate cancer trial showed a **40-44% positive response rate** and the treatment only had **mild side effects** and was well tolerated by participants who underwent six rounds of the treatment.

Further, Invion is currently undertaking a Phase I/II non-melanoma skin cancer trial (NMSC). *In vivo* studies show its lead drug candidate, INV043, is **safe, non-scarring and non-toxic and only accumulates in cancer cells** and not healthy tissue.

Less invasive than surgery and with minimal side effects, Photosoft offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.

Off the back of the NMSC trial, Invion plans to undertake a Phase Ib/II anogential clinical study in partnership with the Peter McCallum Cancer Centre.

Additionally, Invion has signed agreements with Hanlim and Dr.inB. These partners will fund and undertake studies using Photosoft to treat GBM and HPV.

JCBIO.CO.,Ltd

Country	Booth No.
Republic of Korea	A23
CEO Name	**Pavilion**
Jae-chan Yoo	
Main Sector	
Pharma	
Website	
http://jcbio.co.kr	

Company Description

The Junction where Cutting-Edge Biotechnology meets Research for a Better Life

To Buy or Sell Technology/Product

- Immunoassay reagent & Microplate, revvity
- Cell Expansion System, Terumo
- Cell Processing System , Eurekabio
- Cell culture supplement, PL Bioscience
- Super resolution microscope, ONI

JEIO TECH Co., Ltd.

Country	Booth No.
Republic of Korea	F21
CEO Name	
HYUN JU SHIN, GI SUNG KIM	**Pavilion**
Main Sector	
Medical Device	
Website	
http://jeiotech.com	

Company Description

JEIO TECH Co., Ltd. is a laboratory equipment manufacturer based in South Korea, offering a wide range of research and experimental instruments in the biotechnology field. With the goal of localizing laboratory equipment production, the company is also dedicated to developing advanced technologies, such as production equipment for biopharmaceuticals and secondary batteries.

To Buy or Sell Technology/Product

JEIO TECH Co., Ltd. develops safe equipment to improve laboratory environments, aiming to help researchers focus on their experiments. For example, the company manufactures essential instruments for biotechnology research, such as constant temperature and humidity chambers, incubators, and shaking incubators. These products are highly regarded for their reliability and quality.

JEON TECH. CO., LTD

Country	Booth No.
Republic of Korea	E25
CEO Name	
yoonjoong jeon	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://jtch.co.kr	

Company Description

JeonTech Co., Ltd. has specialized technologies for energy innovation in industrial wastewater/waste, including high-efficiency evaporative concentration technology that drastically lowered energy consumption, bioenergy production technology through high-concentration organic wastewater treatment, and new concept nitrogen treatment technology. As an energy environmental facility engineering company, it provides optimal solutions with abundant reference from overseas technology partners and systematic consulting systems from technology research institutes.

To Buy or Sell Technology/Product

An energy innovative vacuum evaporation concentration technology that mechanically compresses all steam generated in an evaporation pipe and recovers and reuses energy as much as possible. Compared to the existing steam method, energy consumption is only 1/20, so maintenance costs are low, and various designs are possible to suit the properties and capacity of wastewater, so it can be applied to all industrial wastewater. It has a large number of applications of electronic wastewater such as semiconductor process cleaning waste liquid.

Jeonbuk Technopark

Country	Booth No.
Republic of Korea	L19
CEO Name	
Lee Gyu Taek	**Pavilion**
Main Sector	Jeonbuk Technopark
Academic/Non-Profit	
Website	
http://www.jbtp.or.kr/index.jbtp	

Company Description

Jeonbuk Technopark is the Chief Technology Officer (CTO) organization of Jeonbuk Special Self-Governing Province. It serves as an industrial technology innovation hub that promotes the advancement of Jeonbuk's industries and supports the establishment and growth of technology-intensive companies through a collaborative network of local governments, academia, research institutions, and industry. Jeonbuk Technopark is committed to leading a significant transformation in Jeonbuk's industries by discovering and nurturing new industries within a new paradigm and accelerating digital innovation, thereby supporting the high growth of enterprises.

To Buy or Sell Technology/Product

-Leading Fourth Industrial Revolution & Digital Transformation
-Supporting for Growth of Small and Medium Businesses
-Advance Local Industries
-Managing R&D funding program of Government and Jeonbuk State
-Build Systems to Nurture Eco Friendly and Smart New Industries

JEONNAM BIO FOUNDATION

Country	Booth No.
Republic of Korea	N32
CEO Name	
HOYEOL YOON	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
http://www.jbf.kr/main/main.action	

Company Description

The Jeonnam Bio Foundation was established to foster future strategic industries in biotechnology in Jeollanam-do. It operates specialized bio-centers in fields such as biopharmaceuticals, natural products, marine biotechnology, food technology, nanotechnology, and Eco-Friendly Agri-Bio.

Our efforts led to the successful acquisition of major national projects, including the Hwasun National Advanced Strategic Industry Specialized Complex and the Jangheung Natural Product Full-Cycle Standardization Hub Construction Project. In 2024 alone, it transferred 10 technologies to leading domestic bio-companies, demonstrating its extensive portfolio of proprietary technologies.

To Buy or Sell Technology/Product

Jeonnam Foundation Infrastructure Overview

1. Health functional food manufacturing facilities (GMP-certified)
2. Biopharmaceutical raw material and finished product manufacturing facilities (GMP-certified)
3. Supercritical fluid extraction and high-pressure extraction facilities
4. Natural product pharmaceutical raw material production facilities (GMP-certified), natural oil extraction facilities
5. Eco-friendly agricultural material production facilities
6. HACCP-certified seafood convenience food production facilities, finished cosmetic product manufacturing facilities

Johnson & Johnson

Johnson&Johnson

Country	Booth No.
Republic of Korea	K11
CEO Name	
John Choi	**Pavilion**
Main Sector	
Pharma	
Website	
http://jnjinnovation.com/locations/jlabs/jlabs-korea	

Company Description

Johnson & Johnson JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors.
JLABS is a no-strings-attached model, which means innovators are free to develop their science and technology while holding on to their intellectual property. Our goal is to catalyze and accelerate the delivery of lifesaving, life-enhancing solutions to patients around the world.

To Buy or Sell Technology/Product

JLABS Korea activate the global JLABS network to enhance the competitiveness of Korean biotech and medtech startups, catalyzing the country's innovation ecosystem to serve the critical mission of enhancing and saving lives.
Our global network provides early-stage innovators with:
- Access to expertise & resources
- Funding & investor connections
- Programming and talent development
- Visibility
- Global Network

Juno Pharmaceuticals

juno. PHARMACEUTICALS

Country	Booth No.
Canada	C1
CEO Name	
Mr. Ian Jacobson	**Pavilion**
Main Sector	Embassy of Canada to the Republic of Korea
Pharma	
Website	
https://www.junopharm.ca/	

Company Description

Juno Pharmaceuticals is a Canadian based consortium of international specialty pharmaceutical and healthcare companies led by a team of highly skilled experts, with decades of collective industry experience.

Our business model is to invest in and help support the development of front-end businesses around the world, but with a primary focus in the territories of Australia, Canada, South Africa, and the UK. Corporate resources, such as finance, intellectual property, and business development experts are shared amongst the Juno global network generating topline sales more than $600M in 2024.

To Buy or Sell Technology/Product

Throughout our network, Juno operates across a range of spaces within the pharmaceutical market, from branded to generic, and hospital to retail. Our focus and expertise have been directed towards the identification and in-licensing of scarce and niche generic pharmaceuticals with inherent barriers to market entry. The targeting of these opportunities means we have a robust commercial focus in our markets, with experienced commercial and regulatory departments with a proven track record of detailing products to specialists and achieving approvals for complex pharmaceutical products. Juno is one of the largest specialty injectable businesses in Canada. Our Montreal based parenteral manufacturing facility is EU GMP and FDA certified and currently exports to over 20 markets worldwide.

K LAB Co.,Ltd.

Country	Booth No.
Republic of Korea	E30
CEO Name	
Kim Soohyun	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
http://klab.im	

Company Description

Based on our technical experience, K LAB Co., Ltd. has been leading the development and dissemination of a spectrophotometer having a monochromator applied with a high-precision scanning mechanism developed for the first time in Korea. We also consider the convenience and satisfaction of customers as our core value and we constantly challenge ourselves.

To Buy or Sell Technology/Product

K LAB is a company that develops and manufactures high-performance analytical instruments capable of precisely measuring the transmittance or absorbance of samples at each wavelength within the ultraviolet (UV) and visible light spectrum, enabling accurate analysis of quantitative characteristics such as concentration and purity.

From basic analytical experiments to advanced research applications, K LAB instruments deliver high accuracy and excellent reproducibility. They provide reliable results across various fields, including environmental science, biotechnology, and chemistry.

Committed to supporting both research and industrial progress, K LAB continuously provides analytical solutions that ensure precision and reliability.

Karisbio Inc.

Country	Booth No.
Republic of Korea	G16
CEO Name	
Young-sup Yoon	**Pavilion**
Main Sector	
Pharma	Korean Pavilion for Advanced Regenerative Medicine
Website	
http://karisbio.com	

Company Description

KarisBio is developing cardiovascular cell therapies using iPSC differentiation and direct reprogramming technologies. The company was the first to demonstrate iPSC-based vascular regeneration and has secured a core patent for directly reprogrammed endothelial cells. Karis Bio is currently conducting the world's first clinical trial using iPSC-derived endothelial cells (iPSC-ECs) for peripheral artery disease patients, with results expected in the second half of 2025.

To Buy or Sell Technology/Product

KarisBio develops iPSC-derived endothelial cells (iPSC-ECs) and directly reprogrammed endothelial cells (rECs) for cardiovascular therapy. iPSC-ECs are currently in the world's first clinical trial for peripheral artery disease in Korea and successfully completed a pre-IND meeting with the FDA in 2024. rECs are generated by directly converting fibroblasts or urine cells using transcription factors, avoiding pluripotency-related risks. Both cell types show strong therapeutic effects in ischemic models and are produced using KarisBio's patented technologies. Safety and toxicity evaluations followed FDA and MFDS guidelines, supporting their potential as next-generation cell therapies for vascular regeneration

KBI BIOPHARMA

Country
Republic of Korea

CEO Name
Tim Lowery

Main Sector
Professional Services and Consulting

Website
http://www.kbibiopharma.com

Booth No.
N28

Pavilion

Company Description

KBI Biopharma is a global CDMO providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies.
With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs. Global partners are utilizing KBI's technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of 11 commercial products.
Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs.

To Buy or Sell Technology/Product

Technologies including,
SUREtechnology Platform (CHO-based cell line development)
SUREmAb (Monoclonal Antibody Development)
PUREcoli (microbial cell line development)
Digital Solutions (PROGRAMview and Analytics Portal)
Services including,
Cell Line Development
Process/Analytical/Formulation Development
Characterization
Clinical and Commercial Manufacturing

K-BioCELF Inc.

Country
Republic of Korea

CEO Name
Oh, MyungRyurl

Main Sector
Pharma

Website
http://www.k-biocelf.com/

Booth No.
F4

Pavilion
Rising Pavilion

Company Description

K-BioCELF Inc. is a bio-venture company focused on AI-driven bioprocess robotic systems, integrating advanced technologies derived from new drug development, in vitro diagnostics, and automated bioprocess systems. The product line up is CELF™ System (Advanced Biopharmaceuticals Production, Bioink and Cultured Meat Production Equipment), CELP™ System (Artificial Skin Model Production Equipment), and Other Devices. Through our initiatives, we're at the forefront of revolutionizing healthcare, leveraging automation to enhance efficiency and effectiveness in diagnostics and treatment. We aim to build an overseas bio process (i.e biopharmaceutical/Bioink/Cultured meat) manufacturing hub utilizing cutting-edge automation technology and grow together with various Bio companies.

To Buy or Sell Technology/Product

[Product I. CELF™ System]
Equipment tailored for advanced biopharmaceutical production, bioink, and cultured meat manufacturing.
● Enables automated cell culture for bioink, advanced biopharmaceuticals (immune cells, stem cells, CGT, organoids), and cultured meat.
● Fully Automated System : Covers entire processes from vessel coating and medium replacement to cell harvesting.
● Mass Production & Scalability : Modular design allows expansion (e.g., CO_2 incubator, centrifuge, microscope, vision systems).
●Versatile Cell Culture : Suitable for adherent and suspension cells, cancer cells, and stem cells.
● Automatic Dispensing System : Compatible with various protocols, including medium, enzyme, and cell dispensing.
● Standardized Processes : COptimized for R&D and industrial-scale production.

[Product II. CELP™ System]
Automated production systems specifically designed for artificial skin and organoid 3D bio-printing.
●Fully Automated System : Capable of dispensing up to 40 plates simultaneously, with optional automated incubation.
● Mass Production : Capable of producing 240 to 960 units at once.
●Temperature Control System : Maintains optimal temperatures throughout dispensing and culturing processes.
● Precision Dispensing : Ensures consistent temperature maintenance for dispensing medium, matrix (collagen/ matrigel), and cells. 44 45
● Standardized Processes : Ideal for R&D and biopharmaceutical CRO applications.

KBIOHealth

Country
Republic of Korea

CEO Name
Myoung Su Lee

Main Sector
Academic/Non-Profit

Website
http://www.kbiohealth.kr

Booth No.
H1

Pavilion

Company Description

KBIOHealth was established in 2010 as a public institution under the Ministry of Health and Welfare. We serve as a CRO, CMO, and CDMO for the development of biopharmaceuticals and BT-based medical devices, leading the advancement of the high-tech medical industry toward the global market.

To Buy or Sell Technology/Product

KBIOHealth provide a one-stop service to support industries, academia, research institutes, and hospitals in the areas of biopharmaceutical development, BT-based medical device development, biopharmaceutical production, non-clinical trials, and regulatory science. Additionally, we contribute to the advancement of the biomedical industry by offering programs to train professionals in biopharmaceuticals.
Starting this year, InnoLabs opened. It works to promote innovative companies by providing technical and business commercialization support to resident companies.

KCL

Country
Republic of Korea

CEO Name
Cheon Young-ghil

Main Sector
Professional Services and Consulting

Website
http://kcl.re.kr

Booth No.
K27

Pavilion

Company Description

The Korea Conformity Laboratories (KCL), an affiliated organization of the Korean Agency for Technology and Standards under the Ministry of Trade, Industry and Energy, efficiently carries out testing, evaluation, certification, and research and development across all industrial sectors, including components and materials, medical devices, public health and environment, and biotechnology. Recently, KCL has been further strengthening its testing and certification infrastructure and technological capabilities in emerging industries such as ESS (Energy Storage Systems) and renewable energy, aiming to ensure a safer and more secure life for the public.

To Buy or Sell Technology/Product

- Testing and Evaluation
KCL's testing and evaluation services are organized across various sectors, including construction and energy, consumer safety, bio and healthcare, chemical and environmental, components and materials, mobility, electrical and electronics, and fire safety. By issuing approximately 190,000 test reports annually, KCL contributes to public safety and technological advancement.

KEYFRONBIO/ARDENA

Country
Republic of Korea

CEO Name
Kang Jong Ku

Main Sector
Professional Services and Consulting

Website
http://www.keyfronbio.com

Booth No.
H16

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description

Keyfron Bio is a nonclinical CRO that provides a wide range of pharmacological evaluation services, including efficacy studies, pharmacokinetics (PK), biodistribution assessments, and bioanalysis. Holding both domestic and international GLP and GCLP certifications, Keyfron Bio ensures highly reliable analytical capabilities. Our expertise covers a broad spectrum of drug modalities-from small molecules to cell and gene therapies-and includes Korea's largest PCR-based biodistribution studies, as well as CDMO services within a bio total service.

To Buy or Sell Technology/Product

Keyfron Bio provides clinical and non-clinical testing services including bioanalysis, pharmacokinetics (PK), ADME, biodistribution, and efficacy evaluations for small molecules, antisense oligonucleotides (ASOs), peptides, biologics, and cell and gene therapies (CGTs). Keyfron Bio also offers integrated research solutions encompassing immunogenicity testing including ADA analysis, efficacy studies focused on oncology, metabolic and liver diseases, and CDMO services.

KEYPRIME RESEARCH

KEYPRIME RESEARCH
Trustworthy, Creative, and Collaborative Research Institute

Country
Republic of Korea

CEO Name
Dongil Kim

Main Sector
Professional Services and Consulting

Website
http://www.keyprime.com/

Booth No.
H17

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description

Keyprime Research is a nonclinical CRO specializing in Non-Human Primate studies, offering a comprehensive range of nonclinical research services. With extensive expertise and a wealth of experience, we are committed to supporting our sponsors' drug development success with accurate and reliable study results. Keyprime Research offers optimal solutions and provides tailored services to help sponsors achieve their research goals.

To Buy or Sell Technology/Product

KPR adheres to the highest ethical standards in the care and use of laboratory animals, and is fully accredited by AAALAC International. Holding GLP certification from the Ministry of Food and Drug Safety (MFDS), we offer a variety of research services utilizing non-human primates, including General Toxicology (GLP), Pharmacology, and Safety Pharmacology. In addition to more common administration routes (such as oral, intravenous, subcutaneous, and intramuscular), we also offer specialized administration methods, such as via the ocular, intrathecal, and intra-articular routes. Our expertise enables us to offer highly specialized services to support the development of a wide range of therapeutics.

KH Neochem

KH NeoChem

Country
Japan

CEO Name
Michio Takahashi

Main Sector
Professional Services and Consulting

Website
https://www.khneochem.co.jp/en/solution/features/glycans/library/

Booth No.
M7

Pavilion

Company Description

KH Neochem Co., Ltd. is a chemical materials manufacturer established in 2010, with roots tracing back to the founding of Kyowa Yuka Co., Ltd. in 1966.
KH Neochem is advancing a new business initiative focused on glycan technology. Glycans are known for their ability to provide organ-specific recognition and significantly enhance the blood stability of peptide drugs through conjugation. To leverage these unique properties, we have developed an exclusive glycan library. Furthermore, we offer technology that enables flexible glycan modification of proteins and peptides, aiming to achieve innovative drug discovery that maximizes the potential of glycans.

To Buy or Sell Technology/Product

Glycans as a Key Element in Drug Discovery Solutions

The modification of peptide drugs with glycans offers a promising approach to improving their pharmacokinetics. This modification enhances water solubility, prevents rapid renal clearance, and significantly extends the retention time of the drugs in the bloodstream.

In addition, the introduction of specific glycan structures to peptides enables targeted drug delivery by facilitating selective binding to target cells or organs. This approach enhances drug targeting, thereby improving therapeutic efficacy while minimizing off-target effects and reducing adverse side effects.

K-Health MIRAE Initiative

Country
Republic of Korea

Booth No.
L1

CEO Name
Soon do CHA, Kyung SUN

Pavilion

Main Sector
Academic/Non-Profit

Website
http://khidi.or.kr/khmi

Company Description

The K-Health MIRAE Initiative is an organization that conducts challenge-driven and innovative R&D to address Republic of Korea's healthcare challenges. It was launched in 2024 as a direct subsidiary of the Korea Health Industry Development Institute (KHIDI). The organization's name was selected through a public contest, and "MIRAE" stands for Medical Innovation and ReseArch Evolution, signifying its mission to lead the future of healthcare through medical research and innovation.

To Buy or Sell Technology/Product

The K-Health MIRAE Initiative is a public-driven R&D program designed to solve national healthcare challenges and bring transformative innovations to medical and health services. The program identifies five urgent missions-health security, unconquered diseases, bio-health breakthrough technology, welfare and care servies and essential medical services-and supports high-cost, high-risk research to address them. From 2024 to 2032, the program is operated with 1.2 trillion KRW.

KNR

Country
Republic of Korea

Booth No.
B23

CEO Name
chang-hyun shim, jong-hwan kim

Pavilion

Main Sector
Medical Device

Website
http://eknr.com/

Company Description

KNR Instrumentation offers customized service with our hightechnical power and accumulated experience of years. KNR`s products are used in air Quality analysis, water analysis, analysis of agricultural and meterological observation.

To Buy or Sell Technology/Product

APK5100H
- Korea's First/Only Gas Safety Corporation Acquires Certification of Hydrogen Management Safety ActAct Certification
APK2950 Series (W,A)
- VOC in the atmosphere, PAMS, odor and underwater VOC online continuous monitoring system, low concentration analysis below ppb level

Kogenebiotech

Country	Booth No.
Republic of Korea	E2
CEO Name	
YONG SUK NAM, JU HYUN NAM	**Pavilion**
Main Sector	Rising Pavilion
Digital Health	
Website	
www.kogene.co.kr	

Company Description

KogeneBiotech, established in 2000, is a research and development company that pioneered the field of molecular diagnostics in Korea by developing and commercializing the country's first Real-time PCR assay kits. Over the past 25 years, we have developed over 2,000 diagnostic reagents for various fields such as infectious diseases, animal diseases, and food safety. By proactively developing and providing innovative testing methods and products needed by national institutions, we have contributed to the establishment of Korea's national standard testing system. Our core value is to deliver a "Total Molecular Diagnostic Solution," including automated nucleic acid extraction systems, PCR reagents and equipment, result interpretation tools, and on-site technical support to meet customer needs

To Buy or Sell Technology/Product

1. Rapid Development and Optimization Expertise
- Developed and supplied Korea's first diagnostic kit for the pandemic Influenza A/(H1N1) pdm09 virus (2009) to the Korea Disease Control and Prevention Agency (KCDC).
- Obtained Korea’s first Emergency Use Authorizations (EUA) for diagnostic kits for MERS (2016) and COVID-19 (2020).
- Supplied COVID-19 variant diagnostic kits as the only company in Korea to pass efficacy evaluations conducted by KCDC.
- Supplied Korea's first FDA-approved simultaneous COVID-19/Influenza diagnostic kit.

2. Development of National Standard Test Method
- Developed and supplied diagnostic methods for various respiratory viruses and infectious diseases, including Dengue, Zika, Chikungunya, Measles, and Malaria, supporting national monitoring programs conducted by KCDC and the Research Institute of Public Health & Environment, thus significantly contributing to national public health.
- Proactively proposed diagnostic testing methods at the national level for novel pathogens with potential global spread, completing performance evaluations and preparing strategic responses to potential outbreaks.
- Supplied molecular diagnostic kits for surveillance of foodborne pathogens, GMO testing, Halal testing, rice variety identification, and more, supporting regulatory activities by Korea’s Ministry of Food and Drug Safety (MFDS) and the National Agricultural Products Quality Management Service (NAQS), enhancing food safety nationwide.
- Our products have been adopted as standard testing methods for Halal certification of food and pharmaceuticals by the Indonesian Council of Ulama (MUI), one of the world's top three Halal certification authorities.
- These achievements demonstrate our strong capability to consistently deliver high-performance products and maintain exceptional quality standards.

KOMA BIOTECH

Country	Booth No.
Republic of Korea	F30
CEO Name	
Moon SangHoon	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://komabiotech.co.kr/	

Company Description

KOMA BIOTECH, based in Seoul, Korea, provides reagents and custom service for life science research. The comprehensive product lines support applications in the study of all major life science research areas, including molecular biology, immunology, cell biology, proteomics and genomics research.

To Buy or Sell Technology/Product

KOMA Biotech provides various manufacturing and analysis services from basic to preclinical through overseas R&D service partners to successfully develop therapeutics using immuno-oncology, genes and cells. We will do our best to become a reliable research partner by out sourcing high-quality services and supplying research reagents

KoMo GmbH

Country	Booth No.
Germany	A1
CEO Name	
Ing. Marcel Koidl	**Pavilion**
Main Sector	
Professional Services and Consulting	Bavarian Pavilion c/o Bayern International GmbH
Website	
www.komo.bio	

Company Description

We at KoMo have been building grain mills, flakers, and combo devices for over 35 years. Our vision is to inspire joy in healthy eating and well-being. We prioritize sustainability, fair trade, and regional suppliers, producing in Tyrol. As a family business, we blend tradition with innovation to create high-quality, eco-friendly products.

To Buy or Sell Technology/Product

At KoMo, we focus on quality, sustainability, and the natural processing of grains. Our grain mills, flakers, and combination devices allow you to create fresh, nutrient-rich foods right in your own kitchen – supporting a conscious and healthy lifestyle. Thanks to high-quality materials and precise craftsmanship, our devices are exceptionally durable. That's why we offer a **12-year warranty** on our grain mills – a testament to their reliability and quality.
Our **grain mills** are specially designed to grind various grains, including rice, into fine and consistent flour. Rice flour is an essential ingredient in many Asian cuisines, perfect for gluten-free baking, traditional dough-based dishes, or delicate sweets. With our proven corundum-ceramic millstones, rice can be effortlessly ground into ultra-fine flour without clogging or overheating the mill.
With our **flakers**, you can easily produce fresh oat flakes and other rolled grains at home – ideal for a nutritious breakfast or as a healthy ingredient in various recipes.
Our **combination devices** bring the best of both worlds together: a powerful grain mill and a flaker in one machine – perfect for those who value versatility in grain processing.
Through sustainable production, premium materials, and continuous technological improvements, we ensure that our devices are reliable, durable, and easy to use – enabling wholesome nutrition in kitchens worldwide.

KOREA FUND FOR REGENERATIVE MEDICINE

Country
Republic of Korea

CEO Name
INHO JO

Main Sector
Academic/Non-Profit

Website
http://www.kfrm.org

Booth No.
H15

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description

KFRM(Korea fund for regenerative medicine)was established in 2021 to coordinate the regenerative medicine research and development(R&D) project jointly funded by the Ministry of Science and ICT and the Ministry of Health and Welfare of Republic of Korea with KRW 600 billion(USD 410M) for 10 years(2021-2030).

To Buy or Sell Technology/Product

Our goal is to improving public health through regenerative medicine, an innovative medical technology intended to overcome the limitations of existing therapies and medical technologies. KFRM(Korea fund for regenerative medicine) aims to develop advanced regenerative medicine treatments and technologies for intractable and severe diseases. It supports the entire cycle of the Pan-Ministerial Regenerative Medicine Technology Development Project, from the development of core and fundamental technologies such as stem cells, genes, and tissue engineering to the development of domestic and international clinical therapeutic agents.

Korea Innovative Pharmaceutical Company

Country
Republic of Korea

CEO Name
Soondo Cha

Main Sector
Academic/Non-Profit

Website

Booth No.
A19

Pavilion

Company Description

The Ministry of Health and Welfare and the KHIDI foster Innovative-Pharmaceutical companies that will lead pharmaceutical industry innovation in accordance with the Special Act on Fostering and Support of Pharmaceutical Industry.

To Buy or Sell Technology/Product

In 2024, a total of 49 companies have been certified as Innovative Pharmaceutical Companies, including 33 pharmaceutical companies, 12 bio ventures, and 4 foreign pharmaceutical companies, demonstrating the excellence of Koreans innovative pharmaceutical companies in new drug manufacturing platforms and candidate substances.

KOREA INSTITUTE OF INTELLECTUAL PROPERTY PROMOTION

한국특허기술진흥원 Korea Institute of Intellectual Property Promotion

Country
Republic of Korea

CEO Name
MYEONG SUP KIM

Main Sector
Professional Services and Consulting

Website
http://www.kipro.or.kr

Booth No.
M2

Pavilion

Company Description

KIPRO(Korea Institute of Intellectual Property Promotion), a public institution affiliated with KIPO(Korean Intellectual Property Office), supports KIPO's policies and offers various patent information services such as IP research, analysis, evaluation and consulting, etc.
KIPRO takes pride in making every effort to meet the needs of clients by providing high quality patent information and developing various patent services.
KIPRO will continue to provide intellectual property information to industries, research laboratories and academia to encourage creativity, competitiveness and technological advancement.

To Buy or Sell Technology/Product

1. Support for KIPO's Patent Examination
- The KIPRO contributes to the improvement of the KIPO's examination by searching and analyzing.
2. IP Information Service
- We search, analyze, evaluate and provide you with critical IP information to support effective R&D and increase competitiveness.
kiwee provides patent information to meet our clients' needs, including prior art searches, patent maps, patent statistical analyses, patent evaluations, patent consultations and patent education support.
- IP Research Service
3. Premium Search Services for Overseas Customer
- Validity Search, State of The Art Search, Trademark/Design Search

Korea Institute of Toxicology

KIT 국가독성과학연구소 Korea Institute of Toxicology

Country
Republic of Korea

CEO Name
Jeong-Doo Heo

Main Sector
Academic/Non-Profit

Website
http://www.kitox.re.kr

Booth No.
D11

Pavilion
DIPS 1000+ project

Company Description

Korea institute of Toxicology(KIT) is a government-funded research institute, which conducts toxicology research with safety assessments of chemical and biological materials consisting of medicines, agricultural chemicals, dietary supplement food, food additives and cosmetics, and develop future technology to contribute to the improved public health and safe society.

To Buy or Sell Technology/Product

- Field of Research: Providing advanced and predictive toxicology research, advanced pharmaceuticals R&D and evaluation with world-class non-clinical test R&D
- Industrial Support: Support for domestic and international licensing and commercialization of national innovative bio-health products
- Global Licensing: Certified as a GLP-compliant Testing Organization, Forestry and Fisheries of Japan, and by OECD, and as a Testing Organization by US FDA inspection
- Professional Manpower: Equipped with expert group of non-clinical test field with new drug development experiences
- Infrastructure: Furnished most advanced analysis test equipment

KS Medical Inc.

Country
Republic of Korea

CEO Name
Kyong San Chai

Main Sector
Medical Device

Website
http://www.ksmedical.net

Booth No.
E28

Pavilion

Company Description

KS Medical Inc. is a company with extensive experience in medical devices for the blood sector, with major clients including blood centers and university hospitals. As the exclusive distributor of TerumoBCT in Korea, the company imports and sells medical and bio equipment and consumables in the fields of blood component separation, therapeutic apheresis, and cell therapy technologies.

To Buy or Sell Technology/Product

B Medical Systems is a global manufacturer that provides medical refrigerators, freezers, ultra-low temperature freezers, and transport boxes. Their products can maintain stable temperatures at +5 °C, -41 °C/-32 °C, -82 °C, and can perform reliably even at high temperatures of +32 °C and +43 °C. They supply products to over 170 countries.

KYMOS GROUP

Country
Republic of Korea

CEO Name
JOAN PUIG, YOONJIN KIM

Main Sector
Professional Services and Consulting

Website
http://www.kymos.com

Booth No.
F27

Pavilion

Company Description

The Kymos Group is an analytical CRO with three European laboratories devoted to providing bioanalytical and CMC services for the life science industry throughout the entire product life cycle: from early research and development to manufacturing and commercialization. We are GLP- and GMP-certified, have been successfully inspected by the EMA, ANVISA and the FDA and are experts in analytical and quality control work with small molecules, biologics, advanced therapies and oligonucleotides

To Buy or Sell Technology/Product

Analytical Development and Validation
Bioanalysis of Small mol &Large mol(aka Immunology)
Bioanalysis of Oligonucleotides
QC(aka Biopharmaceutical testing)
Elemental Analysis
Microbiology
Stabilities

Kyungpook National University Hospital

Country	Booth No.
Republic of Korea	C19
CEO Name	
Dong Heon Yang, WeonJu Lee	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
http://knuh.kr	

Company Description

Kyungpook National University Hospital has been working to protect the health of local residents for the past 100 years through the main hospital, Chilgok Kyungpook National University Hospital, and Kyungpook National University Children's Hospital. As a research- driven hospital designated by the Ministry of Health and Welfare, it is contributing to the advancement of health care through the development and commercialization of cutting-edge medical technologies.

To Buy or Sell Technology/Product

KNUH do national funded research projects about 12 billion won per year, such as the "Research-driven Hospital Development R&D Project" and the "Korean ARPA-H Project," as well as about 200 externally funded projects and about 30 hospital-funded research projects. We are fulfilling our role as a regional research hub through the "Clinical Trial Center for Pharmaceuticals and Medical Devices," the "Brain Bank Support Project for Collaborating Hospitals," the "Effectiveness Evaluation Center," and the "Core Lab."

Labnote Scholar

Country	Booth No.
Republic of Korea	E32
CEO Name	
Sangyoon Lee	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http:// labnote.co	

Company Description

Aaant is creating LabNote, a smart research data recording and management solution specialized in the fields of bio, nano, and chemistry. Like Notion and GitHub, we hope to improve research efficiency by providing a smart research environment in the BT (Bio-Tech) & NT (Nano-Tech) fields.

Our UX-driven LabNote provides the optimized data recording systems and data pipeline to be applied for machine learning solutions specialized for BT&NT research.

To Buy or Sell Technology/Product

Labnote Scholar efficiently manages/operates R&D organizations to meet the needs of chemical, material and bio companies that want to utilize/introduce AI technology.

Our Ant has been in charge of digital transformation, analysis, and utilization of research data for various companies and research institutes (Seoul Asan Hospital, Korea Chemical Research Institute, etc.),
Even now, customers who have introduced our solution are achieving efficiency in various areas, such as shortening the project period by 27-33%, increasing the number of projects per researcher by 2.3%, and decreasing the number of same experiments (trial and error) by 20-40%.

LABnPEOPLE

LAB n PEOPLE

Country	Booth No.
Republic of Korea	D11
CEO Name	
CHO, SUNG YOUN	**Pavilion**
Main Sector	DIPS 1000+ project
Medical Device	
Website	
www.labnp.com	

Company Description

Founded in 2016, LABnPEOPLE is a bio venture company that has developed magnesium patches, bioabsorbable implants, and microinvasive medical devices using only essential components of the human body. With over 20 years of expertise, the research team has filed more than 110 intellectual property applications and registered 45 patents domestically and internationally. In addition to the magnesium patches and medical devices currently on the market, we are collaborating with hospitals & pharmaceutical companies at home & abroad to develop innovative products that are not yet available.

To Buy or Sell Technology/Product

[Bioabsorbable Metal Material]
•The world's only ultra-thin, high-strength, high-elongation bioabsorbable metal made from human-compatible elements, offering excellent biocompatibility.
•Features electrical conductivity, lightness, and flexibility, with applications in membranes, threads, and microneedles due to advanced thin-film and wire technologies.
[Microneedle Patch]
•Micron-scale patterning enables diverse designs of bioabsorbable metal sheets.
•Microneedles can form channels for active ingredient delivery and are customizable in length and quantity.
[Wearable Device Platform]
•Utilizes self-powered microcurrent generation module technology to create wearable patches without the need for batteries or circuits, ensuring convenience, eco-friendliness, and hygiene.
•Improves drug delivery efficiency and energy transmission in various wearable forms, with applications in medical and cosmetic fields.
•Applications
-Transdermal drug delivery (TDD) via iontophoresis.
-Creation of battery-free electronic patches (e.g., LED, pulse) and wound dressings that accelerate healing using microcurrent technology.
[Aesthetic implant]
•Patented bioabsorbable metal for aesthetic implants, safely excreted without side effects.
•Produces a skin-filling effect as the magnesium alloy degradation releasing hydrogen (H_2).

LAMEDITECH

Country	Booth No.
Republic of Korea	C32
CEO Name	
JongSeok Choi	**Pavilion**
Main Sector	
Medical Device	
Website	
http://lameditech.com	

Company Description

Lameditech is a company that develops innovative medical and aesthetic devices based on ultra-compact laser technology. We lead the global healthcare market with the needle-free laser blood sampling device 'HandyRay' series and the skin disease treatment device 'CAREVEAM'. Our goal is to provide a convenient and safe medical environment through continuous R&D, delivering user-friendly healthcare solutions.

To Buy or Sell Technology/Product

Lameditech's 'HandyRay' series enables painless blood sampling without needles using advanced laser technology, while 'CAREVEAM' effectively treats various skin diseases such as psoriasis and vitiligo using a 308nm excimer wavelength. Our proprietary precision laser technology ensures high safety and efficacy, designed for use in both home and clinical settings.

Liberi Group

Country	Booth No.
Netherlands	B11
CEO Name	
Frans Trouwen	**Pavilion**
Main Sector	
Professional Services and Consulting	Netherlands Bio Lounge
Website	
www.LiberiGroup.com	

Company Description

Liberi Group is a global boutique consultancy specializing in personalized business development support for biotech, pharma, diagnostics, and medical device companies. Operating across the EU, US, and Asia, Liberi connects early to late-stage clients with strategic partners for licensing, co-development, investment, M&A, and asset divestment. Liberi also provides asset and pipeline valuation upon request. Its tailored, selective approach ensures high-impact partnerships, especially for clients seeking cross-border growth. Liberi takes on a limited number of projects annually to deliver focused, results-driven service.

To Buy or Sell Technology/Product

Global BD & Investment Consultancy

Liberi Group offers comprehensive business development support for biotech and pharma companies of all sizes. Services include in- and out-licensing, M&A support to identify strategic opportunities, and co-development facilitation to advance assets collaboratively. The firm also assists in investment searches, from seed to pre- and post-IPO funding, and provides valuation services to assess asset or pipeline value for strategic decision-making. Additionally, Liberi supports companies in divesting non-core assets by identifying suitable buyers or partners. With a flexible, tailored approach, Liberi helps clients navigate critical growth milestones and maximize their business potential through strategic partnerships.

Linear Clinical Research

Country
Australia

Booth No.
B1

Delegate Name
Harry Li

Pavilion
Australian National Pavilion

Main Sector
Clinical trials site

Website
https://www.linear.org.au/

Company Description

Linear Clinical Research is an innovative not-for-profit clinical trial organisation based in Perth Western Australia. Linear has worked on over 500 studies for international biopharma since its formation in 2010 across a wide range of therapeutic areas. With three state-of-the-art clinical facilities, Linear can
support the execution of all trial phases with a key focus on delivering your study as fast as possible without compromising on quality and data integrity.

To Buy or Sell Technology/Product

Nedlands - BBlock : Linear's B Block clinic is co-located with a 600 bed tertiary hospital within one of the largest medical precincts in the Southern Hemisphere. Our 24 bed facility is purpose built to execute clinical trials from Phase I to Phase III, and has 24/7 Medical Emergency Team (MET) coverage to ensure safety oversight.

Joondalup - JEPC : Linear's purpose built healthy volunteer clinic was completed in August 2022, and has 24 state-of-the-art beds, with a built in telemetry safety monitoring system. Linear's Joondalup facility is one of Australia's newest clinical trials facility, and provides clients and participants an innovative, cutting edge, clinical trial experience.

Nedlands – ACTC : The Advanced Clinical Trials Centre (ACTC) is a first of its kind in Australia - an accredited private hospital dedicated to clinical trials that will be accessible to private and public trial participants. The ACTC houses six (6) consultation rooms, a processing laboratory and is able to admit eighteen (18) participants with six (6) overnight capabilities.

LNPsolution Inc.,

Country
Republic of Korea

Booth No.
L11

CEO Name
Summer Dabin Lee

Pavilion
Gangwon Technopark

Main Sector
Professional Services and Consulting

Website
www.lnpsolution.com

Company Description

LNPsolution is an in-silico drug development company that supports the discovery of hit compounds in the early stages of new drug development based on molecular modeling and artificial intelligence (AI) technology. Innovative computer simulation and advanced AI technology are helping researchers conduct research on new drug development more efficiently and accurately.
LNPsolution does our best to help our customers succeed.

To Buy or Sell Technology/Product

LNP AI Smart Bench, the core platform of us, is an AI-based analysis tool for new drug research, providing an environment where researchers can easily integrate and utilize deep learning and molecular modeling technologies. In addition, it aims to provide customized support to innovatively accelerate the R&D process of customers and maximize R&D results beyond providing a platform.

LNPsolution provides professional analysis services and partnerships for successful new drug development for customers.
We are part of the journey of new drug development and want to contribute to creating a better R&D environment with innovative molecular modeling and AI technology.

Lonza

Country
Switzerland

CEO Name
Wolfgang Wienand

Main Sector
Professional Services and Consulting

Website
https://www.lonza.com/

Booth No.
K14

Pavilion

Company Description
Lonza is one of the world's largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of customers - from emerging biotechs to global pharmaceutical companies - to transform their therapeutic discoveries into life-saving and life-enhancing treatments for their patients. Our vision is to be the pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology and lean manufacturing.

To Buy or Sell Technology/Product
Our business is structured to meet our customers' complex needs across three synergistic Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Our services span from early development to drug substance and drug product manufacturing, and we lead in both established and emerging technologies including mammalian biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, microbial, and cell and gene. Across technologies, we deliver integrated solutions to meet our customers' needs throughout the entire treatment lifecycle.

LUCASBIO

Country
Republic of Korea

CEO Name
Nayoun Kim, Keon Il Im

Main Sector
Pharma

Website
http://www.lucasbio.com

Booth No.
H12

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description
LucasBio is a biotech company developing cell therapies for viral infections. We aim to treat infectious, cancerous, and inflammatory diseases with personalized and donor-derived off-the-shelf therapies.

To Buy or Sell Technology/Product
LucasBio develops DTK, an off-the-shelf and personalized virus-specific T-cell therapy targeting CMV, EBV, and AdV. The company is also a GCLP-certified central lab with strong clinical sample testing capabilities.

MABPLEX INTERNATIONAL CO.,LTD

Country
China

Booth No.
N12

CEO Name
Xinfang Li

Pavilion

Main Sector
Professional Services and Consulting

Website
http://www.mabplex.com

Company Description
MabPlex International Co., Ltd. is a Contract Development and Manufacturing Organization (CDMO) which focuses on CMC development for biologics. The company specializes in offering customized and integrated services for biologics development, including but not limited to antibodies, antibody drug conjugates (ADC), and other recombinant proteins. MabPlex so far has built four facilities in Yantai, covering from development to commercial production of DS and DP, for anatibody, linker-payload and ADC. This makes MabPlex one of the few companies that offers comprehensive, one-stop CDMO service, especially for ADC products.

To Buy or Sell Technology/Product
MabPlex subsidiary, CelluPro, has a series of chemically-defined culture media developed for commercial CHO cell lines. This series includes a variety of basal media, feed media and perfusion media, which can fully support the expansion and protein expression of different CHO cell lines (CHO-K1, CHO-ZN, Lonza, Horizon, CHO-DG44, etc.).
The media products use the international leading pin mill powder production equipment and international mainstream raw material suppliers. The products has supported the commercial production of a number of marketed antibody drugs in China for years and can support FDA filing.

MaH Clinical Trial Solutions

Country
Australia

Booth No.
B1

CEO Name
Huanyi (Gigi) Chen

Pavilion
Australian National Pavilion

Main Sector
Clinical trials logistics

Website
www.mahpharma.com

Company Description
MaH are experts in the storage, distribution, labelling and packing of clinical trial materials in APAC and Global regions. Our GMP/GWP facility is designed to meet the needs of clinical trial sponsors, contract research organisations (CROs), and other vendors involved in the clinical trial supply chain.

Medi N Research.Co.,LTD

Country
Republic of Korea

CEO Name
Lee SeoHyung

Main Sector
Pharma

Website
www.menre.co.kr

Booth No.
L19

Pavilion
Jeonbuk Technopark

Company Description
Medi N Research is growing based on differentiated technology and R&D capabilities, focusing on the development of bio-cosmetics and beauty medical devices.

To Buy or Sell Technology/Product
With proprietary technology of bio-material 'Deinoxathin' and 'JUSTBEME 6 types' for skin soothing and barrier strengthening based on Houttuynia cordata

-Deinoxanthin is a proprietary biomaterial derived from radiation-resistant microorganisms and has a strong antioxidant function and is a high value-added material applicable to various fields
-6 types of JUSTBEME maximize the effectiveness with only essential ingredients while minimizing the skincare stage.

MEDIAIPLUS, Inc.

Country
Republic of Korea

CEO Name
Jihee Jung

Main Sector
Professional Services and Consulting

Website
https://www.mediaiplus.com/

Booth No.
D11

Pavilion
DIPS 1000+ project

Company Description
“Create a virtuous cycle in clinical trials to provide more treatment opportunities for patients.”

MEDIAIPLUS specializes in clinical trial business intelligence, supporting pharmaceutical, biotech, and medical device companies in the trial preparation stages. We offer the world’s largest curated clinical trial dataset, powered by AI, to enhance trial success rates. Our platform analyzes and matches the most suitable global CROs based on data—not personal networks. By addressing inefficiencies across trial stages with big data and AI, we accelerate drug development and improve patient access to innovative treatments.

To Buy or Sell Technology/Product
1.MediC is a platform designed to provide global clinical information necessary for trial planning. It collects and processes global trial data using NLP and annotation, then trains AI to generate critical insights. This innovation has achieved an 80% reduction in preparation time, previously requiring over a year by PhD-level experts.

2.FiCRO offers a solution that matches sponsors with the most suitable CROs based on their RFPs. FiCRO has built a comprehensive database of 295,00CROs worldwide, scores RFP data, and recommends the optimal CRO. This has shortened six months process to just two weeks, delivering over 80% efficiency in time savings.

Medihub Co., Ltd.

MEDIHUB

Country	Booth No.
Republic of Korea	M17
CEO Name	
YEOM HYUN CHEOL	**Pavilion**
Main Sector	Gyeonggi Business & Science Accelerator
Medical Device	
Website	
www.medihub.co.kr	

Company Description

We are a medical technology venture company that is building a ‘Smart Healthcare Platform’ that combines medical devices and platforms to solve problems experienced by medical staff (risk of medical accidents, occupational diseases due to repeated injections), patients (injection pain, exposure to medical accidents), and hospitals (difficulty in obtaining and managing medication information) in the existing manual injection procedure.

To Buy or Sell Technology/Product

Our core technologies are based on patents and have been developed through technology development. We are currently developing and commercializing a ‘smart syringe’ that can automatically inject drugs in a safe and painless manner by utilizing our patented technologies such as ‘Injection Pain Relief Algorithm (Patent Name: Painless Anesthesia Injection Device/Registration Number: 1026738210000, Pain Relief Algorithm Automatic Injector/Application Number: 10-2023-0060607)’ and ‘Drug Prescription and Information Reading (Patent Name: Automatic Injector Reading Drug Information/Registration Number: 1026235030000, Automatic Injector for Quantitative Drug Injection Based on Prescription Information/Application Number: PCT/KR2021/012933)’.
The global medical device market is expected to grow at an annual average of 6.0% to USD 487.1 billion in 2022, and is expected to reach USD 654.2 billion in 2027. The domestic medical device market is expected to grow at an annual average of 8.3% to KRW 10.5878 trillion in 2023 over the past five years.
In particular, one of our core technologies, the ‘DDS (Drug Delivery Systems)’ technology, has the potential to expand to not only the domestic but also the global medical market and has high growth potential.

In addition, based on our core patented technology, we are promoting research and development and commercialization of ‘self-injection auto-injectors’ for the general public as well as the medical field, and aim to develop a drug monitoring platform linked to medical devices that allows the general public (patients/guardians) to safely and conveniently perform precise, quantitative, and automatic drug injections at home.
We have developed automatic injectors for medical professionals (doctors/nurses) and supplied products to domestic and overseas hospitals (buyers), and have continued R&D and commercialization since our founding in 2017. - As of February 2025, we have received medical device approval in six countries: the US, Japan, Taiwan, Thailand, Indonesia, and Ukraine and have begun exporting, and are currently in discussions with local buyers for additional registrations in Singapore, Peru, UAE, and the Philippines in the first half of this year.

Mediimg Inc.

Country	Booth No.
Republic of Korea	M17
CEO Name	
Jeong Seul Ki	**Pavilion**
Main Sector	Gyeonggi Business & Science Accelerator
Digital Health	
Website	
mediimg.com	

Company Description

Mediimage has developed NeuFlow medical device s/w that calculates cerebral hemodynamic information based on MRA images and colorizes it in 3D, and obtained FDA 510(k) in 2024 after receiving domestic MFDS approval ('23). Based on big data from 1,500 cases of the world's only cerebrovascular biomarker clinical study certified by the US FDA, it predicts stroke occurrence and post-procedure prognosis and generates a report with recommendations for cerebrovascular health management with its own LLM engine. Currently, 1,771 patients are receiving cerebrovascular health management through its products.

To Buy or Sell Technology/Product

Computer simulation (computer fluid dynamics, CFD)
CFD is a hemodynamic simulation that allows for various environmental condition experiments for specific shapes, but each individual's blood vessels have very different basic conditions such as shape and blood flow rate, making it difficult to find and apply conditions that are appropriate for each individual. VINT s/w is a method that directly utilizes each individual's blood vessel shape, blood flow rate, and other biological data and displays the results.

Medinno Inc.

Country	Booth No.
Republic of Korea	D11
CEO Name	
Kyeungmin Joo	**Pavilion**
Main Sector	DIPS 1000+ project
Pharma	
Website	
www.medinno.co.kr	

Company Description

Medinno Inc. is a biotechnology company developing stem cell therapies, as well as cell and gene therapies, for the treatment of orphan central nervous system diseases. The company was founded in 2018 by Professor Kyeungmin Joo of Sungkyunkwan University School of Medicine, based on over 20 years of research.
Our pipeline consists of four types of stem cell therapeutics and two types of stem cell-based gene therapies, two of which have completed Phase I clinical trials in South Korea.

To Buy or Sell Technology/Product

HIEstem is a thrombin-preconditioned allogenic Wharton's Jelly-derived mesenchymal stem cell product targeting neonatal hypoxic-ischemic encephalopathy (HIE) and preterm intraventricular hemorrhage (IVH). It has completed Phase 1 in Korea and received ODD there, as well as ODD and RPDD from the U.S. FDA.

BSO-101 is an allogeneic neural stem cell therapy derived from the temporal lobe, being developed to treat spinal cord injury and ischemic stroke.

MG2201 is a stem cell-based gene therapy using mesenchymal stem cells engineered with tumor-targeting genes, leveraging their natural cancer-homing ability to enhance therapeutic efficacy.

MedInTech Inc.

MedInTech

Country	Booth No.
Republic of Korea	E7
CEO Name	
Chun, Steven	**Pavilion**
Main Sector	Rising Pavilion
Digital Health	
Website	
www.medintech.co.kr/company	

Company Description

MedInTech Inc., a med-tech startup founded in 2020, capitalizes on a research project started in 2015 at the Korea Electrotechnology Research Institute, with an investment of about $4.5M. In 2021, we were selected to lead a cross-ministerial medical device R&D project worth about $7M, alongside Seoul National University Hospital and other prestigious institutions, pushing forward the localization of endoscopes. With a Series A in 2022 and Series B in 2024 totaling $20M, we successfully developed both endoscopy system hardware product and the automatic abnormality detection software product. As of now, with a total of 50 employees, we continue to develop innovative features that benefit both physicians and patients, utilizing our motorized platform and AI integration.

To Buy or Sell Technology/Product

The Intelligent Endoscopy System developed by MedInTech goes beyond traditional mechanical operations by incorporating autonomous control, making user operation much easier and more intuitive, thereby significantly reducing the learning curve. Additionally, by decreasing the weight of the endoscope handle by 50% and reducing the human force required for operation to 33%, it is expected to lower the incidence rate of Endoscopy-Related Injuries (ERI) among doctors. Moreover, the implementation of Full HD quality—twice as clear as standard HD—enhances diagnostic accuracy. Furthermore, the motorization of the endoscope's control method enables precise system control over endoscope movements, paving the way for the active integration of artificial intelligence.
The first objective of the AI algorithms is to provide assistive features for physicians. There are instances especially for beginners having difficulties when inserting endoscope and navigating through human organs due to lack of experiences and 100% manul operations. MedInTech aims to resolve these issues by harnessing AI onto the motorized platform to detect the right direction inside the lumen and also steers itself without controlling by physicians.
The second objective of the AI algorithms is to prevent misdiagnoses. In endoscopic diagnostics, the level of physicians' proficiency can lead to overlooking lesions or incomplete examination, contributing to a misdiagnosis rate of up to 35%, as reported by academic studies. To address this, we are developing automatic lesion detection algorithms and algorithms to prevent blind spots by assessing the possibility of their occurrence through 3D reconstruction of the stomach's interior, ultimately aiming to reduce the misdiagnosis rate to below 5%.

MEDIPOST

Country	Booth No.
Republic of Korea	G11
CEO Name	
Wonil Oh	**Pavilion**
Main Sector	Korean Pavilion for Advanced Regenerative Medicine
Pharma	
Website	
http://www.medi-post.co.kr	

Company Description

MEDIPOST is a pioneering biotechnology company in Korea that focuses on the development of Cord blood bank, Nutritional supplements, and Cell therapy, and has been recognized for its technological expertise in the field of manufacturing technology of the world's first allogeneic cord blood-derived mesenchymal stem cell therapy product, CARTISTEM and the manufacturing & platform technology of SMUP-Cell, a next-generation stem cell culture technology. In addition, MEDIPOST provides CDMO services for CGT developers, leveraging its extensive experience and expertise.

To Buy or Sell Technology/Product

1. Stem Cell Therapeutics: Commercialization of allogeneic cord blood-derived stem cell products
2. CDMO: Contract Development and Manufacturing Organization for Cell and Gene Therapy
3. Cord Blood Bank: CELLTREE®, Korea's first and largest cord blood bank
4. Nutritional Supplements: MOVITA®, Tailored nutritional and dietary supplement solution

Microgentas

Country	Booth No.
Republic of Korea	A27
CEO Name	
Sehyun Shin	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.microgentas.com	

Company Description

Microgentas is a leading pioneer in exosome isolation and application technologies, driving next-generation life science research and therapeutic development. Through our proprietary ExoFilter, ExoTFF, ApoFilter technologies, we achieve high-yield, high-purity exosome isolation and analysis. Our technologies are applied to sample preparation of liquid biopsy, breast cancer biomarker research, exosome-based raw materials, and cosmetics.

To Buy or Sell Technology/Product

ExoFilter™ is charge based filter for efficient extracellular vesicle isolation, suited to 200 uL~1L sample loading volumes of biofluids and cell culture media. It can be customized to tens of liters. It is for large-capacity biofluids and cell culture media(CCM) as well as small volume samples, including plasma, serum, urine, and saliva. ExoTFF™ is combination of size exlusion technology and charge based filter for efficient extracellular vesicle isolation, suited to 5~10 mL sample loading volumes.

Miltenyi Biotec

Country	Booth No.
Republic of Korea	D27
CEO Name	
Stefan Miltenyi	**Pavilion**
Main Sector	
Medical Device	
Website	
http://www.miltenyibiotec.com	

Company Description

Miltenyi Biotec, founded in 1989 in Germany, provides innovative solutions in cell and gene therapy. Its MACS® technology enables efficient cell separation for research and clinical use. The company offers products for sample prep, cell culture, flow cytometry, and spatial biology. CliniMACS Prodigy® supports clinical grade cell therapy manufacturing, while Miltenyi Bioindustry provides CDMO services and operates GMP facilities for commercial cell and gene therapy production. Miltenyi Biotec has contributed to the life sciences and medical fields for over 30 years, leading the advancement of precision medicine and next-generation therapeutic technologies through continuous innvoation.

To Buy or Sell Technology/Product

Miltenyi Biotec provides innovative solutions for cell and gene therapy. MACS® enables high-purity cell separation, while CliniMACS Prodigy® supports automated cell therapy manufacturing. The MACSima™ imaging technology-based spatial biology solution allows high-resolution analysis of cellular interactions within tissues, and the UltraMicroscope Blaze enables 3D light sheet imaging. The company also offers flow cytometry solutions for IPC/QC in cell therapy, along with an innovative flow cell sorter that safely isolates high-purity cells while minimizing cell damage. Additionally, Miltenyi Biotec provides cell culture systems, antibodies, and reagents, while Miltenyi Bioindustry supports Lentivirus CDMO services and GMP manufacturing for commercial cell therapies.

Mindstech

Country	Booth No.
Republic of Korea	E27
CEO Name	
Sang Hee Han	**Pavilion**
Main Sector	
Medical Device	
Website	
http://mindstech.co.kr	

Company Description

Mindstech is a hardware platform specialized company in the digital healthcare field, and provides hardware devices and device manufacturing solutions for the commercialization of bio-diagnostic devices. Main products and services include organoids for animal testing replacement and drug screening, spheroid platforms, ultra-precision bio-diagnostic device manufacturing, and micro 3D printing services

To Buy or Sell Technology/Product

Our core technologies are bio-chip injection molding, micro/nano 3D print systems, and hybrid micro injection mold. Main business areas include [1] organoid & spheroid platform, [2] customized bio-diagnostic device manufacturing, and [3] ultra-precise 3D mold manufacturing service.

Main products, services
[1] Organoid & Spheroid platform
Customized (OEM, ODM) micro-well plate-based organoid platform that can implement ultra-precision micro-fluidic channels with 100 Î¼m.
[2] Micro injection mold factory
The micro injection mold factory is developing complex precision molds based on MEMS, 3D printing, and machining technologies for commercialization and mass production of molds for biochips and precision parts

Mobius Medical

Country
Australia

CEO Name
Stefan Czyniewski

Main Sector
Medical Device

Website
www.mobius-cro.com

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Mobius Medical is a Contract Research Organization (CRO) providing a turnkey solution, end-to-end service, for the management of clinical trials. Our focus is on medical device clinical trials and specifically Class II, III and active implantable medical devices. Our key focus is designing and implementing a clinical strategy specific to our clients' needs and their investigational product. Mobius conducts clinical trials in the United States, Australia and New Zealand.

To Buy or Sell Technology/Product

Our core capabilities include clinical trial design, ethics applications, identification of trial sites and investigators, regulatory submissions for clinical trials, data management, project management, electronic data capture (EDC) systems and clinical trial management systems (CTMS), statistical analysis and clinical trial reports for regulatory submissions.

Molecule2Market

Country
Australia

Delegate Name
Kenny Namkoong

Main Sector
Medical Device

Website
https://molecule2.com.au

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Molecule2Market (M2M) is a boutique CRO dedicated to the research and development of innovative medical treatments diagnostics and devices. With an average of 20 plus years' experience, our team members cover all major cities in Australia, New Zealand and the USA to provide high quality services across all phases of clinical research and a broad range of therapeutic areas. M2M is a proud member of AICROS, the Association of International Contract Research Organizations. AICROS is an alliance of local well established CROs providing high quality clinical research services on a global scale.

To Buy or Sell Technology/Product

M2M services cover the following clinical research activities: • Project/ site feasibility • Site management • Study start-up, monitoring and close out • Project management • Patient recruitment • Pharmacovigilance • Audit/ quality management services • Medical writing • Local study sponsorship • Resident Director services M2M also offers the following services: • Regulatory • Data management/ statistics • Medical monitoring • Applying the Australian R&D Tax Incentive when conducting research in Australia

MolGenBio Co., Ltd.

Country	Booth No.
Republic of Korea	D11
CEO Name	
Yeo Joon Yoon	**Pavilion**
Main Sector	DIPS 1000+ project
Professional Services and Consulting	
Website	
www.molgenbio.com	

Company Description

MolGenBio is developing a novel proprietary synthetic biology platform technology targeting intractable diseases such as neurodegenerative diseases and cancer. Our innovative and robust platform technology aims to develop the first/best-in-class small molecule therapeutics by harnessing the expertise in microbial genome scanning, editing and assembly. Our proprietary MTG (Molecule Through Gene) platform enables us to generate structural derivatives of small molecule drug candidates that are difficult to synthesize through the conventional medicinal chemistry approach.
Our CEO/founder Prof Yoon at Seoul National University elucidated the complete biosynthetic pathway of FK506 for the first time.
Development Pipelines: Anti-CNS, Anti-cancer, Anti-hairloss, Anti-tuberculosis

To Buy or Sell Technology/Product

Our lead pipeline program, MG-TA (Anti-CNS: AD & PD),

- A novel disease-modifying small molecule with combinatorial effects to target neurodegenerative diseases such as AD & PD
- Robust activation of neural regeneration/protection
- Inhibition of toxic protein aggregates (eg. a-synuclein, amyloid-b, tau)
- Inhibition of neuroinflammation
- Through selective and precise modifications on FK506 structure we developed structural derivatives of FK506 (MG-TA) having dampened immunosuppressive property and enhanced neural regeneration activity.
- Pre-clinical studies are planned in 2026, and the materials for the pre-clinical study will be produced at a domestic CMO.
- MolGenBio team has world-class expertise in tacrolimus R&D/manufacturing

MVRIX Co.,Ltd.

Country	Booth No.
Republic of Korea	D11
CEO Name	
Sangwon Jung	**Pavilion**
Main Sector	DIPS 1000+ project
Professional Services and Consulting	
Website	
https://www.mvrix.co.kr/	

Company Description

MVRIX is at the forefront of pioneering innovative drugs that surpass the capabilities of traditional medicines through advanced protein technologies. We have established three core platforms drive our research and development:
(1) Grab antibody Platform:
- Enables self-assembly into LNP (Lipid Nanoparticles) without chemical modifications
- Delivers mRNA precisely and safely to target cells, minimizing side effects
(2) Recombinant Botulinum Toxin:
- Safely produced and engineered in *E. coli*
- With faster onset and extended duration of action
(3) Virucidal Therapeutics:
- Applicable to a variety of viruses, including COVID-19 and influenza
We welcome inquiries regarding collaborative research from partner companies.

To Buy or Sell Technology/Product

The grab antibody platform enables precisely delivers mRNA to targeted cells. The grab antibody is a recombinant protein composed of an antibody domain that targets specific cells and a grab domain that attaches to lipid nanoparticles. The grab antibody self-assembles with LNP through simple mixing for 30 minutes, without any chemical treatment. This approach offers the highest process convenience and CMC feasibility compare to conventional antibody-LNP conjugation techniques.
We are developing mRNA-based targeted cancer therapies and in vivo CAR-T therapeutics, and provide customized Grab antibody platform services tailored to customer needs.

namuSum Co.,Ltd.

Country	Booth No.
Republic of Korea	L19
CEO Name	
CHO DONG SUL	**Pavilion**
Main Sector	Jeonbuk Technopark
Pharma	
Website	
www.namusum.co.kr	

Company Description

Natural preservatives, health foods, and functional raw materials development and natural bio raw material products “As an innovative convergence bio company that manufactures NS-100 [sleep, deep sleep supplement] last night, we have unique technology and production facilities to directly produce natural oil and natural plant extracts containing more than 45% alpha-pinene from Korean Red Pine, a Korean pine tree, and apply them to bio material development and products. We have succeeded in maintaining the volatile natural organic compound components of natural 100% red pine oil while pulverizing it into water-soluble powder [registered as a food manufacturing item of red pine oil powder [NS-10]] and established production facilities, and secured technology that can be applied to various bio material raw material industries through this. We focus on developing various high-performance bio materials through continuous research utilizing pine oil and natural raw materials, and solidify our position in the global bio market through innovative bio raw material development achievements, and grow into the world’s best bio material company through overseas product exports.

To Buy or Sell Technology/Product

Creating the future through bio-convergence, innovating life.
Pioneering biotechnology to design our future.

National Institute for Health and Care Research

Country	Booth No.
United Kingdom	C6
CEO Name	
James Richards, Richard Brooks	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
https://www.nihr.ac.uk/support-and-services/industry	

Company Description

Since 2006, the National Institute for Health and Care Research (NIHR) has become the world’s most integrated health research system. With over £1.3 billion invested annually, the NIHR drives the transformation of scientific discoveries into life-saving treatments, diagnostics, and HealthTech. It supports translational, clinical, and applied research across the full innovation pathway, accelerating the development and adoption of evidence-based innovations. By working in partnership with the NHS, patients, academia, and industry, the NIHR enables high-impact research that improves health outcomes, strengthens the UK’s global research leadership, and ensures patients benefit from cutting-edge innovation as quickly and safely as possible.

To Buy or Sell Technology/Product

The NIHR supports health and social care research across all therapeutic areas and phases-from early translational studies to large late-phase clinical trials. We work with companies of all sizes, including start-ups, SMEs, CROs, and global life science firms, offering tailored support at every stage of the research journey-from study design to delivery. Our free Expertise Partnering Service (EPS) connects companies to the right people, funding, facilities, data, trial support, and patients across the NIHR and UK research ecosystem, helping accelerate innovation and ensure successful research outcomes in the NHS and beyond.

National Institute of Health

국립보건연구원 National Institute of Health

Country	Booth No.
Republic of Korea	D1
CEO Name	
Hyun-Young Park	**Pavilion**
Main Sector	
Academic/Non-Profit	
Website	
http://www.nih.go.kr	

Company Description

The Korea National Institute of Health (KNIH), as Korea's premier national research institute, creates knowledge and technologies to help overcome infectious and chronic diseases and produces scientific evidence for the health authorities to develop health policies. As part of the efforts to build an ecosystem for biomedical innovation, the KNIH also provides diverse research resources and data for researchers in the private sector and promotes health research

To Buy or Sell Technology/Product

It is on the cutting edge of research in key areas, including infectious diseases, chronic diseases, genom sciences, and public vaccine development. Its ultimate mission is to build the foundation for a healthy Korea.

- Precision Medicine Research
- Chronic Diseases Convergence Research
- Infectious Diseases Research

Nbios. Inc

Nbios

Country	Booth No.
Republic of Korea	L11
CEO Name	
Dae-Hee Lee	**Pavilion**
Main Sector	
Pharma	Gangwon Technopark
Website	
www.nbiostec.com	

Company Description

We are an innovative biotech company developing long-acting targeted anticancer therapies through joint efforts with leading domestic and international oncology researchers, based on world-class infrastructure for anticancer drug discovery and exceptional technological expertise.

To Buy or Sell Technology/Product

We are building a long-acting and immuno-oncology drug platform utilizing an anti-albumin antibody that binds to endogenous albumin, aimed at extending the half-life of TRAIL — a tumor-selective agent known for its minimal side effects but short half-life.
Our platform enables high-affinity binding of antibody fragments (Fab) to serum albumin, offering excellent scalability for fusion with various therapeutic agents. Our proprietary Anti-HSA technology employs a smaller scFv fragment rather than Fab, enhancing efficacy within the tumor microenvironment (TME). This long-acting platform allows for the development of diverse immuno-oncology therapeutics tailored to specific tumor types.
Currently, we are developing a long-acting TRAIL-based complex that improves both the half-life and anticancer efficacy of TRAIL. This approach offers strong potential for overcoming drug resistance and for use in combination therapies. Backed by scientific publications and patents, the platform has high commercial potential. We are pursuing technology licensing opportunities with domestic and global pharmaceutical companies, with the goal of entering the global market.

N-BIOTEK

Country	Booth No.
Republic of Korea	D23
CEO Name	
Daeyong Kim	**Pavilion**
Main Sector	
Medical Device	
Website	
http://www.n-biotek.com	

Company Description

N-BIOTEK is the only one company providing ‘Stem Cell Total Solution’ which is the turn-key solution combined with life science equipment, bio cleanroom and stem cell culture technology consulting. As the Stem Cell Total Solution provider, it has established stem cell processing facilities in various countries and developed other stem cell business and items such as stem cell isolation kit, cosmetics and the International Society for Stem Cell Application.
N-BIOTEK is a leader of life science and regenerative medicine.

To Buy or Sell Technology/Product

Multi-workstation - REBORN CELL
A clean working table combined with a centrifuge and a shaking incubator. All procedures are preformed under a clean environment, minimizing the risk of external contamination. This setup enables convenient and safe stem cell extraction.

SVF Isolation Kit - STEMPIA KIT
Simplifies the traditional manual SVF isolation process, allowing for quick and easy extraction of SVF by anyone. The STEMPIA KIT provides high cell yield while minimizing the risk of contamination and cell damage.

Neumous Inc.

Country	Booth No.
Republic of Korea	C28
CEO Name	
Juyoung Park	**Pavilion**
Main Sector	
Medical Device	
Website	
http://neumous.com/	

Company Description

Neumous Inc. has developed the ultrasound medical device that can non-invasively and temporarily open the Blood-Brain Barrier (BBB) in targeted brain regions. Using Neumous' device, we are developing the brain drug delivery platform that significantly enhances the efficiency of drug delivery into the brain.

To Buy or Sell Technology/Product

Neumous' ultrasound medical device enables the safe and temporary opening of the BBB, allowing the delivery of neurological therapeutics regardless of their properties and size of drugs in targeted brain regions.
The performance and safety of BBB opening have been successfully validated in non-human primates using Neumous' ultrasound-BBB opening device, Clinical trials are scheduled for 2025 to evaluate the safety and efficacy of BBB opening in patients with brain diseases, including brain cancer and Alzheimer's disease.

NEURIVE Co., Ltd.

Country	Booth No.
Republic of Korea	E8
CEO Name	
Jaejun.Song	**Pavilion**
Main Sector	Rising Pavilion
Digital Health	
Website	
http://eng.neurive.com/	

Company Description

Neurive is a Korean manufacturing company specializing in non-invasive vagus nerve stimulation devices, including the Soricle and Healaon Pro, designed to manage symptoms of tinnitus and sleep disorders. Founded in April 2018, Neurive was established by CEO Dr. Jae-Jun Song, a professor of Otolaryngology at Korea University Guro Hospital in the Republic of Korea. Dr. Song brings over 20 years of clinical experience in otolaryngology and has an impressive research record, including 150 international publications and 4,500 citations. Leveraging his expertise, Dr. Song developed the core technology for non-invasive vagus nerve stimulation (ASENS technology), which serves as the foundation for the Soricle and Healaon Pro devices.

To Buy or Sell Technology/Product

<SoriCLEAR>
Soriclear is a digital therapeutic device for tinnitus treatment, based on Cognitive Behavioral Therapy (CBT) and sound therapy. It is a clinically proven digital therapeutic solution that effectively alleviates symptoms in patients with severe tinnitus.
<Soricle>
Soricle is a personal VNS medical device that treats tinnitus and insomnia through vagus nerve stimulation (ASENS Technology) using electrical signals and sound
<Healaon Pro>
Healaon Pro is a personal healthcare device based on Soricle, our medical device developed for the treatment of tinnitus and insomnia. Utilizing electrical and sound stimulation (ASENS Technology), it stimulates the vagus nerve to enhance focus, induce sleep, and promote relaxation. Experience mental and physical stability and improve your quality of life with Healaon Pro in your daily routine.

New England Biolabs Korea

Country	Booth No.
Republic of Korea	F28
CEO Name	
Sue Yap	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.neb.com	

Company Description

Established in 1974, New England Biolabs is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research.
NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics, and RNA analysis.
Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines.

To Buy or Sell Technology/Product

Cloning, PCR&qPCR reagent, Genome Editing, NGS library prep, Epigenetics, Protein expression, Purification, etc.

NEXTROVE KOREA LLC

Country
Republic of Korea

Booth No.
G29

CEO Name
Anjani Jha

Pavilion

Main Sector
Professional Services and Consulting

Website
http://www.nextrove.com

Company Description

Nextrove, headquartered in New Jersey, USA, is a global professional services firm exclusively serving pharmaceutical and biotech organizations. Its professionals have extensive experience of performing complex integrations between PV, clinical, regulatory, and product quality databases. The company also provides a comprehensive range of tools and accelerators to aid data migrations and analysis of data issues, and fast-track new platform/solution implementations.

To Buy or Sell Technology/Product

Our team of experts brings an average of over 15 years of experience in ArisGlobal, Argus Safety, and across the life sciences industry. We have developed a suite of reusable tools to enable high-quality and rapid implementations and upgrades. Nextrove supports clients across a wide range of services including pharmacovigilance, hosting, eTMF, RIM, regulatory affairs, clinical operations, medical information, artificial intelligence, Salesforce, and integration services.

NorthX Biologics

Country
Sweden

Booth No.
A11

CEO Name
Janet Hoogstraate

Pavilion
Swedish Pavilion

Main Sector
Pharma

Website
https://www.nxbio.com/

Company Description

NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.

To Buy or Sell Technology/Product

NorthX Biologics Innovation Hub
NorthX Biologics is an innovation hub and CDMO designed to support the development of advanced biologics. At NorthX, we offer tailored process and analytical development, connections with financiers (both public and private), and GMP production for clinical and commercial applications. In the innovation hub, early-stage companies and projects have access to modern infrastructure, multi-skilled staff, and state-of-the-art technology, enabling a faster route to concept testing.

NOVALIX

Country	Booth No.
France	N11
CEO Name	
Denis Zeyer	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.novalix.com	

Company Description

Leading European CRO in early drug discovery research, Novalix has a team of 350 scientists dedicated to speeding up the therapeutic programs.

We cover chemistry, biophysics, and pharmacology fields, from target identification to the delivery of preclinical candidates.

Strong expertise in oncology, immuno-inflammation, infectious diseases, fibrosis, metabolic disorders, osteoarthritis & kidney diseases.

To Buy or Sell Technology/Product

Chemistry: Organometallic and heterocyclic chemistry, Process development, High-throughput synthesis (HTE, HTOS), Lipid chemistry, Flow chemistry, DNA-encoded libraries synthesis, PROTACs, Photo and electro-chemistry, Compound management
Biophysics: Protein production, Cryo-EM, X-ray crystallography, MS, NMR, SPR, MST, ITC

Pharmacology and DMPK: Biochemical assays, Cellular and primary tissue assays, in vivo models and histology, Translational science, ADME-PK and preformulation, PK/PD, and biomarkers, Biobank

Drug discovery programs: Medicinal chemistry, Cheminformatics, DNA-encoded libraries
Biologics: Antibody-Drug Conjugates (ADCs), peptides, Monoclonal Antibodies (mAbs), Bispecific Antibodies, RNA-based Therapeutics, etc.

NOVAMEDILAB

Country	Booth No.
Republic of Korea	L11
CEO Name	
Nak-Won Sohn	**Pavilion**
Main Sector	Gangwon Technopark
Professional Services and Consulting	
Website	
www.novamedilab.com	

Company Description

Novamedilab Co., Ltd. is a CRO specializing in non-clinical animal testing and an organization that conducts research and development of functional food and pharmaceutical materials.
The development of in vivo test animal models optimized for efficacy testing is essential for medical research and new drug development. However, most development companies in Korea focus only on the development of new drugs and new materials, and their interest and expertise in the development and use of appropriate disease animal models are significantly lacking. In reality, they simply utilize disease animal models commonly used in papers.
We have unique animal testing technology based on neuroscience, and based on this, we aim to become a true research and development partner that goes beyond simple consignment-service experiments and supports the entire research process, including the production and selection of animal testing models, selection of observation indicators, and analysis of results, and guarantees the production of research results at the level of reliable international papers.
In addition, based on our international-level performance capabilities, we will not stop at simple consignment-service CRO work, but will discover functional food and pharmaceutical materials based on food and natural products with safety, thereby achieving the development of original technologies for the pharmaceutical industry using bio-food technology, industrialization utilization, and commercialization of functional substances.

To Buy or Sell Technology/Product

[CRO] Efficacy testing service using disease animal models
• A specialized non-clinical animal testing CRO in the field of brain diseases through the development of an in vivo test animal model for optimizing efficacy testing in the field of brain diseases

[Animal Models]
• Stroke: MCAO, BCAO, intrastriatal hemorrhage model
• Parkinson's disease (PD): alpha-synuclein PFF model, MPTP model, mThy1 tg model
• Alzheimer's disease (AD): stereotaxic Aβ injection model, 5xFAD tg model, PS19 tau model
• AAV route-specific administration (ICV, IT, IV)
• EAE-MS: MOG35-55-induced EAE model
• Spinal cord injury: spinal compression model
• Neuro-oncology: metastatic brain cancer (intracranial, intracardiac, intracarotid injection)
• Sarcopenia, etc.

[Specialty]
• Animal surgery, Immunohistochemistry, Immunofluorescence, Confocal imaging, Image analysis

[Behavioral Tests]
• Learning & Memory, Addiction & Reward, Anxiety & Depression, Motor & General Activity

[R&D] Research and development of disease treatment and functional food and pharmaceutical materials
• Development of a test animal model for brain disease (autism spectrum disorder) and development of new natural product drugs
• Discovery of monoclonal antibodies for brain diseases and sarcopenia and development of antibody treatments

NOVOTECH ASIA KOREA

NOVOTECH™
Biotech's Partner at Every Phase

Country
Republic of Korea

Booth No.
D21

CEO Name
John Moller

Pavilion

Main Sector
Professional Services and Consulting

Website
http://novotech-cro.com/kr

Company Description
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.

To Buy or Sell Technology/Product

Novotech offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies.

NPCHEMBIO

Country
Republic of Korea

CEO Name
JUNG-Hee KWON

Main Sector
Professional Services and Consulting

Website
http://npchembio.com

Booth No.
E21

Pavilion

Company Description
NPChemBio is a KOLAS-accredited testing laboratory that evaluates antibacterial, antifungal, and antiviral efficacy using pathogens classified as biosafety level 2 or lower. We provide efficacy testing and genetic analysis services for a wide range of applications, including cosmetics, health functional foods, and pharmaceuticals, supporting product development and research. In addition to standardized tests, we offer high-quality, customized experimental analysis services and professional consulting tailored to client needs.

To Buy or Sell Technology/Product
We are capable of conducting tests in accordance with international standards such as ISO 10993-5, ISO 11930, ISO 21702, ISO 18184, ASTM E1052-20, and KS K 0693, as well as performing STERILITY TEST and MICROBIAL LIMIT TESTS specified in 'MFDS in Republic of Korea' Notices No. 2023-75 and No. 2024-9. Additionally, we can conduct in vivo efficacy evaluation tests using mice and rats.

Nucleus Network Pty Ltd

Country
Australia

Delegate Name
Jeffery Wong

Main Sector
Clinical trials site

Website
https://www.nucleusnetwork.com/au/

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description
Nucleus Network is Australia's largest and only multi-site Phase 1 clinical research organisation and the only Clinical Pharmacology specialist globally with facilities in the USA and Australia.

For over two decades, Nucleus Network has been conducting Phase 1 clinical trials for Biotechnology and Pharmaceutical Companies from across the globe, including China, Europe, Japan, South Korea, Taiwan and the USA.

Recognized as Phase 1 clinical trial experts, we operate over 200 beds, and have overseen more than 1,000 trials, of which 50% are first-in-human.

Our Australian Phase 1 facilities are in Melbourne and Brisbane, and our USA Phase 1 facility is in Minneapolis.
All three clinics are strategically co-located within leading medical, research and biotech precincts; the Alfred Hospital in Melbourne, the Royal Brisbane and Women's Hospital in Brisbane, and Medical Alley in Minneapolis.

To Buy or Sell Technology/Product
Through Nucleus Network's dedicated early phase clinical trial units across both Australia and USA, we specialize in the full spectrum of clinical pharmacology healthy volunteer study designs such as (but not limited) to FIH SAD/MAD, DDI, TQT, BA/BE, Ethnobridging, Biosimilar and Vaccine programs.

OPIS Research CRO

Country
Poland

Booth No.
N26

CEO Name
Laura Ambrosoli

Pavilion

Main Sector
Professional Services and Consulting

Website
https://opisresearch.com/

Company Description

OPIS provides full-service, 360° clinical trial support from study concept creation and protocol development to full project execution, study data handling and up to study closure, analysis, and reporting. We manage Phase I-IV, interventional, non-interventional and medical devices studies on an international level. In addition, OPIS also manages pre- and post-marketing clinical investigations for medical and diagnostic devices, nutraceutical, and food supplement studies.

To Buy or Sell Technology/Product

Our qualified, fully trained, and dedicated staff has managed 1500 studies to date.
OPIS's strength lies in its people and its specialized teams who assist clients from A-Z with medical writing, scientific and statistical consultancy for trial design and skilled teams of operational staff that ensure high quality project execution, with global coverage.

ORACLE

Country
Singapore

Booth No.
F29

CEO Name
Steve Ko

Pavilion

Main Sector
Professional Services and Consulting

Website
https://www.oracle.com/kr/life-sciences/

Company Description

Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements-empowering the Life Sciences industry to improve patient outcomes. Learn more at www.oracle.com/lifesciences.

To Buy or Sell Technology/Product

A complete and open, interoperable platform for health and life sciences innovation. Discover solutions designed to unify data from clinical trials, streamline and automate safety case management, generate real-world evidence from unique data sets, and guide brand strategy with commercial insights.

ORCA Therapeutics B.V.

Country	Booth No.
Netherlands	B11
CEO Name	
Wenliang Dong	**Pavilion**
Main Sector	Netherlands Bio Lounge
Pharma	
Website	
https://www.orca-therapeutics.nl/	

Company Description

ORCA Therapeutics B.V. is a Dutch biopharmaceutical company developing oncolytic immunotherapies using proprietary Oncolytic Replication Competent Agents (ORCA). Its lead candidate, ORCA-010, is an engineered adenovirus targeting treatment-naive prostate cancer patients by selectively killing cancer cells and inducing antitumor immune responses. Originating from research at VU University Medical Center in Amsterdam, ORCA holds a strong IP portfolio and continues to expand through academic and industry partnerships. ORCA is dedicated to advancing innovative viral therapies to treat cancer and improve patient outcomes through scientific excellence and collaboration.

To Buy or Sell Technology/Product

ORCA-010
ORCA-010 is ORCA Therapeutics' lead oncolytic adenovirus therapy, developed using the company's proprietary T1 technology. This novel therapeutic selectively targets and destroys cancer cells while sparing healthy tissue. ORCA-010 self-replicates within tumors, offering superior pharmacokinetics compared to conventional therapies. It not only enhances direct tumor cell killing but also triggers antitumor immune responses. With a mechanism of action distinct from chemotherapy, radiation, and monoclonal antibodies, ORCA-010 shows strong potential for combination therapies. Designed for high efficacy and safety, ORCA-010 represents a promising next-generation approach for treating cancer, starting with treatment-naive prostate cancer patients.

ORGANELLE Co., Ltd

Country	Booth No.
Republic of Korea	L19
CEO Name	
Jihee Yoon	**Pavilion**
Main Sector	Jeonbuk Technopark
Pharma	
Website	
http://www.organelle.kr/	

Company Description

Organelle Co., Ltd. pioneers eco-friendly bio-products using natural lysosomes, enhancing industry competitiveness with ongoing innovation. Since 2021, its R&D center has developed and launched disinfectants, deodorants, cosmetics, and cleaning agents.

To Buy or Sell Technology/Product

The world's first lysosome-applied cosmetics were manufactured, and lysosomes have various functions such as oxidation, skin barrier improvement, whitening, wrinkle improvement, acne improvement, and antibacterial, so we developed cosmetics that apply them. It consists of brands and product lines tailored to each target and sells a total of 9 types of cosmetics.

Organelle Co., Ltd. pioneered lysosome-based cosmetics.
Lysosomes provide antioxidant, whitening, anti-wrinkle, acne relief, and antibacterial benefits.
A single ingredient delivers multifunctionality without extra costs.
The company offers nine lysosome-based skincare products.
Patented technology drives ongoing innovation in raw materials and cosmetics.

ORTHOTECH.Co.Ltd

Country
Republic of Korea

CEO Name
Ilhwan Kim

Main Sector
Medical Device

Website
http://www.orthotech.co.kr

Booth No.
N6

Pavilion

Company Description
ORTHOTECH was established in 2003 with orthopedic implants as its main business. We expanded by having a research center built end of 2022 to research, develop, and manufacture human tissue grafts and wound care as our new business model.

To Buy or Sell Technology/Product
Our main product include Human tissue that is used as a replacement and transplant to patients who have lost or damaged certain tissue due to an accident or disease to help restore physical impairment or prevent further damage, also a Wound dressing product used for the care and protection of wounds in areas where the skin barrier has been damaged. Lastly our main product which is orthopedic implant that can be used in fractures and corrections. We will continue to launch the market range to show a variety of products needed in medical market.

Osteo Pharma B.V.

Country
Netherlands

CEO Name
Jan Gossen

Main Sector
Pharma

Website
https://www.osteo-pharma.com/

Booth No.
B11

Pavilion
Netherlands Bio Lounge

Company Description
Osteo-Pharma is a life sciences company developing novel pharmaceuticals and medical devices for orthopedic and dental applications. Its patented OsteoActivator® technology enables sustained local delivery of bone-healing compounds over several weeks. The technology is protected by composition of matter patents in the EU, US, and Japan. Preclinical studies in both small and large animal models, including osteoporosis and jaw regeneration models, have shown strong bone healing and regeneration effects. Osteo-Pharma is preparing for clinical trials and actively seeking partners or out-licensing opportunities to bring OsteoActivator®-based products to market in orthopedic and dental care.

To Buy or Sell Technology/Product
OsteoActivator
OsteoActivator is a patented regenerative medicine technology by Osteo-Pharma for local treatment of bone fractures and defects in orthopedic and dental applications. It delivers two bone-healing compounds—testosterone and alendronate—via a PLGA-based depot over four weeks. Testosterone stimulates osteoblasts, while alendronate suppresses osteoclasts, promoting robust bone regeneration. After eight weeks, medication release is complete and normal bone remodeling resumes. Clinical data show no systemic testosterone increase, confirming localized effect. Patents have been granted in the EU, US, and Japan. Osteo-Pharma seeks partners or out-licensing opportunities to bring this novel, targeted bone-healing solution to market.

P&D Solution & revvity signals

Country	Booth No.
Republic of Korea	N10
CEO Name	
Seongki Kim	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://pndsolution.com	

Company Description

P&D Solution is a Korean company specialized in visual data analytics in Korea. Since introducing Spotfire for the first time in Korea back in 2003, we have supported corporate BI innovation in various industries with our rare expertise in analytics field and active engagement in problem solving.

To Buy or Sell Technology/Product

Spotfire provides fast and intuitive insights, even from large and complex data, through powerful data handling and in-memory analytics. Discover hidden insights in your data with Spotfire.

PAN-Biotech GmbH

Country	Booth No.
Germany	A1
CEO Name	
Jens Hartmann, Isabel Obermillacher	**Pavilion**
Main Sector	
Professional Services and Consulting	Bavarian Pavilion c/o Bayern International GmbH
Website	
https://www.pan-biotech.com/	

Company Description

PAN-Biotech is your trusted partner for OEM and CMO solutions in the biotech industry. With over 30 years of experience, we offer high-quality cell culture media, sera, and custom manufacturing sterile liquid solutions. Benefit from our expertise and expand your business in Europe with a reliable partner by your side.

To Buy or Sell Technology/Product

Gateway to Europe with PAN-Biotech
At PAN-Biotech, we understand the challenges when setting foot on a new continent. We are here to assist you every step of the way. From manufacturing and product storage to delivering your products to new customers, we provide comprehensive support to help you achieve your goals.

PCMO

PCMO
미생물실증지원센터

Country
Republic of Korea

CEO Name
MIN CHO, JINYOUNG SONG

Main Sector
Professional Services and Consulting

Website
http://www.pcmo.or.kr

Booth No.
I30

Pavilion

Company Description

PCMO is a public CDMO(specialized in “microorganism-based”) in Hwasun Bio-medical Cluster, Republic of Korea.
We've been operated in 2020 obtained GMP certification for the industrialization of biopharmaceuticals and provided customized Services.
Also, We are building an additional "mRNA manufacturing facility (mRNA synthesis/modification, LNP and finished product manufacturing)" in conjunction with existing GMP facilities. (*run in 2025 3Q)

To Buy or Sell Technology/Product

[Process Development & Optimization Service]
- Up/Downstream
- Formulation(Lyophilization)
- mRNA Process

[GMP Contract Manufacturing Service]
- Cell bank
- DS : up to 50L, 200L, 1000L scale
- mRNA : IVT(5L, 15L) / LNP
- DP : Liquid & Lyophilized Vials
(Prefilled syringes (*run in 2026)

[Contract Testing Service]
- Physicochemical Test
- Biochemical Test
- Microbial Test
- Stability Test etc.

[Contract Storage Service]
- Deep Freezer (≤-70°C)
- LN2 Tank (≤ -130°C)
- Refrigerator (2 ~ 8°C)

Peptoide, Inc.

Country	Booth No.
Republic of Korea	L11
CEO Name	
Ha Yun Jung	**Pavilion**
Main Sector	Gangwon Technopark
Pharma	
Website	
www.peptoide.com	

Company Description

Peptoide, Inc. is a specialized company that researches and develops innovative treatments for human health. Peptoide, Inc. is accelerating the development of treatments for the silent pandemic, super bacteria (multi-drug resistant bacteria). The strategy of Peptoide, Inc. is to develop new drug candidates for various indications through the expansion of new pipelines. We will take a step forward in new drug development through the discovery of excellent compounds, non-clinical trials, and clinical trials. Peptoide, Inc. provides high-purity, high-quality customer-specific compound production services and efficacy test analysis consulting with years of synthesis experience.
Peptoide, Inc. will not hesitate to sail the inevitable long journey to become a global leader as a specialized research and development company.

To Buy or Sell Technology/Product

Antibiotics drug discovery

Novel class of Triazine based Antibacterial drug discovery Targeting both wild and multi-drug resistant strain Active against both gram positive and negative bacteria Rapid killing rate.

Antituberculosis durg discovery

New class of Triazine based Antituberculosis drug discovery targeting both wild and drug resistant strains

Targeted Protein Degradation

Cutting-edge state of art protein degradation technology, Anticancer agent development, Catalytic and can overcome drug resistance.

Custom Organic Chemical Synthesis Service

Small molecule inhibitors

Target molecules for pharmaceutical, industrial applications,

Building blocks for bioactive molecules

Customed bio-active molecules, Peptides,

Peptidomimetics, Conjugated drug molecules,

Heterocyclic compounds, Lipids and long-chain lipids molecules,

Organic materials

Peter MacCallum Cancer Centre, Nexomics

Country
Australia

Delegate Name
Minesh Lalla

Main Sector
Professional Services and Consulting

Website
www.nexomics.org

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Peter MacCallum Cancer Centre is a world leading cancer research, education and treatment centre ranked 16th out of 330 oncology hospitals globally.
Nexomics, which is powered by the Peter MacCallum Cancer Centre, offering comprehensive and specialised cancer diagnostic testing solutions from our state-of-the-art laboratories at the Victorian Comprehensive Cancer Centre (VCCC). Accredited by NATA and compliant with GLP, GCLP, ISO/IEC 17025 and 15189, nexomics harnesses cutting-edge technologies, with a focus on specialised genomics testing. Their expert team of pathologists, scientists and dedicated clinical trial staff, support clinical and academic researchers, Clinical Research Organisations (CROs), and pharma/biotech companies throughout all stages of clinical development.
Nexomics provides a wide range of services, including:

• **Anatomical Pathology & Hematopathology** with comprehensive histology solutions including IHC, ICC, and CISH.

• **Immuno-Oncology** utilising flow cytometry, ELISA, and multiplex assays for in-depth immunological analysis; and

• **Molecular Pathology**, offering high complexity as well as routine molecular diagnostics pathology testing alongside advanced assays like FISH, germline, somatic, ctDNA, cfDNA, qPCR, ddPCR, and NGS.

• **Clinical Trials Services & Support**, assisting clients in understanding the Australian government's R&D tax incentive and providing guidance on study testing requirements.

Our dedicated team are committed to quality, compliance, and delivering precision testing solutions for your clinical trials.

To Buy or Sell Technology/Product

Anatomical Pathology

Our specialised histopathology services encompass comprehensive tissue processing and embedding, haematoxylin and eosin (H&E) staining, specialised stains, immunohistochemistry (IHC), immunofluorescence (IHC-IF), in situ hybridisation (ISH) and advanced digital imaging solutions.

Hematopathology

Nexomics provides optimal testing and interpretation for both clinicians, clinical researchers and commercial clients, delivering accurate diagnoses and relevant prognostic information for a wide range of hematologic diseases, including lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia and myeloma.

Immuno-Oncology

Our immunological services encompass advanced techniques such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), and multiplex assays. These methods allow for precise analysis of immune cell populations, detection of specific antibodies, immunophenotypic characterisation and quantification of cytokines, providing comprehensive immunological insights.

Molecular Pathology

Our extensive portfolio includes routine diagnostic molecular pathology testing, alongside a comprehensive array of fluorescence in situ hybridisation (FISH), germline, somatic, ctDNA, cfDNA, qPCR, ddPCR and NGS assays tailored to meet the demands of clinical trials. We are committed to innovation and excellence, ensuring that our assays are at the forefront of scientific advancement.

Clinical Trials Services & Support

Explore the Australian government's appealing 43.5% R&D tax incentive. Consult with our team to understand the eligibility requirements, study testing requirements and learn about our steadfast dedication to quality and compliance and precision oncology delivered with international quality standards.

Pharmaron Korea

Country	Booth No.
Republic of Korea	K21
CEO Name	
Dujin Lee	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
https://www.pharmaron.com/	

Company Description

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier service provider for the life sciences industry as global Top Tier CRO. Pharmaron a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 24,000 employees and operations in China, the U.S., the U.K., Korea, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. And now, Pharmaron wants to expand in delivering its R&D solutions to Korea partners.

To Buy or Sell Technology/Product

[R&D, Preclinical & Manufacturing - US/UK/China]
1. Discovery, Chemistry, DMPK and Safety Assessment (GLP)
2. CMC
3. Biologics & CGT

[A Full Clinical CRO Service] - US/China/Korea]

Pharmicell Co., Ltd.

Country	Booth No.
Republic of Korea	G6
CEO Name	
Hwang, Il Soon	**Pavilion**
Main Sector	
Pharma	Rising Pavilion
Website	
www.pharmicell.com	

Company Description

Pharmicell Co., Ltd. is a leading innovator in the field of raw pharmaceuticals. In 2011, we developed the world's first stem cell therapy, called Hearticellgram-AMI. Through a wide range of activities within the biotechnology and pharmaceutical industries, our primary goal is to achieve ongoing growth and to explore new markets based on our advanced technological capabilities in various fields such as biotechnology and pharmaceutical industry. The biomedical Business Unit of Pharmicell Co., Ltd. is engaged in researching and developing stem cell and immune cell therapies, as well as conducting various clinical trials and managing a cosmetics business. In the biochemical business unit, we produce a range of advanced materials, including nucleosides which are essential raw materials for pharmaceuticals and diagnostic reagents, pharmaceutical-grade mPEG derivatives, low-dielectric materials for 5G, eco-friendly halogen-free flame retardants, and catalysts for polyol synthesis.

To Buy or Sell Technology/Product

<Half-Serum DMEM>
Half-Serum DMEM is an innovative cell culture technology that achieves results equivalent to standard DMEM while using only half the amount of fetal bovine serum (FBS). This medium, developed by Pharmicell Co., Ltd., demonstrates the same effectiveness with just 5% FBS instead of the conventional 10-15%. Tests conducted over 20 days on 293T, PC3, and MDA-MB-231 cell lines showed that it maintains equivalent performance to traditional media in cell proliferation rates, morphology, cell cycle, protein expression, transfection efficiency, and lentivirus production. Major cellular signaling pathways were also fully preserved. This technology offers various benefits including reduced research costs, minimization of animal-derived products, and decreased environmental impact. It is particularly beneficial for pharmaceutical development requiring large-scale cell culture.

< By Pharmicell Lab>
By Pharmicell Lab presents an innovative line of cosmetic products developed through advanced stem cell technology. Our premium skincare collection harnesses the regenerative properties of stem cell culture media to deliver exceptional anti-aging and skin revitalization benefits. These products represent the culmination of Pharmicell's extensive research and expertise in stem cell cultivation and biotechnology.
<Cell Theraphy>
HeartiCellgram-AMI is the world’s first approved stem cell therapy designed to treat acute myocardial infarction (AMI).
The therapy utilizes autologous bone marrow-derived stem cells, meaning cells are extracted from the patient’s own bone marrow, minimizing immune rejection. These stem cells promote myocardial regeneration and effectively repair damaged heart tissue, leading to a reduced risk of heart failure and improved survival rates. As the first commercially available stem cell therapy, HeartiCellgram is pioneering the future of regenerative medicine and setting new standards for cardiovascular treatments.

Pharos iBio Co., Ltd.

Country	Booth No.
Republic of Korea	F3
CEO Name	**Pavilion**
Yoon, JeongHyeok	Rising Pavilion
Main Sector	
Pharma	
Website	
www.pharosibio.com	

Company Description

Pharos iBio, a biotechnology company founded in 2016 and listed on KOSDAQ in 2023, develops innovative treatments for rare and refractory diseases using its AI- and big data-based Chemiverse® platform. The company has approximately 10 pipelines, including four clinical-stage programs: PHI-101 for acute myeloid leukemia (AML) preparing for Phase 2, ovarian cancer (OC) in Phase 1, an IIT for minimal residual disease (MRD), and PHI-501, targeting refractory solid cancers in Phase 1. Headquartered in South Korea, Pharos iBio has subsidiaries in Australia and the U.S. and seeks global partnerships to co-develop and commercialize its drug candidates.

To Buy or Sell Technology/Product

<PHI-101, a “Best-in-Class” next generation FLT3 inhibitor for acute myeloid leukemia (AML)>
- Targeting FLT3 mutations that present in 25-35% of AML patients- Existing FLT3 inhibitors are limited by high relapse rate and resistance leaving a large unmet medical need to adjust current treatments- PHI-101-AML has been validated in Phase 1a study as a potent next generation FLT3 inhibitor for relapsed/ refractory (R/R) AML. PHI-101-AML was well tolerated at all dose levels with no drug limited toxicity.- Currently the last patient has been enroled for global Phase 1b clinical trial in Australia and Korea for the patients with FLT3 mutation positive R/R AML while high CRc rates were observed- Expanding the indication through Chemiverse®, “First-in-Class” PHI-101-OC targeting CHK2 is currently in Phase 1 clinical trial for platinum-resistant recurrent ovarian cancer patients - PHI-101 has been granted Orphan Drug Designation by the FDA and is designated as a rare disease drug in the development stage MFDS in Korea. Additionally, an EMA ODD application has been submitted.

<PHI-501, a “First-in-Class” pan-RAF/DDRs dual kinase inhibitor for refractory solid tumors>

- Currently in preclinical development and It is potent against BRAF, KRAS or NRAS mutation mediated MAPK signalings in malignant melanoma, refractory colorectal cancer, and triple-negative breast cancer- Superiorly potent to other RAF kinase inhibitors and overcome the resistances induced by FDA approved BRAF or MEK inhibitors- Phase 1 clinical trial targeting advanced solid cancers, including malignant melanoma and refractory colorectal cancer, is ongoing.

pixelRo

pixelRo
Accelerated by SAMSUNG

Country
Republic of Korea

Booth No.
M17

CEO Name
Kang SEOKMYONG

Pavilion
Gyeonggi Business & Science Accelerator

Main Sector
Digital Health

Website
www.pixelro.com

Company Description

Pixello Co., Ltd. started its business through Samsung Electronics' in-house venture program, 'C-Lab'. Under the slogan of 'For a better future', the goal is to realize technology based on digital eye care. Development and commercialization of AI eye health self-diagnosis kiosk. Designation of special case for verification: Contact lens online delivery platform (first in Korea). Grand Prize in Daestar Solution Platform, Grand Prize in Hanwha Able, etc.. Composition of a team of healthcare experts: Composition of a production team of healthcare experts from Samsung Electronics with abundant experience in manufacturing and selling eye care products, along with advisory groups from Seoul National University Bundang Hospital and Korea University Medical Hospital, equipped with professional engineering and medical knowledge on eye examinations.

To Buy or Sell Technology/Product

- AI Eye Health (Macular Degeneration, Vision Measurement, Presbyopia Accommodation) Self-Diagnosis System Kiosk Solution
Eye Health Self-Diagnosis Screening Equipment for Macular Degeneration, Presbyopia Accommodation, and Vision Measurement Based on Sensing with Ophthalmology Medical Software
Provides optimal environment according to user measurement through sensor-based real-time distance measurement and eye tracking (Real-time distance measurement and head pose algorithm with existing distance accuracy within 10%)
Applying vision/presbyopia/macular degeneration algorithm based on sensor data Medical device class 1
Prints results or saves them on the server according to user registration

Porton Pharma Solutions Ltd.

Country	Booth No.
China	J30
CEO Name	
Nianfeng Ju	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.portonpharma.com	

Company Description

With over 4200 employees, Porton Pharma Solutions, a global company with R&D and GMP-compliant manufacturing facilities across the US, EU and China, provides customer-centric innovative and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercial stages.

To Buy or Sell Technology/Product

With over 4200 employees, Porton Pharma Solutions, a global company with R&D and GMP-compliant manufacturing facilities across the US, EU and China, provides customer-centric innovative and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercial stages.

PRECLINA Inc.

Country	Booth No.
Republic of Korea	G25
CEO Name	
Young Mo Kang	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.preclina.com	

Company Description

Preclina Inc. is a leading nonclinical CRO with over 20 years of accumulated expertise, and the only company in Korea to offer a dedicated efficacy pharmacology platform for immune-related diseases. We perform the entire process in-house-from the production to the supply of humanized mice-and possess distinguished capabilities in the efficacy evaluation of immuno-oncology therapeutics using CDX/PDX models.

To Buy or Sell Technology/Product

Arthritis Models
- CIA, DMM/ACLT

Fibrosis Models
- BISF, BILF, MASH

Atopic Dermatitis & Psoriasis Models
- Imiquimod-induced psoriasis, IL-23-induced psoriasis

Inflammatory Bowel Disease Models
- DSS-induced colitis

Lupus Model
- MRL/lpr Lupus Model

Humanized Mouse Models
- PreHu-PBMC, PreHu-UCB HSc

Prestige Biologics

Country	Booth No.
Republic of Korea	C14
CEO Name	
Michael J. Kim, Jaeyoung Yang	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://prestigebiologics.com/	

Company Description

Prestige Biologics has established the first Full Single-Use-System in Korea. Single-Use-System has the advantage of lower contamination rates and reduced cleaning times between batches. We provide integrated CDMO services with a Full Value Chain and comply with cGMP management standards to ensure high-quality pharmaceuticals.

To Buy or Sell Technology/Product

CDO: We provide comprehensive services from early-stage development, including cell line development, MCB manufacturing, and characterization, to process development for USP/DSP, as well as the development of various analytical methods.
CMO: We support clinical and commercial production using a Full Single-Use System.
CPO: We provide labeling, storage, and distribution services for clinical trials.

ProAbtech Co.,Ltd

Country	Booth No.
Republic of Korea	D11
CEO Name	
Cho, Jeon-Haeng	**Pavilion**
Main Sector	
Pharma	DIPS 1000+ project
Website	
www.proabtech.com	

Company Description

ProAbTech is developing a novel bioconjugation platform to overcome the limitations of current drug conjugates. We focus on long-acting bioconjugates, Albubody-based ADCs (long-acting scFvs), and glycan-based targeted TPD drugs for metabolic diseases, cancer, and rare diseases. Our proprietary SelecAll^{TM} and Albubody^{TM} platforms enable site-specific incorporation of non-natural amino acids (frTet) via IEDDA click chemistry, allowing precise conjugation on any protein backbone. This leads to therapeutics with improved drug properties, reduced toxicity, and better safety. Our platform is versatile, compatible with proteins, antibodies, and peptides, and offers significant advantages over conventional bioconjugation technologies.

To Buy or Sell Technology/Product

SelecAll™ is a next-gen bioconjugation platform enabling site-specific incorporation of frTet via an expanded genetic code, improving drug properties, safety, and yield across proteins, antibodies, and peptides. It also enables dual-function agents by combining different modalities. **Albubody™** is a long-acting scFv platform designed for constructing antibody-drug conjugates and targeted protein degradation drugs with superior tumor penetration while maintaining conventional antibody fragment functionality. **PAT101**, an Alburicase-HSA conjugate for refractory tophaceous gout, shows improved PK, reduced immunogenicity, and greater safety versus Krystexxa. With successful 2024 tox studies, PAT101 is being developed for monthly dosing, with a Phase 1 IND planned for 2025.

ProBio Korea

Country
Republic of Korea

CEO Name
LINGLING PAN

Main Sector
Professional Services and Consulting

Website
http://www.probiocdmo.com/

Booth No.
E14

Pavilion

Company Description

ProBio is a global CDMO offering end-to-end services for biopharmaceutical and advanced therapy development. We provide comprehensive CMC solutions across antibody drugs and cell and gene therapies, including plasmids, viral vectors, and mRNA. With over 100 IND approvals and four ongoing commercial programs, ProBio complies with global regulatory standards such as FDA, MFDS, NMPA, and PMDA. Leveraging proprietary platforms and deep expertise, we ensure high yield, top quality, and client-focused support from early-stage development to commercialization-helping partners accelerate innovation.

To Buy or Sell Technology/Product

ProBio provides end-to-end CDMO services in cell and gene therapy and antibody therapeutics, including CMC consulting and GMP manufacturing. We possess advanced technologies for LVV, AAV, and RVV production, as well as antibody discovery platforms such as Hybridoma, Single B Cell, and fully human libraries. With over 90 IND approvals from global regulatory bodies (FDA, MFDS, NMPA, etc.), ProBio delivers expert support across all stages of drug development.

Prove Clinical Laboratories Pty Ltd

Country
Australia

Delegate Name
Priyashiel Parikh

Main Sector
Central Lab

Website
https://provelabs.com/

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Prove Clinical Laboratories is a Sydney based ISO17025 accredited Central Laboratory that offers safety testing, bioanalytical analysis, PD analysis, flow cytometry, histopathology, PBMC isolation, kit assembly, sample storage and vendor management (logistics). We offer customised or complete solutions for Phase I-III clinical trials in multiple therapeutic areas with 6-8 weeks study startup time. At present we are supporting biotechs, CROs and other labs executing clinical trials in Australia. Our clients are globally located. As we are an Australian based and registered central lab, engagement with us helps biotechs maximise the R&D tax incentives in Australia. The data from our lab is internationally accepted.

To Buy or Sell Technology/Product

- Safety testing services (clinical chemistry, hematology, coagulation & urinalysis)
- Bioanalytical services (small & large molecules)
- Histopathology
- Flow cytometry
- PD analysis (ELISA analysis)
- Sample processing (PBMC isolation, ctDNA extraction & others)
- Sample storage for short & long term (ambient, -20 ºC, -80 ºC & -195 ºC (liquid nitrogen))
- Kit assembly for APAC, US & Europe based sites.
- Project management services
- Logistics management for kits and samples
- Database management
- Site training
- Logistics management • Vendor management

PSI CRO

Country
Switzerland

Booth No.
N15

CEO Name
Nick Sinackevich

Pavilion

Main Sector
Pharma

Website
https://psi-cro.com/

Company Description

PSI is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI's global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors.

To Buy or Sell Technology/Product

PSI CRO specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.

PURITECH

Country
Republic of Korea

Booth No.
J13

CEO Name
YUN JAE CHO

Pavilion

Main Sector
Professional Services and Consulting

Website
http://www.puritech.co.kr

Company Description

Puritec Co., Ltd. is the leader of cleamroom comsumable industry with the slogan as To be one! To the first(best)!! To the world!!

To Buy or Sell Technology/Product

1.CLEANROOM GARMENTS
- Highest particle filtration- Customized colors and design are available on request
- Meets class 1~1000 cleanroom requirements

2.CLEAN WIPER
- The highest quality filaments and the clean environment of fabric manufacturing create the advanced synthetic wiper
- All processes are strictly controlled by ISO9001/14001- Excellent Dry particle / Liquide particle / Lint

QurCan Therapeutics Inc.

Country
Canada

Booth No.
C1

Contact Name
Dr. John Reid, Chief Business Officer

Pavilion
Embassy of Canada to the Republic of Korea

Main Sector
Pharma

Website
www.QurCan.com

Company Description

QurCan Therapeutics (www.QurCan.com), has developed a novel nanoparticle drug delivery technology (TERP) to enable systemic delivery of RNA therapeutics (ASOs, siRNA,mRNA) to extrahepatic tissues, including CNS and Spleen.

To Buy or Sell Technology/Product

We have world-leading expertise in the design of polymer shell nanoparticles and TERP is an IND-ready breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine.

We are working with several biopharma companies to help develop TERP-enabled therapeutics for multiple applications while building an internal pipeline of therapeutics focused on monogenic CNS disorders.

QureTech Bio

Country
Sweden

Booth No.
A11

CEO Name
Markus Thor

Pavilion
Swedish Pavilion

Main Sector
Pharma

Website
www.quretech.com

Company Description

QureTech Bio develops new synthetic antibacterial agents that address significant medical need in infectious disease. The compounds are new small molecules from a well-developed chemical platform that are protected by strong intellectual property. The company's lead program is focused on developing a new class of antibiotics. The GmPcides are bactericidal against Gram-positive bacteria, such as Staphylococcus aureus, Streptococcus pyogenes and Enterococcus ssp, including drug-resistant strains such as MRSA and VRE. No resistance development has been detected in vitro or in clinical isolates. Compounds have also been identified with activity against Gram-negative bacteria.

To Buy or Sell Technology/Product

Preclinical stage first-in class small molecule antibiotics active against multidrug- resistant bacteria and showing no resistance development. First indication pursued is ABSSSI.

REMEDI Inc.

REMEDI
REVOLUTION MEDICAL DEVICES

Country
Republic of Korea

CEO Name
Bongho Cho

Main Sector
Digital Health

Website
www.remedihc.com

Booth No.
E4

Pavilion
Rising Pavilion

Company Description

REMEDI is a mission-driven organization ready to provide high quality, low cost, and effective imaging access to the world's most underserved populations and all global citizens. A global leader in medical technology innovation, REMEDI has revolutionized the portability of handheld X-ray devices and broadened the number of applications within the medical, dental, veterinary, and industrial sectors. REMEDI has 83 regulatory clearances with 7 products in 43 countries. We can save human lives together, using high intensity focused X-ray technology to drive innovation in imaging diagnostics and cancer treatment.

To Buy or Sell Technology/Product

REMEDI has developed an X-ray generator applying lightweight / compact / low-dose technology and is expanding global sales based on product competitiveness. Introducing the REMEX KA6, a handheld X-ray camera revolutionizing point-of-care imaging. Weighing just 2.4 kg, it eliminates the need for large shielding rooms thanks to internal generator shielding, reducing scattered radiation. Safe, lightweight, and affordable, it offers ease of operation. With new battery technology, it can capture days' worth of X-rays allowing over 250 exposures, perfect for busy practices, reducing retakes and saving time and money while maintaining high image quality, which is capable by the current capacity of 12mAs and a small focal spot of 0.4mm. While traditional large X-ray machines were only used for precise diagnostic purposes within hospitals, our portable REMEX-KA6 enables the use of X-ray imaging equipment for on-site diagnosis outside of hospital settings, making it applicable in a variety of fields as outlined below.

- Traditional in-hospital use (Precision Diagnosis): Intensive Care Unit (ICU), Operating Room (OR), Emergency Room (ER), Inpatient Room, Orthopedics, Pediatrics
- New use: Outside of hospitals (Distinguishing the presence or absence of disease) such as Ambulances, Emergency Helicopters, Medical Volunteer Sites, Homecare and Related Areas, Military, Governmental Projects, Border Care, Natural Disaster, Sports

RMAF

Country
Republic of Korea

CEO Name
Sora Park

Main Sector
Professional Services and Consulting

Website
http://rmaf.kr

Booth No.
H11

Pavilion
Korean Pavilion for Advanced Regenerative Medicine

Company Description

The Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products
came in force in August 2020. RMAF was established to efficiently and systematically promote the ARM projects
through the establishment of a public-private ownership to realize and facilitate the intent and objectives of the legislation.

To Buy or Sell Technology/Product

- Policy and institutional support
- Supporting Industry Vitalization
- Supporting the Designation of Regenerative Medicine Institutions
- Fostering regenerative medicine experts
- Activation Support for Advanced Regenerative Medicine Clinical Research
- Cell-Based Artificial Blood Technology Development Project Group

Robots and Design

Country
Republic of Korea

CEO Name
Jin-oh Kim, Jin Seog Han

Main Sector
Medical Device

Website
http://www.RND.re.kr

Booth No.
F13

Pavilion

Company Description

Since its establishment in 1999, Robots and Design Co., Ltd. has developed over 400 types of optimized robots that meet the customer's needs and various environments, and based on this robot technology, it is expanding its business to the semiconductor, dental, and biomedical fields.
We will advance as a global leader in the robot field by realizing Robot Development as a Service with customer satisfaction as the top priority.

To Buy or Sell Technology/Product

RoboCell® is a cell line automation platform for biopharmaceutical production, and can also be optimized according to GMP regulations.
RoboStor is an automated sample storage and retrieval system for biobanking.
Kubical is a modular solution for laboratory automation, equipped with robot for each unit, supporting process modification and expansion according to experimental protocols.

ROKIT Genomics

Country	Booth No.
Republic of Korea	E20
CEO Name	
Taewoo Kwon, Yunki Gil	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://rokitgenomics.com	

Company Description

We provide cutting-edge single-cell RNA sequencing (scRNA-seq) services and next-generation sequencing (NGS) services. Our team consists of first-generation experts in single-cell analysis, with extensive experience and know-how in the field. Through partnerships with BD Korea, Bertis, Biosolvix, and Macrogen, we continuously expand the scope of our technologies and applications. We have successfully carried out major projects for organizations such as the Korea Disease Control and Prevention Agency (KDCA), the Ministry of Food and Drug Safety (MFDS), and the pharmaceutical companies.

To Buy or Sell Technology/Product

We offer comprehensive single-cell RNA sequencing services, covering the entire process from raw tissue samples to bioinformatics analysis suitable for scientific paper publication. With experience in processing more than 70 types of tissue samples, we possess advanced tissue dissociation techniques. Our team of bioinformatics specialists provides customized data analysis tailored to each client's research needs. In addition, we operate the largest range of single-cell analysis platforms among domestic companies and offer professional consulting services from research design to data interpretation.

RudaCure Co., Ltd

Country	Booth No.
Republic of Korea	G5
CEO Name	
Harith hasrul	**Pavilion**
Main Sector	
Pharma	**Rising Pavilion**
Website	
www.rudacure.com	

Company Description

RudaCure is a clinical bio-pharmacutical company founded with the vision to solve current unmet needs for intractable and incurable diseases by developing innovative first-in-class treatments to help suffering patients have quality and painless lives.

To Buy or Sell Technology/Product

① RCI001 (the treatment of Dye eye disease)
●RCI001, a Rac1 inhibitor formulated as an ophthalmic solution, has demonstrated potent anti-inflammatory and antioxidant effects, effectively treating and promoting recovery of the ocular surface in various dry eye and corneal injury models.
● Its multimodal mechanism of action, combining anti-inflammatory and antioxidant properties, represents an innovative approach to dry eye treatment. Current therapies primarily target either inflammation or tear film recovery, which is suboptimal given the multifactorial nature of Dry Eye. These limitations lead to low efficacy, prolonged treatment durations, and discomfort during instillation.
● RCI001's dual action—addressing both inflammation and oxidative stress—is a more comprehensive and effective approach for managing a complex, multifactorial disease like Dry Eye.

② RCI002 (TRPV1 antagonist for chronic pain)
● While synthetic drug antagonists targeting TRPV1 have been developed since the early 2000s due to high interest, most of these were discontinued during clinical trials due to severe adverse effects, such as hyperthermia.

● RCI002 is not only inhibits the activity of the TRPV1 ion channel but also effectively alleviates pain in various neuropathic pain models.
●To address the significant hurdle of abnormal hyperthermia associated with TRPV1 antagonists, non-human primates and mice were tested, confirming that the abnormal hyperthermia observed with existing TRPV1 drugs did not occur with RCI002.
● The lead-peptide demonstrated TRPV1 antagonist effects and pain relief in an animal model of osteoarthritis and several neuropathic pain (CIPN, DPN, CCI).

Sacco System

Country
Australia

Booth No.
B1

Delegate Name
Howard H Kim

Pavilion
Australian National Pavilion

Main Sector
Professional Services and Consulting

Website
https://saccosystem.com

Company Description

Sacco System is an international biotechnology group of excellence specializing in the research, development and production of natural and innovative biotechnological solutions for the food, nutraceutical, pharmaceutical and agro-veterinary sectors. For more than 150 years, we have supported customers through the production of enzymes, milk enzymes and probiotics designed to enhance the culture of wellness and quality of life. Our innovative approach covers manufacturing, research and development in the nutraceutical and pharmaceutical sectors, including the development, process validation and commercial production of probiotics, postbiotics, next-generation bacteria (aerobic and obligate anaerobic strains) and live biotherapeutics (LBP).

To Buy or Sell Technology/Product

Sacco System has over 90 years' experience in probiotics. We have produced our first live biotherapeutic for the pharmaceutical industry in 1996. Since then we have helped our customers select, develop and produce a number of strains ranging from LAB to the most challenging anaerobes for pharmaceutical development. Around 30% of our 500 colleagues work in our R&D laboratories, the remaining workforce manages customer projects ranging from screening strains for ease of production to toll manufacturing at 40,000L scale. Our GMP facilities offer fermenters at 80L, 200L, 500L, 5,000L, 10,000L and 20,000L. Our centrifuges, TFF kits and freeze drying facilities are to scale. Advanced process management means our customers follow their project with ease and are constantly informed of progress.

Salipro Biotech AB

Country	Booth No.
Sweden	A11
CEO Name	
Jens Frauenfeld	**Pavilion**
Main Sector	Swedish Pavilion
Pharma	
Website	
https://www.salipro.com	

Company Description

Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins.
The majority of drug targets are so-called membrane proteins; however, these drug targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design in multiple research collaborations with top-tier pharma and biotech companies (e.g. GSK, Sumitomo Pharma, AstraZeneca, Sanofi).
In addition to their platform technology, Salipro Biotech is pursuing an internal pipeline program with GPCRs, ion channels and transporters that are ready for collaboration.

To Buy or Sell Technology/Product

Membrane proteins are of critical importance for the pharmaceutical industry. More than 60% of all current drugs interact with proteins that are embedded in the lipid membrane. However, these proteins are inherently unstable, and this is a major challenge.
Salipro Biotech has developed the proprietary Salipro® platform that stabilizes challenging membrane protein targets (GPCRs, ion channels, receptors, transporters, etc). With Salipro® it is possible to radically improve workflows to develop therapeutic antibodies as well as small molecules targeting membrane proteins.
In addition to their platform technology, Salipro Biotech is pursuing an asset pipeline program with several GPCRs (CXCR4, GPR75, CXCR2, CXCR7), channels (Pannexin 1, TRPV3), receptors, (TCR/CD3, EGFR) and transporters (MCT1) that are ready for collaboration.

SAPIENSBIO

Country	Booth No.
Republic of Korea	B32
CEO Name	
Kanghyun Ryoo, Incheol Ryu	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.sapiensbio.com	

Company Description

SapiensBio is dedicated to analyzing biological complexity to develop innovative therapeutics. Utilizing the SAPIENTIA 1.0 platform, we analyze single-cell genomic data (Single-Cell RNA Seq) to identify novel therapeutic targets. Our SAPIENTIA 2.0 platform based on hPCTS (human Precision-Cut Tissue Slices) technology, enhances clinical trial success rates by providing a precision medicine solution. Through these advanced platforms, SapiensBio accelerates the discovery and development of next-generation therapies, offering cutting-edge solutions to improve patient outcomes and advance the field of biomedical research.

To Buy or Sell Technology/Product

PCTS preserves the structure and cellular complexity of human tissue, allowing drug efficacy to be predicted in preclinical stages. SAPIENTIA 2.0 utilizes donor-specific PCTS to analyze genetic information and model drug response variations, enabling the prediction of clinical outcomes. This enhances drug reliability and increases the success rate of drug development. By offering a data-driven approach, SAPIENTIA 2.0 serves as an innovative solution that provides effective strategies for new drug development.

Sci-Key Biotech Inc

Country
Republic of Korea

CEO Name
Dr. Eun Young Kim

Main Sector
Pharma

Website
www.sci-key.com

Booth No.
D11

Pavilion
DIPS 1000+ project

Company Description

Sci-Key Biotech is a startup biotech company that was established on Sept. 8, 2020 based on aptamer developments. Sci-Key Biotech has received many awards and grants in its short span since its creation, with most notably Big3, Amgen-KHIDI Pitching (2nd), and Novo Nordisk-KHIDI Pitching (1st). In addition, Sci-Key Biotech partnered with several companies and government institutions as research partners.

To Buy or Sell Technology/Product

<Aptamer Library Pre-Organized Structure (ALPS) Technology>
It was developed to minimize the aptamer discovery period. It's 4 to 12 times faster than normal aptamer and antibody development. 7 scimers were obtained for the use of development of anti-obesity and MASH/NASH drugs. 2 of 7 aptamers are being used for drug delivery system development, and their potential has been confirmed.

<Fast Agile Aptamer Development (FAAD) System>
Our FAAD system consists of ALPS screening system to minimize the number of SELEX rounds needed for aptamer discovery and our aptamer modification software utilizing ML techniques to optimize aptamers and increase performance. Scimers our DNA aptamers were developed through our speedier screening system.

SCL Healthcare

Country
Republic of Korea

CEO Name
Kyoung-Ryul Lee

Main Sector
Professional Services and Consulting

Website
http://www.sclhealthcare.co.kr

Booth No.
J29

Pavilion

Company Description

Established in 2006, SCL Healthcare Central Laboratory was Korea's first independent laboratory specializing in clinical trials. In 2017, it emerged as a dedicated analytical CRO following its separation from Seoul Clinical Laboratories (SCL), and it now offers a wide range of analytical services in collaboration with SCL.

To Buy or Sell Technology/Product

Central Laboratory[C-LAB]
- Clinical Trial Sample Analysis (IHC, FACS, NGS, PK/ADA, PD, Nab, qPCR, etc.)
- Assay Validation
- Result Reporting & Data Transmission Service (eCRF Upload)
- Clinical Trial Management
- Sample Collection Kit Management
- Provision of Lab Manuals & Guidelines
- Sample Storage
- Data Archiving

Bio-Logistics Service
- Investigational Product Transport
- Clinical Trial Sample Transport
- Medical Cold-Chain Logistics
- Vaccine & Biologics Transport
- Infectious Substance Tra

SELTA SQUARE Inc.

Country	Booth No.
Republic of Korea	J27
CEO Name	
Minkyoung Shin	**Pavilion**
Main Sector	Health Insurance Review & Assessment Service
Digital Health	
Website	
www.seltaglobal.com	

Company Description

SELTA SQUARE Inc. is revolutionizing pharmacovigilance (PV) by combining industry expertise with cutting-edge AI and digital technology. Pharmacovigilance is essential not only during clinical trials but throughout the entire lifecycle of marketed drugs, requiring significant commitment and diligence from pharmaceutical companies.

The comprehensive PV services are critical for effectively managing adverse effects and ensuring patient safety. As a Safety Data Orchestrator, SELTA SQUARE is dedicated to creating a safer healthcare environment. We deliver end-to-end validated PV services and AI-driven digital transformation solutions specifically designed to address our clients' most pressing challenges. Many customers have solved their problems with our proven services and trusted solutions.

To Buy or Sell Technology/Product

The SELTA SQUAE Inc. has launched the AI/DX enabled PVaaS (PV as a service) platform. We currently offer several integrated solutions on our PVaaS platform, including SELTA-LITUS & SELTA-WAVE, SELTA-OCTO, and SELTA-TUBE. The SELTA-LITUS leverages AI technology to automatically detect the adverse event data from diverse literatures sources. The SELTA-WAVE extracts the adverse event data from various CIOMS/SAE report formats, and converts it into standardized XML, enables revision of extracted data, and facilitates authority submission. SETLA-OCTO recommends the standards MedDRA adverse event term and SELTA TUBE analyzes the various raw data for re-approval submission.
The PVaaS platform has continuously expanded with strategic development roadmap. Our customers have experienced our platform and realized the business benefits.

SeraNovo B.V.

Country	Booth No.
Netherlands	B11
CEO Name	
Niall Hodgins	**Pavilion**
Main Sector	Netherlands Bio Lounge
Pharma	
Website	
www.seranovo.com	

Company Description

SeraNovo specializes in improving bioavailability for small molecules and oral peptides using its proprietary NanoGlass Technology. This platform offers 1.5–3x bioavailability enhancement, rapid 4–8 week formulation timelines, and simple manufacturing. SeraNovo partners with major pharma companies such as Johnson & Johnson, AstraZeneca, Arvinas, and J2H to improve delivery of challenging compounds, including protein degraders. By combining deep formulation expertise with a customer-focused approach, SeraNovo helps partners advance water-insoluble candidates and deliver innovative treatments to market more efficiently.

To Buy or Sell Technology/Product

NanoGlass Technology
SeraNovo's NanoGlass Technology is a cutting-edge oral drug delivery platform designed to enhance the bioavailability of poorly soluble small molecules and peptides. It includes multiple formulation types tailored to different drug characteristics and release profiles

- LiGlass: High drug load lipid-based formulation
- PepGlass: Oral peptide formulation with enhanced absorption
- HyGlass: Instant-release hydrophilic liquid
- GlassE: Instant-release solid form
- GlassA: Controlled-release solid form

This versatile technology enables efficient, scalable drug development with improved absorption and simplified manufacturing.

SG Medical, Inc.

SG MEDICAL

Country	Booth No.
Republic of Korea	A28
CEO Name	**Pavilion**
JE-IN YOUN, YUNSIK CHOI	
Main Sector	
Pharma	
Website	
https://www.sgmedical.kr	

Company Description

SG Medical is a biotech company specializing in the development of anticancer drugs using patient-derived tumoroid (cancer organoid) technology. By leveraging highly predictive models, the company accelerates efficacy study and clinical translation. SG Medical also offers preclinical services for the development of small molecules, antibodies, and ADC-based therapies to external partners. In addition to service offerings, it is actively developing its own pipeline of anticancer drugs using tumoroids, aiming to lead innovation in cancer treatment through collaborative research and technical partnerships.

To Buy or Sell Technology/Product

SG Medical's patient-derived tumoroid (PDT) technology offers physiologically relevant tumor models that retain patient-specific features, enabling high-precision drug screening. It supports efficacy testing and resistance profiling across small molecules, antibodies, and ADCs. The platform is scalable, reproducible, and adaptable to various preclinical stages. By integrating PDO-based screening, we improve the translational relevance of oncology pipelines and reduce clinical attrition. Our solutions accelerate hit discovery, lead optimization, and preclinical validation. SG Medical actively collaborates with global pharma, biotech, and CRO partners to bring innovation into cancer drug development through predictive and patient-centric organoid platforms.

SOCIOTECH Co., Ltd.

SOCIOTECH

Country	Booth No.
Republic of Korea	M17
CEO Name	**Pavilion**
Jung Wonsup	Gyeonggi Business & Science Accelerator
Main Sector	
Digital Health	
Website	
www.sociotech.co.kr	

Company Description

The product DTx4CBT-i that the company is trying to implement is capable of utilizing all senses including vision to maximize the effect of educational cognitive behavioral therapy, and by providing users with a sense of purpose and treatment motivation in a two-way interactive extended reality space, it has developed a treatment with superior treatment effect and superior treatment acceptability and universality than existing sleep treatment methods. As a result, it was selected for the '24 Gyeonggi-do Digital Innovation Medical Device Development Support Project, and completed the development of a sleep digital treatment prototype (SURAM®, September 2024) and exhibited it at '24KADEX (October 2-6, 2024). As a result, it has gained visibility and educational effects as a digital treatment, and has attracted the interest of participants, and has been recognized for its potential use in various fields such as the care of soldiers who may suffer from psychological anxiety factors such as new military training camps, and the promotion of mental health in occupational groups such as firefighters and police officers who suffer from trauma.

To Buy or Sell Technology/Product

Digital treatment (solution) using cognitive behavioral therapy

Development of augmented reality-based sleep disorder digital treatment to support expert cognitive behavioral therapy using interactive AI combined real-time CG-based reality under the concept of medical cognitive behavioral therapy (CBT-i)
1) State-of-the-art technology interactive healthcare/treatment that can enhance visibility and imprint by maximizing reproducibility and immersion
2) Supporting cognitive behavioral therapy implemented face-to-face by medical staff and psychologists to enable fee application and minimize the expected decrease in compliance when used alone by patients, and using a strategy to enhance the treatment effect will also secure marketability.

Southern Star Research Pty Ltd

Country	Booth No.
Australia	B1
CEO Name	
David Lloyd	**Pavilion**
Main Sector	Australian National Pavilion
Professional Services and Consulting	
Website	
Southernstarresearch.com ccc	

Company Description

Southern Star Research is a leading Australian, privately owned, full-service Contract Research Organisation. We specialise in providing early phase clinical research support to biotech, device and pharmaceutical sponsors looking to accelerate their clinical program in Australia and springboard their clinical program into the US, Europe and South-East Asia. Headquartered in Sydney we actively support studies in Australia, New Zealand, US, Europe and South-East Asia across a range of different therapeutic areas including oncology, Neurology, Endocrinology, Infectious Disease, Pediatric as well as emerging Cell & Gene Therapies

To Buy or Sell Technology/Product

- Project Management
- Clinical Monitoring & Operations
- Biostatistics & Data Management
- Medical Monitoring & Safety
- Study Feasibility
- Quality Assurance
- Medical Writing
- Regulatory Affairs
- Local Sponsorship

Spiderwort Biotechnologies Inc

Country
Canada

CEO Name
Dr. Charles M. Cuerrier

Main Sector
Pharma

Website
https://spiderwortbio.com

Booth No.
C1

Pavilion
Embassy of Canada to the Republic of Korea

Company Description

Spiderwort Biotechnologies is a clinical stage company developing plant-derived cellulose biomaterials for use in a number of regenerative medicine applications. The company's proprietary AerocellTM biomaterial platform involves isolating and manufacturing a repertoire of unique cellulose derived microstructures to match the extracellular matrix structure of the target tissues.

To Buy or Sell Technology/Product

Our biomaterial platform provides multiple advantages compared to its competitors.

First, the platform offers precise control over stiffness, shape, texture, and architecture of the biomaterial to be able to control tissue regeneration.
Second, the biomaterials are biocompatible and immunologically inert in in vitro and in vivo models (FDA ISO 10993).
Third, the biomaterials support cell infiltration and vascularization.
Fourth, the platform allows the functionalization of biomaterials (e.g., material coating, drug delivery, cell adhesion).

Finally, the biomaterials are GMP manufactured in a certified ISO 5 cleanroom (ISO 13485, ISO 14971).
Spiderwort Biotechologies is developing two lead proprietary products using its AerocellTM biomaterial platform. CelluBridge® is a spinal cord injury scaffold that has been granted a Breakthrough Device Designation from the US Food and Drug Administration (FDA), and CelluJuve® a dermal filler for soft tissue augmentation for aesthetic enhancement.

ST PHARM

Country
Republic of Korea

CEO Name
Mooje Sung

Main Sector
Professional Services and Consulting

Website
http://stpharm.co.kr

Booth No.
K19

Pavilion

Company Description

ST PHARM is a global custom API CDMO company based in South Korea, specializing in small molecules, oligonucleotides, mRNA-LNP and xRNAs (including circRNA, guide RNA). Our mRNA manufacturing platform have our own IP materials, proprietary 5-capping analogue SmartCap® and novel lipid nanoparticles STLNP® with experience of clinical phase I for SARs-Cov2 mRNA vaccine. Leveraging its profound know-hows in development and manufacturing of nucleotides and oligonucleotides, ST Pharm expanded its business scope to mRNA CDMO, utilizing its own mRNA platform technology. To learn more about ST Pharm, visit www.stpharm.co.kr or follow ST Pharm on LinkedIn.

To Buy or Sell Technology/Product

1) mRNA & xRNA(including gRNA, circRNA) CDMO
- Offering seamless development from IVT synthesis to LNP formulation
- Services including linear mRNA and circular RNA
- Providing both GMP and non-GMP grade options

2) SmartCap®
- Novel, proprietary 5'-capping analog for your discovery and clinical developments
- Providing 30 different capping analogs (SmartCap®)
- Offering capping library screening services to identify the most suitable capping analog for your specific mRNA
- Strong IP position
- SmartCap® proved its safety in clinical phase 1

3) STLNP® (LNP Technology)
- Offers novel proprietary ionizable lipids for LNP formulation (STLNP®)
- Strong IP position

ST1

Country	Booth No.
Republic of Korea	B31
CEO Name	
Yong-jun Yoon	**Pavilion**
Main Sector	
Medical Device	
Website	
http://www.artipore.com	

Company Description

We specialize in the development, production, and sale of three-dimensional cell culture scaffolds, utilizing advanced electrospinning and 3D bioprinting technologies. Our products, based on nanofibers and porous materials, are distinguished by their superior quality and unique functionalities, made possible through proprietary equipment and process technologies. Through in-house innovation and collaborative research with hospitals, research institutions, and universities, we are continuously expanding our product applications and advancing in the field of biomedical research and development.

To Buy or Sell Technology/Product

Well-INSERT is our flagship cell culture platform, optimized for cell migration and co-culture. Featuring a one-touch assembly/disassembly structure, it enhances the convenience of cell observation and analysis. The product offers a range of DISK types, allowing users to select the most suitable option for their specific experimental needs.
Our nanofiber-based products for 3D cell culture are particularly advantageous for precise evaluation of cell experiments, offering a variety of benefits in cell culture applications.

Standigm

Country	Booth No.
Republic of Korea	F6
CEO Name	
Sangok Song	**Pavilion**
Main Sector	
Pharma	Rising Pavilion
Website	
www.standigm.com	

Company Description

Standigm harnesses the power of AI to pioneer drug discovery, developing both proprietary and collaborative research pipelines. Our AI platform approach includes a biology platform for uncovering novel drug targets and a chemistry platform for designing molecules to modulate these targets effectively. In addition to pipeline development, we also offer AI platform services, empowering partners across the globe to accelerate their drug discovery processes and achieve groundbreaking advancements in medicine.

To Buy or Sell Technology/Product

Standigm has developed AI platforms to accelerate drug discovery by optimizing target identification, molecular design, and compound evaluation. Standigm ASK™ and Standigm BEST™ integrate AI models, database, and predictive analytics to streamline early-stage drug discovery.

Standigm ASK™ focuses on AI-driven drug target identification, integrating knowledge-based and omics based technologies.

Key Features:

ASK-Pathfinder™ predicts target-disease associations using a biomedical knowledge graph.
ASK-SCREENER™ extracts disease-target relationships from text.
ASK-PWN™ identifies disease-specific targets by applying omics data to a modified PPI network.

ASK-GSM™ identifies metabolism-related targets using patient- or disease-specific metabolic models based on transcriptomic data.

Standigm BEST™ accelerates hit-to-lead and lead-to-preclinical candidate selection with AI-powered drug design and optimization, combining generative AI, predictive modeling, and automation to streamline drug discovery process.

Key Features:

BEST-STELLA™ generates molecules with desired multi-pharmaceutical properties.
BEST-SPICA™ provides a rapid novelty assessment for compounds.
BEST-QIP-ADMET™ predicts ADMET properties using Quantum-Informed pretrained model.
BEST-GT-autoML™ automates SAR modeling and AI optimization.

Starodub B.V.

Country
Netherlands

CEO Name
Valentyna Starodub

Main Sector
Professional Services and Consulting

Website
https://www.starodub.nl

Booth No.
B11

Pavilion
Netherlands Bio Lounge

Company Description

Starodub B.V. is a qualified SME in Europe offering cost-effective regulatory solutions for bio pharmaceuticals, medical devices, and combination products. With expertise in small molecules, biologics, ATMPs, and vaccines, we help companies navigate complex European regulatory pathways. Our services include regulatory strategy, product registration, and ISO 13485-compliant quality system setup. We combine deep knowledge in Quality/CMC, non-clinical, and clinical areas with strong engagement with global health authorities. Supported by a skilled regulatory operations team and efficient document systems, Starodub accelerates market access while minimizing risk and cost.

To Buy or Sell Technology/Product

Starodub B.V. offers comprehensive regulatory support for medicinal products across all development stages. Services include due diligence and gap analysis, clinical trial applications, and expert support in regulatory quality/CMC, nonclinical, and clinical areas. We prepare and review briefing packages for Scientific Advice, Protocol Assistance, and pre-IND meetings. Our team provides CTD writing and eCTD publishing. As a qualified SME, our clients benefit from up to 90% fee reductions or derogations, ensuring cost-effective regulatory advancement.

STEMDEN

Country	Booth No.
Republic of Korea	G4
CEO Name	
Jang, Il-Ho	**Pavilion**
Main Sector	Rising Pavilion
Pharma	
Website	
www.stemden.co.kr	

Company Description

STEMDEN is developing a variety of oral tissue regeneration products, including dental dimensions, dentin, periodontal ligament and alveolar bone. Oral tissue is highly active in adult stem cells, which is expected to induce high success in inducing tissue regeneration. STEMDEN aims to discover oral stem cell activity regulators and study how to efficiently deliver them to patients and complete products that are effective for clinical application. We will lead the future of dental treatment that restores natural functions through regenerative treatment rather than replacement of artificial substances by providing high-satisfaction finished products to both practitioners and patients.

To Buy or Sell Technology/Product

PNUT1TM : Combination product for oral tissue regeneration (Maximizing efficacy and diversifying the product range through the convergence of therapeutic agents that promote oral tissue regeneration via stem cell activation and bio-materials)

- STEMDEN's small molecule drugs and combination products with collagen promote the regeneration of damaged dentin and replace root canal treatment.
- PNUT1TM, a combination therapy of small molecule, Compound P and clinical grade collagen sponge, effectively regenerates dentin in minipigs in 3 months, achieving 90% density of nearby natural dentin.
- Currently, preliminary toxicity toxicity testing is underway. Clinical trials of PNUT1TM is planned in 2026.

[Key Words] stem cells, caries, dentin, pulp, tissue regeneration, collagen etc.,

SUNWOO ENG.CO.,LTD

Country	Booth No.
Republic of Korea	E31
CEO Name	
JAE WOO AHN	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://sunwooeng.com	

Company Description

Sunwoo ENG Co., Ltd. was established as a corporation in 2001 and is engaged in the distribution and service of products such as standard particles and various laboratory equipment from Thermo Fisher, nanoparticle analyzers and EV separation reagents from IZON, and other related products in Korea. Additionally, the company contributes to domestic EV research and various development activities through participation in academic events and exhibitions upon customer requests.

To Buy or Sell Technology/Product

- Analyzers and separation reagents for EV research
- Standard particles for experiments and research
- Clean room monitoring systems and environmental management products
- Indoor air quality monitoring systems

Symeres drug discovery & development CRMO

Country	Booth No.
Netherlands	A6
CEO Name	
Guillaume Jetten	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://symeres.com	

Company Description

Symeres is a leading transatlantic drug discovery and development CRO/CDMO for solving your challenges and driving your programmes from hit to clinic, with over 600 scientists located in Europe and the USA.

We provide integrated drug discovery, medicinal, computational, parallel chemistry, ADME/Tox and PK profiling delivered by our Admescope platform, biochemical and cellular assays, including the Oncolines in vitro oncology platform, hit finding using HTS with, our proprietary "SymeGold" library, fragment-based approaches, virtual screening, scaffold hopping etc.

To Buy or Sell Technology/Product

- Drug Developability Roadmap
- Solid State Characterization
- Process Research and Development
- DS and DP Production under cGMP
- Oncology characterization
- Integrated Drug Discovery
- Parallel Chemistry for SAR and/or IP enhancement
- SymeGold library
- Custom Synthesis
- Radio Therapy Chemistry
- Linker-warhead design and synthesis
- Lipid chemistry
- Steroid chemistry
- X-Tacs chemistry

SYMYOO

Country	Booth No.
Republic of Korea	I28
CEO Name	
Dong Jin Yoo	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
https://symyoo.co.kr/	

Company Description

Since its establishment in 2009, Symyoo Co., Ltd. has successfully conducted over 230 clinical trials, providing comprehensive support as a Full-Service CRO to deliver optimal outcomes across diverse clinical research areas. To enhance global clinical trial capabilities, Symyoo established Symyoo America and, as a partner of AICROS-a multinational CRO alliance-offers customized clinical solutions through a network spanning 38 countries.

To Buy or Sell Technology/Product

We provide comprehensive research and development services, including clinical strategy consulting, clinical protocol development, monitoring, clinical trial management, statistical analysis, clinical study reporting, safety documentation, and regulatory submission support for clinical trials. By leveraging collaboration between experienced specialists in various fields and our proprietary clinical systems, we minimize risks and enhance operational efficiency in clinical trials.

Synex Consulting Ltd.

Country	Booth No.
Republic of Korea	I32
CEO Name	
Young Kim	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://synex.co.kr	

Company Description

Synex is a professional service firm that helps healthcare companies with market access issues.
We offer integrated solutions which ensure successful market entry in Korea.

To Buy or Sell Technology/Product

By working with us, you will have answers to questions concerning regulatory approval, clinical research, reimbursement approval, market research, distribution, and logistics.

SYNSMART

Country	Booth No.
India	G30
CEO Name	
Saurabh Kapure	**Pavilion**
Main Sector	
Pharma	
Website	
https://synsmart.in/	

Company Description

Founded in 2014, SynSmart is a leading contract research organization specializing in medicinal, computational, and synthetic chemistry services. With a team of over 100 chemists, we support early-stage discovery projects and offer collaborative scale-up and manufacturing services. Our expertise spans traditional heterocyclic chemistry, transition metal-mediated reactions, and handling sensitive reagents. In 2023, we appointed industry veteran Saurabh Kapure as CEO, established a U.S. affiliate, and inaugurated a state-of-the-art chemistry research facility. BUSINESS WIRE INDIA Committed to innovation and customer-centric solutions, SynSmart serves global clients across pharmaceutical, biotech, agrochemical, and specialty chemical industries.

To Buy or Sell Technology/Product

SynSmart offers a comprehensive suite of chemistry services and products tailored for early-stage discovery and development projects. Their services encompass computational chemistry, medicinal chemistry, synthetic chemistry, process research, and scale-up, as well as ADME-PK services. In addition to these services, SynSmart provides a diverse range of products, including custom synthesis, flavoring agents, pharmaceutical intermediates, and pharmaceutical standards. With a team of over 100 chemists, SynSmart has successfully delivered projects ranging from milligram to multi-tonne scales across various chemical modalities for global clients.

Sysmex Corporation

Country	Booth No.
Japan	K5
CEO Name	
Kaoru Asano	**Pavilion**
Main Sector	
Pharma	
Website	
http://sysmex.co.jp/en/	

Company Description

Sysmex Corporation is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives.

To Buy or Sell Technology/Product

Sysmex has medical equipment and diagnostics for in vitro diagnostics. In the field of hematology in particular, we rank among the top 10 companies in the world. We also possess cell analysis technology and equipment, which are used in the research and development of cell therapies and quality control tests for manufacturing.

Taikun Pharmaceutical Technology Pty Ltd

Country	Booth No.
Australia	B1
Delegate Name	
Isaac Huang	**Pavilion**
Main Sector	Australian National Pavilion
Professional Services and Consulting	
Website	
https://www.taikunpharma.com	

Company Description

As the expert in global clinical services, Taikun Pharma provides bespoke clinical trial services solutions for our clients.

Whether it's optimizing flexibility in clinical supply timelines or assisting with regulatory guidelines and packaging design, Taikun Pharma is committed to delivering client centric solutions to support the success of clinical trials globally.

To Buy or Sell Technology/Product

Through our GDP/GMP compliant facilities located in Australia, U.S., Belgium and China, and our partner depot network across South America and Europe, Taikun Pharma provides full range of clinical trial services. These services include:

- Specialized clinical supply management
- GCP/GMP compliant packaging solutions
- Label and carton design and manufacturing
- Temperature-controlled storage
- Clinical site distribution
- Import & export of clinical materials/QP release
- Returns and destruction services
  IRT

TARGET HEALTH

Country
United States of America

Booth No.
F31

CEO Name
Jay Jeon

Pavilion

Main Sector
Professional Services and Consulting

Website
http://www.targethealth.com

Company Description

Founded in 1993 in New York, Target Health is a full-service CRO specializing in regulatory affairs, clinical operations, data management, and digital clinical trials. Backed by a dedicated team of clinical operations experts with experience across diverse therapeutic areas, Target Health has successfully completed over 900 projects since its inception and collaborated with more than 180 pharmaceutical, biotech, medical device, and diagnostic companies. We are also committed to helping Korean startups thrive in the US. Whether it's through strategic partnerships, market exposure, or advisory support, Target Health offers a one-stop solution to empower companies to achieve their goals.

To Buy or Sell Technology/Product

Target Health's standout feature is its Clinical Trial Software Suite, fully compliant with FDA 21 CFR Part 11, ensuring secure electronic records, robust audit trails, and electronic signatures. This state-of-the-art software has been instrumental in numerous global studies, contributing to the approval of over 40 drugs and medical devices by regulatory authorities, including the US FDA, Health Canada, the EU, Japan, and other regions worldwide. We specialize in supporting biotech companies as they navigate the complexities of entering the US market. Our comprehensive program is designed to ensure a smooth and effective transition, offering everything from strategy development to market.

THAILAND (VNU Asia Pacific)

Country
Thailand

Booth No.
A7

CEO Name
Justin Pau

Pavilion

Main Sector
Professional Services and Consulting

Website
https://www.vnuasiapacific.com/

Company Description

VNU Asia Pacific is part of VNU Group, a globally operating exhibition company with offices in Utrecht, Bangkok. VNU Asia Pacific covers all key exhibition markets in South East Asia and has a constantly expanding portfolio with 18 trade shows including brands from the Agriculture, Horticulture Technology, Livestock-Aquaculture, Animal Husbandry, Pet, Food, Life Sciences and Biotechnology industries, Health Technology and Cybersecurity.

To Buy or Sell Technology/Product

Thailand LAB INTERNATIONAL is one of the leading laboratory exhibitions in Asia Pacific Region, showcasing all laboratory equipment and instrument covering areas of Analytical & Testing, Calibration & Metrology, Clinical & Safety, Diagnostic, Research & Development and Environmental Safety. Bio AP International is the conference and exhibition platform for Biotechnology, Life Sciences and Smart Health. Thailand LAB INTERNATIONAL together with Bio Asia Pacific aim to offer a one-stop solution for our trade participants' laboratory, life sciences and chemicals-related needs. It is a collaborative platform showcasing a wide range of technologies from Labtech, Biotech and Medtech, extending to Digital.

Thermo Fisher Scientific

Country	Booth No.
Republic of Korea	H19
CEO Name	
BongSu Seo, Hyeeun Choi	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.thermofisher.com/kr/ko/home.html	

Company Description

Thermo Fisher Scientific CDMO provides industry-leading pharma services for drug development, clinical trial logistics, and commercial manufacturing through our Patheon™ brand.
We partner with customers in the pharmaceutical, biotech, and life sciences industries as their trusted CDMO to deliver medicine to patients faster. We believe that doing this successfully not only requires science, technology, and world-class expertise, but also requires a strategic partnership—bonded by key elements such as trust, communication, and collaboration. We embed these elements into every operation, interaction, and step in the drug development journey.

To Buy or Sell Technology/Product

With around 60 locations worldwide, we are committed to providing integrated, end-to-end solutions across all phases of development. Our pharma services include API, biologics, cell therapy, viral vectors, formulation, clinical trials solutions, logistics services, and commercial manufacturing, and packaging.
We couple our scientific and technical excellence in these areas with a strategic partnership, to provide customers of all sizes access to a global network of facilities and dedicated experts across the Americas, Europe, Asia, and Australia.

Thermo Fisher Scientific Solutions

Country	Booth No.
Republic of Korea	G14
CEO Name	
Soo Jin Seok	**Pavilion**
Main Sector	
Medical Device	Korean Pavilion for Advanced Regenerative Medicine
Website	
http://www.thermofisher.com/patheon-kr	

Company Description

Thermo Fisher Scientific is a company dedicated to helping customers make the world healthier, cleaner, and safer. The company focuses on accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, and increasing laboratory productivity.

To Buy or Sell Technology/Product

Our company provides biobanking total solutions that include equipment, consumables, and software for sample storage and processing. Our key products include automated cell freezing devices, low-temperature storage equipment (4°C refrigerators, -80°C freezers, Cryopreservation system), coded/2D barcode cryogenic storage consumables, automated sample processing equipment, and monitoring systems. These solutions enable efficient and secure sample management.

Tissue Repair Ltd

TISSUE REPAIR

Country	Booth No.
Australia	B1
CEO Name	
Darryl Reed	**Pavilion**
Main Sector	Australian National Pavilion
Pharma	
Website	
trproplus.com, tissuerepair.com.au/	

Company Description

Tissue Repair Limited (ASX TRP) is an Australian biotechnology company developing next generation skin healing agents. The technology platform is Glucoprime®, a proprietary beta glucan purified from yeast which has been shown to have immunomodulatory properties. Glucoprime® has been formulated into two novel hydrogels (TR Pro+® and TR987®) that are being used across discrete applications:

i. TR Pro+® - aftercare product for medical (skin cancer removal, biopsy, dermatitis, surgical excisions, scar management) and aesthetic (ablative and non-ablative laser, skin needling, chemical peels) procedures, and
ii. TR987® – treatment of chronic wounds (venous leg ulcers).

TR Pro+® was launched in Australia in June 2023 and is being used and recommended by plastic surgeons, dermatologists, dermal therapists, and GPs interested in skin. The hydrogel TR987® will be further evaluated for use in chronic wounds in a Phase 3 clinical trial program (Australia and the US) with patient recruitment expected to commence in October 2024.
Tissue Repair's longer-term strategy is to commercialize its Glucoprime® API to treat a variety of wounds and skin conditions.

To Buy or Sell Technology/Product

- TR Pro+® represents a new standard in aftercare, with the proprietary active ingredient Glucoprime®, which has been demonstrated clinically to accelerate healing and improve skin quality. Glucoprime® is a beta glucan purified from the yeast cell wall so that the native structure is substantially retained. When applied topically in a hydrogel formulation, the Glucoprime® provides a breathable biofilm barrier that reduces transepidermal water loss and retains deeper tissue hydration, which assists in skin repair.
- Macrophages also recognise Glucoprime in the dermis, and their subsequent activation leads to increased production of cytokines, growth factors and collagen that further assist in regenerating damaged skin. TR Pro+® is formulated for skin healing, repair and regeneration, allowing it to be used as an aftercare treatment for aesthetic procedures, including ablative and non-ablative laser, RF and micro skin needling, chemical peels, light treatments and other methods designed to stimulate collagen production. It can also be used for aftercare treatment for medical procedures, including skin cancer removal, biopsy, dermatitis, surgical excisions, and scar management.

TNO

TNO innovation for life

Country	Booth No.
Netherlands	B11
CEO Name	
Tjark Tjin-A-Tsoi	**Pavilion**
Main Sector	Netherlands Bio Lounge
Academic/Non-Profit	
Website	
https://www.tno.nl/en/healthy/efficient-drug-development/preclinical-adme/	

Company Description

TNO is a leading research and technology institute offering innovative drug development services. Its expertise includes disease models with high translational value (MASH, fibrosis, diabetes, sarcopenia), target safety assessments using predictive algorithms, and advanced ADME/DMPK platforms. These include InTESTine (oral absorption), Comp3 (high-sensitivity plasma protein binding), and ex vivo liver/kidney perfusion for metabolism and biodistribution studies. TNO is the global leader in microtracer AMS (accelerated mass spectrometry) for early hADME data generation, serving top pharmaceutical companies.

To Buy or Sell Technology/Product

1. Microtracer AMS: As a global leader, TNO provides early-stage ADME packages using microtracer AMS, including PK, absorption, metabolite profiling, and identification.
2. In vitro & ex vivo DMPK Platforms: TNO delivers validated tools like InTESTine (intestinal absorption), I-screen (microbiome metabolism), ex vivo perfused liver/kidney systems (clearance and metabolism), and Comp3 for highly sensitive plasma protein binding (Fu < 0.01%).
3. Disease Models: TNO provides translational disease models for MASH, fibrosis, diabetes, and sarcopenia, including biomarkers to assess early efficacy.

Top Cell Bio Health

㈜탑셀바이오헬스 Top Cell Bio Health

Country	Booth No.
Republic of Korea	G32
CEO Name	
Bun Jun Kim	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.topcellbiohealth.com	

Company Description

Top Cell Bio Health pioneers stem cell solutions for incurable diseases and regenerative medicine, offering collection, storage, and treatment services to ensure a healthier future.

To Buy or Sell Technology/Product

A personalized stem cell storage service, professionally handled by certified doctors and researchers-TopCell BioHealth ensures safe, reliable care for your future health.

Translational Research Institute (TRI)

TRI TRANSLATIONAL RESEARCH INSTITUTE AUSTRALIA

Country
Australia

Delegate Name
Dr Ryan Parlett

Main Sector
Pharma

Website
www.tri.edu.au

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

The Translational Research Institute (TRI) is a global leader in providing facilities, resources and expertise to enable our tenants translate biomedical research and innovation into new and improved therapies, vaccines and health technologies.

TRI connects scientists, clinicians and industry in a unique setting; providing access to research, preclinical, clinical trial and manufacturing facilities and expertise.

TRI is home to more than 1,100 researchers, clinicians, and industry personnel who support the translation of biomedical discoveries from bench to bedside and the development of assets through pre-clinical and clinical trials to successful commercial outcomes.

TRI's new translational manufacturing facility will become Australia's first on-demand cGMP cleanroom facility. Tenancy will enable international and Australian companies to manufacture Phase 1, Phase 2 and Phase 3 clinical trial material for the development of advanced therapies, cell therapies, biologics, vaccines and drug-device combination products.

To Buy or Sell Technology/Product

The Translational Research Institute's new translational manufacturing facility will deliver Australia's first on-demand cGMP cleanroom facility for maturing, high-potential, biotech, pharma and medtech companies.

The facility will enable the manufacture of a range of products, including biologics (both mammalian and microbial), pDNA, RNA-based products (including mRNA-LNP), cell therapies (both allogeneic and autologous), drug-device combination products, and fill and finish needs (including sterile liquid vials).

Opening early 2026, the facility has been designed and constructed to comply with international and Australian regulations and standards, including relevant cGMP and ISO requirements.

Tenancy provides access to cGMP cleanrooms, wet labs (PC2 compliant) and office space to enable companies to undertake their own cGMP manufacturing, on-site Quality Control (QC), process and analytical development.

Combined with onsite technical support and training, companies will be able to scaleup and continue ongoing cGMP manufacturing for Phase 1, Phase 2 and Phase 3 clinical trials that meets both international and Australian requirements.

Companies will be able to manage their own manufacturing processes, giving them control over production and scheduling and the flexibility to use capacity across their pipeline, while preserving their intellectual property.

TrialKey

Country
Australia

Booth No.
B1

Delegate Name
Dr Minh-Thu Cao Xuan

Pavilion
Australian National Pavilion

Main Sector
Professional Services and Consulting

Website
Trialkey.ai

Company Description

TrialKey is revolutionising clinical trials through AI-driven solutions designed to optimise trial designs, predict outcomes, and address key healthcare challenges. Our mission is to streamline clinical research, accelerate medical advancements, and improve patient outcomes using AI to enhance efficiency and accuracy.

TrialKey's team combines expertise in regulatory affairs, clinical research, pharmacogenetics, precision medicine, clinical trial design, biostatistics, clinical operations, patient care, clinical pharmacology, drug safety, nutrition, and medical research. This diverse knowledge allows us to create tailored solutions that optimise clinical trial processes from design to execution, ensuring efficiency and regulatory alignment. Our senior leadership has decades of experience in AI, technology commercialisation, and clinical research, keeping TrialKey at the forefront of clinical trial optimisation. With expertise in machine learning, predictive analytics, and regulatory affairs, our leadership drives the scaling of innovative solutions that accelerate clinical trials and improve outcomes.

Strategic partnerships are central to our success. Collaborating with leaders like Commercial Eyes, Biointelect, Alithia Life Sciences, Southern Clinical Development Consulting, Phenix Health, L39 Capital, NeuOrphan, and Avion Medical, we leverage collective expertise to deliver data-driven solutions. These partnerships enable us to optimise trial designs, improve patient recruitment, and execute smarter, faster trials, leading to quicker market access for life-saving treatments.

To Buy or Sell Technology/Product

TrialKey is an AI Agent automating processes with AI to improve efficiency and enhance result accuracy. As the global leader in AI-driven biostatistical validation, TrialKey's advanced simulators analyse real-world data and generates optimised clinical trial designs. Our platform draws on an extensive dataset of over 468,000 trials, covering more than 114,000 conditions and insights from 2.69 billion patients. By analysing 1,300 variables per trial, TrialKey offers actionable insights that optimise patient recruitment, refine inclusion and exclusion criteria, determine ideal site locations, and enhance study arm structures. These innovations reduce trial timelines, improve outcomes, and conserve resources.

Our Services:

- Predict Outcomes: Advanced analytics and real-world data allow TrialKey to accurately forecast trial results, helping researchers minimise risks and make informed decisions.
- Optimise Trials: We enhance ongoing trials by adjusting key parameters such as patient touchpoints, site distribution, and study duration to improve efficiency and outcomes.

Create Trial Designs: TrialKey leverages AI to design trials with the highest probability of success from the outset, ensuring precision and regulatory alignment.

TrialKey partners with contract research organisations, pharmaceutical companies, and biotech innovators to revolutionise clinical research. Through AI-driven insights and tailored solutions, we help create faster, more efficient, and patient-centered trials.

TruwayBio

Country
China

Booth No.
N27

CEO Name
Heng Li

Pavilion

Main Sector
Professional Services and Consulting

Website
http://www.truwaybio.com

Company Description
Truwaybio is dedicated to providing flexible and cost-effective preclinical drug development services for pharmaceutical innovators. Our comprehensive offerings include ADME, DMPK, cancer efficacy models, and autoimmune disease animal models, supported by state-of-the-art in vivo platforms for mice, rats, canines, and non-human primates. We operate on a simple yet powerful philosophy: Become your extended R&D lab. Through our customer-centric approach and risk-free commitment model (no upfront payments), we ensure every study delivers maximum scientific value. Trust Truwaybio to transform your preclinical research into a strategic advantage - where every study advances both your pipeline and your competitive edge.

To Buy or Sell Technology/Product
Truwaybio accelerates drug discovery through cost-effective preclinical solutions. We provide in vitro ADME, multi-species PK studies, and therapeutic validation via 200+ CDX models (aiming to build the world's most comprehensive collection) and autoimmune disease platforms. Our expertise spans diverse modalities-small molecules, PROTACs, peptides, ADCs, nucleic acids, and cell therapies-supported by flexible, risk-free partnerships (no upfront fees). Combining rigorous science with tailored workflows, we act as your extended R&D lab to maximize data ROI and accelerate timelines. Every study prioritizes data integrity, transparent communication, and actionable insights for informed decision-making.

TS Cell Bio.Inc.

Country
Republic of Korea

Booth No.
L11

CEO Name
Ji-Min Park

Pavilion
Gangwon Technopark

Main Sector
Pharma

Website
www.tscb.co.kr

Company Description
TS Cell Bio Co., Ltd. was established in October 2020 and is developing EV-based treatments and preventive agents by establishing a brain-derived EV-based brain disease diagnosis platform and securing technology for separating Fetal Origin EVs with high efficiency.

To Buy or Sell Technology/Product
-Establish a healthy aging ecosystem by preventing brain diseases, including Alzheimer's disease, by entering the market with diagnostic technology-based preventive agents and treatments.

-Development of a technology for predicting and early diagnosis of low-cost/high-convenience brain diseases (brain aging, dementia, Parkinson's disease, brain cancer, etc.) using brain-derived exosomes-based non-invasive blood, body fluids, hair, etc

TWIST BIOSCIENCE

Country	Booth No.
United States of America	A30
CEO Name	
Emily Leproust	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.Twistbioscience.com	

Company Description

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist manufactures synthetic DNA-based products, including synthetic genes, tools for NGS preparation, and antibody libraries for drug discovery and development.

To Buy or Sell Technology/Product

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.

Variational AI

Country	Booth No.
Canada	C1
CEO Name	
Handol Kim, Co-Founder & CEO	**Pavilion**
Main Sector	
Professional Services and Consulting	Embassy of Canada to the Republic of Korea
Website	
https://variational.ai/	

Company Description

Variational AI is a techbio company with proprietary platform technology for de novo small molecule drug design. The company launched first commercially accessible foundational model for drug discovery with generative AI based drug design and retrosynthesis capability.

To Buy or Sell Technology/Product

Enki is a pre-trained foundation model for small molecule drug discovery. Enki's proprietary algorithm trained on 450M+ experimental and computational samples for 700+ drug targets.

Enki is a fully trained generative AI foundation model that rapidly generates novel and diverse leads and performs lead optimisation. Enki is capable of designing lead-like molecules in line with the collaborators TPP. Every designed molecule by Enki incorporates synthetic accessibility information so that the proposed molecules can be made and tested in the lab.

VIDO (Vaccine and Infectious Disease Organization)

Country
Canada

Contact Name
Dr. Paul Hodgson, Director-Operation

Main Sector
Academic/Non-Profit

Website
https://www.vido.org/

Booth No.
C1

Pavilion
Embassy of Canada to the Republic of Korea

Company Description

The Vaccine and Infectious Disease Organization (VIDO) is a world leader in infectious disease research and vaccine development for humans and animals. VIDO's expertise, infrastructure, and history put us at the forefront of innovation and make us a valuable resource and a source of pride for Canada. For 5 decades, we have been developing solutions to emerging threats and currently have over forty animal models of infectious disease.

To Buy or Sell Technology/Product

VIDO is expanding our capabilities as a Centre for Pandemic Research. This includes our Vaccine Development Centre, a containment level 3 capable biomanufacturing facility that meets GMP requirements, adding containment level 4 capacity and building a new animal facility capable of housing a wider range of animals to expand our preclinical research and development capacity. These important enhancements will support scientists from Canada and around the world to develop vaccines and therapeutics for humans and animals.

Our containment infrastructure and infectious disease expertise is accessible to the Government, Industry and Academia on a contract basis.

ViEL-T Inc.

Country
Republic of Korea

CEO Name
Sangmin Kang

Main Sector
Pharma

Website
www.viel-t.com

Booth No.
L19

Pavilion
Jeonbuk Technopark

Company Description

ViEL-T is a pioneering biotech company dedicated to developing treatments and therapeutic technologies for RNA viruses. By 2030, ViEL-T plans to market 3 new antiviral drugs and 2 new anticancer drugs, aiming to enter the top 50 global pharmaceutical company rankings.

To Buy or Sell Technology/Product

Highly lethal and contagious viruses are mostly RNA viruses. Since RNA viruses continuously produce variants, the development of antiviral drugs targeting the virus specifically is crucial, rather than relying solely on vaccines. ViEL-T is developing RNA virus- specific antiviral drugs, RNA therapy for the simultaneous treatment of viral and infectious diseases, CRISPR/Cas13b antiviral platforms against novel viruses and variants, and virus research models for evaluating these treatments.

ViEL-T has developed two antiviral drugs from its proprietary chemical library of previously unreported chemical compounds. ViEL-T also developed a groundbreaking treatment technology that simultaneously treats viral infections and infectious diseases by regulating the activity of lnc RNA, as well as antiviral platform against novel viruses and variants within just a one month.

Viral Vector Manufacturing Facility Pty Ltd (VVMF)

Country
Australia

Delegate Name
Anita van der Meer

Main Sector
Professional Services and Consulting

Website
vvmf.com.au

Booth No.
B1

Pavilion
Australian National Pavilion

Company Description

Viral Vector Manufacturing Facility (VVMF) is an Australian CDMO offering services in the design, development, and clinical-grade manufacturing of rLV and rAAV viral vectors.
With a purpose-built facility located within Sydney's Westmead Health and Innovation Precinct, VVMF supports production for small- and large-scale clinical applications.
With embedded scientific and clinical expertise, including direct connections to cutting edge academic research laboratories, cell & gene therapy is at the core of who we are and what we do.
Accelerate your path to market with the advantage of Australia's 43.5% R&D tax incentive for eligible activities, a pragmatic regulatory environment, and access to an advanced clinical trial ecosystem.
From concept to clinic - we're here, with you, unlocking the future of medicine.

To Buy or Sell Technology/Product

Delivering technical excellence in rLV and rAAV manufacturing including:

- Vector research and development
- Construct design and optimisation
- Process development
- Pre-clinical and clinical compliant manufacturing 5L to 500L
- Technology transfer
- Wrap-around services to take advantage of the Australian ecosystem including clinical trials

VPIX Medical

Country
Republic of Korea

CEO Name
Hwang, Kyungmin

Main Sector
Digital Health

Website
www.vpixmedical.com

Booth No.
E5

Pavilion
Rising Pavilion

Company Description

VPIX Medical is an innovative medical device company dedicated to improving cancer patients' quality of life by enhancing surgical success rates with its real-time digital biopsy platform, cCeLL. In cancer surgery, complete tumor removal while preserving healthy tissue is critical. However, identifying residual cancer cells during surgery is challenging, often leading to excessive tissue removal and impacting the patient's quality of life. cCeLL provides real-time, high-resolution cellular imaging in a non-invasive manner, allowing surgeons to assess tissue with precision. This enables accurate cancer removal while minimizing damage to healthy tissue. By transforming the surgical approach, VPIX Medical aims to create a safer, more effective operating environment for both doctors and patients.

To Buy or Sell Technology/Product

The cCeLL real-time digital biopsy platform offers two types of products: an ex vivo device and an in vivo device for real-time tissue assessment during surgery.

❖cCeLL - Ex vivo (Regulatory Approvals: MFDS, FDA(Class I Exempt), CE
cCeLL - Ex vivo acquires images from excised tissue samples during surgery, helping assess tumor characteristics and resection margins to reduce the risk of recurrence before the operation is completed. It enables pathologists to rapidly obtain high-resolution images, facilitating intraoperative diagnosis and decision-making.

❖cCeLL - In vivo (Regulatory Approvals: MFDS, FDA 510k)
Designed for brain tumor surgery, cCeLL - In vivo enables real-time, in-situ identification of tumor type and presence. Handheld for ease of use by neurosurgeons, it provides immediate

imaging upon contact with stained tumor tissue. This allows for real-time confirmation of residual tumors, guiding further resection while preserving healthy brain tissue—surpassing the limitations of conventional intraoperative pathology.

With real-time digital imaging, the cCeLL product line enhances surgical precision, improves patient recovery, and contributes to a better quality of life.

WuXi AppTec Korea

Country	Booth No.
Republic of Korea	E11
CEO Name	**Pavilion**
Yang Steve, Sukyoung Cho	
Main Sector	
Professional Services and Consulting	
Website	
http://www.wuxiapptec.com/	

Company Description

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life
sciences industry to advance discoveries and deliver groundbreaking treatments to patients. “Every drug can be made and every disease can be treated” through building the open-access platform with the most comprehensive
capabilities and technologies in the global healthcare industry.

To Buy or Sell Technology/Product

Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO, biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO, helping customers
improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

WuXi Biologics

Country	Booth No.
China	I19
CEO Name	
Chris Chen	**Pavilion**
Main Sector	
Professional Services and Consulting	
Website	
http://www.wuxibiologics.com.cn/	

Company Description

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics - from concept to commercialization - for the benefit of patients worldwide.

To Buy or Sell Technology/Product

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

Xcell Therapeutics

Country	Booth No.
Republic of Korea	G17
CEO Name	
Uri Lee	**Pavilion**
Main Sector	
Pharma	Korean Pavilion for Advanced Regenerative Medicine
Website	
http://www.xcell.co.kr	

Company Description

Since our inception in 2015, Xcell Therapeutics' focus has been to create a better future for humanity through the application and use of ethical science. With 10 years of research, we have made a breakthrough and developed CellCor™, a serum-free chemically defined media composed of over 200 known compounds. CellCor™ does not contain any animal or plant-derived components, making it a pure CD media.

To Buy or Sell Technology/Product

XPorT, the main core technology of Xcell Therapeutics, is aimed at developing optimal media from the perspective of users using various cells. Currently, we are developing customized media for various cells by incorporating XPorT technology, and we are building a diverse pipeline by expanding its application. Starting with the launch of serum-free medium for mesenchymal stem cells, we have succeeded in developing and launching chemically defined medium with animal origin free.

YiPSCELL

YiPSCELL

Country	Booth No.
Republic of Korea	G3
CEO Name	
Choi, Jinhyeok	**Pavilion**
Main Sector	Rising Pavilion
Pharma	
Website	
www.yipscell.com	

Company Description

YiPSCELL Inc. is Korea’s biotechnology start-up specializing in induced pluripotent stem cell (iPSC) technology. We produce high-quality stem cell lines from healthy individuals and patients, offering advanced solutions for disease modeling and drug development. Our iPSC-based platform enhances the accuracy of disease research and personalized therapy development while reducing reliance on animal testing. Beyond disease modeling, we develop stem cell-based therapeutics for regenerative medicine. Our pipeline focuses on degenerative diseases like osteoarthritis and Alzheimer’s. Recently, we expanded into artificial blood development and extracellular vesicle-based therapeutics and cosmetic ingredients.

To Buy or Sell Technology/Product

Induced Pluripotent Stem Cell (iPSC) Line Production Service
YiPSCELL offers a service to researchers and companies who need iPSCs for research purposes. Using samples provided by consumers, YiPSCELL generates iPSCs and analyzes them before providing them to the clients. We have successfully entered into a licensing agreement with Japan and has secured facilities equivalent to GMP (Good Manufacturing Practice) standards. With proprietary iPSC technology, YiPSCELL provides iPSC production services to those who cannot generate them in-house. The company also distributes clinical grade iPSCs produced in GMP facilities to various companies, enabling the development of cell therapies for clinical applications.

Disease Modeling Platform Service
YiPSCELL provides drug screening services for new drug development and the validation of existing drug effects. With growing concerns about animal rights and increasing restrictions on animal testing, YiPSCELL offers an alternative by using patient-derived iPSCs or normal human iPSCs to differentiate into target tissues. These tissues are then used to test the efficacy and toxicity of drugs. By utilizing human-derived iPSCs, YiPSCELL can offer a more ethical and efficient way of testing drug candidates.

Cell Therapy Development
YiPSCELL is actively engaged in developing cell therapies aimed at addressing unmet medical needs. Key areas of research include cartilage regeneration treatments for osteoarthritis (OA) patients, neuroregenerative therapies for spinal cord injury, Alzheimer's disease, and patients with COVID-19-related nerve damage to taste and smell. Additionally, YiPSCELL is developing artificial blood. These therapies are built on YiPSCELL's robust technological platform and aim to provide cutting-edge solutions for a variety of medical conditions.

Yonsei University K-NIBRT

Country	Booth No.
Republic of Korea	B19
CEO Name	
Gyoonhee Han, Seong-Bo Kim	**Pavilion**
Main Sector	
Pharma	
Website	
http://knibrt.com/main/main.php	

Company Description

The K-NIBRT Training Center was founded to cultivate professional talent in bioprocessing, a core sector of Korea's future growth industries. Leveraging Ireland's NIBRT training system and adapting it to local needs, the center delivers a wide range of practical, experience-based programs for job seekers, current employees, high school students, and international trainees.

To Buy or Sell Technology/Product

K-NIBRT is a government-led initiative jointly undertaken by the Ministry of Health and Welfare, the Ministry of Trade, Industry and Energy, Incheon Metropolitan City, Yonsei University, and Incheon Technopark. It serves as a specialized training center for global bioprocessing professionals, utilizing the educational framework of Ireland's NIBRT and customizing it to align with Korea's industrial landscape.

Young Science, Inc.

Country	Booth No.
Republic of Korea	G21
CEO Name	
KWANG DUK CHUNG	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.youngscience.com	

Company Description

Since its founding in 1992, Young Science has grown with the bio industry, providing quality and service under the motto "Together, Joyfully, Meaningfully." It specializes in automated equipment for cell therapy production, gene transfer devices, and services, contributing to the industry's growth while expanding domestically and globally.

To Buy or Sell Technology/Product

LONZA Cocoon, Nucleofector System, SINO Antibody, Cytokine

YOUTH BIO GLOBAL Co., Ltd.

Country	Booth No.
Republic of Korea	D11
CEO Name	
Seung Ho Yoo	**Pavilion**
Main Sector	DIPS 1000+ project
Pharma	
Website	
www.youthbioglobal.com	

Company Description

YOUTH BIO GLOBAL is a regenerative medicine company based in the Republic of Korea, developing *xeno-free* endothelial colony-forming cell (ECFC) therapy for diabetic foot ulcers and critical limb ischemia. Our proprietary ECFC platform, derived from umbilical cord blood, is combined with advanced wound covering materials formulated with bioactive natural ingredients. This integrated approach enables high-level total wound care through parallel treatment. With robust GMP capabilities and clinical pipelines, we are accelerating global partnerships in the vascular regeneration and wound healing fields.

To Buy or Sell Technology/Product

YOUTH BIO GLOBAL has developed a proprietary xeno-free ECFC culture medium and scalable expansion technology based on natural bioactive ingredients. Recognized as a New Excellent Technology (NET) and certified as an Innovative Product, this platform enables the first-ever clinical-grade ECFC production for cell therapy. The same natural compounds that enhance ECFC function are applied to hydrogel wound dressings to accelerate skin regeneration in diabetic foot treatment. Our hydrogel product is a Class II medical device with ISO 13485 and KGMP certifications, now generating domestic and global sales. In addition, we have completed standardization of the culture medium for non-commercial export, initiated international joint research, and are preparing secondary OEM production.

YUHAN Corporation

Country	Booth No.
Republic of Korea	K1
CEO Name	
Wook Je Cho	**Pavilion**
Main Sector	
Pharma	
Website	
http://www.yuhan.co.kr	

Company Description

Yuhan Corporation is a pharmaceutical company founded in 1926 by Dr. Ilhan New, an independence activist and successful entrepreneur. With corporate culture built on integrity and honesty, we continue with R&D efforts to expand globally.

To Buy or Sell Technology/Product

Yuhan comprises many business sectors including pharmaceutical drugs, healthcare, home care products, veterinary medicine, and CDMO.
In 2021, we launched LECLAZA® in South Korea for EGFR-mutant NSCLC patients and our partner Janssen received the FDA approval for the first-line (combination) therapy.

ZEISS

Country	Booth No.
Republic of Korea	F25
CEO Name	
Francois Chung	**Pavilion**
Main Sector	
Pharma	
Website	
http:// www.zeiss.co.kr/microscopy	

Company Description

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 7.5 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2021) With over 35,000 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities.Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany

To Buy or Sell Technology/Product

ZEISS is one of the world leading manufacturers of microscopes. In addition to excellent light and electron/ion microscopes, ZEISS also offers a broad range of optical sectioning systems as well as high-resolution X-ray microscopes. ZEISS Microscopy is a leading provider of microscope solutions in the life sciences, materials research, routine and industry markets. Our microscope systems are much more than just hardware. A dedicated and well-trained sales force, an extensive support infrastructure, and a responsive service team enable customers to use their ZEISS instruments to their full potential.

Sponsors

AMGEN Johnson&Johnson

Acro BIOSYSTEMS ST PHARM sysmex MSD

Promotional Partners

Australian Government Australian Trade and Investment Commission · Boehringer Ingelheim · Canada

BioJapan · Netherlands · Lilly

novo nordisk · BioPartner · Roche

SK bioscience · Business Sweden · Takeda · BioTaiwan Taiwan Bio Industry Organization

Using the power of leading-edge science to save and improve lives around the world

For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for some of the world's most challenging diseases.

With scores of "firsts" in our legacy, we know what it takes to nurture emerging ideas and we will be an enthusiastic and experienced partner on your journey. Meet our team and learn about our interests at msdlicensing.com.

MSD

sysmex

Together for a better healthcare journey

At Sysmex, we are dedicated to the universal desire of people to live long and healthy lives. Through our proprietary technology and solutions, we are committed to supporting each individual's lifelong healthcare journey.

Healthcare journey movie
Scan the QR code

Sysmex Corporation
www.sysmex.co.jp

BIOSYSTEMS Acro

Organoid-related Solutions

Organoids

Ready-to-Use | Native-like | Physiological Reproduction

- Cardiac Organoids
- Cerebral Organoids
- Liver Organoids
- Intestinal Organoids

Organoid Kits

iPSC-derived | Optimized GFs | Organ-specific Protocols

- Differentiation Kits
- Maintenance Kits
- Cryopreservation Kits

Organoid Services

Customized | Professional | Efficient

- Organoid Differentiation &Validation
- Neurodegenerative Disease Modeling
- Organ-specific AAV Screening Studies
- Cardiotoxicity Screening by Microelectrode Array

Booth No. J19

오가노이드 선물을
받으러 오세요!

글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521 Web: kr.acrobiosystems.com

Scan the QR code to access the Korean version

세상의 모든 중증질환을 극복할 때까지

생명공학 분야의 선구자로서 암젠의 도전은 멈추지 않습니다

암젠은 모든 사람들이 보다 편안한 삶을 오래도록 누릴 수 있기를 바랍니다.
암젠은 생명공학 분야의 발전을 주도하는 세계적인 바이오테크놀로지 기업으로서
전 세계 환자들이 중증질환의 고통에서 자유로워지는 그날까지,
혁신적인 생명공학 기술로 오늘의 한계를 넘어 내일의 희망을 만들겠습니다.

AMGEN

암젠코리아유한회사 서울특별시 중구 을지로5길 19, 20층 Tel. 02-3434-4899 | For further medical information, please contact : | 수신자 부담 : 00798-611-3554 | e-mail : medinfo.JAPAC@amgen.com

KOR-NP-42225-80002

BIO KOREA
INTERNATIONAL CONVENTION

2026 BIO KOREA

International Convention

April 29(Wed) ~ May 1(Fri), 2026
COEX, SEOUL